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Summary 
 
Carbon Monoxide, CO, has been recognized as an endogenously produced, potent 
biological mediator involved in many defense mechanisms both in physiologic 
and pathologic situations. As a result of these signaling processes, CO possesses a 
strong therapeutic potential on a wide range of disease indications. However, the 
hardly avoidable safety and practical problems associated with therapeutic 
inhalation of toxic CO gas, led to the search for molecules capable of delivering 
CO to tissues in a living organism in a controlled and therapeutically useful 
manner. From all the areas of the chemical space where such CO-Releasing 
Molecules (CO-RMs) can be found, Metal Carbonyls Complexes (MCCs) seems 
to be the most versatile. 
It is the purpose of this Thesis to provide an extensive characterization of the 
behavior of MCCs in the presence of biological molecules and media, in order to 
identify the chemical and structural parameters that are more relevant to define 
the profile of a therapeutically effective metal-based CO-RM drug. 
In pharmacological terms, CO-RMs are prodrugs which carry and appropriately 
deliver molecular CO as the therapeutically active principle. This delivery 
requires the chemical decomposition of the CO-RM. Such decarbonylation is 
triggered by an interaction of the CO-RM with the biological entity or medium. 
Ideally, a CO-RM should be targeted to the diseased tissue or organ in order to 
minimize its effective dose and prevent toxicity issues resulting from the 
indiscriminate, non-specific release of CO in the organism. Therefore, targeting of 
the CO-RM is largely dependent on the matching between the chemistry of 
decarbonylation and the chemical properties of the tissue or organ where it should 
take place, to produce the desired therapeutic effect.  
As mentioned above, MCCs were selected as the most versatile molecular 
structures that can provide controlled, targeted CO delivery because of their ease 
of decarbonylation compared to other organic functionalities. To give a meaning 
to the words “controlled, targeted CO delivery” it will be necessary to adjust and 
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tune the nature of both the inner coordination sphere of the MCC (wherefrom CO 
will have to be released), and the nature of the outer sphere made up by the distal 
substituents appended to the ligands which will mediate the interaction between 
the CO-RM and the biological environment. 
However, the anticipated complexity of such a delivery process, together with the 
fact that at the outset of this work extremely little was known about the 
interaction between MCCs and biological molecules and systems, required a 
stepwise approach towards the understanding of the chemistry of MCCs in such 
biological media. 
The starting point is the unavoidable need of establishing the “islands of stability” 
of MCCs in the aqueous, aerobic solutions that are needed for administration to 
living species. It is very loosely assumed by the chemical community that the vast 
majority of MCCs, that are metal complexes in low oxidation states, are unstable 
in air and water. In practice, very few such complexes have been manipulated in 
aqueous, oxic conditions and very little is indeed known about their actual 
stability under such conditions. Regardless of mechanistic details to be discussed 
later, CO release results from the decarbonylation of the MCC dissolved in the 
biological medium.  Initially in solution, free molecular CO gas can later escape 
(diffuse) to the headspace of the in vitro experimental setup. Using a simple gas 
chromatography method, Chapter II describes the screening of the CO release 
profile (extension and rate) of a large variety of organometallic carbonyls 
dissolved in biologically relevant media/conditions. This mode of CO release is 
called spontaneous because it ensues after simple dissolution in the biological 
medium at 37°C under air and in the dark. Most compounds tested were 
octahedral carbonyl complexes and cyclopentadienyl containing carbonyl 
complexes all of which with 18-electron configurations. The compounds are 
based on Mo0, MoII, MnI, FeII and RuII with classical, N, O, P and S-donor ligands 
or alkyl, acyl and halides. All the Mo0 compounds, ionic or neutral, showed a 
high rate of CO dissociation unless a strong π acceptor like cyanide or phosphines 
is present as co-ligand. On the contrary, their MnI counterparts do not release CO 
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at high rates unless an halide (preferentially Cl-) is coordinated to the metal. Most 
of the FeII and RuII compounds tested do not release CO in the conditions studied.  
The influence of pH and O2 was also evaluated for a set of Mo0 ionic compounds 
and it was established that O2 is the main trigger to promote CO release from 
these complexes, leading to the formation of hydroxyl radical, which was detected 
by ESR. The most remarkable fact was that ca. 2/3 of the compounds tested only 
released between 0-9% of their total CO contents. Unexpectedly, the common 
idea that MCCs are unstable in air and water is largely wrong. The need to study 
the influence of pH derives from the need to see which CO-RMs are able to resist 
the acidic environment of the stomach which is a determinant piece of 
information for developing orally available CO-RMs. Moreover, acid sensitive 
CO release may be particularly useful when driven to happen in the cellular 
lyzosome following drug internalization through the cell membrane. 
Since the most prominent biological activity of CO is anti-inflammatory, useful 
CO-RMs should be targeted to inflamed tissues. Such tissues are rich in reactive 
oxygen species (ROS), and therefore, the use of CO-RMs that are specifically 
activated by ROS inside cells or in the intercellular space seems a reasonable and 
promising strategy for targeting CO-RMs. Presently, very little is known about 
the reactivity of organometallic carbonyls under any of these conditions. Chapter 
III describes our studies on this type of CO release profile and concludes that: the 
concept of oxidatively triggered CO release is valid for the overwhelming 
majority of MCCs tested; this oxidation can be tuned by the choice of ancillary 
ligands and the nature of the particular ROS (H2O2 or ROOH), and that ROS can 
activate air stable MCCs turning them into active CO-RMs. 
The specific mechanisms through which CO exerts its biological activity are still 
not fully understood but is generally accepted that heme-proteins are the main 
targets (if not the only) for the molecule in the organism. In Chapter III the rate of 
CO release from several MCCs to Myoglobin (Mb) is evaluated by incubating 
them with deoxy-Mb and following the rise of carboxy-myoglobin (CO-Mb). The 
RuII(CO)3Cl(X)L complexes present the fastest rates of formation of CO-Mb 
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although they do not release CO to the headspace of their solutions. This effect 
was named CO donation. Since MCCs are rather reduced, electron-rich species, 
they may engage in electron transfer processes with redox active proteins, namely 
Myoglobin or Cytochrome C. A selected group of MCCs was also used to survey 
this issue. Most of the compounds tested do not interfere with the redox state of 
heme-proteins but almost all the Mo(0) complexes are strongly reducing agents 
and this reduction is accompanied by CO transfer to the reduced Myoglobin to 
give CO-Mb. This activity extends to Hemoglobin (Hb). Since animals have a 
natural protection against high levels of CO, hemoglobin, the efficiency of the CO 
delivery process requires that the CO-RM remains intact in the blood circulation. 
Otherwise, Hb will scavenge free CO from the blood stream and transport it to the 
lungs where it will be exhaled. The first studies of the behavior of MCCs and CO-
RMs in blood that we know of, revealed that most CO-RMs do not release CO to 
the erythrocytes, but those that do, are fully decarbonylated within a few minutes. 
In fact, CO release from most Mo0 CO-RMs is much, much faster in blood than in 
any other medium tested, including ROS rich media. We conclude that kinetic 
stability towards CO substitution is necessary to achieve stability of CO-RMs in 
blood.  Ease of oxidation can be additive to substitutional lability but is not the 
key factor to determine stability of transition metal CO-RMs in blood. 
At the time this Thesis was initiated, very little work had been published on the 
therapeutic activity of CO-RMs. The most promising results were obtained with 
two Ruthenium complexes – CORM-2 and CORM-3. Chapter V focus the 
attention on the development of a new series of Ru-based CO-RMs of the general 
formula Ru(CO)3Cl2L, where L is a ligand with a N-, O-, P- or S- donor atom. 
None of the compounds releases CO to the headspace of the GC apparatus but all 
are able to transfer CO to deoxy-Mb. Interestingly, it was possible to show that 
the amount of CO transferred can be tuned by the nature of L: from 0.2 equiv. 
(when L is a strong ligand) to 1 equiv. CO  (when L is a weak ligand).  
The interaction between drugs and plasma proteins is one of the key aspects that 
determine their pharmacological activity. The metabolic stability, half-life and 
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pharmacokinetic profile are just some of the parameters that may be determined 
by the degree of interaction of a given drug with the several proteins. Essentially 
nothing was known at the outset of this work with regard to the interaction of 
plasma proteins with MCCs.  In Chapter VI some exploratory studies using 
Circular Dichroism and Absorbance Spectroscopy techniques are presented, 
which aim to that determine the interaction between CO-RMs and the plasma 
proteins Albumin and Transferrin. Although observed for all complexes with 
substitutionally labile ancillary ligands it is not possible to ascertain the molecular 
aspects of such interactions from the data available. 
From all this work it can be concluded that MCCs are a suitable source of CO-
RMs because they can be tuned to resist attack by water, air and blood and, 
therefore, may be equipped with the necessary properties to be administered to a 
living animal to deliver CO in a controlled, targeted fashion. 
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Resumo 
 
O Monóxido de Carbono, CO, tem sido reconhecido como potente mediador 
biológico produzido endogenamente e envolvido em diversos mecanismos de 
defesa tanto em situações fisiológicas como patológicas. Como resultado destes 
processos de sinalização o CO possui um forte potencial terapêutico numa vasta 
gama de doenças. No entanto, é dificil contornar os problemas de segurança e 
questões práticas associadas à administração por inalação deste gás tóxico, o que 
desencadeou a procura de moléculas capazes de distribuir CO aos tecidos de um 
organismo vivo de um modo controlado e terapêutico. De todas as áreas do 
espaço químico onde tais Moléculas Libertadoras de CO (ML-CO) podem ser 
encontradas, os Complexos Metálicos de Carbonilos (CMCs) parecem ser os mais 
versáteis. 
O objectivo desta Tese é fornecer uma caracterização extensiva do 
comportamento dos CMCs na presença de moléculas e meios biológicos, de modo 
a identificar os parâmetros químicos e estruturais mais relevantes para definir o 
perfil de uma droga tipo ML-CO com acção terapêutica. 
Em termos farmacológicos, as ML-CO são pró-drogas que carregam e distribuem 
CO molecular como o princípio activo terapêutico. Esta distribuição requer a 
decomposição química da ML-CO. Tal descarbonilação é despoletada por uma 
interacção da ML-CO com a entidade ou meio biológico. Idealmente, uma ML-
CO deve ser dirigida para um tecido ou orgão doente de modo a minimizar a sua 
dose efectiva e prevenir a toxicidade resultante de uma libertação de CO 
indiscriminada e não específica no organismo. Portanto, o direccionamento da 
ML-CO depende da semelhança entre as condições em que ocorre a química da 
descarbonilação e as propriedades químicas do tecido ou orgão onde deve ocorrer 
para produzir o desejado efeito terapêutico.  
Como mencionado acima, os CMC foram escolhidos como as estruturas 
moleculares mais versáteis que permitem distribuir CO de forma controlada e 
direccionada devido à sua facilidade de descarbonilação quando comparada com 
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outras funcionalidades orgânicas. Para dar um significado à expressão 
“distribuição controlada e direccionada de CO” é necessário ajustar e afinar ,tanto 
a esfera de coordenação interna do CMC (de onde o CO irá ser libertado) como a 
natureza da esfera externa, constituída pelos substituintes nos ligandos que irão 
mediar a interacção entre a ML-CO e o ambiente biológico.  
No entanto, a complexidade de tal processo de distribuição, juntamente com o 
facto de no início deste trabalho, muito pouco ser conhecido sobre a interacção 
entre CMCs e moléculas e sistemas biológicos, forçou a que se efectuasse uma 
abordagem faseada de  modo a entender a química dos CMCs em meio biológico.  
O ponto de partida é a inevitável necessidade de identificar “ilhas de estabilidade” 
dos CMCs em soluções aquosas, aeróbias necessárias para a administração a seres 
vivos. É vagamente assumido pela comunidade química que a grande maioria dos 
CMCs, que são complexos metálicos em baixos estados de oxidação, são 
instáveis ao ar e na água. Na prática, muito poucos desses complexos foram 
manuseados em condições aquosas, oxigenadas e muito pouco se sabe de facto 
sobre a sua verdadeira estabilidade nas referidas situações. Independentemente de 
detalhes mecanísticos que serão discutidos à frente, a libertação de CO resulta da 
descarbonilação do CMC dissolvido no meio biológico. Inicialmente em solução, 
o CO gás livre pode escapar (difundir) para a fase gasosa do apparatus 
experimental in vitro. Usando um método simples de cromatografia gasosa, (CG) 
o capítulo II descreve o escrutínio dos perfis de libertação de CO (quantidade e 
velocidade) de uma grande variedade de complexos de carbonilos 
organometálicos dissolvidos em meio/condições biológicas relevantes. Este modo 
de libertação de CO é denominado espontâneo pois ocorre após dissolução no 
meio biológico a 37ºC, ao ar e no escuro. A maioria dos compostos testados são 
complexos carbonílicos octaédricos e complexos carbonílicos contendo o ligando 
ciclopentadienilo, todos com configuração electrónica de 18 electrões de valência. 
Os compostos são baseados em Mo0, MoII, MnI, FeII e RuII com ligandos clássicos 
com átomos doadores N, O, P e S ou ligandos alquilo, acilo e halogenetos. Todos 
os compostos de Mo0, iónicos ou neutros, mostraram uma grande taxa de 
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dissociação de CO, a não ser que os co-ligandos sejam fortes aceitadores π como 
cianeto ou fosfinas. Pelo contrário, os compostos de MnI não libertam CO em 
grande quantidade a não ser que um halogeneto (preferencialmente Cl-) esteja 
coordenado ao metal. A maior parte dos compostos de FeII e RuII testados não 
libertam CO nas condições estudadas.  
A influência do pH e O2 também foi avaliada para um grupo de compostos 
iónicos de Mo0 e foi concluído que o O2 é o principal estímulo para promover 
libertação de CO destes complexos, levando à formação do radical hidroxilo, que 
foi detectado por Ressonância Electrónica Paramagnética. 
O facto mais impressionante é que ca. de 2/3 dos compostos testados apenas 
libertaram 0-9% do total de CO possível. Inesperadamente, a ideia comum de que 
os CMC são instáveis ao ar e água parece estar errada. A necessidade do estudo 
da influência do pH advém da necessidade de perceber que ML-CO são capazes 
de resistir ao ambiente acídico do estômago, que é uma informação vital para o 
desenvolvimento de ML-CO para administração oral. Mais ainda, a libertação de 
CO catalizada em meio acído pode ser útil se acontecer no lisossoma após 
internalização da droga através da membrana celular.    
Uma vez que o efeito biológico mais proeminente do CO é a sua acção anti-
inflamatória, ML-CO úteis devem ser direccionadas para tecidos inflamados. Tais 
tecidos são ricos em espécies reactivas de oxigénio (ERO) e portanto o uso de 
ML-CO que sejam especificamente activadas por ERO dentro das células ou no 
espaço intercelular parece ser uma estratégia razoável e promissora para 
direccionamento das ML-CO. Presentemente, muito pouco se sabe acerca da 
reactividade dos complexos organometálicos contendo carbonilos, nestas 
condições. No Capítulo III descrevem-se os estudos deste tipo de perfil de 
libertação de CO e conclui-se que o conceito de libertação de CO por estímulo 
oxidativo é válido para a grande maioria dos CMC testados; esta oxidação pode 
ser afinada pela escolha dos ligandos auxiliares e pela natureza da ERO (H2O2 ou 
ROOH), e ainda que as ERO podem activar CMCs estáveis ao ar tornando-os 
ML-CO activas. 
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Os mecanismos específicos pelos quais o CO exerce a sua actividade biológica 
ainda não estão totalmente compreendidos, mas é geralmente aceite que as 
proteinas hémicas são o principal alvo (se não o único) para o CO no organismo. 
No Capítulo IV a taxa de libertação de CO de diversos CMCs para a Mioglobina 
(Mb) é avaliada por incubação destes com deoxi-Mb e seguindo a formação de 
carboxi-mioglobina (CO-Mb). 
Os complexos RuII(CO)3Cl(X)L apresentam as mais rápidas taxas de formação de 
CO-Mb apesar de não libertarem CO para a fase gasosa das suas soluções. Este 
efeito foi denominado de doacção de CO. Uma vez que os CMCs são espécies 
reduzidas, ricas em electrões, podem participar em processos de transferência 
electrónica com proteínas com actividade redox, nomeadamente Mb ou 
Citocromo C. Um grupo selecccionado de CMCs foi também usado para abordar 
este processo. A maioria dos compostos testados não interfere com o estado redox 
das proteinas hémicas mas quase todos os complexos de Mo0 são fortes agentes 
redutores e esta redução é acompanhada pela transferência de CO para a 
Mioglobina reduzida originando CO-Mb. Esta actividade é extensivel à 
Hemoglobina. Uma vez que os animais têm uma protecção natural contra níveis 
elevados de CO, a hemoglobina, a eficácia do processo de distribuição de CO 
necessita que a ML-CO permaneça intacta na circulação sanguínea. De outro 
modo a hemoglobina irá capturar o CO livre na corrente sanguínea e transportá-lo 
ao pulmões onde será expelido. 
Ao efectuar os primeiros estudos conhecidos sobre o comportamento de ML-CO 
no sangue, mostrou-se que a maioria das ML-CO não libertam CO para os 
eritrócitos mas os que o fazem, são completamente descarbonilados em poucos 
minutos. De facto, a libertação de CO da maioria das ML-CO de Mo0 é muito 
mais rápida no sangue do que em qualquer outro meio testado, incluindo meios 
ricos em ERO. Conclui-se que a estabilidade cinética em torno da substituição de 
CO é necessária para obter estabilidade das ML-CO no sangue. A oxidação pode 
ser um processo adicional à labilidade substitucional, mas não é o factor-chave 
para determinar a estabilidade da ML-CO no sangue.  
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À altura do início desta Tese, muito pouco trabalho tinha sido publicado sobre a 
actividade terapêutica das ML-CO. Os resultados mais promissores tinham sido 
obtidos com 2 complexos de Ruténio – CORM-2 e CORM-3. No Capítulo V, 
foca-se a atenção no desenvolvimento de uma nova série de ML-CO baseadas em 
Ruténio, de forma geral Ru(CO)3Cl2L em que L é um ligando com átomo doador 
N-, O-, P- ou S. Nenhum dos compostos liberta CO para a fase gasosa do 
apparatus experimental de CG, mas todos são capazes de o transferir para a 
deoxi-Mb. Curiosamente, foi possível demonstrar que a quantidade de CO 
transferido pode ser ajustada pela natureza de L: desde 0.2 equiv. CO (quando L é 
um ligando forte) até 1 equiv. CO (quando L é um ligando fraco). 
A interacção entre drogas e proteínas do plasma é um aspecto-chave que 
determina a sua acção farmacológica. A estabilidade metabólica, tempo de meia-
vida e perfil de fármaco-cinética são apenas alguns dos parâmetros que podem ser 
modelados pelo grau de interacção de uma determinada droga com diversas 
proteínas. No início deste trabalho muito pouco era conhecido a respeito da 
interacção de proteínas do plasma com CMCs. No capítulo VI, são apresentados 
alguns estudos exploratórios recorrendo a técnicas de Dicroísmo Circular e 
Espectroscopia de Absorção que pretendem determinar a interacção entre ML-CO 
e as proteínas do plasma Albumina e Transferrina. Apesar de tais interacções 
terem sido observadas para todos os complexos com co-ligandos lábeis, não foi 
possível determinar os aspectos moleculares envolvidos a partir dos dados 
disponíveis. 
De todo este trabalho pode-se concluir que os CMCs são uma fonte viável de ML-
CO pois podem ser modificadas para resistir a àgua, ar e sangue e portanto, 
capazes de serem munidos das propriedades necessárias para serem administrados 
a um ser vivo, de modo a distribuir CO de forma controlada e direccionada. 
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List of Abbreviations: 
 
Ac    acetyl   
acac    acetylacetonate 
ADME   absorption, distribution, metabolism and excretion 
AIP    Alfama’s Intelectual Property 
AUC    area under curve 
bipy    bipyridyl 
BMPO    5-tert-butoxycarbonyl 5-methyl-1-pyrroline N-oxide 
bpa    N-(p-carboxy-benzyl)bis(2-picolyl)amine 
Bu    butyl 
BSA    Bovine Serum Albumin 
bw    body weight 
CD    Circular Dichroism 
CDs    cyclodextrins 
choline   N,N,N – trimethylammonium cation 
CHT    1,3,5-cycloheptatriene 
cit    Citrate 
CMT    cyclopentadienyl manganese tricarbonyl 
CO    carbon monoxide 
CO-Hb   carboxy-hemoglobin 
CO-RM   CO releasing molecule 
Cp    cyclopentadienyl 
Cp*    pentamethylcyclopentadienyl 
Cp’    general abbreviation for a substituted Cp ring 
Cy    cyclohexyl 
Cyst    Cysteine 
Cyt    Cytochrome 
DAB    1,4 – diazabutadiene 
DAPTA   3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane 
detpa    diethylenetriaminepentaacetate 
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DMSO    dimethylsulfoxide 
E.A.     elemental analysis 
Equiv.    equivalent 
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Chapter I: Introduction 
 
1. The biological activity of Carbon Monoxide 
 
Carbon monoxide (CO) is a colorless, odorless and tasteless gas that has always 
been tagged as a noxious and dangerous molecule. It is a product of incomplete 
combustion of organic compounds and the most common sources are car exhaust 
fumes, smoke from fires, gas-powered engines and wood-burning fireplaces.[1]  
Historically, this poisonous reputation was built upon countless episodes of CO 
exposure with fatal outcome; since CO binds to hemoglobin with more affinity 
than O2 it drastically decreases the oxygen transport capacity of the 
cardiovascular system. Moreover, when CO is bound to hemoglobin the oxy-
hemoglobin dissociation curve changes. If CO is bound to two heme sites in the 
hemoglobin molecule, oxygen affinity increases and therefore it is no longer 
available to be released in the tissues.[2] 
Nevertheless, the binding between CO and hemoglobin is reversible and CO can 
be replaced with oxygen applying common methodology like substitution 
hyperbaric chambers[3] since the ratio between oxy-hemoglobin and CO-Hb is 
determined by the relative partial pressure of CO and O2. This is not a 
straightforward process and the same partial pressures of CO and O2 give 
different results in different species and individuals, as demonstrated in the 
extensive work of Haldane and co-workers.[4] Thus, the toxic effects are largely 
dependent on CO concentration and duration of the exposure.  
The current methodology to assess CO levels in the body is the measurement of 
the percentage of carboxy-hemoglobin (CO-Hb) in the blood. Table 1 lists 
examples of several CO concentrations, the calculated CO-Hb levels and related 
human health effects. 
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Table 1: Ambient CO concentration, % CO-Hb and human health symptoms associated 
(adapted from references [5] and [6]). 
%CO-Hb in blood 
Concentration/ 
ppm 
Symptoms 
2 
10 
20 
30 
40-40 
60-80 
10 
70 
120 
220 
350-520 
1950 
10 000 
Asymptomatic 
Exhaustion in healthy people and headaches 
Dizziness, nausea, dyspnea 
Visual disturbance 
Confusion, syncope, seizures and coma 
Cardiopulmonary dysfunction and death 
Lethal in minutes 
 
Human levels of CO-Hb differ depending on the external source they have been 
exposed to, and, obviously, different individuals may experience different 
symptoms. For instance, regular smokers present CO-Hb baseline levels 
significantly higher (up to 9%) than non-smokers (typically below 2%).[7]   
Despite being common sense that CO is a harmful poison for the organism[8, 9] 
several scientific discoveries forced scientists to look at this molecule from a 
different angle. It was already in the middle of the 20th century that Sjöstrand 
made a discovery that was one of the most important milestones in CO history, 
when he reported the Endogenous production of carbon monoxide in man under 
normal and pathological conditions.[10]  
Sjöstrand, and later Coburn[11, 12] found that CO is endogenously generated in the 
body through the degradation of senescent red blood cells. It was only 30 years 
after Sjöstrand’s original paper that Tenhunen and co-workers[13-15] characterized 
the enzyme responsible for breaking down the hemoglobin with concomitant CO 
release – Heme Oxygenase (HO).   
The heme degradation is a concerted action catalyzed by HO with NADPH-
cytochrome c (P-450) reductase and oxygen. During the heme degradative 
process, CO formation is accompanied by the liberation of ferrous ion and 
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biliverdin-IX α (blue-green pigment) that is rapidly converted into bilirubin-IX α 
(yellow pigment) by biliverdin reductase.[16-19] 
This process is usually observed in bruises. During the injury, a dark red/purple is 
observed, which arises from deoxygenated hemoglobin released from lysed red 
blood cells. The released heme is then oxidized with formation of biliverdin, 
which is responsible for a green tinge. Later, biliverdin is reduced into bilirubin 
and a yellow coloration typical of this molecule is observed. 
What at the first sight could look as a pure catabolic process results in the 
production of biological active elements.[20-22] Iron regulates several genes 
expression, including HO as well as transferrin receptors, ferritin (Fe 
homeostasis) and NO synthase. Bilirubin and biliverdin are antioxidants and are 
essential for the maintenance of the redox imbalance inflicted on cells and tissues 
by oxidative and nitrosative stress.[23]  
Therefore, HO has both anabolic and catabolic functions inside the cell. In its 
catabolic functions it reduces the levels of intracellular heme concentration and 
hemeprotein and therefore inactivates the most potent catalyst for free radicals 
formation, the heme. In its anabolic functions HO produces the bilic pigments, 
CO and iron, all biological active elements. 
So far three isoforms of HO were identified but only two were studied in detail[24] 
(reviewed in reference [25]). HO-2 is constitutively expressed in tissues such as 
brain, liver and endothelium and regulates the basal levels of free heme, acting as 
a neurotransmitter and regulator of vascular tone. HO-1 is an inducible isoform 
that represents a pivotal defense against stressful stimuli like ischemia-
reperfusion damage, endotoxic shock, UVA radiations and other stressful insults 
derived from oxidative and nitrosative stress.  
HO-3 is so far a very poorly studied isoform, whose functions are not clearly 
understood.[19] It has been found in the brain, heart, kidney, liver and spleen of 
rats but it does not possess any heme degrading activity. 
Characterization of constitutive HO-2 and inducible HO-1 isoforms of heme 
oxygenase as well as studies on the kinetics and tissue distribution of these 
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enzymes revealed the importance of this pathway in the physiological degradation 
of heme and this production, under some pathophysiological conditions could 
even be enhanced.[26-28]  
Indeed, oxidation of heme by HO accounts for ca. 86% of the total CO production 
in the body, ca. 79% directly from RBC breakdown[27, 29] and the remaining 21% 
from the turnover of other hemeproteins like myoglobin, cytochromes and 
others.[14] The remaining CO comes from other non-heme sources like lipid 
peroxidation (e.g. NADPH-dependent oxidation of microssomal lipids[30]) photo-
oxidation, Fe3+-ascorbate catalyzed oxidation of microssomes,[31] bacterial 
activity[32, 33] and xenobiotics. 
For instance, methylene chloride which is often inhaled from paint strippers, 
mixtures used for degreasing machinery and pesticide products, is converted to 
CO by hepatic enzymes in the liver.[34]  
Under normal physiological conditions, the rate of CO production in human body 
is 16.4 µmol.h-1[35] but these basal levels may increase under stress or pathological 
conditions. Activation of HO-1 can lead to a local increase of CO in a determined 
tissue and this is evidenced by the increase levels of CO in exhaled breath of sick 
individuals.[36-41] 
Taken altogether these results challenged CO toxic reputation and the scientific 
community became more interested in its physiological profile rather than the 
widely described toxic effects. 
The discovery that CO activates soluble guanylyl cyclase (sGC)[42] was one of the 
first evidences that this molecule could act as an intracellular messenger.[43, 44] 
Currently, a wide range of biological effects attributed to CO are already well 
documented showing anti-inflammatory, anti-apoptotic and anti-proliferative 
properties both in vitro and in vivo (reviewed in references [5, 20, 45, 46]). Also, 
the protective effects of exogenously applied CO have been demonstrated in 
several models such as organ ischemia/reperfusion injury, hepatitis, vascular 
injury, inflammatory lung disease and organ transplantation (for reviews see 
references [45] and [47]). The positive results obtained with inhalation of CO 
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levels between 10-250 ppm led the pharmaceutical company IKARIA® to test CO 
gas as a therapeutical molecule in on-going clinical trials in humans 
(http://clinicaltrials.gov/ct2/results?term=carbon+monoxide). 
With CO inhalation therapy stable CO-Hb levels (typically 12-20%) are 
maintained during a desired period of time (usually 1h). However, the need for a 
controlled hospital environment and appropriate machinery favor the quest for 
better alternatives. CO-releasing molecules emerge as a suitable alternative to 
deliver CO to tissues in a living organism in a controlled and therapeutically 
useful manner, without increasing CO-Hb levels to dangerous limits. 
 
2. CO and Heme Proteins 
 
Endogenously produced CO as well as exogenously administered CO (as a gas) 
both depend on hemoglobin transportation to reach the cellular targets. CO binds 
hemoglobin in the heme center[48, 49] and is transported across the body until it 
reaches the tissues. The affinity for heme is the driving force that leads to 
formation of CO complexes with other hemeproteins. Plenty of evidence exists 
for the formation of such adducts with myoglobin, soluble guanylyl cyclase, 
inducible nitric oxide synthase, cytochrome P-450, cytochrome-c oxidase, 
NADPH oxidase and the heme-oxygenase complex[43, 50-56] which leads 
hemeproteins to be considered the most likely (if not the only) target for CO in 
biology.[47, 57] As a consequence of heme binding, intracellular CO potentially 
influences the activity of these hemeproteins and these changes in activity may 
result either in activation or inhibition of the metabolic functions. Indeed, the 
most well-known and documented effect is undoubtedly CO “poisoning” that 
arises from CO competition against O2 for binding to the four heme iron centers 
of hemoglobin and producing carboxy-hemoglobin the formation of which is 
favored by the 245 times higher affinity of CO over O2.  
Binding to other heme centers such as cyt P450 and cyt c oxidase has important 
effects on the respiratory chain and the contribution of this effect to toxicity is 
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still under debate. For instance, coordination of CO to cyt c oxidase may prevent 
oxygen activation giving protection to reperfusion injury.  
Myoglobin is a heme protein mainly found in muscle tissues whose primary 
function is to buffer the oxygen concentration in these tissues.[58] The protein is a 
monomer, containing a single five-coordinate heme center (iron protoporphyrin 
IX) that reversibly binds O2, without auto-oxidation. It stores O2 in muscles and 
allows the consumption of the stored O2 in aerobic metabolism, providing “extra 
O2” to small metabolic bursts, which wouldn’t be possible if only the circulating 
O2 in hemoglobin was available. The crystal structure of Myoglobin was the first 
protein structure to be revealed at atomic level. It was determined in the late 
1950s by Kendrew and co-workers[59, 60] and since then new resolution structures 
were published in several ligation states.[61, 62]  
Like other iron-based heme proteins, Mb also binds a broad range of ligands 
depending on the redox state of the metal. The ferric form reacts readily with 
water and anions like F, Cl, CN, N3 and OH. The ferrous form, in addition to 
dioxygen also binds CO, NO, several alkyl isocyanides and nitroso aromatic 
compounds.[63] 
The heme site is “lodged” between two helices and the spatial design of the 
environment (steric effect) as well as the pocket polarity determines several 
important functions such as an effective discrimination of CO over O2 and the 
prevention of irreversible aerobic auto-oxidation. This prevention is achieved by 
enhancing stability of the oxy-heme form, favored by globins, against heterolytic 
cleavage of the Fe-O bond, formed in peroxo-bridged hemes that would result in 
the release of superoxide.  
These complicated heme ligand affinities are regulated by polar, hydrophobic and 
steric interactions between heme, ligands and distal aminoacid residues. The high 
number of variables involved makes the kinetics of ligand binding a complex 
process that involves multiple stereochemical constrained steps, that include (O2 
is presented as an example): 1) displacement of a non-coordinated water molecule 
from the distal pocket; 2) entry of O2 into the empty distal pocket; 3) non-
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covalent binding of O2 in the distal pocket and hydrophobic internal pockets; 4) 
covalent bond formation through the in-plane movement of the iron atom forming 
the hexacoordinate species; 5) relaxation of the protein and formation of a new 
electrostatic interaction with the distal pocket, typically hydrogen bonding.[56]  
Despite sharing the same general “architectural displacement”, some differences 
are observed between O2 and CO binding forms. Similar iron-to-ligand bond 
lengths are observed (around 1.8 Å) but CO binds normal to the heme plane while 
the O2 adduct is intrinsically bent. This results in a higher localization of the 
negative charge at the distal O of oxy-heme (often viewed as ferriheme-
superoxide adduct) contrary to the little charge separation in the heme-CO adduct. 
Also the distal groups, through steric, electrostatic and H-bonding effects 
contribute to the CO vs O2 discrimination.    
These binding differences and conformational changes are reflected in the 
spectroscopic properties of the different states that strongly vary according to the 
ligand. 
In the ferrous state the iron has six 3d electrons whereas in the ferric ion it has 
five. The tetrapyrrole ring of protoporphyrin-IX divides the d orbitals into three 
deg (dxy, dyz and dzx) and two t2g (dx2-y2, dz2) degenerated orbitals. In the ferrous 
liganded (O2 and CO) forms, the energy difference between deg and t2g orbitals is 
high so the three orbitals are filled with six electrons of opposite spin giving a low 
spin state of S=0.  
In ferrous deoxy state, the energy difference between the two set of orbitals is low 
so that all the orbitals are filled with electrons according with Pauli’s exclusion 
principle and Hund’s rule. In result, a high-spin species with S=2 ( ½ + ½ + ½ + 
½ ) is obtained. 
Ferric met-Mb has five 3d electrons and the energy difference between the two 
energetic states will depend on the 6th ligand, giving rise to S = ½ or S = 5/2 
species. These electronic differences are illustrated in Figure 1.  
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Figure 1: Electronic configuration and spin state of the iron metal in Hb: Top: 
Degenerescence of the 3d electrons in free Fe in the presence of the ligand field of the 
porphyrin ring into three deg (dxy, dyz, dzx) and two t2g (dx2-y2, dz2) orbitals. Bottom: A- Fe 
atom in ferrous low spin state (S=0), e.g. Oxygen and carbonmonoxy Hb; B- Fe atom in 
ferrous high spin state (S=2), e.g. deoxy Hb; C- Fe atom in ferric high spin state (S=5/2), 
e.g. fluoromet and aquomet Hb; D- Fe atom in ferric low spin state (S=1/2), e.g. cianomet 
and azidemet Hb.   
 
These electronic properties are reflected in different spectroscopic profiles which 
allow the determination of different ligation states between “free” deoxygenated 
heme and CO adducts.  
 
3. Plasma binding proteins and interactions with 
drugs  
 
Most pharmaceutical drugs depend on bloodstream to reach the diseased tissues 
or organs. Different delivery routes like oral dosing (per os), intraperitoneal (IP), 
intravenous (IV), intramuscular (IM), subcutaneous (SC) or even transdermal rely 
on blood to transfer the drug to targets.  
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When drugs are administered to living systems there are several barriers that 
reduce the amount of dosed compound that reaches the target. The barriers 
encountered are diverse and include physicochemical and biochemical processes 
such as cell membranes, metabolic enzymes, local pH variations, efflux 
transporters and binding blood constituents.[64] The sequence of barrier events 
found by the molecules strongly depends on the route of administration and when 
such barriers are met the drugs’ behavior is determined by the physicochemical 
properties of the molecules. Their binding and reactivity with specific enzymes, 
binding to transporters and plasma proteins as well as non-specific binding to 
macromolecules, affects their absorption, distribution, metabolism and excretion 
(ADME).[65-67] In the bloodstream, three barriers affect free drug availability: 
enzymatic hydrolysis, red blood cell binding and plasma protein binding.   
The hydrolytic enzymes in bloodstream include diverse enzymes like lipase, acid 
and basic phosphatases, aldolase, dehydropeptidase, cholinesterase, 
glucuronidase, phenol phosphatase and dehydrogenase. The concentration of such 
enzymes and substrate specificity vary with factors like age, gender, race or 
disease state. 
Red blood cell binding is another factor affecting free unchanged drug 
concentration since the cell membrane may bind drug molecules through 
lipophilic interactions. Nevertheless, the ratio of RBC binding observed is very 
small compared with plasma protein binding (PPB). Indeed, the major cause 
leading to a decrease of free drug concentration in solution is PPB. 
Approximately 6% to 8% of the plasma content are proteins, being the vast 
majority transporters for natural occurring compounds. Their concentration in 
plasma may vary with age or even disease states[68-70] but a more relevant fact is 
that drugs are also able to reversibly bind to these proteins. The affinity of 
binding determines the ratio of bound and unbound drug in solution and a 
stronger affinity will obviously decrease the amount of free drug in circulation.  
Unless very high drug concentrations are used, the total protein binding is a 
constant fraction of bound and unbound drug over a wide total drug concentration 
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range due to the high capacity of drug binding in plasma which is never fully 
saturated. The high binding capacity is provided by three types of binding 
proteins: albumin, α1-acid glycoprotein and lipoproteins. 
Human serum albumin is the main carrier in the human organism and possesses 
six binding sites with high specificity which may carry different products such as 
fatty acids, bilirubin or drugs like warfarin and ibuprofen.[71] 
The concentration of α1-acid glycoprotein in blood (15 µM) is much lower than 
that of Human Serum Albumin (HSA) (500-800 µM). It has only one binding site 
and binds to basic drugs such steroids (e.g. disopyramide and lignocaine) 
essentially by non-specific hydrophobic interactions.[72, 73] 
Lipoproteins (very-high-density lipoprotein [VHDL], high-density lipoprotein 
[HDL], low-density lipoprotein [LDL] and very-low-density lipoprotein [VLDL]) 
are particles constituted by non-polar lipids surrounded by more polar lipids and 
protein that work as natural transport for cholesterol and triacylglycerols. Drug 
binding to these proteins includes non-specific lipophilic interactions. 
For most drugs, PPB has different effects some of which even contradictory. 
However, the interpretation of these effects for CO-RMs is not so straightforward. 
For most drugs binding prevents that the desired pharmaceutical effect is 
maximized since in order to reach a therapeutic concentration in the tissues, the 
drug must be unbound to permeate the membranes. In the case of CO-RMs, CO – 
the active principle – is able to permeate the membranes so binding to proteins 
may not have a deleterious effect, as the binding interaction itself may lead to 
disruption of metal-carbonyl bonds and favor the release of the therapeutic agent. 
On the other hand, half-life in circulation may also be increased since bound 
drugs do not permeate into the liver and kidney for clearance. This will depend on 
kinetics (on/off rates)[65] and affinity for the protein.  
 
 
 
  Chapter I 
 
 
11 
4. The Chemistry of CO release from Metal Carbonyl 
Complexes 
 
Metal Carbonyl Complexes (MCCs) are coordination compounds of the general 
type LxM(CO)y where M is a transition metal in various oxidation states, Lx 
represents a set of ancillary ligands and y ≥1.  
The vast majority of the MCCs have an 18-electron count in the valence shell of 
the central metal atom. This is called the Effective Atomic Number (EAN) or 18-
electron rule, first stated by Nevil Sidgwick in 1927.[74] In this electronic 
situation, the bonding between ligands and metal is maximized by the 
involvement of all the s, p and d orbitals of the metal. The 18 electrons 
correspond to the full occupancy of the nine bonding molecular orbitals generated 
by the nine metal valence orbitals (one ns orbital; three np orbitals and five (n-1)d 
orbitals) and the appropriate ligand based orbitals. The nine corresponding anti-
bonding orbitals remain empty. Exceeding the 18-electron count requires the 
occupation of an empty anti-bonding orbital which in metal carbonyl complexes 
lies usually at rather high energies, that is, they have high HOMO-LUMO gaps. 
Exceptions to the 18-electron rule are usually found at the earlier (Groups 3-5) 
and later groups (Groups 9-10) of the transition metal series in the periodic table, 
and in some particular cases like the [Fe(II)(porphyrin)] complexes of which 
hemes are an example. However, the exceedingly high reactivity of low-valent 
CO derivatives of group 3-5 metals on the one hand, and the high toxicity 
associated with the sulphophilic metals of groups 9-10 on the other hand, 
preclude their pharmacological use.  
The carbonyl group is one the most studied ligands in organometallic transition 
metal chemistry due to its particular bonding mode.  
The bonding of CO to a metal consists of two contributions: a σ bond is formed 
through a two-electron donation of the lone pair on carbon into a vacant and 
suitably directed d-orbital on the metal. This electron donation increases the 
electron density of the metal and to balance for this increased electron density, a 
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filled metal d-orbital backdonates electrons to an empty π* orbital on the carbonyl 
ligand. The second effect which delocalize electron density over the ligands is 
known as π-backdonation or π-backbonding.[75] The 2 components of M-CO 
bonding are illustrated in Figure 2. 
 
(a) 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
Figure 2: (a) Molecular orbital diagram of a M(d2)-CO complex showing the σ  and π 
components contribution to the bond formation. (b) Schematic representation of the 
orbitals overlap in M-CO bonding. Blue: σ overlap and donation from the lone-pair on C 
into a vacant (hybrid) metal orbital to form a σ M-C bond; Red: π overlap and donation 
from a filled d orbital on M into a vacant antibonding π* orbital on CO to form a π M-C 
bond. 
 
CO is the archetypal π-acceptor ligand, a class that also includes C≡NR, N≡O and 
C≡N- all of which possess empty π* orbitals with suitable energies to accept π-
backdonation from the metal. These 2 effects are synergistic and a stronger σ 
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donation from another ligand, immediately increases the π-backbonding to CO to 
alleviate the excess charge on the metal. An increase in backbonding leads to a 
decrease in C≡O bond order which is reflected in a slight increase of CO 
interatomic distance from 112.8 ppm in free CO to higher values in many 
complexes. The longer CO bond is also reflected in a lower stretching frequency 
in the IR spectra, changing from 2143 cm-1 in free CO to 2125-1850 cm-1 for 
terminal carbonyls in neutral metal carbonyl complexes. In fact, IR spectroscopy 
provides important information on the structural identity and geometry of 
carbonyl metal complexes, since carbonyl groups afford very distinct and intense 
bands, depending on their bonding mode. Carbon monoxide typically binds in an 
end-on fashion through carbon, although some extremely rare cases of 
coordination through oxygen have already been reported, namely for 
Aluminium[76] and Europium(III).[77] Apart from binding as a terminal ligand, CO 
may also act as a symmetrical or unsymmetrical bridging ligand between two (µ2) 
or three (µ3) metal centers. These are exemplified in Figure 3 and Table 2 reports 
their IR stretching frequencies.  
 
 
 
 
 
Figure 3: Typical CO bonding modes to metal center: a) “free” b) terminal; c) doubly 
bridging; d) triply bridging. 
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Table 2: Carbonyl group IR symmetric stretching frequencies and interatomic distances 
depending on the binding mode in neutral metal complexes. 
 
 
 
 
 
 
 
 
 
 
As can be observed from Table 2, the position of the carbonyl bands in the IR 
spectrum depends mainly on the bonding mode of the CO (terminal, bridging) but 
also on the amount of electron density on the metal being backdonated to the CO.  
As the number (and intensity) of the carbonyl bands observed depend on the 
number of CO ligands present and the symmetry of the metal complex, 
introduction of a strong σ donor or a worse π acceptor will lead to a decrease in 
CO stretching frequency. Accordingly, Lewis base substituents, whose donor 
atoms are mainly phosphines or sulphides possess energetically accessible vacant 
dπ orbitals which can also enter into π bonding with the metal. However, almost 
all the ligands that replace CO in substitution reactions are poorer π acceptors, 
when compared to CO. Therefore, successive replacement of CO from M(CO)n 
by other types of incoming ligands leads to progressive lower CO stretching 
frequencies in the resulting complexes M(CO)n-xLx since the carbonyls accept a 
grater share of the metal electronic density in comparison with the other 
substituents.  
The rupture of one or more of the M-CO bonds of a MCC by physical or chemical 
processes leads to the liberation of CO and, therefore, CO release.  The physical 
processes are heat and light. Warming a MCC will eventually provide enough 
energy to break one of the CO bonds and thermally induced CO release will take 
place. The classical example is the thermal decomposition of Ni(CO)4 into 
metallic nickel and gaseous CO that takes place at 40°C or that of Pd(CO)4 which 
Binding mode Typical IR stretching frequency / νCO 
CO interatomic 
distance / dCO 
“free” CO 
terminal M-CO 
doubly bridging (µ2-CO) 
triply bridging (µ3-CO) 
2143 cm-1 
2125 to 1850 cm-1 
1850 to 1750 cm-1 
1730 to 1620 cm-1 
112.8 ppm 
112-118 ppm 
117-122 ppm 
117-122 ppm 
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happens even below room temperature. Compounds of this kind cannot be 
considered for pharmacological uses because of the small gap that exists between 
the physiological temperature of living organisms (37°C) and room temperature. 
If they decompose at 37°C they surely have a very short shelf life at room 
temperature.  
Interaction of a MCC with UV or more rarely with visible light causes the 
labilization of M-CO bonds, and promotes photo-induced CO release. This is a 
general characteristic of MCCs. However, with the exception of topical uses on 
the skin, or local photodynamic methods this kind of activation of CO release has 
no other practical pharmacological use.   
Besides these two strictly physical processes that lead to M-CO bond breaking 
even in vacuum, ligand substitution reactions are the most common chemical 
pathway to CO release. Ligand substitution is a chemical process whereby one 
molecule reacts with a MCC and replaces CO within the coordination sphere of 
its central metal atom. CO is then liberated to the reaction medium from which it 
may escape to the atmosphere or enter into another chemical reaction. In the case 
of biological applications this free CO will be taken up by an appropriate target 
and initiate a biological cascade of events of therapeutic significance. 
From the previous we have to conclude that in order to use MCCs as CO-RMs for 
biological/pharmacological applications, we need to control their reactions with 
the biological molecules in the medium, which will eventually replace CO in the 
coordination sphere of the metal in a reaction called ligand substitution.   
The hundreds of studies published on the topic of ligand substitution in metal 
carbonyl complexes were carried out under inert atmosphere because most MCCs 
have low valent metal centers that are sensitive to oxidation by atmospheric 
oxygen.[78, 79] Moreover, with very few exceptions all these studies were carried 
out in organic solvents of low polarity (e.g. toluene, cyclohexane 1,2-
dichloroethane) due to the lipophilic nature of most MCCs and the need to 
simplify the kinetic models of reactivity.  Studies carried out in water or protic 
solvents are exceedingly rare.[80, 81] 
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Although air and water exclusion are obviously absent under biological 
conditions it is nevertheless instructive to recapitulate the fundamental aspects of 
ligand substitution in MCCs as they are described and interpreted in the literature. 
In this regard we call the attention to the importance of the monumental review 
made by Howell and Burkinshaw in 1983 where a large amount of information is 
reported that pertains mainly to the kind of complexes that are dealt within this 
Thesis.[78] 
If we consider an octahedral complex L5MCO, the substitution of CO by another 
ligand L’ can occur by one of the four paradigmatic pathways (see Scheme 1): D 
or dissociative; A or associative; Id or intermediate dissociative and Ia or 
intermediate associative.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: Ligand substitution processes showing CO substitution by an incoming L’ 
ligand. Pathway D is dissociative; Pathway A is associative; Pathway Ia is intermediate 
associative; Pathway Id is intermediate dissociative. 
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In the D pathway the rate limiting step is the complete breaking of the M-CO 
bond and the formation of a pentacoordinated transition state or intermediate. 
This one intercepts the incoming substituent L’ yielding the final product. Since 
usually k2[L’] >> k-1 the final rate law reduces to the first order  rate equation (Eq. 
1) 
rate = k1[L5M(CO)]      Equation 1 
 
This pathway is essentially similar to the well known organic SN1 paradigm and 
complies with the EAN rule which states that organometallic complexes of low 
valent metals exist only as 18- or 16-electron species and that their chemical 
transformations involve only 16- or 18-electron species.  
For this reason, the associative pathway A does not exist for strict 18-electron 
complexes because the formation of the transition state leads to an energetically 
inaccessible 20-electron compound.  On the other hand, this is a very common 
and actually the most followed kinetic pathway for 16-electron organometallic 
complexes which are not being considered for pharmacological applications (see 
above).  
Of course, these remarks apply to the situation in which the incoming nucleophile 
attacks the central metal directly. However, associative kinetics will result when 
the nucleophile attacks the coordinated CO ligand in which case there is no 
elevation of the 18-electron count at the metal (scheme 2). 
 
 
 
 
Scheme 2: Nucleophilic attack on coordinated carbonyl and concomitant decarbonylation 
without elevation of the 18-electron count.   
 
Finally, both intermediate mechanisms Id and Ia have a bimolecular rate law 
identical to that of pathway A (Eq. 2) 
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rate = Kdiffk2[L5M(CO)][L’]     Equation 2 
 
but corresponding to a transition state where the formation of the M-L’ occurs 
simultaneously with the M-L bond breaking. k2 is assumed as the rate determining 
step. Ia corresponds to more advanced formation of the M-L’ bond in the 
transition state and Id to more advanced breaking of the M-L bond in the 
transition state. In both cases the 18-electron number is not actually exceeded 
because the total number of coordinated bonds remains at 6.   
Another important case arises when the initial complex has the formula (L-
L)M(CO)4 where L-L is a chelating ligand (scheme 3). 
 
 
 
 
 
 
 
 
Scheme 3: Schematic representation of the ring-opening mechanism where complexes of 
the general formula (L-L)M(CO)4 liberate CO upon opening the chelating ring, attack 
from an incoming ligand (L’) and re-closing the ring, eliminating one carbonyl group. 
 
Scheme 3 shows a situation where the chelate ring opens to give an unsaturated 
intermediate that reacts with the incoming ligand and then loses CO (or L’) in a 
fast re-closing step. The rate law (Eq. 3) 
 
rate = k1k2[(L-L)M(CO)4][L’]/k-1 + k2[L’]   Equation 3 
 
will now be simplified according to the relative values of k-1 and k2[L’]. It will 
have a bimolecular dependence in the case where k-1>> k2[L’] and a first order 
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dependence on [(L-L)M(CO)4] when k2[L’] >> k-1. When k-1 ≈ k2[L’] the kinetics 
becomes more complex and plots of kobsd against [L’] become non-linear.[78, 79] 
These cases become quite interesting when the bidentate ligand has different 
coordinating atoms, e.g. P-N ligands.[82, 83] Systems of this type of bidentate P-N 
or P-O ligands, sometimes called hemilabile ligands, have been explored from the 
point of view of their catalytic activity.[84, 85] 
These general substitutional patterns hold for the vast majority of the low valent 
metal carbonyl complexes encompassing the octahedral species LxM(CO)y (x + y 
= 6), the trigonal bipyramidal species LxM(CO)y (x + y = 5) as well as 18-electron 
complexes with CO and carbocyclic rings as arenes, cyclopentadienyl and 
polyolefins. As already mentioned with regard to the area of application of the 18-
electron rule, such complexes are found mainly in groups 6-8 which are the most 
important ones in terms of actual and future applications in medicinal chemistry 
and in particular in CO-RM therapeutic development.  
Interestingly, a very large number of the substitution reactions of these complexes 
obeys a rate law which is composed of two terms: one corresponds to the 
dissociative or ligand independent pathway and the other to the associative or 
interchange ligand dependent pathway, as in equation 4. In most cases where the 
solvents are nonpolar k1 > k2 and the reaction approaches limiting dissociative 
behavior. However, associative mechanisms may become dominant due to 
interactions like those in scheme 2 or when there are transition state interactions 
between reagents and solvent. The latter kind of situation is much more likely in 
polar and protic solvents and may become particularly decisive in water.[81]  
 
rate = k1[L5M(CO)] + k2[L5M(CO)][Y]   Equation 4 
 
Besides, reactions involving ring-opening may result in two-term rate laws with a 
ligand dependent term as mentioned above.[78, 79]  
Early work on substitution reactions of metal carbonyls put a very strong 
emphasis on attempting to predict the favored sites of substitution in a 
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polycarbonyl complex as well as predicting relative reaction rates of CO 
substitution on the basis of parameters that describe the strength of the CO bonds 
in the intervening complexes.[79] Much of this effort was directed to establish CO 
substitution predictions based upon the values of the stretching frequencies of the 
CO ligands which are coupled to the strength of the corresponding M-CO bonds. 
As we stated above, higher values of νCO correspond to stronger C≡O bonds 
which, in turn, are found when the main component of the M-CO bond, π-
backdonation, is weak. Since CO is also a weak σ donor high values of νCO 
signal a weakly coordinated CO ligand (weak σ + weak π bonds) with a low M-
CO bond energy. Since most reactions are dissociatively activated their activation 
energy should correlate with M-CO bond energy, and when comparing two 
isoelectronic and isostructural complexes, higher νCO values should correlate 
with faster CO substitution (lower activation energy for CO dissociation).  
In spite of being very simple, elegant and easily computable, this kind of 
prediction is very limited. One just needs to remember that the low π-acidity of 
most L ligands results in M(CO)5L complexes having lower values of ν(CO) than 
their M(CO)6 parents. Yet, they all are much more reactive towards CO 
substitution. For instance, [Mn(CO)6]+ does not exchange with 14CO at 60°C over 
a period of days. However, this exchange is fast in the halides Mn(CO)5X.[86] This 
last fact also shows that some ligands (in this case the halides) are capable of 
activating CO substitution.  
In 1965, Angelici presented an empirical rule that could predict the relative rate of 
substitution of CO in complexes with the same number of substituents and 
relative stereochemistry: hard base type ligands labilize carbonyls relative to soft 
base type ligands.[86] This very simple and early rule may raise several pro and 
con explanations as summarized by Dobson.[79] Nevertheless, it simply explains 
correctly the relative order of CO substitution in the family Mn(CO)5X to give 
Mn(CO)4LX which decreases in the order of decreasing halide hardness Cl- > Br- 
> I-. Likewise, Cr(CO)4(bipy) reacts much faster with other ligands to give 
Cr(CO)3L(bipy) than Cr(CO)4(PR3)2. More strikingly, it predicts that replacement 
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of bipiridyl (pKa = 4.50) by the stronger base 4,4’-dimethyl-bipiridyl (pKa = 5.45) 
accelerates the substitution from Cr(CO)4(bipy) relative to  Cr(CO)4(4,4’-
Me2bipy).[86] As we will see, this rule is most useful to help understanding many 
of the results reported below. However, it must be noted that qualitative and 
quantitative studies on the nature of the substitution reactions showed that some 
exceptions may occur, and the rule is not always obeyed. 
The Mn(CO)5X examples just mentioned call the attention to another important 
point: the stereochemistry of CO substitution in octahedral complexes of formula 
LM(CO)5 or (L-L)M(CO)4. Experiment reveals that the CO that is labilized and 
eventually replaced is almost invariably the one in cis position with regard to L or 
to (L-L). This can be assigned either to ground state factors that labilize the CO in 
cis position relative to the L ligand, or to site preferences of that L ligand in the 
pentacoordinated transition state that is formed after the initial dissociation step.  
Accordingly, cis labilization in M(CO)5L complexes will be stronger for good pi-
donor ligands, e.g. halides. Very strong sigma donor ligands, e.g. H-, still have a 
much lower preference for cis labilization but other weaker sigma donors may not 
labilize and may even inhibit cis labilization. Obviously, pi-acceptors stronger 
than CO are prone to labilize the trans CO ligand.  
Many other examples of CO substitution reactions are reviewed and discussed in 
reference [78].  
As mentioned, such reaction patterns have been found under anaerobic 
conditions. What differences can we expect if such reactions are carried out under 
atmospheric conditions with the normal partial pressure of molecular oxygen?  
The main differences will arise as the result of the oxidative action of O2 on the 
MCCs.  Not much has been reported on this topic but seminal studies by the 
groups of Poliakoff and Downs have revealed the mechanism of the reaction 
between M(CO)6 (M = Cr, Mo, W) and O2 under UV-vis irradiation in frozen Ar 
or CH4 matrices at 10-20K (scheme 4).[87]  
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W, 414 nm. (v) Cr, Mo, W (?), 314 nm; W tentative because bands due to WO2 may be 
obscured. 
 
The ultimate products are the oxides MO2 (M = Cr, Mo, W) and MO3 (for Mo and 
W only)[88] but relevant intermediate peroxo- and oxo-carbonyl complexes were 
identified.  These mixed oxo-carbonyl species decompose readily not much above 
the matrix temperature of 20K releasing essentially CO with some CO2 present in 
some cases as a side product. Of course, one may expect that the stability of this 
kind of complexes and their rate of CO release varies with the nature of the 
ancillary ligands that surround the central M atom. These studies are also relevant 
having in mind the large number of the Mo(0) complexes that were tested for 
biological CO release as described in chapter II.  
The oxidative reactions described in scheme 4 are inner sphere redox reactions 
because the oxidant, O2, initially binds to the metal occupying the vacant 
coordination position created upon light irradiation. One might also imagine that 
in the cases where such coordination position is not made readily available, either 
*
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no reaction occurs or a different course of events may take place. In fact, in the 
absence of irradiation, M(CO)6 complexes (M = Cr, Mo, W) are indefinitely 
stable in air although they react very quickly with M(CO)5 at the extremely low 
temperature of the frozen Ar or CH4 matrices. In principle, when a vacant 
coordination position is not available for the entry of O2 in the coordination 
sphere of the metal an outer sphere redox process might take place according to 
Equation 5.  
 
[LxM(CO)y] + O2 [LxM(CO)y]
+ + O2
-
   Equation 5 
 
The 17-electron radical [LxM(CO)y]+ formed in this process, together with 
superoxide anion, will undergo CO substitution at a much faster rate than its 18-
electron precursor. This rate acceleration, which has been reported to be as high 
as 1010,[89, 90] may then result in a very fast CO release process from the initial 
MCC. In this case one could write the mechanism for CO release as depicted in 
scheme 5. 
 
 
 
 
 
 
 
 
Scheme 5: CO substitution via 17-electron intermediate complex 
 
Furthermore, the superoxide dismutation will generate H2O2 a stronger oxidant 
than O2 quite likely to be an extra accelerator of the CO release process, as will be 
discussed in Chapter III.   
One last important note refers to the fact that our studies are done in aqueous 
solution a medium that has been very seldom used for CO substitution chemistry. 
 
M CO
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In fact, in the early 1980s the first attempts to transpose organometallic chemistry 
reactions to the aqueous phase were reported.[84] By means of using phosphine 
ligands modified with water solubilizing groups, like sulfonates and quaternary 
ammonium ions, several important reactions were carried out in aqueous phase 
with remarkable success. Probably the most relevant example is the 
hydroformylation reaction which has been turned into an industrial process.[91] 
However, fundamental kinetic studies of CO substitution in aqueous solution are 
very scarce. In one seminal paper, Elias revealed the complex kinetic behavior 
taken by otherwise straightforward dissociatively activated substitution reactions 
of Mo(CO)4py2 with phenanthroline and related diimines, when they are 
performed in alcohols instead of toluene or hexane.[80] More closely to our case, 
Burgess has reported the only study we could find in the literature of a 
substitution of CO by amino acids in aqueous media.[81] In particular, the reaction 
of Mn(CO)5Br  with glycine and β-alanine shows rather different rate constants 
for both amino acids that are not dependent on their concentration but are 
dependent on their nature. Furthermore, the activation parameters do not support 
the apparent and expected dissociative mechanism. It seems that solvation and 
other different interactions between the Mn(CO)5Br molecule and the amino acids 
govern the transition state of such substitutions, and according to the authors may 
render any forecast of the activation parameters impossible.[81]  
Taken altogether, the factors that affect and control the rate of CO release under 
biological conditions are exceedingly complex and do not allow any accurate 
predictions. Therefore, our approach was just to carry out a simplified kinetic 
study of the liberation of CO from metal carbonyl complexes dissolved or 
suspended in biological media under air at 37°C and in the dark. Besides the 
temperature control and light exclusion all other factors that affect the possible 
mechanisms and rates of CO release (or CO substitution) are not controlled and 
remain largely unknown.  Nevertheless, our expectation is that integrated over a 
rather large number of compounds the outcome of this exercise provides empiric 
means of identification of chemical and structural parameters that embody 
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preferred motifs for the obtention of CO releasers appropriate for therapeutic 
applications as CO-RM drugs.  
 
5. The CO-RMs in the literature 
 
Carbon Monoxide has now been recognized as an important therapeutical agent, 
however, the concept of CO-releasing molecule is slowly emerging as a viable 
alternative. CO-RMs have only been introduced into the scientific community in 
2002, in a seminal paper by Motterlini et al.[92] 
The first generation CO-RMs were lipophilic molecules like Fe(CO)5, Mn2(CO)10 
and [Ru(CO)3Cl2]2 (CORM-2). While the iron and manganese compounds are 
activated by light, the ruthenium dimer is able to transfer CO to Mb upon 
dissolution in DMSO.  
CORM-2 was the first example of a CO-RM exhibiting beneficial biological 
effects as observed with CO gas, such as vasodilatation of pre-contracted aortic 
rings or reducing acute hypertension in vivo.[92] 
In order to facilitate their use in biological systems, water solubility was a 
requirement and an important step forward was taken with the first example of a 
water-soluble CO releaser: Ru(CO)3Cl(glycinate) (CORM-3).[93] Its biological 
activity has been recognized in several in vitro and in vivo assays (reviewed in 
references [94] and [95]) and its chemistry has also been extensively studied in 
aqueous medium.[96] 
Another water-soluble CO-RM is the boranocarbonate CORM-A1 
(Na2[BH3CO2]),[97] the only non-metal containing CO-RM described in the 
literature. Its family as recently been extended with new derivatives of the parent 
molecule.[98] It has a half-life of t1/2 = 21 min which is a CO release profile 
completely contrary to CORM-3 that carbonylates deoxy-Mb within 1 min.[93]  
Other complexes like Na[Mo(CO)3(histidinate)][99] and [Et4N][Mo(CO)5Br][100] 
have also shown pharmacological activity and served as proof-of-concept to use 
CO-RMs as therapeutical agents. 
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At the time this Thesis was initiated, only CORM-2 and CORM-3 were known by 
the scientific community. While performing the work described here, different 
CO-RMs have been produced with different metals, namely iron,[101-104] 
molybdenum,[104] chromium,[105] manganese[47, 105, 106] and cobalt.[107] However, 
most of these studies intended to evaluate mechanistic details concerning the CO 
release rate of different structures, or the toxicity profiles of these new structures 
and not their pharmacological activity.   
Although several compounds present acceptable toxicological profiles and varied 
CO release rates they still lack good pharmacological properties like air-stability 
or water solubility, for instance.  
Nevertheless, the published data helps orienting future research into new 
directions, looking for pharmacological properties like solubility and stability in 
water, viable CO release in the diseased tissues, with good therapeutical activity 
and ADME profile.   
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Chapter II: Evaluating spontaneous CO release 
from Metal Carbonyls by Gas Chromatography 
 
1. Summary 
 
CO release from several Metal Carbonyl Complexes (MCCs) in a biological 
relevant medium was evaluated by Gas Chromatography. The vast majority of 
compounds tested were octahedral or cyclopentadienyl piano-stool 18-electron 
carbonyl complexes based on Mo0, MoII, MnI, FeII and RuII with classical N, O, P, 
S-donor ligands or alkyl, acyl and halides. All the Mo0 compounds, ionic or 
neutral, showed a high rate of CO dissociation unless a strong π acceptor like 
cyanide or phosphines is present as co-ligand. On the contrary, their MnI 
counterparts do not release CO at high rates unless a halide (preferentially Cl-) is 
coordinated to the metal. Most of the FeII compounds are CpFe(CO)2L derivatives 
which do not release CO at measurable rates, most probably due to insolubility in 
aqueous solution. Also, CpMo(CO)3L compounds present a similar profile of 
insolubility and low rate of CO release. The RuII compounds tested also do not 
release CO in the conditions studied.  
The influence of pH and O2 was also evaluated for a set of Mo0 ionic compounds 
and it was observed that O2 is the main trigger to promote CO release from these 
complexes, leading to the formation of hydroxyl radical, which was detected by 
ESR with the spin trap BMPO. 
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2. Introduction 
 
Several analytical methods are available for the quantification of free carbon 
monoxide. Infrared absorption spectroscopy, colorimetric, volumetric or 
spectrophotometric methods[1, 2] and high-pressure 13C NMR spectroscopy[3] are 
some of the possibilities. However, not all of them can be readily applied to 
routine measurements in small scale. Electrochemical methods based on CO 
specific electrodes would be ideally versatile judging from the performance of 
their congeners in the biological and biochemical quantitation of NO. Motterlini’s 
group and others devoted some effort to the development of electrochemical 
detection of CO.[4, 5] We tried to apply this methodology to quantify the CO 
released from MCCs but unfortunately, such method fails in the presence of 
transition metal complexes due to the redox processes that take place alongside 
CO oxidation. This behavior was observed with the ruthenium complexes 
CORM-2 and CORM-3, where the RuII metal center was oxidized in the 
electrode, preventing the detection of any CO released.     
On the other hand, Gas Chromatography (GC) has been widely used since the 
1960s in forensic toxicology laboratories to determine CO in blood samples[6-10] 
using either Thermal Conductivity Detection (TCD) or Flame Ionization 
Detection (FID). Both methods give higher accuracy and often lower detection 
limits when compared with the spectroscopic methods. GC emerges therefore as 
an excellent screening tool since it is an easy and inexpensive way of measuring 
the amount of CO released by organometallic carbonyl compounds into the 
headspace of a closed system after their dissolution in biologically relevant 
media. Although the TCD needs larger volumes than the FID, its simplicity still 
makes it a very useful method to follow CO releasing processes in the millimolar 
range. 
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3. Experimental Section 
 
3.1 Methodology 
 
Table A1 in Annex I lists a selection of the compounds tested for CO release. 
Most compounds were prepared as reported in the literature unless indicated 
otherwise. The compounds were characterized by NMR, IR and CHN elemental 
analysis before use.  
The analysis and quantification of CO by GC was performed with a TCD. The 
detection limit of this method is 6000 ppm and the quantification limit is 22000 
ppm. In the experimental conditions of our set-up (Figure 1) this requires an 
amount of compound for each experiment which varies between 5 and 30 mg. 
However, for the rapid screening of simple, readily available or easily prepared 
metal carbonyl complexes these are affordable quantities which produce up to 2 
mL of gaseous CO upon full decomposition.  A Thermofinnigan Trace GC 
equipped with a CTR1 column from Alltech™ and a thermal conductivity 
detector was operated at 36°C using He as carrier gas. CO, CO2, N2 and O2 were 
simultaneously detected but the normal measurements only quantified CO unless 
it was found necessary to quantify any of the other gases. The amount of CO 
liberated from these compounds to the headspace was measured at 2h, 4h and 6h 
in all cases and calculated from a calibration curve recorded prior to the reaction 
course. Sometimes shorter or longer periods of time (e.g. 0.5h or 24h) were 
necessary to study the behavior of some particular compounds in finer detail. 
Experiments were carried out at 37°C, under CO2 free reconstituted air (Ar K) in 
the dark. Absence of light is important since the M-CO bond is often 
photosensitive. The experimental set-up is depicted in Figure 1. 
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Figure 1: Gas Release Machine (GRM). Gas Burette used for measuring CO release from 
the metal carbonyls in different media and conditions. The compound is placed in flask A 
with a magnetic stirrer and the system degassed with the stopcock E closed. After being 
refilled with Ar K to atmospheric pressure, the medium is injected through the septum D 
into the cavity B. The stopcock C is then open letting the medium flow to flask A with the 
magnetic stirrer spinning. As CO is released, the gas diffuses through the system raising 
the mercury level, since the stopcock E is now open. Gas samples for GC analysis are 
taken with a gastight syringe through rubber septum D. 
 
 
The amount of compound used in each experiment was always pre-calculated in 
order to ensure that the liberation of all the carbonyls in the molecule wouldn’t 
exceed the volume of CO contained within the limits of the calibration curve. 
Later on, another simplified method was developed, the “vial method”, which 
presents several advantages. The experiments were performed in 7.5 ml Roth® 
sample vials equipped with a magnetic stirrer inside and capped with PTFE 
rubber or silicone septa and an aluminum cap. The amount of compound used in 
each experiment is close to the amounts used in the GRM. This method allows 
several assays to be performed in parallel. The assays at 37ºC were performed 
inside an oven, equipped with an orbital stirrer to ensure continuous stirring of the 
samples.  
 
 
 
H2O 37°C
B
A
C
D
Vacuum
Dry air
E
Mercury
 
Chapter II 
 
 
35 
Experimental details concerning both methods are given below. 
In order to bring these tests as close as possible to biologically significant 
conditions we chose as solvent RPMI-1630 supplemented with 10% fetal bovine 
serum which will be abbreviated simply to RPMI in the following text. This is a 
tissue culture medium developed by Moore and his co-workers[11] at Roswell Park 
Memorial Institute which is rich in aminoacids, inorganic salts, vitamins and 
proteins. Therefore, upon dissolution in RPMI a given MCC will be exposed to 
the kinds of molecules that are found in biological conditions.  
HPLC traces of several compounds in aqueous medium were obtained using a 
Thermo HPLC system with an automatic injection system and a PDA detector. A 
C18 reverse-phase column was used with a MeOH/water gradient. Experimental 
details about the method are given in the HPLC section. 
 
Gas Chromatography: 
Method description: 
The CO release assays in the GRM system were performed in a biocompatible 
medium, RPMI (pH=7.4) at 37ºC under Ar K (reconstituted air; CO2 free) without 
light from which 500 µL samples were taken with a Gastight Hamilton® syringe. 
These were injected in a Thermofinnigam Trace GC equipped with a CTR1 
column from Alltech™ (double column; inner column 6 ft x 1/8” packed with 
porous polymer mixture and outer column 6 ft x 1/4” packed with molecular 
sieve) and a Thermal Conductivity Detector. The column was inside the oven at 
36ºC and the GC was operated at a constant pressure mode (111 KPa) with He as 
a carrier and reference gas with a 30 mL/min flow. The detector was set at 
constant temperature (150ºC) and the filament temperature to 250ºC. The 
injections were made through a packed column injector (PKD) set at 47ºC and 
111 KPa.  
CO was quantified using a calibration curve recorded prior to the reaction course. 
This was done by injecting 25 µL increments of CO up to a final total amount of 2 
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mL of pure CO gas (Carbon Monoxide 4.7, purity ≥ 99.997%; from Linde Sogas) 
to the system and taking samples that were injected in the GC.  
The concentrations used in each assay ranged from 1.5 mM to 45 mM depending 
on the molecular weight and number of carbonyl groups in the molecule.  
The assays performed in calibrated vials were performed in the same way but the 
reactor vessel was a 7.5 ml Roth® sample vial equipped with a magnetic stirrer 
inside and capped with a PTFE rubber or silicone septa and an aluminum cap. 
PTFE rubber septa were acquired from Sigma Aldrich® and silicone septa from 
Roth®. The assays were performed at room temperature and normal atmospheric 
air was used instead of Ar K. 250 µL samples were taken to analysis and CO was 
quantified using a calibration curve recorded using the same methodology, but 
where the volume of CO injected ranged from 0 to 1.5 mL. 
 
High-Pressure Liquid Chromatography: 
Method description: 
HPLC traces of several compounds in aqueous medium were obtained using a 
Thermo HPLC system (Thermo Fisher Scientific, Inc.) with an automatic 
injection system and a PDA detector. A C18 reversed phase column (Alltech® 
Prevail™ Reversed-Phase Columns from Grace Davison Discovery Sciences; 
150×4.6 mm; 3 µm particle size) was used with a MeOH/water gradient (see 
Table 1). HPLC-gradient grade MeOH from Panreac and Milli-Q water were 
used as eluents in the HPLC system with 1 mL/min flow rate. 
 
Table 1 – Gradient used in the HPLC analysis for 15min runs. 
t / min % H2O % MeOH 
0 90 10 
2 90 10 
8 0 100 
9 0 100 
10 90 10 
12 90 10 
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Electron Spin Resonance 
The spin trap NWT-BMPO, >99% was purchased from Northwest Life Sciences 
Specialties, LLC. 
Method description: 
A stock solution of CO-RM was prepared by dissolving a few milligrams of 
compound in 1 mL of deoxygenated distilled water or MeOH under N2. Another 
stock solution of BMPO was prepared with a final concentration of 250 mM. An 
aliquot was taken from the CO-RM solution and 100 µL from the BMPO solution 
to a closed vial under N2 and deoxygenated distilled water added to perform 1 ml 
total volume. 
 
Table 2: Solvents and concentrations 
Compound Stock Solution Final Concentration [BMPO] 
[Et4N][Mo(CO)5Br] MeOH (0.7%) 199.0 µM 25 mM 
Na[Mo(CO)3(hist)] H2O 203.0 µM 12.5 mM 
Na3[Mo(CO)3(cit)] H2O 199.3 µM 25 mM 
[Mo(CO)3(bpa)] MeOH (0.6%) 199.8 µM 25 mM 
 
A sample was taken from this solution and a control spectrum was acquired 
before bubbling O2. Oxygen was then bubbled in the solution for 3-4 min and 
another sample was taken and analyzed. 
The experiment was performed on a quartz, planar, ESR cell, at room 
temperature, microwave power of 2 mW, modulation frequency 100 kHz, 
modulation amplitude 0.1 mT.  
 
3.2 Technical Details: 
 
General Considerations: 
Elemental Analysis were performed at ITQB, Oeiras, by Engª Conceição 
Almeida. Infrared spectra were recorded on a Unicam Mattson 7000 FTIR 
spectrophotometer using KBr pellets. 1H NMR and 13C NMR spectra were 
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recorded on a Bruker AMX300 or Bruker Avance III 400mHz. Chemical shifts 
are quoted in parts per million from SiMe4 (TMS). 
UV-VIS spectra were acquired in a Shimadzu UV-3100 or a Perkin Elmer 
Lambda35 spectrophotometer. 
 
Synthetic Work: 
All the reactions were carried out under a nitrogen atmosphere, using common 
schlenk techniques. Solvents were dried by standard procedures, distilled under 
N2 and kept over 4Å molecular sieves. Mo(CO)6, Cr(CO)6, Mn2(CO)10, Fe2(CO)9 
and CpMn(CO)3 were bought from Sigma Aldrich and used without further 
purification. [Ru(CO)3Cl2]2 was bought from Strem Chemicals.  
The compounds Mn(CO)5Br@TRIMEB, CpFe(CO)2Cl@TRIMEB, 
CpFe(CO)2Cl@β-CD, [(C2H5)4N][Mo(CO)5Br]@TRIMEB, 
CpMo(CO)3Cl@TRIMEB and (η5–C5H4COOCH3)Mo(CO)3Cl@TRIMEB were 
encapsulated and characterized by the group of Prof. Isabel S. Gonçalves, in 
Universidade de Aveiro, Portugal. 
Mo(CO)3(η6-C7H8)[12], Mo(CO)4(pip)2[13] and DAPTA[14] were prepared according 
to literature procedure as well as most of the complexes, as indicated in Table A1 
(Annex I).  
Some of the new compounds presented were prepared by other members of 
Alfama’s chemistry department and are part of Alfama’s portfolio of compounds. 
Their synthesis is referred as Alfama’s Intelectual Property (AIP). 
The synthesis and characterization of the remaining new complexes are presented 
next:  
 
Mo(CO)4(3-COOH-py)2: 
Mo(CO)6 (1.37 g; 5.189 mmol; 264 g/mol) and nicotinic acid (1.278 g; 10.381 
mmol; 123.11 g/mol) were heated to reflux in 60 ml of a 1:1 mixture of 
toluene/EtOH. After 21h the reaction was stopped and the red solution cooled to 
room temperature giving a red precipitate. This was filtered, washed with hexane 
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and recrystalized from dichloromethane/hexane. It was further dried in vacuum at 
50ºC for 1 week to remove coordinated toluene and EtOH. Yield: 14%.  
IR (KBr/cm-1): 2014(w), 1940(sh), 1898(s), 1873(sh) (C≡O); 1615(br) (C=O);  
E.A. Calc. for MoN2O8C16H10: %C:42.31, %H:2.21, %N:6.17; Found: %C:42.61, 
%H:2.53, %N:6.12;  
1H NMR (MeOD, 400MHz, rt, δ in ppm): δ = 9.02 (s,1H), 8.61 (d,1H), 8.30 
(d,1H), 3.44 (t,1H)  
 
Mo(CO)4(DAPTA)2: 
Mo(CO)4(pip)2 (0.400 g; 1.06 mmol; 376.26 g/mol) and DAPTA (2 equiv.; 0.487 
g; 2.126 mmol; 229.2188 g/mol) were suspended in 40 ml of CH2Cl2 and heated 
to reflux for 15min. While warming, the suspension became a clear solution. The 
yellow solution was cooled to room temperature and concentrated to 
approximatelly 1/3 of the initial volume. Hexane was added and a turbid 
suspension started to form. It was stirred and an orange oil was obtained mixed 
with some solid yellow product. The oily fraction was thoroughly washed with 
Et2O. After washing, a yellow powder was obtained and dried in high-vacuum for 
3 days. Yield: 87%. 
IR (KBr/cm-1): 2027(s), 1909(s) (C≡O); 1632(s) (C=O); 
E.A. Calc. for MoC22H32P2N6O8: %C:39.65, %H:4.84, %N:12.61; Found: 
%C:39.15, %H:4.84, %N:12.83; 
1H NMR (CDCl3, 400MHz, rt, δ in ppm): δ = 5.87 (d,1H); 5.47 (d,1H), 5.01 
(d,1H), 4.63 (d,1H), 4.46 (d,1H), 4.04 (d,1H), 3.94 (d,1H), 3.68 (s,2H), 3.47 
(d,1H), 2.13 (s,3H), 2.16 (s,3H); 
31P NMR (CDCl3, 162MHz, rt, δ in ppm): δ = -26.0. 
 
Mo(CO)3(bpa): 
The bpa (N-(p-carboxy-benzyl)bis(2-picolyl)amine) ligand was prepared as 
follows: 
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To a clear THF solution of methyl-4-(bromomethyl)benzoate (1.13 g, 4.85 mmol; 
229.08 g/mol) was added at once the yellow di-2(-picolyl)amine (0.903 ml; 4.85 
mmol; 1.107 g/ml; 199.25 g/mol) at room temperature. The solution turns light 
yellow. Triethylamine (675 μL; 4.85 mmol; 0.727 g/ml; 101.19 g/mol) is added 
and the solution turns immediately deep yellow. The mixture was allowed to 
reach room temperature and subsequently filtered to remove a white precipitate. 
After removal of the solvent under reduced pressure, the orange oily residue was 
dissolved in diethyl ether (40 ml) and filtered to remove some more precipitate. 
Evaporation of the solvent gives a dark orange oil which was used in the next 
step.  
1H NMR (CDCl3, 400 MHz, rt, δ in ppm): δ = 8.49 (d,2H), 7.98 (d,2H), 7.64 
(dt,2H), 7.53 (d,2H), 7.48 (d,2H), 7.12 (tt,2H), 3.89 (s,3H), 3.81 (s,4H), 3.75 
(s,2H). Note: There is a 5% of the di-2(-picolyl)amine used in slight excess; 
 
The orange oil was dissolved in methanol (20 ml) and a solution of aqueous 
NaOH (0.8 g in 5 ml H2O; 20 mmol; 40 g/mol) was added. The solution gets 
immediately darker and is stirred for two hours at room temperature. The pH was 
adjusted to 7 by dropwise addition of 2M HCl (50 ml HCl 37% in 250 ml water 
solution) followed by removal of the solvent under reduced pressure. The sticky 
yellow residue was ground with CHCl3 (200 ml) followed by filtration to remove 
NaCl. Removal of the solvent under reduced pressure afforded an orange sticky 
oil to which acetonitrile (30 ml) was added, followed by vigorous stirring to 
dissolve all compound. Precipitation is seen after 15 minutes. The solution was 
placed in the refrigerator to effect further precipitation. The white precipitate was 
filtered and dried under vacuum. Yield: < 20%. 
 E.A. Calc. for N3O2C20H19: %C:72.05, %H:5.74, %N:12.60; Found: %C:72.57, 
%H:5.98, %N:13.04; 
1H NMR (CDCl3, 400 MHz, rt, δ in ppm): δ = 8.61 (d,2H), 8.01 (d,2H), 7.70 (dt, 
2H), 7.60 (d,2H), 7.44 (d,2H), 7.12 (t,2H), 3.88 (s,4H), 3.77 (s,2H). 
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Synthesis of the complex: 
Mo(CO)3(η6-C7H8) (0.800 g; 2.94 mmol; 272.1117 g/mol) was dissolved in 40 ml 
of MeOH and added to (C5H4CH2)2NCH2C6H4COOH (0.980g; 2.94 mmol; 333.39 
g/mol) in 25 ml of MeOH. 
The red clear solution became turbid with an abundant insoluble precipitate after 
5 minutes. The reaction was carried on for 2h at room temperature. The 
precipitate was allowed to rest and was filtered. It was washed with 25 ml of Et2O 
and dried in vacuum giving a bright orange powder. Yield: 86%. 
IR (KBr/cm-1; C≡O): 1899(vs), 1759(s); 
E.A. Calc. for C23H19N3MoO5: %C=53.81, %H=3.73, %N=8.19; Found: 
%C=54.01, %H=3.79, %N=7.79; 
1H NMR ((CD3)2CO, 400MHz, rt, δ in ppm): δ = 8.85 (d,2H); 8.14 (d,2H), 7.88 
(d,2H), 7.61 (d,2H), 7.21 (d,2H), 7.11 (d,2H), 4.80 (s,2H), 4.73 (d,2H), 3.92 
(d,2H). 
 
Mo(CO)3(DAPTA)3:  
Mo(CO)3(η6-C7H8) (0.200 g; 7.350x10-4 moles; 272.1117 g/mol) was dissolved in 
30 ml of MeOH to give a red solution. DAPTA (3 eq.; 0.502 g; 2.190 mmol; 
229.29 g/mol) was added as a solid to the previous solution. The red solution 
immediately turned orange and gradually became lighter. After stirring at room 
temperature for 2 hours a small amount of a brownish powder precipitated. The 
mixture was filtered giving a very pale yellow solution. The filtrate was 
concentrated and Et2O was added. A turbid suspension was formed and cooled to 
-30ºC during 6h and then filtered. An off-white powder was obtained and dried in 
vacuum. Yield: 43%. 
IR (KBr/cm-1):1950(s), 1859(s) (C≡O); 1645(s) (C=O); 
E.A. Calc. for MoC30H48P3N9O9: %C:41.53, %H:5.58, %N:14.53; Found: 
%C:41.40, %H:5.60, %N:14.60; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 5.69 (d,1H), 5.25-5.15 (m,2H), 4.48 
(d,1H), 4.28-4.18 (m,2H), 3.86 (m,2H), 3.57 (s,2H),  2.18 and 2.16 (ds,6H); 
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31P NMR (D2O, 162MHz, rt, δ in ppm): δ = -25.8. 
 
The group of compounds Na3[Mo(CO)3(citrate)], [choline]3[Mo(CO)3(citrate)], 
[Et4N]3[Mo(CO)3(nitrilotriacetate)], Na3[Mo(CO)3(nitrilotriacetate)], 
Na5[Mo(CO)3(diethylenetriaminepentaacetate)] were prepared based on the 
published procedure for [Et4N]3[Mo(CO)3(citrate)].[15] 
 
The general procedure is presented for Na3[Mo(CO)3(citrate)]: 
Sodium citrate dihydrate (0.844 g; 2.801 mmol; 294.1 g/mol) and (η6-
C7H8)Mo(CO)3 (0.780 g; 2.866 mmol; 272.12 g/mol) were suspended in 100 ml 
of dry MeOH and stirred for 24 hours at room temperature. The light orange 
solution was filtered and concentrated under vacuum. This was transferred to 
another schlenk, partially filled with a large amount of Et2O. A flocculate 
precipitate was obtained and filtered. It was washed with Et2O and dried in 
vacuum to afford a light brown powder. Yield: 74%.  
IR (KBr/cm-1): 1984(w), 1901(s) (C≡O); 1754(br), 1599(br); 1410(m) (C=O); 
E.A. Calc. for MoC9H5O10Na3.2(CH3OH): %C:26.31, %H:2.61; Found: 
%C:26.49, %H:2.21; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 2.67 (s,1H); 2.63 (s,1H), 2.57 (s,1H), 
2.53 (s,1H).  
 
[choline]3[Mo(CO)3(citrate)] 
IR (KBr/cm-1) 1985(w), 1901(s) (C≡O); 1867(br), 1735(br) (C=O); 
E.A. Calc. for MoC24H47NO13N3: %C:42.29, %H:6.95; %N:6.17; Found: 
%C:41.52, %H:7.09, %N:6.13 
1H NMR (MeOD, 400MHz, rt, δ in ppm): δ = 4.02 (s,6H), 3.52 (s,6H), 3.2 and 
3.31 (ds,27H), 2.8-2.2 (m,4H). 
 
[Et4N]3[Mo(CO)3(nitrilotriacetate)] 
IR (KBr/cm-1) 1985(w), 1901(s) (C≡O); 1867(br), 1735(br) (C=O); 
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E.A. Calc. for MoC33H66O9N4: %C:52.23, %H:8.77, %N:7.38; Found: %C:51.63; 
%H:8.92, %N:7.08; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 3.73 (broad band), 3.29 (m,8H), 1.28 
(t,12H). 
 
Na3[Mo(CO)3(nitrilotriacetate)] 
Yield: 90%; 
IR (KBr/cm-1) 1983(w), 1897(s) (C≡O); 1753(br), 1600(br), 1401(m) (C=O); 
E.A. Calc. for MoC9H6O9NNa3.(CH3OH): %C:25.60, %H:2.15, %N:2.99; Found: 
%C:25.88, %H:2.44, %N:2.94; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 3.73 (broad band). 
 
Na5[Mo(CO)3(diethylenetriaminepentaacetate)] 
Yield: 80%; 
IR (KBr/cm-1):1897(s) (C≡O); 1753(br), 1600(br), 1401(m) (C=O); 
E.A. Calc. for MoC17H18O13N3Na5.(CH3OH): %C=30.23, %H=3.10, %N=5.87;  
Found: %C=29.83, %H=3.66, %N=5.66; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 2.8-3.9 (broad band)  
 
 
4. Results and Discussion 
 
All metal carbonyl complexes that were referenced as possibly useful CO 
releasing molecules (CO-RMs) were screened for CO release in RPMI. The 
number of compounds surpasses 300 and encompasses several transition metal 
complexes with an 18-electron shell, with different charges and a variety of 
ancillary ligands. With only a handful of exceptions, all compounds tested belong 
to metals of the groups 6-8. The reason for this is related to general metal toxicity 
and biocompatibility which discourage the use of metals at both ends of the 
periodic table (Groups 3-5 and 9-10). Late transition metals are normally 
considered toxic due to their strong tendency to react with sulfidryl groups and 
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hence accumulate in living tissues and cells. On the other hand, early transition 
metal carbonyls are usually highly reactive and oxygen sensitive species because 
their low d-electron count requires very low oxidation states to stabilize their M-
CO bonds.  
Figure 2 depicts the main structural types investigated which are divided in two 
broad groups: octahedral carbonyl complexes and cyclopentadienyl containing 
carbonyl complexes.  
 
 
 
 
 
 
 
 
 
 
The octahedral complexes contain mainly classical N, O, P, S or halide donors. 
Only a few complexes have σ-C ligands (alkyl or acyl). A small group of 7-
coordinated complexes was also studied (see Table A1 in Annex I).  
Figure 3 represents the statistics of the results obtained for the amount of CO 
released after 6h, at 37ºC in RPMI and in the dark.   
Since these tests were done under aerobic conditions using an aqueous medium 
very rich in biological molecules, and given the fact that biological molecules in 
aqueous solution are not expected to be very strong nucleophiles, one may only 
expect fast and extensive CO release to be found in compounds that behave close 
to one or both of the following limiting conditions:   
 
 i) high instability to oxidation by O2 
 ii) high kinetic instability towards ligand substitution 
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Figure 2: The main structural types of MCCs tested for CO release. L or L’ mean C, N, O, 
P, S or halide ligands; R means an alkyl or functionalized alkyl bearing amine, alcohol, thiol, 
ether, thioether, or carboxylic functions (acid, ester, amide). 
 
Chapter II 
 
 
45 
The presence or absence of one or both of these conditions will certainly dictate 
which MCCs will lie at both the high and low ends of the CO release spectrum, 
respectively. Between such extremes, a variety of intermediate situations will be 
found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When looking at the results in Figure 3, one surprising observation stands out: the 
largest slice of MCCs tested are rather stable toward loss of CO (62% of the 
compounds release less than 10% of the total CO). These stable compounds cover 
all types of structural families and their stability may be attributed to the presence 
of one or both of the two previously mentioned conditions: oxidative and 
substitutional stability. However, this analysis is not entirely sound since we have 
identified another very important variable that interferes with and often masks the 
interpretation of the CO release results: solubility of the MCCs in aqueous media. 
In fact, a closer look at the tests carried out with these compounds leads to the 
conclusion that a stringent link is often observed between solubility and CO 
release, and the vast majority of water-insoluble compounds do not spontaneously 
release CO or do so to a rather small extent. As a general example, zerovalent 
homoleptic metal carbonyls like Mo(CO)6, Cr(CO)6, Mn2(CO)10 or Fe2(CO)9, are 
 
Figure 3: Distribution of MCCs according to the amount of CO released to the headspace 
of a closed system under standardized conditions: RPMI/10%FBS, under air at 37ºC in the 
dark after 6h. Measurements performed with compounds from ALFAMA’s portfolio by 
GC with Thermal Conductivity Detection.  
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completely insoluble in water and do not release CO under the standardized 
conditions.  
This behavior is independent of the metal and is observed in Molybdenum 
complexes e.g. Mo(CO)4(bipy), Mo(CO)3(TTCN), CpMo(CO)3CH3 and 
Cp*Mo(CO)3Cl; Iron compounds like CpFe(CO)2I and 
CpFe(CO)2(OCOC6H4OCOCH3); Cobalt compounds like [Co(CO)3]2(PhC≡CPh) 
and Ruthenium compounds like CpRu(CO)2Cl and [Ru(CO)3Cl2]2.  However, this 
connection between insolubility and low CO release isn’t a blind rule since it was 
observed that some insoluble compounds were able to spontaneously release CO 
under our standardized conditions. Once more, this behavior wasn’t limited to a 
specific structural family since a wide variety of compounds shared the same 
profile e.g. Mn(I) compounds such as Mn(CO)5Br, Mn(CO)5CH3, 
Mn(CO)5OSO2CF3; Fe(II) compounds such as CpFe(CO)2Cl, Fe(CO)4I2, 
CpFe(CO)2(η1-C3H5), Fe(CO)3Br(η1-C3H5),  CpFe(CO)2OCOC5H4NFe(CO)2Cp, 
Fe(CO)2(Cyst)2; Mo(0) compounds such as [Bu4N][Mo(CO)5I], 
[Me4N]2[(Mo(CO)4(SPh)2], Mo(CO)4(4,4’-COOH-bipy), Mo(CO)4(3-COOH-
py)2, Mo(CO)3(η6-C7H8), Mo(CO)3(bpa); Mo(II) compounds like CpMo(CO)3Cl, 
Mo(CO)2(S2CNMe2)2, Mo(CO)3I2(CH3CN)2, Mo(CO)3I2(p-tolil-DAB), 
Mo(CO)3I2(Cy-DAB), [Mo(CO)4(SPh)]2, CpMo(CO)3OC8H6OBF2, 
[(CO)3Mo(C5Ph4O)]2, CpMo(CO)3CH2COOH. 
From these examples it is clear that the prediction of the CO release profile of a 
given MCC is not a straightforward task, and the thorough screening that was 
carried out was necessary to identify possible CO-RM candidates. Once analyzed, 
the large amounts of data already obtained should allow the identification of the 
nature and importance of the main factors that condition the CO release profile of 
a given MCC. 
To the best of our knowledge, the following discussion stands out as the widest 
existing screening of the stability of MCCs under biologically relevant 
media/conditions. The results are ordered mainly by structural groups and within 
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these by comparison of other factors such as oxidation state of the metal, complex 
charge and nature of the ancillary ligands.  
 
4.1 CO release profiles of octahedral [M(CO)xL6-x]± complexes  
 
Table 3 presents some selected examples of compounds of this very large and 
chemically flexible structural group, which allow insightful comparison and 
inferences with regard to the CO release profiles of this category of compounds. 
The compounds presented are based on Mo0, MoII, MnI, FeII and RuII.  
 
Table 3: Solubility in the medium and equivalents of CO released by several Mo, Mn, Fe 
and Ru MCCs in RPMI (10% FBS), at 37ºC after 6h in the dark. 
Family of compounds 
[M(CO)xL6-x]± 
Ln group/counter-ion 
Solubility in 
RPMI 
Equivalents of 
CO released in 
RPMI after 6h 
Mn(CO)5L Cl insoluble 1.9 
 Br insoluble 1.6 
 OSO2CF3 sp soluble 0.6 
 CH3 sp soluble 0.4 
 CH2C(O)NH2 soluble 0.3 
    
Mn(CO)4L2]0/+/- S2CPh insoluble 0.0 
    
[Mn(CO)3L3]n+ TACN/Br soluble 0.0 
    
[Mo(CO)5L]- CN/Na+ soluble 0.0 
 Br/NEt4+ sp soluble 2.4 
 I/NBu4+ insoluble 0.4 
 I/Na(15-crown-5-ether)+ sp soluble * 0.5 
 I/Na(diglyme)2+ sp soluble* 1.1 
 I/K(diglyme)3+ sp soluble* 1.3 
 I/NH4(diglyme)3+ soluble* 0.8 
 I/½ Ca(diglyme)22+ unstable Not tested 
 I/½ Mg(diglyme)22+ unstable Not tested 
[Mo(CO)5L] morph insoluble 0.5 
 P(C6H4SO3Na)3 soluble 0.0 
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 PTA insoluble 0.0 
 PTA.HCl soluble 0.0 
    
[Mo(CO)4L2] bipy insoluble 0 
 4,4’-(NaO3SCH2CH2OOC)-bipy sp soluble 2.7 
 4,4’-(HOOC)-bipy sp soluble 2.5 
 Me-DAB insoluble 0.0 
 Me-pip-DAB sp soluble 0.9 
 3-(HOOC)-py insoluble 0.4 
 Me-pip insoluble 0.5 
 morph sp soluble 2.3 
 OPPh3 insoluble 0.3 
 PTA insoluble 0.0 
 PTA.2HCl soluble 0.0 
[Mo(CO)4L2]-/ Et4N+ acac soluble 1.7 
 glycinate soluble 1.5 
    
[Mo(CO)3L3] PTA soluble 0.0 
 TTCN insoluble 0.0 
 TACN insoluble 1.5 
 bpa insoluble 2.5 
[Mo(CO)3L3]n-/ nM+ hist/Na+ soluble 2.2 
 hist/K+ soluble 2.5 
 nita/3Na+ soluble 2.1 
 nita/3NEt4+ soluble 2.0 
 citrate/3Na+ soluble 1.2 
 citrate/3NEt4+ soluble 1.1 
 citrate/3choline+ soluble 1.7 
 detpa/5Na+ soluble 2.3 
    
MoI2(CO)3L2 CH3CN insoluble 1.1 
 Cy-DAB insoluble 0.9 
 p-tolil-DAB insoluble 1.0 
    
Fe(CO)4L2 I insoluble 1.4 
    
[Ru(CO)3L2]2 Cl insoluble 0.0 
[Ru(CO)3Cl2L] DMSO sp soluble 0.0 
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 methionine oxide soluble 0.0 
 methionine soluble 0.0 
 DAPTA soluble 0.0 
[Ru(CO)3ClL2] glycinate soluble 0.0 
* highly unstable; CO release rate not properly determined 
 
The family of the MnI complexes, Mn(CO)5L, is a good starting point for this 
discussion because its substitution chemistry has been extensively studied in 
organic solvents and under anaerobic conditions. In spite of its low solubility 
Mn(CO)5Cl releases 2 equivalents of CO after 6 hr. This is in line with the typical 
substitution chemistry of the MI(CO)5 fragment of the group 7 metals that is well 
known to readily lose two cis CO ligands leading to a fac-MnI(CO)3 fragment 
which is rather inert in terms of CO substitution as expected for a d6 octahedral 
coordination. The substitutional inertness of the fac-MnI(CO)3 fragment is very 
well exemplified by the complex [Mn(CO)3(TACN)]+ which is readily made from 
Mn(CO)5Br and neutral TACN. It is fully soluble in RPMI and yet does not 
release CO under our standardized conditions as already mentioned above.  
All the other Mn(CO)5L complexes listed release less CO than Mn(CO)5Cl in the 
same time period. The order of decreasing CO release Cl- > Br - > CF3SO3 - > 
CH3-> -CH2C(O)NH2 can be expected considering that the π-donor capability of 
the L ligands decreases in the order Cl- > Br- > CF3SO3- > CH3-. Under anaerobic 
and non-protic conditions the predicted order of CO release should be exactly the 
same judging from published data.[16-18] This type of data was the basis for 
Angelici’s rule of thumb:[19] harder bases are stronger labilizers. As it was already 
briefly mentioned in the introduction, strong σ-donors are also CO labilizers. The 
expected stronger σ-donor character of CH3 compared to that of CH2C(O)NH2 is 
in agreement with the somewhat stronger  labilization of the former. In any case, 
both alkyl substituents fall well below the labilizing power of the halides and 
triflate. The position of triflate in this series is an exception to Angelici’s rule of 
thumb since in Pearson’s sense[20] it is an harder base than halides. 
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Since these MnI complexes are all rather air stable, it seems that their CO release 
profile is being controlled by their kinetic CO lability. In organic, non-polar 
solvents these processes are dissociatively activated. However, our measurements 
do not allow confirming the substitution mechanism in these aqueous biological 
solutions because even the substituent or substituents that replace the broken M-
CO bond are not identified and may vary from water solvent to proteins present in 
the FBS.  Deviations from a strictly dissociative process as those reported by 
Burgess are most likely to take place.[21]  
The second group of compounds is composed by Mo0 complexes with different 
numbers of CO ligands. Among these we can find the examples of the few 
compounds that release high amounts of CO after 6h, that is > 70% of total CO 
available, namely [Et4N][Mo(CO)5Br], Mo(CO)4{4,4’-
(NaO3SCH2CH2OOC)2bipy}, Na[Mo(CO)3(hist)], [Mo(CO)3(η6-C7H8)], 
Na3[Mo(CO)3(nita)] and (Mo(CO)3(bpa)].  
One of the fastest CO releasers in this group is the complex  [Et4N][Mo(CO)5Br] 
which is also one of the strongest CO releasers of all compounds tested and much 
stronger that its isoelectronic MnI counterpart. The compound is only sparingly 
soluble in water and all attempts to change its counter-ion to an alkaline metal 
cation failed due to instability of the final product.  This was possible with the 
related iodide which is a much weaker CO releaser. The two other [Mo0(CO)5L] 
compounds tested are the cyanide, Na[Mo(CO)5(CN)] and the phosphine 
derivatives all of which are completely stable and do not release CO under the 
standardized conditions.  Many attempts to prepare mono-substituted complexes 
with amines and substituted pyridines invariably led to mixtures of the mono-, di- 
and tri-substituted complexes, all of which were too unstable to isolate in aqueous 
solutions where they decomposed upon dissolution liberating CO in an 
uncontrolled manner. Unlike the rather air stable cyano and phosphino 
complexes, [Et4N][Mo(CO)5Br] is air sensitive.  
The comparison between the complexes [Mo(CO)5X]- among each other and with 
their Mn(CO)5X counterparts immediately raises the attention to some important 
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points. Among the three Mo pentacarbonyl anions [Mo(CO)5X]-, CO release 
decreases in the order  Br- >> I- >> NC-, the later being as stable as the neutral 
analogues with  P(C6H4SO3Na)3 and PTA substituents. This parallels exactly the 
finding for the relative rates of the Mn(CO)5X congeners and is in agreement with 
the order of decrease of the π-donor labilization of these three ligands. In fact, the 
cyanide ligand, being a π-acceptor is expected and found to prevent CO release. 
However, the extent of CO release, which is limited to 2 equivalents of CO in the 
case of Mn(CO)5Cl, is easily exceeded in the case of [Mo(CO)5Br]-. The CO 
labilization from Group 6 [M(CO)5X]- species was investigated using density 
functional calculations by MacGregor and MacQueen[22] and was found that the 
CO labilization was affected by the balance between the energy of the ground 
state 18-electron [M(CO)5X]- species and the relaxation effects of the 16-electron 
[M(CO)4X]- derived species. The results showed that the trends in CO 
dissociation follow the series NH2- > OH- > F- > Cl- > Br- > I- > CH3- > H-. These 
are related not only with the ability of X to afford π stabilization of the 16-
electron species formed but also with the π destabilization of the 18-electron 
ground state, which is equally important. The later arises as a direct consequence 
of the degree of donation from X, which enhances trans M-CO π backdonation 
but reduces cis M-CO π backdonation. Furthermore, strong π donation from X 
also induces cis M-CO σ antibonding interactions weakening the M-CO bond. 
The further extent of the decarbonylation reaction of [Mo(CO)5Br]- can only be 
explained by the air instability of the Mo0(CO)3 fragment. Oxidation of the Mo 
atom by O2 will lead to the formation of Mo-oxides (ultimately molybdate or 
polyoxomolybdates) with total liberation of CO being achieved. This exhaustive 
CO release (5 equivalents released from [Mo(CO)5Br]-) has been observed both in 
vitro and ex-vivo in conditions that are more aggressive that those of the 
standardized conditions of Fig.1. In fact, with tert-butylhydroperoxide within 3h, 
4 equivalents of CO are liberated and 1 CO is oxidized and liberated as CO2 (see 
compound 17 in table 6 in Chapter III). Also, in sheep blood at 37ºC the 5 
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equivalents of CO are released to hemoglobin in 1h15min (see compound 2 in 
table 5 in Chapter IV). 
In contrast, the MnI(CO)3 fragment is stable to O2 oxidation and resists CO 
release because the bond strength of the Mn-CO bonds achieves its highest 
stabilization in the fac-Mn(CO)3 conformation. In fact, after replacing two CO 
ligands from Mn(CO)5X, the three remaining M-CO bonds in the newly formed 
Mn(CO)3L2X are reinforced  whenever their trans-standing ligands are poorer π-
acceptors than the two carbonyls that were replaced. When the substitutions are 
carried out in biological media, the incoming ligands are essentially O, N or S 
bound in which case their π-accepting capacity is either inexistent (for N, and O) 
or marginal for S. The excellent air and water stability of the fac-M(CO)3 
fragments in the group 7 metals (M = Mn, Tc, Re) is reflected in the extensive 
work of Alberto, Schibli, Schubiger and collaborators who have produced a very 
large variety of [MI(CO)3L3]0/+ (M = Tc, Re) complexes[23-25] that are completely 
stable with regard to CO release in vitro and in vivo and can be even excreted 
intact from animals where they were injected as imaging agents.[26]  
This difference in the behavior of the CO release profile of fac-Mo0(CO)3 and fac-
MnI(CO)3 carbonyl complexes opens the possibility of using Mo(CO)3L3 
complexes as CO releasers. As already mentioned, most of the examples of these 
complexes collected in Table 3 are quite fast releasers with rather impressive 
amounts of CO liberated after 6h under the standardized conditions of Fig. 1. 
However, CO release experiments carried out in the apparatus of Fig. 1, also in 
the dark but under N2 showed that the highly water soluble anionic complexes 
Na[Mo(CO)3(hist)], Na3[Mo(CO)3(cit)] and Na3[Mo(CO)3(nita)], are completely 
stable towards CO loss (see table  4). 
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Table 4: Equivalents of  CO released in H2O under N2 in the dark at room temperature. 
Time Na[Mo(CO)3(hist)] Na3[Mo(CO)3(cit)] Na3[Mo(CO)3(nita)] 
6h 0.00 0.00 0.00 
 
 
The same assays as in Table 4 were repeated under N2 and ordinary laboratory 
light. All the compounds released less than 0.1 equiv. CO after 6h, except 
Na3[Mo(CO)3(nita)]. However, even in this case the amount of CO released was 
still marginal: 0.18, 0.29 and 0.29 equiv. CO after 2h, 4h and 6h, respectively. 
When a water solution of Na[Mo(CO)3(hist)] is treated with excess sodium 
histidinate, CO release is noticeably retarded. Taken altogether these results show 
that the trigger to the extensive CO release observed in the above mentioned Mo0 
complexes is their reaction with O2.  The simple reaction sequence shown in 
scheme 1 explains these observations. When excess ligand (e.g. histidinate) is 
present the first equilibrium is pushed to the left and access of O2 to the Mo atom 
in the unsaturated 16-electron intermediate is more difficult and the CO release 
started by the oxidation of Mo0 by O2 is retarded.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: O2 attack on the fac-Mo(CO)3 compounds leading to CO release and Mo 
oxides formation 
 
All three binding atoms of the histidinate ligand are different but we have not 
identified which is the one that is more prone to dissociate as in the first step of 
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scheme 1. When other tridentate ligands are considered to bind the Mo0(CO)3 
fragment, the situation should be similar to that of the histidinate complex.  
Therefore, the difference in total release of CO between the  [Mo(CO)3(hist)]- or 
[Mo(CO)3(nita)]- and [Mo(CO)3(cit)]- is quite surprising and remains unexplained.  
The decomposition of the histidinate complex is almost complete whereas the 
citrate complex only releases about one half of its total CO content in the same 
time span. It is possible that the citrate complex originates dimeric species that are 
slow to decompose and release CO.    
In principle, scheme 1 should be applicable to the description of the CO release 
process of the macrocyclic derivatives (TTCN)Mo(CO)3 and (TACN)Mo(CO)3. 
The main difference should arise from the higher rigidity of these macrocyclic 
rings and their more favorable coordination to the fac-Mo(CO)3 fragment which 
disfavors the opening of a vacant coordination position for attack by O2. Indeed,  
[(TACN)Mo(CO)3],  liberates ½ of its CO content after 6h under standardized 
conditions.  The importance of the macrocyclic effect on the stabilization of the 
Mo(CO)3 fragment becomes evident when this result is compared to the 82% CO 
release in 6h obtained with the tripodal κ3-N ligand bpa in (bpa)Mo(CO)3. It is 
also possible that the reactivity of (TACN)Mo(CO)3 is influenced by other factors, 
namely pH,  because the compound can be oxidized with H+ or with Br2 to give 
characterized Mo(II) complexes  [Mo(CO)3(TACN)X]+ (X = H, Br).[27] 
Furthermore, the stability of the oxidized complexes is dependent on the nature of 
the counter-ion since hexafluorophosphate or perchlorate salts give air stable 
complexes while Br3- gives an unstable and explosive complex. 
Two other compounds contrast with (TACN)Mo(CO)3: the tripodal κ3-S 
macrocycle (TTCN)Mo(CO)3 and the soluble, cationic MnI analogue, 
[Mn(CO)3(TACN)][BF4] both of which are  completely stable towards CO release 
under the standardized conditions.  On the one hand, it is quite likely that the 
extremely low solubility of (TTCN)Mo(CO)3 provides a strong protection against 
oxidation and decomposition. On the other hand, the already discussed stability of 
fac-Mn(CO)3 complexes explains the total inertness of [Mn(CO)3(TACN)][BF4].  
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However, the formal oxidation state of the metal per se is not a unique label that 
codes for oxidative stability because the soluble tris-phosphine complex 
[Mo(CO)3(PTA)3] is totally stable like all the other tested soluble or insoluble PR3 
derivatives of Mo0, like [Mo(CO)5(PR3)] and [Mo(CO)4(PR3)2].   
A variety of mono and bidentate ligands has been tested in the family of  
[Mo(CO)4L2]0/n- derivatives. The first surprising result was provided by the 
bipyridyl derivatives in which case solubility in water causes a strong 
destabilization of the compounds with a high impact on CO release. In fact, the 
completely water insoluble Mo(CO)4(bipy) doesn’t release any CO under the 
standardized conditions. However, the introduction of water solubilizing 
substituents in the bipyridyl rings, such sulfonates and carboxilate substituents at 
the 4 and 4’ positions of the 2,2’-bipyridyl ligand, leads to ready decomposition 
of the complex and strong CO release. HPLC analysis of aqueous solutions of 
these soluble complexes reveals that this rapid decomposition takes place in water 
even under N2 atmosphere but is clearly faster under air. Therefore, it seems that 
the high stability of the Mo(CO)4(bipy) was simply due to its total 
hydrophobicity. Once brought into solution this type of complexes become rather 
labile and CO is rapidly lost. However, as pointed out by Angelici and Graham 
when comparing the rates of CO substitution of Cr(CO)4(bipy) and Cr(CO)4(4,4’-
Me2bipy) the higher basicity of the disubstituted bipiridyl might be enough to also 
explain the higher lability of CO in the case of Mo(CO)4{4,4’-
(NaO3SCH2CH2)2bipy} vs. Mo(CO)4(bipy).[19] In fact, a harder ligand results in 
higher CO lability.  
The vast majority of the diazabutadiene and diimine analogues were also very 
stable under our standardized conditions but, again, this might be due to the poor 
solubility of the examples tested so far. Indeed, the only compounds able to 
release CO in measurable amounts are the 4,4’-substituted bipyridils that could be 
partially or totally solubilized. Nevertheless, imparting solubility to these 
complexes still remains a real challenge.  
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The instability of the complexes with diamine type ligands is even higher and 
clearly accelerated by O2. For instance, the fairly air stable Mo(CO)4(methyl-
piperazine)2 decomposes very rapidly when dissolved in water or under the 
standardized conditions. The traces of HPLC solutions in water under normal 
atmosphere show a mixture of several decomposition products among which 
Mo(CO)6 seems to be always present. However, if the same experiment is 
performed under N2 its stability highly increases and no decomposition is 
observed within 6h. 
Complexes with β-diketone ligands, e.g. acetylacetonate,[28] have a decomposition 
profile rather similar to that of the amines and Mo(CO)6 is also identified as a 
decomposition product in HPLC analysis of aqueous solutions.  
Only one Mn complex of the type MnI(CO)4L2 was tested under our standardized 
conditions: MnI(CO)4(S2CPh). No CO release was observed within 6h but since 
only one example of Mn-dithiolate ligand was tested no conclusions can be drawn 
from this result, whether this observed stability is due to the insolubility of the 
complex or it’s overall stability. 
Another example showing that hydrophobicity alone does not prevent CO release 
is provided by Fe(CO)4I2 which is insoluble in RPMI and yet releases CO both 
under N2 and O2. Comparatively to other iodide substituted MCCs this is a rather 
unexpected behavior, since all the iodide derivatives showed low CO release 
rates. The fast rate of CO exchange for Fe(CO)4I2 with 14CO was reported by 
Wojcicki and Basolo[17] and described as an associative mechanism. This was 
attributed to a greater positive charge on Fe, tending to promote nucleophilic 
attack, which in the present case, in a rich nucleophilic environment like RPMI 
should lead to a high CO release rate (as observed).  
Rather unexpectedly, we observed that the derivatives of the RuII(CO)3 fragment 
do not release CO to the headspace of their aqueous solutions irrespectively of the 
variety of ancillary ligands that has been used. At least, they do not do so to a 
concentration level that can be monitored by GC-TCD. In this sense they form a 
different class of CO releasers which has been reported to mediate a variety of 
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biological activities allegedly via CO delivery.[29, 30] The chemistry of these metal 
carbonyls is rather different from that of the octahedral Mo0 and MnI analogues 
and will be dealt in Chapter V. 
One further comment should be made on the influence of the counter-ions in the 
CO release from ionic complexes because the development of ionic compounds 
for pharmaceutical applications encompasses some important, particular issues. 
The nature of the counter-ion influences the solubility as well as the stability of 
the complex and its choice is also dependent on toxicological effects. Therefore, 
the choice of the counter-ion is not a secondary aspect and has to be taken into 
account when considering an ionic compound to become a drug candidate. 
For anionic complexes sodium and potassium are logical first choices as counter-
cations since they are ubiquitous ions in the body performing a variety of known 
functions. The ratio sodium/potassium concentrations in intercellular and 
extracellular fluids is responsible for the transport ions through the cellular 
membranes (ionic channels), the regulation of the osmotic pressure inside the cell, 
the transmission of nervous pulses and other electrophysiological functions[31] 
therefore our system is already prepared to handle these ions. 
However, from the point of view of drug development it is not always possible to 
use sodium or potassium as cations due to the constraints that charge or size 
introduce in the lattice energy of the ionic compounds. In fact, organometallic 
chemistry rarely uses alkali metal ions as counter-ions to organometallic anions 
because the resulting solid state structures are not stable due to the very large 
difference in the ionic radii of both cation and anion. In practical terms, 
tetraalkylammonium, crown-ether complexes of alkali ions and a few other large 
organic cations or anions are used to produce stable, ionic solid state lattices. 
Pharmaceutically acceptable cations are very few, choline and lysine being the 
most often used.[32] Organometallic complexes with large anion/cation 
combinations are usually soluble in organic solvents where their purification and 
spectroscopic characterization is much easier than in water. Although facilitating 
compound purification, this low water solubility is not a desirable property for 
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biological and pharmaceutical useful compounds and poses severe problems to 
our screening studies.  As an example, Fig. 4 shows the variations observed in the 
amount of CO released by the sparingly water soluble [Et4N][Mo(CO)5Br] along 
seven independent tests all under the same nominal standardized conditions. 
A series of pentacarbonyl 
[Mo(CO)5I]- complexes was 
prepared in diglyme solvent as the 
sodium, potassium, ammonium 
and tetraalkylammonium salts. 
Attempts to prepare divalent 
calcium and magnesium cations 
led to a rather unstable 1:2 
complex with two [Mo(CO)5I]- 
anions per Ca or Mg cation. They 
could be characterized but 
decomposed very rapidly, 
showing that salts of [Mo(CO)5I]- 
with small dications are not stable enough for practical use. 
The complexes prepared with small cations, such as sodium, potassium and 
ammonium held coordinated diglyme molecules. In this way the small cations are 
spontaneously turned into large cationic species with the diglyme coordinating the 
small cation. This is very similar to the effect obtained by coordinating the cation 
to a crown-ether and also results in enhanced lattice stability. The same effect is 
observed with sodium salts of hydride carbonyls.[33] Nevertheless, the sodium and 
potassium salts both released similar amounts of CO with differences of only 4%. 
The ammonium salt released slightly less CO but the variations expected for tests 
with poorly soluble compounds absorb well this difference. In abstract, the same 
rate was expected due to similar stability in solution that would be provided by K+ 
and NH4+since they have similar hydrated radii (1.45Å). Both the Na+/crown-
 
Figure 4: Average of seven CO release 
experiments of [Et4N][Mo(CO)5Br] 
performed in the apparatus of Fig. 1 in 
RPMI(10%FBS) under CO2 free air, at room 
temperature and 37ºC. 
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ether and tetrabutylammonium salts present a less extensive CO release which we 
believe is mainly due to their lower solubility.   
Looking further at the data in table 3, it is immediately apparent that the nature of 
the counter-ion does not influence the CO release profile of a given ionic MCC 
provided the complexes are soluble. Taking the fully soluble anionic 
[Mo(CO)3(hist)]- complexes as an example, it is clear that the values obtained for 
the sodium and potassium salts only differ by 10%. The results obtained for the 
[Mo(CO)3(nita)]- and [Mo(CO)3(cit)]- families of complexes essentially 
corroborate the  above conclusions in spite of the wider variations in size of the 
counter-ions. The choline derivative of the [Mo(CO)3(cit)]- releases a slightly 
higher amount of CO after 6h but the difference is not drastic. It is clear and 
somehow expectable that the release of CO is being triggered by the reactivity of 
the MCC anion independently of the cation since they are both separated in the 
strongly polar aqueous solutions.  
Besides the influence of the counter-ion it was also studied the influence of pH 
variation on CO release.  The interest of studying the effect of pH on the rate of 
CO release of metal carbonyl based CO-RMs results from several practical 
reasons. The first one relates to the need of improving solubility of the 
compounds in aqueous media. In general, and excepting the ionic compounds 
with Na+, K+ or halide counter-ions, most organometallic complexes are rather 
lipophilic and have very limited solubility in aqueous solutions. This lipophilicity, 
which increases with the number of CO ligands, imposes a very strong limitation 
on the selection of MCCs to act as CO-RMs because it hampers the possibility of 
testing them both in cell culture tests in vitro and in injectable administrations in 
vivo.  One of the ways to circumvent this difficulty takes advantage of the 
possible protonation of some uncoordinated functions present in the ligands 
thereby forming water-soluble cationic species.  Once solubilized in the 
appropriate buffers such species may remain soluble for testing and/or 
administration. However, this approach also relies on the stability of the MCCs at 
the low pH values needed for protonation. 
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The other interest of testing the CO release profile of CO-RMs with pH variation 
has to do with the fact that pH variations may be used as passive targeting for CO 
delivery to specific tissues/cells and also because oral administration subjects the 
drugs to extensive pH variations in their transit through the gastrointestinal track.  
The values of the pH in the different tissues of an animal are not all exactly the 
same, as can be seen in Table 5.  
These variations, albeit small, 
may provide the basis for 
passive drug targeting. Using 
pH sensitive compounds the 
local release of CO can be 
enhanced or decreased, 
according with the desired 
effect. In diseases like 
duodenal ulcer, gastric ulcer 
and gastroesophageal reflux 
where a strong inflammatory 
component is present, a local 
CO delivery promoted by 
acidic pH would be ideal for oral applications. It is, therefore very important to 
determine the behavior of CO-RMs in water at an acid pH that mimics stomach 
conditions and also at basic pH, which mimics the intestine where most of the 
drugs are absorbed.  
In the initial stages of the biological research on CO-RMs the family of 
[Mo(CO)3L3]0,/z- derivatives stood up as a very useful one.  More importantly, 
many of them were capable of releasing well defined amounts of CO in vivo 
guiding the initial studies of CO-RM activity which were interpreted under the 
light of existing CO inhalation data. The most versatile compound was the 
aminoacid derivative [Mo(CO)3(hist)]-, which proved therapeutically effective in 
many animal models of inflammatory diseases including the prevention of 
Table 5: pH Values of Human Body fluids and 
secretions[34]  
Body Fluid or Secretion pH 
Blood 
Milk 
Hepatic Bile 
Gall bladder bile 
Urine (normal) 
Urine (in various disease states) 
Gastric juice (parietal secretion) 
Pancreatic juice 
Intestinal juice 
Cerebrospinal fluid 
Saliva 
Aqueous humor of eye 
Tears 
Feces 
Muscle cells, resting 
(at 37ºC; extracellular pH=7.4) 
7.4 
6.6-6.9 
7.4-8.5 
5.4-6.9 
6.0 
4.8-7.5 
0.87 
8.0 
7.7 
7.4 
7.2 
7.2 
7.4 
7.0-7.5 
6.94-7.06 
(intracellular) 
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stomach ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs). 
Since this involves delivery to the stomach it seemed reasonable to select this 
family of compounds to study of the effect of pH variations on the CO release 
profile of a CO-RM. All studies were done under normal aerobic conditions and 
the results are summarized in table 6. 
 
Table 6: Equivalents of CO released in H2O (pH=2.5), distilled water (pH~5.5), PBS 7.4 
and H2O (pH=8.5) in the dark, in air (2h; 4h; 6hours). 
Compound 
H2O 
 (pH 2.5) 
H2O 
(pH~5.5) 
PBS  
(pH 7.4) 
H2O  
(pH 8.5) 
Time 
Na[Mo(CO)3(hist)] 
1.3 
1.5 
1.4 
2.3 
2.5 
2.5 
2.7 
2.8 
2.8 
2.7 
2.9 
2.7 
2h 
4h 
6h 
Na3[Mo(CO)3(cit)] 
--- 
0.8 
0.8 
1.2 
1.2 
1.2 
1.3 
1.4 
1.4 
1.4 
1.2 
--- 
2h 
4h 
6h 
[choline]3[Mo(CO)3(cit)] --- 
1.3 
1.4 
1.3 
1.1 
1.1 
1.1 
--- 
2h 
4h 
6h 
Na3[Mo(CO)3(nita)] 
1.0 
0.9 
1.0 
1.6 
1.5 
1.6 
2.1 
2.1 
2.3 
1.4 
1.4 
1.4 
2h 
4h 
6h 
Na5[Mo(CO)3(detpa)] 
1.4 
1.4 
1.3 
2.6 
2.8 
2.9 
3.0 
3.1 
3.2 
3.6 
3.6 
2.6 
2h 
4h 
6h 
 
After 2h the CO released by these compounds to the headspace is already very 
close to the maximum amount obtained after 6h, showing that the reaction is very 
fast in all the media tested. Na5[Mo(CO)3(detpa)] is quantitatively decarbonylated 
after 2h in distilled water or PBS solutions and in basic pH surpasses the total 
amount of carbonyls present in the molecule (3), suggesting a base-catalyzed 
decomposition of the organic ligand detpa. Some reproducibility problems were 
found and the values in table 6 are arithmetic means of several independent tests.  
The major trigger for CO release is O2, and since the amount of O2 present in each 
experiment is not controlled the CO release may vary accordingly. This issue will 
be addressed later in Chapter III. However, these differences were more common 
during the first 2 to 4 hours of the assay but after the 6h the final values were very 
Evaluating spontaneous CO release from Metal Carbonyls by Gas Chromatography 
 
 
62 
similar. Even when the initial CO release was much higher the reaction tended to 
the same end-point and the final amount of CO liberated was the same.  
In order to check these observations, the reactions were analyzed at earlier time 
points to see CO evolution in the first 2h in PBS7.4 and distilled water. 
The results obtained in these short-term assays are summarized in table 7 and 
complete those of table 6.   
 
Table 7: Equivalents of CO released in distilled water and PBS7.4, in air, in the dark at 
room temperature at 30min, 1h, 1h30min and 2h. 
Compound 
H2O 
(pH~5.5) 
PBS 
(pH 7.4) 
Time  
(Hours) 
Na[Mo(CO)3(hist)] 
0.9 
1.9 
2.1 
2.2 
0.8  
1.3 
1.9 
2.2 
0.5 
1 
1.5 
2 
Na3[Mo(CO)3(cit)] 
0.5 
0.8 
1.1 
1.1 
0.5 
0.6    
1.0 
1.2 
0.5 
1 
1.5 
2 
Na3[Mo(CO)3(nita)] 
0.8 
1.4 
1.7   
1.7   
1.1 
1.6 
1.7 
1.7 
0.5 
1 
1.5 
2 
Na5[Mo(CO)3(detpa)] 
1.5 
2.1 
2.5 
3.0 
1.2 
2.0 
2.3 
2.5 
0.5 
1 
1.5 
2 
 
 
The compounds Na3[Mo(CO)3(hist)] and Na5[Mo(CO)3(detpa)] are the fastest and 
most extensive releasers that is, both in percentage of CO released and also in 
speed. After 2 hours, in water, the 3 COs are released by Na5[Mo(CO)3(detpa)] 
and almost all by Na[Mo(CO)3(hist)] (88%). It is interesting to note that 
Na5[Mo(CO)3(detpa)] loses 2 COs in the first 30 min, probably with O2 playing a 
very important role in this initial burst. The other 2 compounds are more stable, 
Na3[Mo(CO)3(nita)] releases roughly half of the available COs and reaches a 
plateau of 1.7 equivalents after 1h30m. Na3[Mo(CO)3(cit)] is the compound that 
releases less CO in water, only 1 equiv., also after 1h30m.   
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Na3[Mo(CO)3(cit)] and Na3[Mo(CO)3(nita)] have very similar profiles both in 
PBS and in water suggesting that they are not dependent on the interference of the 
electrolytes present in PBS. Na5[Mo(CO)3(detpa)] and Na3[Mo(CO)3(hist)] show 
a higher variability in the results particularly at the initial times which may be 
related to their higher sensitivity to variations in the concentration of O2.  
Overall, Na3[Mo(CO)3(cit)] has a different profile from its ionic [Mo(CO)3L3]0,/z- 
analogues. It releases less than 50% of the total amount of CO and shows similar 
kinetics in RPMI, PBS and water. The oxidation of this complex could in 
principle lead to an analogue of the known compound K4[MoO3(cit)]⋅H2O[35] 
however as we can see from the GC results this isn’t the case. To some extent 
Na3[Mo(CO)3(nita)] is similar but the amounts of CO released are slightly higher.  
No consistent explanation for these facts has yet been reached.  
The HPLC trace of a Na3[Mo(CO)3(cit)] and [choline]3[Mo(CO)3(cit)] in water 
solution under normal atmosphere conditions shows a decomposition profile in 
which Mo(CO)6 raises concentration, similarly to what as been observed with the 
diamine and β-diketonate complexes (Fig. 5).  
 
 
 
 
 
 
 
 
Figure 5: Left: HPLC trace of a water solution of Na3[Mo(CO)3(cit)] under air at room 
temperature over 75 min. At the time of dissolution (t=0), the product is observed at RT= 
10.78 min, Mo(CO)6 formation is observed at RT=13.7 min and Na2MoO4 at RT=2.29 
min. After 15 min, Mo(CO)6 RT is 12.12 min. Right: HPLC trace of a water solution of 
[choline]3[Mo(CO)3(cit)] under air at room temperature over 75 min. At the time of 
dissolution (t=0), the product is observed at RT=11.03 min, Mo(CO)6 formation is 
observed at RT=12.04 min and [choline]2MoO4 at RT=2.22 min. After 15 min the product 
is observed at RT=10.68 min and Mo(CO)6 formation is observed at RT=11.72 min. 
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An early peak is also eluted at RT~2.32 min and the UV absorbance spectrum is 
similar to that of sodium molybdate. Mo(CO)6 typically raises concentration in 
solution until saturation and then precipitates decreasing its concentration in 
solution. 
In spite of the structural similarities of the complexes, and their high activity as 
CO releasers, some interesting trends are still observable. First, the general 
tendency demonstrated in these results is that the stability of the compounds 
decreases as the pH increases, that is, compounds tend to be more stable under 
acidic conditions. This trend is most likely due to the nucleophilic displacement 
of the ligands by excess HO- at higher pH. Given its high CO labilizing power, 
the hydroxide ligand will accelerate the overall rate of CO substitution. In the 
case of the [Mo(CO)3(hist)]- complex deprotonation of a coordinated NH2 ligand 
at higher pH will also result in strong CO labilization by the amido -NH- ligand. 
This kind of effect is known in the chemistry of ammine and amino complexes of 
classical Werner type coordination complexes (no organometallic ligands).[36] In 
practical terms this also means that these chemically sensitive and highly active 
CO-RMs can be administered orally and are likely to survive the acidic conditions 
in the stomach.  
Another interesting observation is that in spite of its basic pH, RPMI seems to 
slightly slow down CO release in all cases except that of [choline]3[Mo(CO)3(cit)] 
(see tables 4 and 6). This retarding effect is more pronounced in the earlier period 
of the reaction, that is, up to 2h reaction time. Given the complexity of the 
composition of RPMI we cannot assign a clear reason to this stabilizing effect. 
Nevertheless, the hypothesis that this initial retardation is due to the protective, 
anti-oxidant effects of species present in the RPMI/FBS mixture is quite strong. 
Likewise, the hypothesis of the stabilization by interaction of the CO-RMs with 
the RPMI/FBS proteins cannot be discarded.  In any case, the suggestion that a 
biological environment may protect the MCC against fast decomposition seems 
plausible and improves the confidence on the use of metal carbonyl complexes as 
therapeutic CO-RMs.  
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4.2 CO release profiles of the polyene and polyenyl carbonyl 
complexes 
 
Contrary to the classical N and O ligands, and similarly to CO, the bonding of 
alkenes, dienes, arenes and their anionic counterparts (like cyclopentadienyls) to 
metal atoms or ions, also contains a strong and decisive component of π-
backdonation. However, this contribution relative to σ-donation varies widely 
across this series of ligands and it shows a strong dependency on the substituents 
attached to the sp2 carbons of these ligands.  
In general, alkene ligands in carbonyl complexes are quite labile because CO 
removes most of the electronic π-density and weakens the (alkene)-M 
backbonding. Of course, a decrease in the number of CO ligands around a given 
metal improves the stability of eventual neutral polyalkene or arene ligands. In 
this work we only dealt with one such polyene-carbonyl complex, namely the 
cycloheptatriene (CHT) derivative [(η6-C7H8)Mo(CO)3]. The substitution kinetics 
of this complex has been reported in the literature long ago in many solvents and 
with many nucleophiles under anaerobic conditions, but the result was always 
substitution of the CHT ligand by three incoming nucleophiles, leaving the three 
CO ligands as unchanged spectators.[18] These reactions are usually dependent on 
the concentration of the incoming ligands and have a fascinating kinetic and 
mechanistic subtlety, which is highly relevant for the understanding of the 
chemistry of coordinated olefins in catalytic transformations. However, in the 
present case, the fact that the reactions are being studied under O2 results in very 
fast molecular substitution and decomposition with strong release of the CO 
ligands. In fact, [Mo(η6-C7H8)(CO)3] is completely water insoluble and totally 
stable under N2 in water suspension. However, under O2 its suspensions rapidly 
decompose with quite fast and extensive liberation of CO (76% of total CO; see 
table 6). One could imagine that if such complex was water soluble, its CO 
release kinetics would probably be among the fastest examined. This is also 
understandable if one notes that water as well as most other ligands present in 
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RPMI/FBS are not π-acceptors and the majority are even π-donors. Such π-donors 
which were mentioned above to aptly labilize M-CO bonds are even more 
efficient in labilizing M-alkene bonds since these have a weaker π-accepting 
component and are, therefore, more fragile.   
This kind of reactivity is expected to be followed by arene complexes but we 
haven’t studied any of those (see reference [18] and references cited therein). 
However, their isoelectronic 6-electron donor counterparts, the cyclopentadienyls 
were intensively studied and represent a different reactivity paradigm.  
The cyclopentadienyl, [η5-C5H5]- ligand (usually abbreviated to Cp) and its 
substituted analogues, [η5-C5H5-nRn]- (generally abbreviated as Cp’), are aromatic, 
planar, carbanionic ligands that possess a set of orbitals with a geometry and 
electronic energy which is almost ideal to coordinate transition metals. In this 
coordination the metal sits on the middle of the Cp ring with all carbon atoms 
equidistant.  Formally this ligand provides three electron pair (6 electrons) and 
occupies three coordination positions. In this way, a complex like [CpM(CO)3]z± 
can be regarded as a distorted octahedron where the Cp ligand occupies one face 
and the three carbonyls occupy the opposite one, as sketched in figure 6. 
 
 
 
 
 
 
 
Figure 6: Comparison between the CpM(CO)3 and (κ3-L)M(CO)3 octahedral structures. 
  
This privileged bonding mode generates a very strong stability on the Cp-M 
fragment which retains its coordination almost unchanged across a very wide set 
of chemical transformations of their complexes. In other words, the Cp ligand 
usually behaves as spectator to the chemistry that takes place with the other 
ligands of the complex. It is this fact that explains the ubiquitous presence of Cp-
M complexes in organometallic chemistry since this kind of ligand accommodates 
a wide variation of metals, oxidation states and ancillary ligands. The exhaustive 
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oxidative decarbonylation shown in scheme 2 which spans six (!) oxidation states 
exemplifies the extension of this capacity of electronic accommodation and metal 
binding of the Cp type ligand.[37] 
 
 
Scheme 2: Six electron oxidative decarbonylation of Cp*ReI(CO)3 to Cp*ReVIIO3. 
 
Within this framework one may expect that complexes [Cp’M(CO)xLy]z± 
containing both Cp type ligands, CO and group 6-8 metals, will display useful CO 
releasing profiles. CO substitution kinetics will follow the same D, A or Id/Ia 
paradigms (see Chapter I, section 4) found for octahedral CO complexes as 
summarized by Howell and Burkinshaw on the basis of reactions carried out in 
organic solvents under anaerobic conditions.[18]  
Table 8 collects some appropriate data on selected complexes with the 
unsubstituted Cp ligand. 
A first inspection of this table immediately reveals that the cyclopentadienyl 
complexes examined are rather inert with regard to CO loss, and therefore poor 
CO releasers.  
In the case of the derivatives of the CpFeII(CO)2 fragment only the Cl, Br and 
carboxylate derivatives liberate CO after 6 h in RPMI, at 37°C, under air and in 
the dark. All the alkyl and acyl derivatives, as well as the iodide CpFe(CO)2I, are 
completely inert under these conditions. These variations closely follow those 
observed for instance in the Mn(CO)5X family and the underlying factors 
pertaining to CO labilization are certainly the same. Reverse migratory insertion 
of the CO in the acyl complexes is obviously playing no role under these mild 
biological conditions since both acyl complexes are completely stable. This 
reaction would need the initial dissociation of one CO ligand in agreement with 
Re
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OC CO
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O
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the fact that it is either photochemically activated or thermally activated above 
130°C for 2h.[38, 39]  
 
Table 8: Solubility in the medium and equivalents of CO released by CpM(CO)xX 
complexes of  Mo, Fe and Ru in RPMI (10% FBS), at 37ºC after 6h in the dark. 
Family of compounds X group Solubility 
Equivalents of 
CO released 
in RPMI after 
6h 
(η6-C7H8)Mo(CO)3 --- insoluble 2.3 
    
CpFe(CO)2X Cl sp soluble 0.5 
 Br sp soluble 0.3 
 I insoluble 0.0 
 OCOC6H4OBF2 sp soluble 0.2 
 CH3 sp soluble 0.0 
 CH2Ph insoluble 0.0 
 COCH3 insoluble 0.0 
 COC6H5 insoluble 0.0 
 CH2CH2CH2Cl immiscible oil 0.1 
 CH2CONH2 soluble 0.0 
 CH2COOH soluble 0.0 
    
CpRu(CO)2X Cl insoluble 0.0 
 I insoluble 0.0 
    
CpMo(CO)3X Cl sp soluble 0.4 
 I insoluble 0.0 
 OCOC8H6OBF2 insoluble 0.2 
 CH3 insoluble 0.0 
 CH2CONH2 soluble 0.7 
 CH2COOH insoluble 0.8 
 CH2CONHCH2OH soluble 0.2 
 CH2COOC(CH3)2C6H5 insoluble 0.0 
 CH2CONHCH2COOMe insoluble 0.0 
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The increase in the strength of Ru-X bonds compared to the Fe-X bonds in 
analogue compounds justifies the high stability of both halide derivatives 
CpRu(CO)2X (X = Cl, I). 
The CpMo(CO)3X complexes show some similarities and differences when 
compared to their Fe analogues. Again, the chloride complex CpMo(CO)3Cl is a 
better CO releaser than its iodide and methyl analogues. The carboxylate 
(OCOC6H4OBF2) derivatives of both families have a similar behavior.  In contrast 
to the CpFe(CO)2X family, both CpMo(CO)3(CH2CONH2) and 
CpMo(CO)3(CH2COOH) are better releasers than CpMo(CO)3Cl. One might 
argue that the solubility of CpMo(CO)3(CH2CONH2) may facilitate its 
decomposition. However, CpMo(CO)3(CH2COOH) is completely insoluble and 
still presents a slightly higher amount of CO released. Indeed, there seems to be 
no clear predictability regarding CO release since, for example, CpMo(CO)3(η1-
N-maleimidato) was already used as labeling tool and showed high kinetic 
stability.[40] 
The relatively good thermal and oxidative stability of the alkyl derivatives of this 
family has been noted.[41, 42] In this family of compounds, CO release is often 
attained by photochemical substitution reactions[43] or nucleophilic substitution 
with e.g. phosphines[44], arsenites[45], NO or under harsh thermal conditions[46] not 
found in biological environments.  
In a thorough study of CpM(CO)3(CH2CONH2), CpM(CO)3(CH2COOH) and 
close analogues (M = Mo, W), Bergman and coworkers identified a facile photo 
induced or chemical loss of CO form these compounds which is stabilized by the 
formation of an oxa-allyl complex. The same authors also report that the Mo 
complexes are less stable than those of tungsten which provided the basis for 
most of their work.[47]  
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Scheme 3: Conversion of η1-enolates into η3-oxa-allyl complexes induced by CO loss 
 
 
We believe that the stabilization caused by this η3-ligand may assist the 
unexpectedly faster CO loss from these compounds when compared to their 
simple alkyl counterparts which are inert. Dissociation of CO would be 
immediately assisted intramolecularly by the haptotropic change from η1-
CH2C(O)X to η3-CH2C(O)X, facilitating CO loss from the molecule (scheme 3).   
In fact, aqueous solutions of CpMo(CO)3(CH2CONH2) under N2 atmosphere 
slowly acquire a green tinge and liberate CO slowly over 24h in the dark. The 
same color change is rapidly seen and goes to deep blue within a few hours when 
the aqueous solution is exposed to ordinary laboratory light. In both cases this 
color change is accompanied by CO release.  
The similar conversion of the allyl complex CpMo(CO)3(η1-CH2CHCH2) to 
CpMo(CO)2(η3-CH2CHCH2) and of CpMo(CO)3(η1-CH2C6H5) to CpMo(CO)2(η3-
CH2C6H5) are classic textbook examples of this type of reactivity.[48-52] 
Although it is only superficially understood, it is clear that the nature of the 
ligands is able to tune CO release rates, either by modifying the complex stability 
or by simply changing solubility and/or redox potential. The presence of different 
substituents in the Cp type rings provides another handle to attempt fine tuning 
CO release profiles. A number of complexes containing modified Cp rings were 
prepared and tested and the results are summarized in table 9. 
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Table 9: Solubility in the medium and equivalents of CO released by Cp’Mo(CO)3L 
complexes (where L is Cl, I or Me) in RPMI (10% FBS), at 37ºC after 6h in the dark. 
Family of compounds RR’ group Solubility 
Equivalents of 
CO released in 
RPMI after 6h 
(η5-C5R4R’)Mo(CO)3Cl R=R’=H sp soluble 0.4 
 R=H; R=CO2CH3 sp soluble 0.2 
 R=R’=CH3 insoluble 0.0 
 R=Ph; R’=OH insoluble 0.0 
    
(η5-C5H4R)Mo(CO)3I H insoluble 0.0 
 COOH sp. soluble 0.1 
    
(η5-C5H4R)Mo(CO)3CH3 H insoluble 0.0 
 CH2CH3 imisc. liquid 0.0 
 CH2CH2CH3 imisc. liquid 0.0 
 CH2CH2CH2CH3 imisc. liquid 0.0 
 CH2C6H5 insoluble 0.0 
 
 
Changing substituents on the Cp ring may induce some changes in solubility as 
well as in the strength of the M-Ligand bonds in the complex. Alkyl substituents 
will increase the electron donor power of the cyclopentadienyl ring and will 
reinforce its bond as well as the M-CO backbonding. This seems to be the case if 
we compare CpMo(CO)3Cl with (C5Me5)Mo(CO)3Cl.  On the other hand, COOH 
or COOR substituents will decrease M-CO backdonation, and eventually facilitate 
CO release, as suggested by the difference between (C5H4COOMe)Mo(CO)3Cl 
and CpMo(CO)3Cl or  (C5H4COOH)Mo(CO)3I and CpMo(CO)3Cl. However, 
these effects are not very strong and only cause minor changes in the total amount 
of CO released. This attests to the high chemical stability of the cyclopentadienyl 
carbonyl complexes.  
The same Mo-CO bond weakening is promoted by the introduction of a COOH 
group in the cyclopentadienyl of the CpMo(CO)3I complex, forming a slightly 
more water soluble complex but no differences were attained in the CO release 
rate. 
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The (η5-C5H4R)Mo(CO)3CH3 family with several alkyl chains bound to the Cp 
ring didn’t reveal any differences in terms of either CO release or water solubility. 
On the contrary, the structural changes prompted different and important 
toxicological responses that will be discussed in the next section. As the result of 
this unexpected hurdle in the biological activity of Cp containing complexes, 
these studies were discontinued and no further correlations/observations were 
established. In the literature there is one study around a family of Cp’Fe(CO)2X 
complexes as CO donors but CO release is not measured chromatographically in 
the headspace of the solutions of the compounds making it impossible to draw 
comparisons with these results.[53]  
 
4.3 Toxicity of cyclopentadienyl metal carbonyl complexes  
 
The main goal of most studies reported in this dissertation is to provide as much 
information as possible about the compounds behavior in diverse situations so 
that this information may be used as a useful tool to develop or improve existing 
biologically active molecules. Although toxicity lies aside the central topic of this 
discussion, the importance of the issue justifies the following excursion. 
The structural modifications introduced are often the most chemically logical 
ones but like it was demonstrated before, they may carry major biological 
consequences. Toxicity is a broad field to which many factors contribute and 
simple changes may accomplish major differences in the toxicological profile of 
the molecule. 
The toxicity of aromatic rings, namely benzene and cyclopentadienyl ring in 
metal carbonyl complexes was first reported by Strohmeier in 1963 and became 
documented through studies on methylcyclopentadienyl manganese tricarbonyl 
(MMT) and cyclopentadienyl manganese tricarbonyl (CMT).[54, 55]  
Animal studies have shown that exposure to MMT can result in damage due to 
accumulation in the liver, kidney, lungs and brain[56-59] and neurotoxicity studies 
showed that seizure activity and death was related and could be due to GABA-A 
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activity.[60, 61] The analogous compound CMT, which doesn’t have a methyl 
substituent in the Cp ring, presents a similar toxicological profile. [62-65]   
In our studies we observed that compounds of the form CpM(CO)xCl (where M is 
Mo and x=3 or M=Fe, Ru and x=2) or CpMo(CO)3CH3 showed highly toxic 
profiles with very low MTDs (typically < 10 mg/Kg). By introducing long or 
bulky alkyl substituents in the Cp ring we were able to decrease the toxicity 
profile, both by preventing seizures and increasing MTD by more than 50-fold.    
It was already demonstrated that the intrinsic CO releasing potential doesn’t 
change with the alkyl chain length (see table 9) but the in vivo toxicity study 
showed that the structural modifications allowed an increase of the MTD. The 
longer and bulky chains reduced the seizures and lethality in a direct fashion. The 
reasons for this behavior are still unknown, but it is clear that the changes in the 
toxicological profile are due to steric effects.  
 
4.4 CO release profile from cyclodextrin-encapsulated complexes  
  
 
Another potentially interesting approach to the modification of CO delivering 
systems based on metal carbonyl complexes involves the use of cyclodextrins 
(CDs) as protective agents.[66-70] CDs are cyclic oligosaccharides that form 
inclusion complexes with a wide range of molecules, including organic 
molecules, inorganic ions and organometallic species.[71-75] 
The use of CDs as carrier devices to promote controlled release, to improve 
solubility, half-lives or bio-availability is nowadays a widespread technique with 
success with many drugs.[76-79]  
Organometallic complexes immobilized in CDs often exhibit markedly different 
physical and chemical characteristics compared to the bulk material, for example 
in their nonlinear optical properties, ligand substitution/insertion reactions and 
catalysis.  
CDs are known to host a broad variety of half-sandwich metal carbonyl 
compounds containing Cp and η6-arene rings like ferrocene derivatives, 
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metallocene dihalides and aromatic ruthenium (and chromium) compounds. In 
these compounds the CDs act as second-sphere ligands non-covalently attached to 
the first-sphere ligands of the metal centre.  
Given the limited solubility of many MCCs in aqueous physiological media, the 
“true” potential of many complexes has not been realized or even evaluated. 
Therefore, the inclusion of MCCs in modified CDs such as 2,3,6-tri-O-methyl-β-
cyclodextrin (TRIMEB) may circumvent this problem. Hydrophobic molecules 
encapsulated in cyclodextrins would then be easily distributed in the circulation 
releasing biologically active compounds under specific conditions in the diseased 
tissues.[80] Usually, the controlled degradation of such complexes is pH 
dependent, leading to the cleavage of hydrogen or ionic bonds between the host 
and the guest molecules. Alternative means for disruption of the host-guest 
complexes take advantage of the action of enzymes able to cleave α-1,4 linkages 
between glucose monomers. Besides this classical way of using the cyclodextrin 
host-guest complexes we also hypothesized that inclusion of MCCs in CDs might 
keep reactive MCCs longer in circulation thereby improving their chance of 
reaching the diseased tissues.  
In this study 1:1 inclusion complexes of Mn(CO)5Br, CpFe(CO)2Cl, 
[Et4N][Mo(CO)5Br], CpMo(CO)3Cl and (Ac-Cp)Mo(CO)3Cl were prepared and 
characterized by the group  of Isabel S. Gonçalves at the Universidade de Aveiro, 
Portugal, using unmodified β-cyclodextrin (β-CD) and 2,3,6-tri-O-methyl-β-
cyclodextrin (TRIMEB).[69, 81] Their performance as CO releasers is summarized 
in Table 10.  
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Table 10: Equivalents of CO released by the complexes Mn(CO)5Br, CpFe(CO)2Cl, 
[Et4N][Mo(CO)5Br], CpMo(CO)3Cl and (Ac-Cp)Mo(CO)3Cl and their encapsulated forms 
in TRIMEB and also CpFe(CO)2Cl encapsulated in β-CD, in RPMI after 2h, 4h and 6h, at 
room temperature, in the dark, under reconstituted CO2 free air.  
 
As expected, all the compounds become more water-soluble after encapsulation. 
However, the differences observed between the CO release profile of the “free” 
and the corresponding encapsulated compounds, are not drastic. Considering that 
within these small variations it is dangerous to extract general rules, one can still 
accommodate some of the trends into a plausible set of explanations. Both 
Mn(CO)5Br and CpFe(CO)2Cl are air stable complexes where CO release is 
expected to follow simple ligand substitution mechanisms. Regardless of being 
associative of dissociative, such mechanisms imply modifications in the 
coordination sphere of the metal atom, which are clearly affected by the 
encapsulation of the MCC inside the CD.  Inside the host cavity the exchange of 
ligands is hampered and therefore retarded by physical reasons. Accordingly, 
Mn(CO)5Br and CpFe(CO)2Cl should be protected upon encapsulation as is 
indeed observed. 
In contrast, CpMo(CO)3Cl and (Ac-Cp)Mo(CO)3Cl are not air stable and CO 
release at physiological temperature in the dark, even minor as it is, requires 
“Free” Compound Equiv. CO released Encapsulated compound 
Equiv. CO 
released 
Time of 
reaction 
Mn(CO)5Br 
0.7 
1.2 
1.6 
Mn(CO)5Br@TRIMEB 
0.7 
1.0 
1.1 
2h 
4h 
6h 
CpFe(CO)2Cl 
0.2 
0.4 
0.5 
CpFe(CO)2Cl@β-CD 
0.0 
0.0 
0.0 
2h 
4h 
6h 
CpFe(CO)2Cl 
0.2 
0.4 
0.5 
CpFe(CO)2Cl@TRIMEB 
0.0 
0.1 
0.1 
2h 
4h 
6h 
[Et4N][Mo(CO)5Br] 
1.7 
2.1 
2.4 
[Et4N][Mo(CO)5Br]@TRIMEB 
1.2 
1.6 
1.6 
2h 
4h 
6h 
CpMo(CO)3Cl 
0.1 
0.2 
0.4 
CpMo(CO)3Cl@TRIMEB 
0.1 
0.3 
0.5 
2h 
4h 
6h 
( Ac-Cp)Mo(CO)3Cl 
0.1 
0.2 
0.2 
(Ac-Cp)Mo(CO)3Cl@TRIMEB 
0.1 
0.3 
0.4 
2h 
4h 
6h 
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oxygen. Given its small size, O2 will have ready access to the guests inside the 
cavity and trigger CO release. Under these circumstances the rate of CO release 
will remain essentially unaffected by encapsulation, as is observed. The case of 
[Et4N][Mo(CO)5Br] is more complex because the compound, besides being very 
little soluble is both substitutionally very labile and oxidatively sensitive. 
Therefore, the information available is not readily interpreted. Nevertheless, the 
encapsulated compound is protected inside the CDs corresponding to a 14% 
decrease when compared with the values obtained after 6h with the free complex. 
 
4.5 The influence of O2 in the CO release from metal carbonyl 
complexes 
   
 
As extensively observed and mentioned in the above results, oxygen is the main 
trigger promoting CO release from metal carbonyl complexes in biological 
compatible media. Experiments performed under N2 showed that the molecules 
were stable, in some cases up to 24h in water. Light was also evaluated as a 
possible trigger but only marginal differences were observed among the assays 
performed with light and in the dark.  
There is not much data reported in the literature concerning the interaction of 
metal carbonyl complexes with O2. The photochemical experiments of the groups 
of Poliakoff and Downs are almost the only source of information on these 
reactions.[82, 83] As hypothesized also in the introduction, the oxidation of the 
metal carbonyl can happen through an inner or an outer sphere mechanism. In the 
latter case, the formation of superoxide as the result of an electron transfer 
between the electron rich metal carbonyl complex and molecular oxygen would 
be a likely outcome. In order to shed some light onto this process a series of 
Electron Spin Resonance (ESR) spin trap studies using the spin trap BMPO was 
performed with four model compounds (Figure 7).  
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Compounds [Et4N][Mo(CO)5Br], Na[Mo(CO)3(hist)], Na3[Mo(CO)3(cit)] and 
[Mo(CO)3(bpa)] were selected based on the results of the GC assays. 
Na[Mo(CO)3(hist)] and Na3[Mo(CO)3(cit)] are ionic compounds and while the 
first one is a very fast CO releaser that very rapidly loses the 3 COs, the second 
one is more stable, only releasing roughly 1 CO in water and decomposes leading 
to the formation of Mo(CO)6 and other unknown species. [Et4N][Mo(CO)5Br] is 
also an ionic compound that readily loses 2 to 3 COs in water depending on the 
conditions. On the other hand, [Mo(CO)3(bpa)] is a neutral compound also with a 
high rate of CO liberation. The spin trap used, BMPO, is a water soluble cyclic 
nitrone able to detect superoxide and hydroxyl radicals with a half-life of 23 
min.[84] Upon hydroxyl attack the adduct obtained gives the characteristic ESR 
spectrum depicted in Fig.7.  
To assess the effect of O2 in the oxidation of the selected model metal carbonyls 
an ESR study was performed as follows: a solution of the compound in water was 
prepared under N2 and an aliquot transferred to the ESR tube together with the 
spin trap BMPO. A control spectrum was taken and no signal was detected in 
N
H
H3C
O
t-BuO
O
H3C
O
t-BuO
O
H
OH
N
OH
Figure 7: Top-Hydroxyl radical attack to 5-tert-butoxycarbonyl 5-methyl-1-pyrroline 
N-oxide (BMPO); Bottom-ESR spectrum of the adduct obtained. 
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every case. Oxygen was then bubbled in the solution for 3-4 min and another 
sample was taken and analyzed. The spectra obtained are given in Figure 8. 
 
 
 
 
 
 
 
 
Figure 8: ESR spectrum obtained after O2 bubbling in a water solution containing: Left - 
Na[Mo(CO)3(hist)] (203 µM) and BMPO (12.5 mM); Right - Na3[Mo(CO)3(cit)] (200 
µM) and BMPO (25 mM).  
 
 
The same procedure was performed with compounds [Et4N][Mo(CO)5Br] and 
[Mo(CO)3(bpa)] but bubbling air instead of pure O2. The spectra obtained are 
given in Figure 9. 
The results obtained for Na[Mo(CO)3(his)], and Na3[Mo(CO)3(cit)] showed the 
unequivocal formation of hydroxyl radical. No superoxide was detected even the 
decay of superoxide to hydroxyl should be discarded since this conversion is not 
plausible in non-enzymatic conditions.[84]  
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Although with less clear spectra, both [Et4N][Mo(CO)5Br] and [Mo(CO)3(bpa)] 
also produced the hydroxyl radical in their reactions with O2 from air (Figure 9). 
No signal typical of the superoxide-BMPO adduct was detected. Therefore, the 
formation of the hydroxyl radical in all these oxidations of Mo0 carbonyls by 
molecular oxygen (O2) is an unequivocal event under these reaction conditions. 
With the exception of the interactions of O2 with Fe ions in heme proteins, 
relatively little is known about the mechanisms of the reduction of O2 by 
transition metal complexes. As a matter of fact, the understanding of these 
mechanisms is emerging as a major research area given the need to understand the 
complex mechanism(s) of the reduction of O2, a decisive process in the areas of 
  
 
Figure 9: ESR spectrum obtained after air was bubbled in a water solution containing: Top 
Left - [Et4N][Mo(CO)5Br] (199 µM; 0.7% MeOH) and BMPO (25mM); Top Right -  
[Mo(CO)3(bpa)] (200 µM; 0.6% MeOH) and BMPO (25 mM); Bottom - ESR spectrum 
obtained after O2 was bubbled in the [Et4N][Mo(CO)5Br] solution. 
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fuel cells and other sustainable energy processes.[85, 86] In the case of zerovalent 
transition metal complexes in water, we are not aware of any study of this kind. 
Therefore, we can only attempt to propose a mechanism for this hydroxyl radical 
formation based upon information gathered in related systems. Our proposal in 
depicted in scheme 4 and is briefly discussed.  
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Scheme 4:: Proposed mechanism for the formation of HO. radicals in the oxidation of 
Mo0 complexes by molecular oxygen (O2). S represents the solvent. 
 
The reaction starts by dissociation of one labile ligand X forming an unsaturated 
16-electron complex (A), where the solvent occupies the ligand site. O2 
coordinates to this vacant position. In the new bond some charge transfer from the 
very electron rich Mo0 to the highly electronegative O2 takes place, forming what 
can also be described as a superoxo complex L5MoI-(O2-) (B). In aqueous medium 
this species is protonated at the distal O atom to form (C). The strong tendency of 
Mo to stabilize terminal Mo=O bonds and its strong reducing power certainly 
assists the breaking of the remaining O-OH bond, thereby facilitating the 
formation of the HO radical which is irreversibly trapped by BMPO. This 
mechanism is reminiscent of the formation of the ferryl (heme)-FeIV=O species in 
the cytochrome P450. In the later, the breaking of the O=O bond from the initially 
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formed (heme)-FeII(O=O) involves addition of two H+ ions to the distal O atom, 
leading to (heme)-FeIV=O  and H2O. In the case of the L5Mo(O-OH) complex (C) 
the O=O bond breaking takes place without the need to add another proton and 
we propose that an oxo-Mo complex is formed. Reduction of O2 at the surface of 
Pt electrodes in aqueous solution, where HO radicals are formed, seems to follow 
a similar path through the fission of the O-O bond of the  Pt-O-OH species 
formed at the surface of the negatively charged, electron rich Pt electrode.[87]  
5. Final Remarks and Conclusions 
 
The study of CO release from metal carbonyl complexes that is described in this 
chapter must not be regarded as a quantitative, accurate mechanistic description 
of the chemistry that presides to this particular decomposition process. Instead, 
this screening intends to  
• reveal the viability of using MCCs to deliver CO in biological media 
• reveal which structures and metal ligand combinations are better 
suited for such CO delivery 
• understand the main molecular properties that contribute to the 
profile of CO release of MCCs 
• identify the main parameters that have to be controlled in order to 
eventually optimize CO release profiles from given MCCs. 
 
The results reported lead to the following main conclusions:  
 
• MCCs are largely compatible with biological media and the vast 
majority is actually rather stable towards decomposition with CO 
release. 
• the fastest and more extensive CO releasers were identified among 
the Mo0 octahedral derivatives  [Mo0(CO)3L3]0/z- bearing hard donor 
ligands mainly those of biological relevance, e.g. amines, 
carboxylates, aminoacids.  
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• CO release from these complexes is mainly triggered by O2 and this 
process seems to favor production of OH⋅ radicals over O2.-   
• CO release from [Mo0(CO)3L3]0/z- complexes can be regulated via 
appropriate π-acceptor ligands. 
• Encapsulation of the MCCs in cyclodextrins retards CO release only 
in those cases where this is not strongly O2 dependent. 
• MnI(CO)5L and  MnI(CO)4L2 lose CO dissociatively to form stable, 
inert [Mn(CO)3X3]+ products.  
• Cyclopentadienyl complexes of MoII, FeII, RuII and MnI are very 
weak CO releasers. 
• The toxicity of CpM(CO)xL (M=Fe, Ru and x=2; M=Mo and x=3) 
complexes can be decreased by introducing long and/or bulky 
substituents in the Cp ring. 
•  [RuII(CO)3L3] complexes do not release CO to the headspace of their 
aqueous solutions. 
• Solubility and air stability are the most important properties that 
need to be manipulated in order to obtain chemically reliable Metal 
Carbonyl CO-RMs. 
 
These data do not intend to elaborate a group of rigorous rules of CO release in 
biological conditions, let alone a “manual” for drug development of 
organometallic carbonyl complexes.  
However, it is fascinating to see how some organometallic chemistry basic 
principles may be applied to the development of potential pharmaceuticals. The 
electronic tuning of the metal center, the modification introduced in the first 
sphere of coordination e.g. changing the halide, introducing an alkyl or aryl 
substituent as well as changing the π acidity of ancillary ligands are some special 
features that determine directly stability to O2 and the CO release rate of the 
molecules and ultimately, how the “active principle” is delivered.     
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From this point onwards achieve good stability in aqueous medium stands out as 
the next important topic to tackle as the way to transform MCCs in 
pharmacologically acceptable CO-RMs. 
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Chapter III: Evaluating ROS induced CO release 
from Metal Carbonyls by Gas Chromatography 
 
1. Summary 
 
As mentioned in Chapter II, many of the MCCs presented are stable entities that 
don’t release any CO or only marginal amounts when exposed to aerobic aqueous 
environment. Therefore, to become CO-RMs they need some kind of activation. 
In diseased tissues, reactive oxygen species (ROS) are highly expressed and the 
use of stable MCCs that may be specifically activated by ROS inside cells seems 
a reasonable and promising strategy for targeting CO-RMs, especially if they 
have reasonable half-lives in the organism.  
Presently, very little is known about the reactivity of organometallic carbonyls 
under any of these conditions and in this Chapter the studies on this type of CO 
release profile is described. 
Most of the complexes studied do not resist ROS as triggers for CO release and 
the oxidation can be tuned by the nature of the ancillary ligand in the case of 
MnI(CO)5X, Mo0(CO)5X and CpMoII(CO)3X complexes. MnI(CO)3 and RuII(CO)3 
complexes do not respond to the ROS used. 
 
2. Introduction 
 
2.1 Reactive oxygen species and biologic oxidative processes  
 
It is well established that ROS and reactive nitrogen species (RNS) are involved 
in a wide variety of human diseases, ranging from atherosclerosis to myocardial 
infarction, cystic fybrosis, fulminant hepatic failure, neurodegenerative diseases 
and diabetes[1-5]. Sometimes they play a pivotal role as injury promoters, while in 
other settings they have a less important contribution as intermediary or signaling 
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agents. A common feature in inflammatory scenarios is the presence of high 
amounts of ROS and RNS due to a disregulation of the oxidative imbalance 
between oxidative agents and anti-oxidant defenses, a process known as oxidative 
stress. These noxious process can be fought in vivo by decreasing the oxidative 
agents or enhancing the endogenous or exogenous reducing agents. Most of these 
oxidative agents are free radicals like superoxide (O2•-), hydroxyl (OH•), peroxyl 
(RO2•), alkoxyl (RO•), hydroperoxyl (HO2•) but also some non-radicals like 
hydrogen peroxide (H2O2), hypochlorous acid (HOCl), peroxynitrite (ONO2) and 
alkylperoxides (ROOH).  
In case of injury or any kind of exogenous aggression where an immune response 
is triggered, ROS/RNS are generated through mediators like phagocytes, 
neutrophiles or macrophages that are activated to fight the injury.[6] 
All these radicals are very different in terms of reactivity or stability, and so the 
damages caused by each of the species produced are different. The difference in 
reactivity arises not only from intrinsic properties but also from the circumstances 
of the event. When a radical meets a non-radical, a new radical results and a chain 
reaction may be started, until two radicals meet to produce a non-radical and 
terminate the chain reaction. 
The most common radical reactions are summarized in Scheme 1: 
 
ADDITION: X  +  Y           [X-Y]
REDUCTION: X  +  Y           X  +  Y
OXIDATION: X  +  Y           X  +  Y
H ABSTRACTION: R3CH  +  OH           R3C  +  H2O 
Scheme 1: Main radical reactions 
 
From all the radicals produced during inflammatory processes, the hydroxyl 
radical is by far the most reactive. It has a life-span of virtually zero because as 
soon as it is formed it reacts with molecules in the vicinity making it the 
predominant species contributing to cellular damage [7-10]. It can be generated by 
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several reactions but the most common in vivo sources are the Fenton reaction 
(Eq. 1) and the reaction between hypochlorous acid and superoxide[11] (Eq. 2). 
 
H2O2 + Fe
2+             Fe(III) + OH + OH-   Equation 1 
HOCl + O2             O2 + Cl
-
 + OH     Equation 2 
 
Peroxyl and alkoxyl radicals[12-16] usually undergo molecular rearrangement to 
other radical species, often abstracting hydrogen and contributing to lipid 
peroxidation.[17, 18] However, the hydroxyl radical essentially reacts with 
everything! The type of reaction depends on the neighboring targets. It may react 
by hydrogen abstraction (e.g. initiating lipid peroxidation), addition reactions[19] 
and electron transfer[16, 20] but independently of the target, the rates of reaction are 
essentially equal. Because no discrimination is made the reactions proceed with 
all the entities at a very fast rate turning all biomolecules into scavengers.  
On the contrary, according to Sawyer[21] superoxide is “not so super” since it is 
much less reactive with non-radicals in aqueous solutions. It is produced in vivo 
(e.g. by activated phagocytic cells) and reacts quickly with NO•, Fe-S clusters and 
phenoxyl radicals (from tyrosine hydrogen abstraction) contributing directly to 
oxidative damage by several mechanisms like lowering the activity of some anti-
oxidant defences (e.g. glutathione peroxidase and catalase[22]) which facilitate 
H2O2 toxicity, generating more damaging reactive species like peroxynitrite (Eq. 
3 at scheme 2) or hydroxyl radical via Haber-Weiss reaction catalyzed by 
transition metal ions, the so-called superoxide-assisted Fenton reaction (Eq. 4 in 
scheme 2) 
However, in vivo, it’s unlikely that a large contribution to hydroxyl radical 
formation is given by Equation 4 since cells contain many reducing agents at 
millimolar concentrations (GSH, NAD(P)H, cysteine, ascorbic acid) which can 
reduce Fe(III) and Cu2+ while superoxide concentration is only at picomolar to 
nanomolar levels.[23]  
 
Evaluating ROS induced CO release from Metal Carbonyls by Gas Chromatography 
 
 
90 
 O2 + NO            ONOO      Equation 3 
  
oxidized metal complex + O2             reduced metal complex + O2
reduced metal complex + H2O2          oxidized metal complex + OH + OH
- 
 
Net reaction: H2O2 + O2                  OH + OH + O2
M catalyst
  Equation 4 
M=Fe(III/II) or Cu(II/I) catalyzed Haber-Weiss reaction[24]  
 
Scheme 2: Superoxide radical reactions to give peroxinitrite (Equation 3) and hydroxyl 
radical (Equation 4). 
 
Nevertheless the importance of superoxide can’t be neglected, mainly because 
when protonated HO2• has a higher reactivity than O2•- and is a more powerful 
reducing agent. Since it is uncharged it can enter the membrane and is also able to 
abstract H• from some isolated fatty acids such as linoleic, linolenic and 
arachidonic acid initiating lipid peroxidation. [25-28] 
Hydrogen peroxide is a weak oxidizing and reducing agent with very low 
reactivity. It is, however, toxic to most cells in the 10-100 µM range and is able to 
directly induce some cellular damage e.g. inactivating glyceraldehydes-3-
phosphate dehydrogenase, but it doesn’t react with most lipids, DNA and 
proteins. Since it is very diffusible it can cross cell membranes and react with cell 
constituents like iron and copper ions rendering much more damaging species. 
This oxidative damage is not mediated by H2O2 alone although it may degrade 
certain heme proteins[29] (including Mb, Hb, Cyt C)  to release iron ions and 
generate the hydroxyl radical.  
The reactivity of these species is not necessarily harmful, although they may 
initiate many adverse events. It is widely known that ROS and RNS play an 
important role in several pathophysiological conditions.[2, 30, 31] Given their 
oxidative potential, ROS may offer a possible targeting mechanism for site-
specific CO generation. In fact, stable metal carbonyls (like many presented in 
Chapter II) that don’t release any CO or release only marginal amounts in solution 
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in physiological medium, are electron-rich complexes, thus quite likely to be 
oxidized by ROS, thereby triggering CO release under specific conditions in 
inflamed tissues or sites.  
 
2.2 Oxidative decarbonylation of metal carbonyl complexes 
 
Although very well recognized, the oxidation of metal carbonyls with O2, 
peroxides and related species has not been systematically studied and literature is 
often contradictory and inexact regarding the nature of the gas(es) evolved during 
the oxidative process.[32, 33] A priori such a process may result in loss of 
unchanged CO or oxidation of the same to CO2. Even the low temperature matrix 
studies already mentioned in Chapter II may lead to some CO2 formation which 
accompanies CO liberation.[34]  
The oxidative decarbonylation of Cp*Re(CO)3 with O2 and light[35] and also with 
H2O2[32] was studied by Herrmann and co-workers. In the first case the ratio of 
CO:CO2 was reported to be 3:1 and in the second case 1:2. Wolowiec and 
Kochi[36] oxidized the same compound with dimethyldioxirane (DMDO) and 
determined the relative ratio of CO:CO2 as 2:1. However, this ratio showed to be 
highly dependent on the substrate concentration, the rate of DMDO addition and 
the temperature. 
The broad field of heterogeneous and homogeneous catalysis has indirectly 
become a fruitful source of information regarding metal carbonyl oxidation due to 
the industrial importance of several metal oxides. A famous example is 
methyltrioxorhenium, MeReO3, known as MTO, that is used as a catalyst in 
several significant reactions in industry, like olefin epoxidation (using H2O2 as the 
oxidant), Bayer-Villiger oxidation and aromatic oxidation.[37-39]   
Olefin epoxidation reactions are also catalyzed by Cp*MoO2Cl[40] and in the 
recent years it was found that complexes of the type CpMoO2X could be easily 
prepared by reaction of CpMo(CO)3X with tert-butylhydroperoxide (TBHP) in n-
decane at room temperature[41] with evolution of 3 equivalents of CO.[42]   
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The CpMo(CO)3R (R = alkyl, halide…) family was widely studied for catalytic 
purposes, but rarely were these studies performed in aqueous environment.[43] 
Often due to the lack of solubility in water the oxidative decarbonylation studies 
are performed in organic solvents with oxidants like TBHP.   
Apart from the catalytic studies TBHP is used to stimulate microsomal 
peroxidation in vivo. It decomposes to alkoxyl or peroxyl radicals and accelerates 
the chain reaction of lipid peroxidation attacking membrane lipids as well as fatty 
acids and lipoproteins.[44, 45]  
This set of properties designated H2O2 and TBHP as front models to simulate an 
oxidative stress environment and evaluate the potential ability of the compounds 
to release CO under oxidative conditions. It was already demonstrated that some 
compounds may release CO at higher rates depending on pH or O2 and another 
key aspect is to understand if compounds that are stable in solution can be 
oxidized and release CO as a result of an oxidative process. The main advantage 
of this approach is the possibility of preventing Hemoglobin loading with CO, 
liberated from spontaneous CO releasers. This process would allow the molecules 
to keep their full “potential” until they reach the target, promoting an in situ 
release of CO directly to the inflamed tissues. 
 
 
3. Experimental Section 
 
3.1 Methodology 
 
The CO liberated from the reaction of the MCCs with ROS species was 
quantified in the headspace with the same GC/TCD method described in Chapter 
II. The decomposition reactions were done under inert atmosphere (N2), at room 
temperature in the same apparatus of Fig.1 (Chapter II) or in calibrated vials. Two 
biological relevant oxidants were used: hydrogen peroxide (H2O2 30% in water) 
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and tert-butylhydroperoxide ((CH3)3COOH 70% aqueous solution). The 
concentration of O2•-, H2O2 and OH• in normal cells is in the order of 10-11, 10-9 
and 10-15 M, respectively, but in inflamed tissues may rise up to 10-3 M. Based on 
these values it was decided to test the compounds with a large excess of oxidant 
over the substrate. The standard conditions of 100:1 (oxidant:MCC) molar ratio 
were set up with typical H2O2 and TBHP concentrations of 0.9M. Under these 
conditions any reaction between the MCC and the peroxide will be easily 
identified and quantified in terms of the amount of CO liberated. Other gases, like 
CO2 or O2 which can be formed in these reactions by oxidation of CO or by 
decomposition of H2O2 are also identified and quantified in the same GC/TCD 
set-up.  
Gas Chromatography: 
Method description: 
The reactions were performed using tert-butyl hydroperoxide (70% aqueous 
solution from Aldrich) and H2O2  (30% aqueous solution from Aldrich) as 
solvents. The reactions were carried out at room temperature, under N2, without 
light and samples were taken with a Gastight syringe from Hamilton® after 1, 3, 5 
and 24 h and analyzed. CO and CO2 were quantified using a calibration curve 
recorded prior to the reaction course. Blank reactions were performed with water 
and t-BuOOH or H2O2 (without compound) and showed that no CO or CO2 was 
liberated. The H2O2 used was titrated prior to use. 
 
Reactions of CpMo(CO)3CH2CONH2 with [Cp2Fe]BF4, AgNO3 and AgBF4  
(IR and GC): 
The reaction between equimolar amounts of [Cp2Fe]BF4 and 
CpMo(CO)3(CH2CONH2) was performed in a closed vial, with 2 mL of solvent 
(H2O, dichloromethane, acetone, THF and acetonitrile) at room temperature, 
under N2 and in the dark. Gas samples were taken after 1h and quantified in the 
GC. The reaction with acetonitrile was extended to 24h. 
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In addition, IR solution spectra were acquired after finishing the reactions and the 
background acquired in the proper solvent. 
The analogous reaction of CpMo(CO)3(CH2CONH2) with AgBF4 (in 
dichloromethane) was performed both in 1:1 and 1:10 molar ratios at room 
temperature, under N2 and in the dark. Samples were analyzed by Gas 
Chromatography after 24h and the final product analyzed by 1H NMR after 48h. 
In a parallel setup the same reaction was performed and samples were taken 
periodically and a solution IR spectrum acquired after 30min, 3h, 5h and 24h. 
The same reaction was performed with AgNO3 (in H2O) also in 1:1 and 1:10 
ratios. Samples were taken to GC analysis after 24h and the final product was also 
characterized by IR and 1H NMR.  
 
3.2 Technical Details 
 
Synthetic Work: 
All the compounds were prepared as indicated in Table A1 in Annex I.  
 
 
4. Results and Discussion 
 
A series of experiments was performed to determine the possibility of using ROS, 
modeled by H2O2 and TBHP to trigger CO release from MCCs.  The compounds 
were selected from Table A1, Annex I, and the presentation of the results is done 
according to the metal selected for possible biological applications, namely, Mn, 
Mo, and Fe. The studies performed with Ru CO-RMs will be addressed in 
Chapter V. 
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The objectives of the present screening are 
i. identify the compounds that are reactive towards H2O2 or TBHP;  
ii. identify the nature of the gaseous products of these oxidation reactions;  
iii. identify any different reactivity (selectivity) between both these ROS 
models. 
 
At the outset is seems quite obvious that most, if not all, MCCs will react with 
these oxidants, because, as it has been already pointed out, MCCs usually contain 
metals in low oxidation states and are expected to be rather electron rich, 
therefore, prone to being oxidized. However, the kinetic stability to such 
oxidations may be high and prevent reaction between certain MCCs and 
peroxides at useful rates. Once again, two kinds of extreme pathways are 
available for reaction: outer sphere and inner sphere electron transfer between the 
MCC and the peroxide. Like in the case of the reaction between O2 and a MCC, 
outer sphere electron transfer from the electron rich MCC to the oxidizing, 
electron accepting peroxide will result in the formation of a 17-electron MCC 
complex which will be highly activated towards CO substitution (see scheme 5 in 
Chapter I).  
In the case of an inner sphere mechanism the peroxide molecule will act as any 
other nucleophile and bind to the metal center of the MCC following a normal 
ligand substitution process. Once coordinated to the metal, electronic 
rearrangement leads to formal oxidation of the metal which triggers further 
modifications in the coordination sphere. In the case of MCCs, the main 
possibilities are: release of CO, release of CO2 by oxidation of CO, release of O2 
by metal catalyzed decomposition of the peroxide. Of course, this bonding 
interaction between the peroxide and the metal will be different for H2O2 and 
TBHP or other alkylhydroperoxides. The fate of the metal will be much more 
difficult to predict but formation of oxo, peroxo, hydroxo and aqua complexes is 
most likely, depending on the nature of the metal, pH and the nature of the 
biological ligands present in the medium. Most likely a number of species will be 
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formed in the final equilibrium which will be defined by the reaction conditions, 
namely the nature and concentration of the biological ligands, pH and the 
concentration of the complex as well as the nature and concentration of the ROS.  
Also important to note is the different aqueous chemistry of each of the metals 
under study. To give an example, the final oxidation products of Mo in aqueous 
solution are likely to be molybdate or polyoxomolybdates, depending on the pH, 
which are the most stable water soluble forms of MoO3, the final product of 
combustion of Mo metal.[46] In the cases of Mn and Fe complexes the nature of 
the final oxidation state of the metal ion is not so obvious. Therefore, it is more 
useful to organize the discussion of the screening on a metal by metal basis.   
Given all this complexity, it is expectable that almost each kind of MCC to be 
tested will represent a different case where the nature of the products, reaction 
intermediates and mechanisms will be different. The expected wide variation of 
mechanistic details is not a problem since they are not necessary to achieve the 
operational objectives i)-iii) above.  Later detailed studies may be required on 
specific complexes that have been shown to possess relevant 
biological/therapeutic activity and are selected for further development as 
therapeutic CO-RMs.  
 
4.1 The Manganese compounds 
 
The results obtained on the CO release profiles induced by H2O2 and TBHP on a 
small number of selected Mn carbonyls are summarized in Table 1. This small 
collection of compounds exemplifies different profiles that cover the main 
possible situations of CO release stimulation by ROS in Mn carbonyls.  
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Table 1: Equivalents of CO and CO2 released by the manganese compounds with 100 
equiv. molar excess of TBHP and H2O2 in water. Gas samples were taken after 1h, 3h, 5h 
and 24h and quantified by GC/TCD.  
TBHP H2O2 
Compound 
Equiv. CO 
released 
after 6h in 
RPMI 
CO CO2 CO CO2 
Time of 
reaction 
CO
Mn
CO
CO
OC Br
OC
 
 
1 
 
1.6 
1.2 
3.0 
3.6 
3.7 
0.2 
0.6 
0.8 
0.9 
1.0 
3.1 
3.7 
3.5 
0.2 
0.6 
0.8 
1.1 
1h 
3h 
5h 
24h 
Mn
OC
OC
CO  
 
2 
0.0 
0.0 
0.1 
0.0 
0.1 
0.0 
0.0 
0.0 
0.2 
0.0 
0.0 
0.0 
0.2 
0.1 
0.1 
0.2 
0.5 
1h 
3h 
5h 
24h 
CO
Mn
OC
OC
CO
Mn
CO
COBr
Br
Br [NEt4]
 
 
3 
0.0 
0.1 
0.8 
1.6 
4.3 
0.0 
0.0 
0.0 
0.1 
0.8 
1.4 
1.8 
4.1 
0.0 
0.0 
0.0 
0.0 
1h 
3h 
5h 
24h 
OC Mn
OC
CH2
CO
CO
OC
C
O
NH2
 
 
4 
0.3 
2.0 
2.8 
3.0 
2.9 
0.4 
0.8 
1.0 
1.2 
1.2 
1.2 
1.3 
1.4 
0.1 
0.3 
0.3 
0.4 
1h 
3h 
5h 
24h 
 
Br
Mn
CO
CO
CO
OC
OC
trimeb  
 
5 
 
1.1 
0.5 
2.6 
2.8 
2.8 
0.1 
0.5 
0.7 
0.8 
1.3 
1.7 
1.4 
1.4 
0.4 
0.2 
0.2 
0.4 
1h 
3h 
5h 
24h 
 
 
Among the compounds selected, 2, 3 and 4 do not spontaneously release CO in 
RPMI after 6h under the standardized conditions of Fig. 1 in Chapter II.  The 
other two, 1 and 5 release relatively small amounts, 33% and 22%, respectively. 
Compound 2 (CMT discussed in chapter II) is completely inert towards oxidation 
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by both peroxides. This is a very rare case but fits in with the tremendous 
oxidative stability of CpM(CO)3 complexes (M = Mn, Tc, Re). In fact, 
CpMn(CO)3 has been commercialized as an antiknock gasoline additive. Its 
oxidative electrochemistry has only been addressed recently.[47]  
This stability allows the use of CpTc(CO)3 derivatives in radioimaging 
applications.[48, 49] The cold counterpart of the useful 99mTc complex, CpRe(CO)3, 
has been found to be stable in circulation and recovered after excretion with the 
Cp ring hydroxilated. This metabolic pathway resembles that of benzene and 
other aromatic rings.[50] Of course, one might blame this inertness on the total 
insolubility of the compound in the aqueous reaction media. However, as will be 
seen in other examples insolubility alone does not prevent oxidation under these 
conditions.   
In contrast, both water soluble complexes 3 and 4 are strongly activated by TBHP 
and H2O2. The former does not show a preference for any of the peroxides but the 
later is clearly more reactive towards TBHP.  3 represents a situation where the 
fac-MnI(CO)3 fragment was no longer able to deliver CO because it had reached 
high substitutional stability, even under O2.  Table 1 shows that ROS can induce 
CO release from this kind of fragment. In a way, 3 exemplifies some of the 
properties of one kind of desirable profile for a CO-RM: some solubility and good 
stability in aqueous solution which is reversed in the presence of ROS to liberate 
CO in inflamed tissues.  
Complex 3 does not catalyze the oxidation of CO to CO2. Interestingly, 4 which is 
also water soluble and stable in aqueous biological solutions would be expected to 
have a similar oxidative chemistry. Instead, it reacts differently with TBHP and 
H2O2 and liberates CO and CO2 in ca. 3:1 ratio. Moreover, this oxidation is very 
fast and essentially terminated after 3h of reaction in TBHP or 1h in H2O2.  Some 
CO in the initial compound is wasted by oxidation to CO2 a process most likely 
catalyzed by some Mn species.  
Compound 1 is a spontaneous CO releaser in aqueous biological aerobic 
solutions. Nevertheless, both TBHP and H2O2 strongly activate this release and 
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the compound liberates its CO load as a CO:CO2  mixture (ca. 4:1), in an 
essentially quantitative way after 5h reaction.   
Complex 5 is formed by encapsulation of 1 in TRIMEB, a functionalized form of 
β-cyclodextrin. The result of this encapsulation is the reduction of its spontaneous 
CO release output by 33%. In the case of the reaction with TBHP, after 5h, this 
inhibition is only 21%. This is surprising because it could be expected that the 
size of TBHP would make its interaction with the encapsulated MCC more 
difficult. This simple expectation is not obviously met.  However, when H2O2 is 
used as oxidant, the inhibition of CO release is 62% and, interestingly, the ratio 
CO:CO2 increases to 7:1 which reveals a strong interference of the encapsulation 
on the mechanism of oxidation of 1 by H2O2. 
 
4.2 The Molybdenum compounds 
 
The number of Molybdenum carbonyls tested is much larger and covers a wider 
spectrum of behaviors. To simplify the discussion and allow a more systematic 
analysis of results, the compounds are arranged in several tables according to their 
structural type and reactivity profiles. 
The influence of solubility on CO release is a recurrent problem in all the 
screenings and will be discussed right at the beginning of this study.  
The compounds assembled in Table 2 were chosen to evaluate the importance of 
solubility in the ROS induced profile of CO release. They are all totally insoluble 
in the aqueous reaction medium, yet they all react slowly with TBHP and H2O2 to 
liberate CO. 
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Table 2: Equivalents of CO and CO2 released by some insoluble molybdenum 
compounds with 100 equiv. molar excess of TBHP and H2O2 in water. Gas samples were 
taken after 1h, 3h, 5h and 24h and quantified by GC/TCD. 
TBHP H2O2 Compound 
Equiv. CO 
released 
after 6h in 
RPMI CO CO2 CO CO2 
Time of 
reaction 
 
CO
Mo
CO
CO
CO
N
N
 
6 
0.0 
0.1 
0.3 
0.6 
2.4 
0.0 
0.1 
0.2 
0.7 
0.0 
0.3 
0.5 
1.8 
0.0 
0.1 
0.2 
0.5 
1h 
3h 
5h 
24h 
 
S
S
S
Mo
OC
OC
CO  
 
7 
0.0 
0.0 
0.4 
0.8 
1.9 
0.0 
0.2 
0.5 
1.4 
0.2 
1.2 
1.5 
1.4 
0.1 
0.9 
1.2 
1.2 
1h 
3h 
5h 
24h 
Mo
OC
OC CO
O
F2
B
O
 
8 
0.2 
0.0 
0.1 
0.2 
0.9 
0.0 
0.0 
0.0 
0.1 
0.1 
0.1 
0.2 
0.7 
0.0 
0.0 
0.0 
0.1 
1h 
3h 
5h 
24h 
 
 
With 6, after 24h reaction time the amount of CO liberated is significantly larger 
than the one obtained after 5h. The reaction is also more extensive with TBHP 
than with H2O2. The other two compounds show the same reactivity trends but are 
still slower releasers in aqueous solution. It is nevertheless important to realize 
that complex 7 loses all its CO as a mixture of CO and CO2 after 24h reaction 
with TBHP.  On the other hand, with H2O2 the reaction is completed after 5h 
reaction time. This behavior is totally opposite to complex 8 which is highly inert 
during the first 5h of reaction and only after 24h reaction high amounts of CO are 
liberated.  
When complex 6 is reacted with TBHP in n-decane using dichloromethane as 
solvent instead of water, a much faster reaction is observed with evolution of 
roughly 2.5 equiv. CO and 1 equiv. CO2 (Table 3). A white powder which showed 
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the characteristic Mo=O stretching vibrations at 901, 931cm-1 was obtained at the 
end of the reaction but wasn’t fully characterized.  
The interesting observation though, is that the results obtained in dichloromethane 
after ca. 8h are very similar to the results obtained in water after 24h. This 
similarity suggests that insolubility is mainly delaying the aqueous reaction, since 
the outcome of the experiment is essentially the same in the long term. However, 
no reliable analysis of the results can be made at shorter reaction times. 
In any case, it seems reasonable to conclude that lack of reaction of a given MCC 
with TBHP or H2O2 in water after 24h really corresponds to an oxidatively stable 
compound, as shown before for CpMn(CO)3. 
Table 3: Equivalents of CO and CO2 released by 6 dissolved in CH2Cl2 with 10 equiv. 
molar excess of TBHP in n-decane. Gas samples were taken after 1h, 3h, 5h, 8h and 24h 
and quantified by GC/TCD. 
Time/Hours Equiv. CO Equiv. CO2 
1 
3 
5 
8 
24 
1.0±0.1 
1.9±0.1 
2.2±0.0 
2.5±0.0 
2.6±0.0 
0.2±0.1 
0.6±0.1 
0.8±0.1 
0.9±0.1 
0.9±0.1 
 
 
After these initial tests, a series of eight derivatives of the (η5-C5R5)Mo(CO)3R 
family was studied and the results are shown in Table 4.  
 
Table 4:  Equivalents of CO and CO2 released by (η5-C5R5)Mo(CO)3R compounds with 
100 equiv. molar excess of TBHP and H2O2 in water. Samples were taken after 1h, 3h, 5h 
and 24h. Gas samples were taken after 1h, 3h, 5h and 24h and quantified by GC/TCD. 
TBHP H2O2  
Compound 
Equiv. CO 
released after 
6h in RPMI CO CO2 CO CO2 
Time of 
reaction 
Mo
OC
OC CO
Cl
 
 
9 
0.4 
0.4 
1.7 
2.6 
2.9 
0.0 
0.2 
0.3 
0.3 
0.1 
0.5 
1.1 
2.9 
0.0 
0.0 
0.1 
0.4 
1h 
3h 
5h 
24h 
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Mo
OC
OC CO
I
 
 
10 
0.0 
0.0 
0.1 
0.3 
2.0 
0.0 
0.0 
0.2 
1.2 
0.7 
1.4 
1.6 
1.1 
0.3 
1.1 
1.2 
0.9 
1h 
3h 
5h 
24h 
 
Mo
OC
OC CO
CH3
 
 
11 
0.0 
0.4 
1.4 
1.9 
2.1 
0.0 
0.1 
0.2 
0.3 
0.2 
0.7 
1.1 
1.7 
0.0 
0.0 
0.0 
0.1 
1h 
3h 
5h 
24h 
Mo
OC
OC CO
O
NH2 
 
12 
0.7 
0.5 
1.4 
1.7 
1.9 
0.1 
0.3 
0.4 
0.5 
1.4 
2.3 
2.3 
2.3 
0.1 
0.2 
0.3 
0.3 
1h 
3h 
5h 
24h 
Mo
OC
OC CO
O
OH 
 
13 
0.8 
0.0 
0.0 
0.0 
0.2 
0.0 
0.0 
0.0 
1.2 
0.0 
0.1 
0.2 
1.4 
0.0 
0.0 
0.0 
0.2 
1h 
3h 
5h 
24h 
 
Mo
O
OMe
OC Cl
OC CO  
 
14 
0.2 
0.2 
1.2 
1.9 
1.9 
0.0 
0.5 
0.8 
0.9 
0.4 
1.1 
1.3 
1.1 
0.2 
0.6 
0.7 
0.6 
1h 
3h 
5h 
24h 
 
Mo
OC
OC CO
Cl
 
 
15 
0.0 
0.2 
1.0 
1.6 
2.3 
0.1 
0.3 
0.4 
0.7 
0.0 
0.1 
0.2 
1.8 
0.0 
0.0 
0.0 
0.3 
1h 
3h 
5h 
24h 
OC
CO
CO
Mo
Cl
trimeb  
 
16 
0.5 
0.2 
1.0 
1.6 
2.0 
0.0 
0.1 
0.2 
0.3 
0.4 
1.6 
1.9 
1.6 
0.0 
0.1 
0.2 
2.1 
1h 
3h 
5h 
24h 
 
The first observation regards the selectivity of the complexes towards both 
oxidants. Looking at the late stages of the reaction, that is 24h reaction time, only 
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two compounds show a stronger release with H2O2: 12 and 13. More extensive 
reactions with TBHP are found for all other compounds except 9 that gives 
almost identical results with both oxidants. In fact, this compound loses 
quantitatively the three carbonyls to CO and CO2 in a ca. 8:1 ratio with both 
TBHP and H2O2, respectively, at 24h. However, the reaction is faster with TBHP 
up to 5h. The later results agree with those reported previously for the oxidative 
decarbonylation of 9 in non-aqueous medium.[42] The reaction was performed in 
CH2Cl2 with 10 equivalents of TBHP in decane and was completed in 3 to 4h 
with 3 equivalents of CO released and a CO/CO2 ratio of ≈ 80 . The in situ 
decarbonylation led to metal-oxo complexes like CpMoO2Cl which are active 
olefin epoxidation and thioether oxidation catalysts with TBHP as oxidant.[41]  
Somewhat surprisingly, the replacement of chloride by iodide has a strong effect 
on the reactivity with both oxidants. Indeed, CpMo(CO)3I (10) reacts initially in a 
very slow rate with TBHP but the reaction goes almost to completion at 24h 
although with a higher amount of CO2 being formed (CO:CO2 = 2:1.2). On the 
other hand, the same CpMo(CO)3I reacts initially with H2O2 at a rate similar to 
that observed for the chloride analogue, but the reaction comes to an halt after ca. 
3h, again with  CO:CO2 < 2:1. Such behavior suggests the formation of 
intermediate species along the reactions, most likely oligomeric species, which 
change the course of the reaction and/or slow down CO release.  
The alkyl analogue of these two compounds, CpMo(CO)3CH3 (11), shows a very 
smooth oxidation profile with both oxidants but is clearly faster with TBHP. Like 
in the case of 9, the oxidative decarbonylation of CpMo(CO)3CH3 was already 
studied for catalytic epoxidation[51] in non-protic media, but the CO/CO2 release 
was not quantified. To allow a comparison between organic and aqueous medium 
the study of the CO release profile under the catalytic conditions (in CH2Cl2 with 
10 equiv. molar excess of TBHP in n-decane) was performed and the results are 
given in Table 5.  
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Table 5: Equivalents of CO and CO2 released by 11 dissolved in CH2Cl2 with 10 equiv. 
molar excess of TBHP in n-decane. Gas samples were taken after 1h, 2h, 5h and 24h and 
quantified by GC/TCD. 
Time/Hours Equiv. CO Equiv. CO2 
1 
2 
5 
24 
0.2±0.0 
0.6±0.0 
1.7±0.0 
2.2±0.1 
0.0±0.0 
0.0±0.0 
0.0±0.2 
0.7±0.2 
 
 
Despite a slightly slower initial rate of CO release in dichloromethane, the results 
of both assays become very close after 5h with 1.7 equiv. of CO liberated in 
organic medium against 1.9 equiv. in aqueous solution. The final amount of CO 
released (2.2 equiv.) is nearly the same in both conditions although a higher 
amount of CO2 is formed in CH2Cl2 solution. These data show that all the 
carbonyls were released but 23% are lost as CO2 while in aqueous solution only 
9% CO2 was produced. Importantly, no CH4 was formed in any of the reactions 
either in water or in CH2Cl2. Therefore, it is quite likely that oxo species as the 
well known CpMo(O)2CH3[52] are formed under these conditions in a controlled 
way. 
Introducing a functionalization at the alkyl substituent, as in the cases of 
CpMo(CO)3{CH2C(O)NH2)} (12) and CpMo(CO)3{CH2C(O)OH} (13) produces 
a drastic change in the reactivity of the complexes.  
As already noted above these two compounds are the only in the list that show a 
stronger release with H2O2. In fact, 13 doesn’t even react with TBHP at 24h and 
stimulation with H2O2 only produced appreciable amounts (1.4 equiv. CO; 47% of 
the total CO contents) after 24h. In contrast, 12 reacts smoothly with TBHP 
(similar to the alkyl analogue) but shows a very strong activation in the presence 
of H2O2 which is completed before 3h reaction time. This reaction is discussed 
below in a closer detail.  
The three last compounds in table 4 introduce different types of perturbations 
relative to CpMo(CO)3Cl. 
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The introduction of an electron withdrawing group on the cyclopentadienyl ring 
as in (η5-C5H4C(O)OMe)Mo(CO)3Cl (14), does not alter the relative reactivity 
towards TBHP and H2O2 in a very significant way but reduces the reactivity in 
both instances relative to CpMo(CO)3Cl. It seems that the electron-withdrawing 
effect of the substituent on the ring makes the compound a little more difficult to 
oxidize and, therefore, a slower releaser compared to its parent, unsubstituted 
congener. This is a logical and expected variation. Some increase in steric 
hindrance may also contribute to slow down the reaction. 
The presence of five methyl substituents on the ring in Cp*Mo(CO)3Cl (15) 
should have the opposite effect: the metal becomes more electron rich and is 
easier to oxidize than the parent unsubstituted CpMo(CO)3Cl. However, the 
increased steric bulk introduced by the five methyl substituents together with the 
increase in the Mo-CO bond strength resulting from a better π-backdonation from 
the richer Mo to the CO ligands should make the approach of the oxidants to the 
inner sphere of the complex much more difficult and, therefore, retard the 
reactivity of the complex with both TBHP and H2O2. In other words, this kind of 
substitution might favor an outer sphere electron transfer reaction between the 
complex and the oxidant but disfavor an inner sphere oxidation mechanism that 
requires coordination of the peroxides to the metal.  
The experimental results in Table 4 reveal not only a general decrease in 
oxidation rates but also a widening of the reactivity gap between 15 and 9 from 0 
to 5h reaction time.  While the reaction with H2O2 was clearly disfavored (7% CO 
released for 15 vs 35% for 9 at 5h), that with TBHP occurred smoothly (52% at 
5h for 15) albeit slower than that of 9 (88% at 5h). This fact strongly suggests that 
there is an important mechanistic difference between the oxidation induced by 
TBHP and by H2O2 in these complexes. This difference is also apparent in the 
studies of catalytic oxidation performed with both types of systems, that is 
Cp’Mo(CO)3X/TBHP vs Cp’Mo(CO)3X/H2O2 and will be further infirmed below 
in the context of the detailed study of the  oxidation  of 
CpMo(CO)3{CH2C(O)NH2)}. 
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In any case, the overall effect of introducing substituent groups on the Cp ring 
showed a reactivity decrease relative to the parent unsubstituted compounds. 
From the molecules studied, 9 is the only that loses 3 carbonyls with both 
oxidants, effectively as CO, similarly to what was demonstrated in organic 
medium.   
As expected,[53] encapsulation of 9 in TRIMEB (CpMo(CO)3Cl@TRIMEB) (16) 
clearly decreased the rate of decarbonylation. With TBHP only 2.0 equiv. CO are 
released after 24h against 3 equiv. of the free compound 9. The difference in the 
amount of CO released for 9 and 16 after 5 h was 1 equivalent and this difference 
was maintained up to 24 h with a final CO:CO2 ratio close to 8:1. With H2O2, 
decarbonylation of 16 starts faster but at 24h when completion is attained, the 
CO:CO2 ratio is close to 0.8. This means that somehow encapsulation has 
changed the pathway of the oxidative reaction with H2O2 and produced an oxidant 
species capable of oxidizing CO to CO2 in good yields. Furthermore the total 
amount of CO + CO2 at 24h (3.7 equivalents) exceeds that of the initial CO (3 
equivalents) so that the oxidant which is formed is capable of oxidizing either the 
cyclodextrin or the Cp ring.  
Again, the difference between activation by H2O2 and TBHP is notorious and may 
lead to different chemical outcomes.  
Besides, it seems clear that the host:guest interaction is relatively strong in 
aqueous solution and that association of the complex with the cyclodextrin 
strongly reduces its reactivity towards the oxidants (including O2 as seen in 
chapter II, table 8). 
Information on the oxidation reactions of a last group of Mo carbonyls complexes 
all containing the fragment Mo(CO)5 is collected in Table 6.  In terms of 
spontaneous CO release, these compounds vary from high stability in aerobic 
aqueous RPMI solution, as the cyano (19) and the phosphine derivatives (21-24) 
to a rather high instability that gives rise to an extensive and fast CO release, as 
found for the sparingly water soluble [NEt4][Mo(CO)5Br] (17). Another 
subdivision of these complexes can be made according to their charge since five 
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of them are anionic and the other three are neutral. However, there is a large 
chemical difference between the effects expected from a metal based negative 
charge as in (X = Br, I, CN) (17-19) and those expected from a highly ionizable 
charge located at the distal, non-coordinating end of the structure of the 
phosphonated triphenylphosphine derivative (24). Indeed, the chemistry of 
P(C6H5SO3Na)3 is recognized as essentially similar to that of PPh3 with the 
exception that it allows its complexes to be water soluble.[54, 55] For this reason the 
next discussion considers the complex [Mo(CO5)P(C6H5SO3Na)3] as a “neutral” 
species like the other PR3 derivatives considered. 
 
Table 6: Equivalents of CO and CO2 released by molybdenum pentacarbonyl compounds 
with 100 equiv. molar excess of TBHP and H2O2 in water. Gas samples were taken after 
1h, 3h, 5h and 24h and quantified by GC/TCD. 
TBHP H2O2 
Compound 
Equiv. CO 
released in 
RPMI 
after 6h 
CO CO2 CO CO2 
Time of 
reaction 
CO
Mo
CO
CO
OC Br
OC
[NEt4]
 
17 
2.4 
2.5 
3.8 
3.9 
3.9 
0.5  
1.0  
1.1  
1.1 
1.1 
1.5 
1.5 
1.4 
0.4  
0.8  
0.9  
0.9 
1h 
3h 
5h 
24h 
CO
Mo
CO
CO
OC I
OC
[NBu4]
 
18 
1.0 
0.5 
1.8 
3.5 
4.3 
0.0 
0.2 
0.6 
1.0 
1.3 
3.0 
3.2 
--- 
0.1 
0.4 
0.5 
--- 
1h 
3h 
5h 
24h 
CO
Mo
CO
CO
OC CN
OC
Na
 
19 
0.5 
1.6 
2.9 
3.1 
3.1 
0.4 
0.7 
0.7 
0.8 
1.8 
2.8 
2.6 
--- 
0.7 
1.3 
1.2 
--- 
1h 
3h 
5h 
24h 
OC CO
CO
Mo
CO
trimeb
OC Br
Et4N
 
20 
1.6 
1.9 
2.9 
3.2 
3.2 
0.4 
0.9 
1.0 
1.1 
1.7 
2.4 
2.6 
2.2 
1.0 
1.6 
1.8 
1.6 
1h 
3h 
5h 
24h 
CO
Mo
CO
CO
OC P(CH2OH)3
OC
 
21 
0.0 
0.0 
0.0 
0.1 
0.4 
0.0 
0.0 
0.0 
0.2 
0.2 
2.7 
4.6 
4.5 
0.0 
0.1 
0.2 
0.3 
1h 
3h 
5h 
24h 
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CO
Mo
CO
CO
OC P(CH2CH2CH2OH)3
OC
 
22 
0.0 
0.0 
0.0 
0.0 
0.3 
0.0 
0.0 
0.0 
0.1 
0.1 
2.4 
3.9 
2.6 
0.0 
0.4 
0.2 
0.2 
1h 
3h 
5h 
24h 
CO
Mo
CO
CO
OC P(CH2CH2CO2H)3
OC
 
23 
0.2 
0.0 
0.0 
0.0 
0.1 
0.0 
0.0 
0.0 
0.1 
0.1 
0.5 
1.7 
1.7 
0.0 
0.0 
0.1 
0.1 
1h 
3h 
5h 
24h 
CO
Mo
CO
CO
OC P(C6H4SO3Na)3
OC
 
24 
0.0 
0.0 
0.1 
0.2 
1.1 
0.0 
0.0 
0.1 
0.4 
0.2 
0.4 
0.6 
1.3 
0.0 
0.1 
0.1 
0.3 
1h 
3h 
5h 
24h 
 
In terms of the relative reactivity with TBHP and H2O2, the anionic complexes are 
more reactive towards TBHP than towards H2O2 whereas the neutral ones are 
essentially unreactive with TBHP but reactive towards H2O2.  Insolubility of the 
PR3 derivatives is not the cause of such low reactivity because the water soluble 
24 is also rather unreactive towards aqueous TBHP.  
Although 17 and 18 are recognizedly substitutionally labile, the cyanide complex 
19 is not. Yet their rates of reaction with TBHP are relatively close to each other. 
Certainly, TBHP is able to trigger its oxidation reactions in a different mode than 
H2O2. A priori, the substitutional inertness of the PR3 complexes suggested a very 
low reactivity towards both TBHP and H2O2. This is the case for TBHP but not 
for H2O2 which oxidizes the complexes. It is possible that oxidation of the PR3 
ligand to the labile phosphine oxide OPR3 is the actual trigger to the oxidation of 
the neutral PR3 complexes by H2O2.  This interpretation is entirely consistent with 
the observation that the amount of CO released is inversely correlated to the bulk 
of the PR3 substituents. Even without quantifying cone angles for these 
phosphines the increase in this bulk rises obviously in the order: 
 
R= CH2OH < CH2CH2CH2OH < CH2CH2CO2H  < C6H5SO3-. 
 
The higher bulk of TBHP might be enough to block any reaction within this 
family of complexes. Yet, the smaller size of some phosphines might still allow 
H2O2 to interact with the coordinated P atom and oxidize it. Once OPR3 is formed 
. ,~ 
',' 
. ,~ 
, , . 
. ,~ 
, , , 
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it will be rapidly lost leaving a vacancy that will allow for faster oxidation of the 
Mo center by coordinated H2O2.  This peroxide attack at the empty orbitals of the 
P atom of coordinated PR3 is essentially of the same kind proposed to explain the 
2nd order, associative term in the substitution reactions of M(CO)5PR3 complexes 
(M = Mo, W).[56]  
Encapsulation of 17 in TRIMEB produced a modest decrease of the rate of CO 
release induced by TBHP from 20 relative to the free metal carbonyl compound. 
Interestingly, the reverse happened with regard to the reaction with H2O2 which is 
actually faster for 20 than for the free metal carbonyl compound 17.    
In any case, all examples shown reveal that interaction of [Mo(CO)5L]0/- 
complexes with peroxides leads to a faster and more extensive liberation of CO 
which can reach 4 equivalents: 18 could triplicate the amount of CO 
spontaneously released while 19, previously a non-releaser, is able to release 
nearly 3 COs in a short period of time (3h). With TBHP the CO:CO2 ratio is 
usually close to 4:1 and there are no signs of the formation of a strong oxidation 
catalyst during the reaction which might lead to higher values for CO2. 
Nevertheless, reactions of the anionic complexes in water essentially sacrifice one 
equivalent of CO via oxidation to CO2. As an example, the reaction of 17 with 
TBHP in water gives a CO:CO2 ratio of 4:1 but in CH2Cl2 solvent with TBHP/n-
decane leads to the essentially quantitative liberation of 5 equivalents of CO and 
only a small amount of CO2 as can be seen in table 7.  
Reactivity with H2O2 is not so consistent. The reaction is always incomplete and 
none of the compounds released the 5 carbonyls. The maximum amount liberated 
is roughly 4 equiv. (3CO + 1CO2) and in general lower amounts of CO are 
obtained. 
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Table 7: Equivalents of CO and CO2 released by 17 dissolved in CH2Cl2 with 10 equiv. 
molar excess of TBHP in n-decane. Gas samples were taken after 5min, 30min, 1h, 
1h30m, 2h and 3h and quantified by GC/TCD. 
Time Equiv. CO Equiv. CO2 
5min 
30min 
1h 
1h30min 
2h 
3h 
0.9±0.2 
2.9±0.1 
4.1±0.1 
4.4±0.1 
4.7±0.1 
4.9±0.1 
0.0±0.0 
0.0±0.2 
0.1±0.2 
0.1±0.2 
0.2±0.2 
0.2±0.2 
 
 
Comparing the several instances tested, it is fair to say that the parallelism 
observed between the oxidation assays in organic and aqueous medium shows 
that the reaction course is the same in both situations. The main differences are 
kinetic aspects since the reaction in aqueous solution is slower and sometimes is 
incomplete. These results show that the “oxidative yield” is comparable after 24h 
and the different rates observed within the first hours of the assay may indeed be 
partially influenced by solubility factors. 
 
4.3 The Iron compounds 
 
The group of iron carbonyl complexes examined with regard to ROS induced CO 
release is presented in Table 8. It is a modest sample in terms of the vast amount 
of Fe-carbonyl complexes available in the literature but features two types of 
structurally important species in terms of putatively useful CO release profiles for 
therapeutic applications. The cyclopentadienyl containing complexes of the type 
Cp’Fe(CO)2X are readily available, usually fairly air stable complexes which can 
be modified at the Cp and X ligands to provide for adequate tuning of their 
solubility and biocompatibility as well as CO release properties. Under the 
conditions of these tests, they will release CO to the headspace irreversibly like 
all compounds studied and examined up to this point. On the contrary, the 
example of the second type of Fe carbonyl complexes chosen for this study, 
Fe(cyst)2(CO)2, is a  reversible CO carrier where the moiety Fe(cyst)2 loses CO 
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which after being lost may be recaptured at atmospheric pressure.[57, 58] This 
compound has even been claimed to play a role in the homeostasis of CO and 
Fe2+ liberated by Heme-Oxygenase and part of catalytic oxidation of Cysteine in 
cells.[59] At the outset of these experiments we were also aware of the difficulties 
that might arise due to the well established chemistry involving Fe ions and 
peroxides. However, no predictions could be made on a safe basis.   
Table 8: Equivalents of CO and CO2 released by some iron compounds with 100 equiv. 
molar excess of TBHP and H2O2 in water. Gas samples were taken after 1h, 3h, 5h and 
24h and quantified by GC/TCD. 
TBHP H2O2 
Compound 
Equiv. CO 
released in 
RPMI after 
6h 
CO CO2 CO CO2 
Time of 
reaction 
Fe
CO
C
O
CH3
OC
 
28 
0.0 
0.0 
0.0 
0.0 
0.2 
0.0 
0.0 
0.0 
0.2 
0.6 
0.6 
0.3 
0.1 
0.5 
2.5 
2.8 
2.1 
1h 
3h 
5h 
24h 
Fe
OC
OC
Cl
 
29 
0.5 
0.0 
0.0 
0.2 
0.8 
0.0  
0.0  
0.1  
1.0 
0.8 
0.7 
0.5 
0.4 
1.4 
2.6  
2.3  
2.1 
1h 
3h 
5h 
24h 
Fe
OC
OC
I
 
30 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.1 
0.0 
0.2 
0.3 
1.0 
0.0 
0.2 
0.2 
1.6 
1h 
3h 
5h 
24h 
Fe Fe
OC
C
O
O
C
CO
 
31 
0.0 
0.0 
0.1 
0.1 
0.6 
0.0 
0.1 
0.1 
0.6 
0.0 
0.2 
0.4 
0.9 
0.0 
0.3 
0.7 
4.1 
1h 
3h 
5h 
24h 
Fe
NH2
O
OC
CO  
32 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.1 
0.4 
0.3 
0.5 
0.5 
0.5 
0.4 
0.8 
0.9 
1.0 
1h 
3h 
5h 
24h 
Fe
OC
OC
CH3
 
33 
0.0 
0.1 
0.2 
0.2 
0.2 
0.2 
0.4 
0.6 
0.7 
0.2 
0.2 
0.3 
0.3 
0.3 
1.2 
2.1 
3.3 
1h 
3h 
5h 
24h 
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O
O
O
Fe
OC
OC
 
34 
0.0 
0.0 
0.0 
0.0 
0.5 
0.0 
0.1 
0.1 
0.3 
0.0 
0.4 
0.6 
0.7 
0.0 
0.4 
0.8 
1.0 
1h 
3h 
5h 
24h 
trimeb
FeCl
OC
CO
 
35 
0.1 
0.0 
0.1 
0.1 
0.5 
0.0 
0.0 
0.1 
0.7 
0.4 
0.6 
0.8 
0.8 
0.4  
1.5  
2.7 
8.9 
1h 
3h 
5h 
24h 
Fe
OC
OC
Cl
 
36 
0.0 
0.2 
0.8 
1.1 
1.0 
0.1 
0.4 
0.6 
1.0 
0.7 
0.5 
0.5 
0.4 
1.6 
2.9 
3.4 
4.3 
1h 
3h 
5h 
24h 
Fe
H2N
H2N CO
CO
S
S
HO2C
HO2C  
37 
0.9 
0.5 
0.9 
1.0 
1.0 
0.2 
0.6 
0.7 
1.0 
0.2 
0.2 
0.2 
0.2 
1.2 
1.2 
1.3 
1.4 
1h 
3h 
5h 
24h 
 
 
Inspection of table 8 reveals that most of the iron carbonyl complexes tested do 
not react readily with TBHP. Weak signs of decomposition can only be measured 
at 24h reaction time. The exceptions are Fe(cys)2(CO)2 (37) and Cp*Fe(CO)2Cl 
(36) the only compounds that are able to release 1 equiv CO at 5h. In each of 
them, both CO ligands are liberated but one of them is oxidized to CO2 since the 
final CO:CO2 ratio becomes 1 at long reaction times (24h).  In the case of 36 the 
ratio CO:CO2 is ca. 2:1 in the beginning of the reaction up to 5h . However, this 
ratio becomes 1 at 24h. The results show that one of the CO ligands initially 
liberated was later oxidized to CO2 by some species present in solution.   
The reaction of 37 has a similar profile although the excess CO over CO2 is 
always small. Nevertheless, the final CO:CO2 ratio also becomes 1 at long 
reaction times (24h).  Most interestingly, this profile is almost identical to that 
observed under O2 in RPMI. It seems that TBHP does not really interfere with the 
dissociative kinetics typical of this reversible CO carrier.   
The reactions with H2O2 are quite different and in some cases very surprising 
because: 
~ ~/-1j 
'I ~ 
~
~
~I ~ 
'(\, 
, , 
', .... 
-Lv 
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• the amount of CO2 always exceeds that of CO in the cases studied; 
• in several cases the final amount of liberated CO + CO2 exceeds the 2 
equivalents of CO present in the initial complexes; 
• some of these reactions are very fast compared to those of the other 
metals, like Mn and Mo. 
 
The two first observations are consistent with the formation of oxidation catalysts 
that are able to oxidize CO and some of the ancillary ligands. The example of the 
encapsulated complex CpFe(CO)2Cl@TRIMEB (35) is remarkably clear with 
regard to this catalytic mechanism because it is able to produce ca. 9(!) 
equivalents of CO2 at 24h reaction time. This amount actually surpasses the 
amount expected from the total oxidation of the metal guest which should yield 7 
equiv. of CO2 at the limit. Therefore, it is necessary to conclude that part of the 
host cyclodextrin is also being oxidized. There is literature precedent for this 
behavior because cyclodextrins were reported to favor Fenton Chemistry “inside” 
the cavity, by coupling iron ions and H2O2 in processes aiming at the destruction 
of organic matter in environmental disposals.[60, 61]   
Some complexes show an initial fast reaction that liberates a considerable amount 
of CO at 1h which, however, is oxidized during the rest of the experiment due to 
the high excess of oxidant.  
To better understand this process the reaction of 29 with sub-stoichiometric 
amounts H2O2 was carried out and the results are shown in table 9. The reaction 
proceeds, with small amounts of CO released even under an 8-fold excess 
complex over H2O2. This process is slightly accelerated when the ratio 29:H2O2 is 
raised to 4:1. When the reagents reach a 1:1 stoichiometry, the initial reaction is 
clearly a fast CO burst, corresponding to the release of ca. 25% of the total CO 
available in the initial complex, after only 5 minutes. However, this amount 
increases very slowly only to reach 1 equivalent of CO released after 24h. In any 
case, the amount of CO does not decrease as in the standard assays of table 8 
where the excess of H2O2 is much larger and consumes free CO.  
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These findings substantiate the idea that a high excess of oxidant is deleterious for 
the CO releasing process from iron carbonyls, leading to undesired oxidation to 
CO2.  
Table 9: Equivalents of CO released from oxidation of 29 with H2O2 using different 
substrate:oxidant ratios. Gas samples were taken after 5min, 30min, 1h, 3h, 5h and 24h 
and quantified by GC/TCD. 
  substrate:oxidant ratio 
Time 
Control 
complex 29 in 
H2O 
8:1 4:1 1:1 
5min 0.0 0.1 - 0.5 
30min 0.0 0.1 - 0.6 
1h 0.0 0.1 0.2 0.6 
3h 0.0 - 0.2 0.6 
5h 0.1 0.2 0.2 0.6 
24h 0.1 0.3 0.3 0.9 
 
 
It is quite likely that this chemistry is the result of the so-called “Fenton 
Chemistry”, a broad collection of free radical reactions catalyzed by transition 
metals, namely Fe2+. It was first described by the British chemist Henry John H. 
Fenton who reported in 1876 the oxidation of tartaric acid by Fe2+/H2O2 
system.[62-64] The mechanism of oxidation was object of debate for decades, 
however the commonly accepted general reaction is shown in Equation 5: 
 
“Fenton Reaction” 
H2O2 + Fe
2+             Fe(III) + OH + OH-   Equation 5 
 
The basis for the mechanistic studies were seeded by Haber and Weiss[65] showing 
the relevance of radical intermediates like OH• and HO2•. New mechanistic details 
and contributions from different authors led to modifications[66, 67] of the original 
theory and some highlighted the importance of intermediate species like ferryl ion 
(FeIVO)2+ [68] instead of the highly reactive hydroxyl radical.[69, 70] 
Since most of the mechanisms studied were developed for classical Fe2+/3+ 
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complex ions, the situation in our organometallic complexes could not be 
immediately applicable. Nevertheless, it is possible to imagine that small amounts 
of Fe2+/3+ ions are generated in solution from decomposition of the organometallic 
species, and that these ions carry on their powerful oxidizing chemistry with the 
excess H2O2 present.  
The number of possible reactions already identified in many chemical and 
biological studies is large (see scheme 1) and depends on the nature of the Fe 
complex, pH and H2O2/complex ratio. 
Independently of mechanistic details it is now generally accepted that when 
excess Fe2+ over H2O2 is employed a quantitative oxidation of Fe2+ to Fe(III) 
occurs. 
2 Fe2+ + H2O2             2Fe(III) + 2OH
-    Equation 6 
 
In the presence of excess H2O2, in addition to iron oxidation, a catalytic 
decomposition of H2O2 is observed. 
 
2H2O2              2H2O + O2     Equation 7 
 
It is also accepted that further reactions of Fe(III) with excess peroxide lead to 
superoxide formation, although this is a slower reaction at physiological pH and 
dependent on the ligand coordinated to Fe(III). This class of reactions, involving 
products of Fenton reaction or catalysts like Cu(I) or Mn (II) are called Fenton-
like chemistry and are generally believed to proceed via similar mechanisms[71-73] 
as oxidation reactions.  
H2O2 + Fe(III)             Fe
2+ + O2 + 2H    Equation 8 
 
Other parallel reactions can also occur (Scheme 3): 
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OH + H2O2              H2O + H
+ + O2
O2 + Fe(III)             Fe
2+ + O2
HO2 + Fe
2++ H+             Fe(III) + H2O2
OH + Fe2+             Fe(III) + OH-
HO2 + Fe(III)             Fe
2+ + H+ + O2  
Scheme 3: Parallel radical reactions occurring in vivo involving iron and H2O2 derived 
species.[74] 
 
Assuming that OH• is formed, it is expected to attack aromatic rings, namely 
Cp.[75, 76]  
This attack leads to the disruption of the aromatic ring and its oxidation with the 
release of CO2. In all the compounds tested the amount of CO2 released was 
higher than the amount of carbonyls in the molecule so CO2 must come from the 
oxidation of the organic material.  
Interestingly, the CO releasing rate of CpFe(CO)2(acetylsalicylate) (34) is 
continuous and the amount of CO2 obtained is not exaggerated. Since the only 
structural difference to the other CpFe(CO)2 complexes studied is the presence of 
the acetylsalicylate ligand we propose that its anti-oxidant power[77, 78] is actually 
slowing down the decomposition of the organometallic compound. 
 
4.4 Complementary observations relevant for the 
understanding of ROS induced CO release processes  
 
4.4.1 Methane formation in TBHP assays 
 
It was noted above that TBHP is used as a model for alkylhydroperoxides, 
ROOH, which are formed in vivo in the process of lipid peroxidation. It was also 
noted that TBHP has a different activation mode than H2O2 since most MCCs 
used can discriminate between both reagents. Moreover, the presence of a tert-
-
-
-
-
-
-
• 
-
-
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butyl substituent in TBHP opens a number of competing pathways for its 
decomposition that must be kept in mind when interpreting its redox chemistry.  
In particular, the tert-butyl radical is a rather stable alkyl radical with several 
decomposition pathways available. 
In fact, an important result that was observed in some TBHP assays and isn’t 
reported in the previous tables is the high amount of methane detected in some 
experiments. 
Although the quantification of methane was not possible under our experimental 
conditions, it is still possible to compare chromatographic peak areas to rank the 
compounds according to their “methane producing” capacity. 
The order observed was the following (area under peak):  
 
Complex 15 >> 35 > 9 > 11 > 12 > 29 > 33  
  
 
 
 
 
 
 
Interestingly, all these compounds have the same structure, CpM(CO)nR, where 
Cp is either Cp or Cp*, M = Mo or Fe, n is 3 for Mo and 2 for Fe and R is either 
Cl, CH3 or CH2CONH2.  
Due to the very similar geometry of the complexes it seems logical to conclude 
that the reactivity observed is structurally related. Even more interesting is the 
fact that the 3 most active complexes all have a chloride as a co-ligand suggesting 
an active role of the halide in the reaction mechanism. Moreover, the first two 
compounds in the list have a modified Cp (15) and an encapsulated compound 
(35), while the remaining compounds all have “naked” molecules. This also 
suggests that a bulky steric hindrance or active metallic center protection is also 
relevant.  
TBHP radical decomposition is dependent on many factors[79, 80] and some 
pathways lead to methyl radical formation. The usually accepted mechanism 
Mo
OC
OC CO
Cl > trimeb
FeCl
OC
CO
> 
Mo
OC
OC CO
Cl  > 
Mo
OC
OC CO
CH3 > 
Mo
OC
OC CO
O
NH2 > 
Fe
OC
OC
Cl
 > 
Fe
OC
OC
CH3
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involves peroxide one electron reduction originating the tert-butoxyl radical and 
hydroxide anion. A β scission then occurs giving a methyl radical (see Scheme 4).  
 
(CH3)3COOH + e
-          (CH3)3CO + OH
-
(CH3)3CO           CH3 + (CH3)2CO  
Scheme 4: Methyl radical formation from t-BuOOH 
 
This methyl radical in aqueous solution can easily capture an hydrogen giving 
methane. This mechanism was already documented in literature and demonstrated 
by spin trapping techniques with Fe(II)/Fe(III) working as an electron donating 
system.[81]   
Interestingly, this mechanism fits well the observed steric influence. Indeed, when 
electron transfer from the metal to TBHP takes place within the activated 
complex [LnM(CO)x.(HOOtBu)]≠, steric repulsion favors the expulsion of bulky 
(CH3)3CO. and it’s subsequent breakdown, when the Ln ligands are also bulky.  
If the steric room around the metal is larger, other pathways may be more 
favorable for the evolution of the [LnM(CO)x.(HOOtBu)]≠ species. 
 
4.4.2 Oxygen formation in TBHP and H2O2 assays 
 
Also in some TBHP assays an unusual O2 burst was observed. These results were 
obtained with ruthenium compounds CpRu(CO)2Cl (38) and 
Ru(CO)3Cl(glycinate) (39) and also the iron complex 29. In these cases a different 
decomposition pathway is observed, with formation of other radicals (Equation 
9). A tert-butylperoxyl radical is formed from the homolytic decomposition of 
MII-O-O-But adduct and two of these radicals couple together to generate tert-
butoxyl radical and oxygen.[82, 83]  
 
 
Chapter III 
 
 
119 
2(CH3)3COO          2(CH3)3CO + O2    Equation 9 
 
A large amount of oxygen formation was a peculiar feature also observed in the 
course of the assays with H2O2. Once more it was not quantified but from the 
peak areas it was possible to rank the compounds according to the amount of O2 
detected. When compared with the TBHP assays the levels of O2 measured were 
substantially higher. The speed of the reaction was also very high, sometimes was 
almost immediate, since after the first hour the maximum levels of O2 were 
already achieved. This reactivity was observed with a wide variety of complexes 
and is also dependent on the H2O2 concentration. Nevertheless the compounds 
that produced more O2 were the following: 
 
Complex 28 > 38 > 29 > 18 > Co2(CO)6(PhCCPh) > 5 > 31 >  39  
 
Hydrogen peroxide decomposition with O2 evolution is a well-known biological 
relevant reaction since it is one of the anti-oxidant defensive mechanisms 
performed by catalases (Eq. 10). 
 
2H2O2              2H2O + O2     Equation 10 
 
In the present case no correlation among the complexes could be found. Within 
the first 6 complexes, 2 are iron compounds (28 and 29), 1 is a ruthenium 
compound (38), 1 is a molybdenum compound (18) and 1 is a cobalt compound 
(Co2(CO)6(PhCCPh)). Except for the first three compounds in the series that 
share the same structural feature CpM(CO)2L (and 31:[CpFe(CO)2]2), none of the 
other complexes are structurally related. As demonstrated above the iron 
complexes also have Fenton chemistry reactivity, therefore, the two effects are 
competing. In an in vivo situation the outcome of the reaction would be dependant 
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on various factors, and factors like the local concentration of ROS and iron 
complex will be vital to determine which of the opposing reactions will prevail.   
 
4.5 Oxidative Decarbonylation of CpMo(CO)3(CH2CONH2): a 
case study 
 
 
It is now clear that oxidation is a main inducer or accelerator of CO release from a 
MCC. In scheme 5, chapter I, this situation was sketched in terms of the dramatic 
acceleration that substitution of CO can exhibit in 17-electron complexes vs their 
18-electron counterparts. The first kinetic evidence for this acceleration was 
obtained from de bona fide 17-electron complexes. For instance, V(CO)6 reacts 
with phosphines ca. 1010 times faster than its 18-electron isostructural analogue 
[Cr(CO)6], and [V(CO)6]- is practically unreactive in the dark.[84] Likewise 
nucleophilic substitution of [Fe(CO)3(PPh3)2]+ by pyridine nucleophiles occurs 
109 times faster than for the 18-electron analogue Fe(CO)3(PPh3)2.[85] Later on 
Kochi and coworkers led this observation to practical applications in 
electrocatalysis where the 17-electron catalysts were obtained by electrochemical 
oxidation of comparatively inert 18-electron precursors.[86-88]  
Due to its favorable stability and solubility properties CpMo(CO)3(CH2CONH2) 
(12) was selected as a model to study the effect of oxidation on CO labilization. 
It is an 18-electron complex soluble in most organic polar solvents like 
dichloromethane, chloroform, diethyl ether, THF, acetone, acetonitrile and 
methanol. It is also soluble in water at low concentrations and very stable when 
kept under N2 and in the dark. The presence of O2, oxidants and light initiates a 
decomposition process that leads to CO release. In aerobic RPMI solution this 
release is small reaching 0.7 equiv CO in 6h. However, as shown in Table 4 this 
compound is activated both by TBHP and by H2O2 to release 1.4 and 2.3 equiv 
CO after 3h in TBHP and H2O2, respectively.  We performed our studies in the 
dark since light also triggers CO release from this complex. 
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4.5.1 Reaction with 1-electron oxidants 
 
A set of experiments was performed to establish whether a 1 electron oxidation 
was enough to trigger off CO release from CpMo(CO)3(CH2CONH2).  
[Cp2Fe]BF4, AgBF4 and AgNO3 were employed as 1-electron oxidants in 
different solvents and the reaction was followed by GC and IR. 
The reaction between equimolar amounts of [Cp2Fe]BF4 and 
CpMo(CO)3(CH2CONH2) was followed over 24 h at room temperature, under N2 
and in the dark. The very intense characteristic purple color of [Cp2Fe]+ 
disappears rapidly upon mixing both reagents and CO liberation stops after 1h. 
The amount of CO liberated in several solvents during the first hour remained 
essentially unchanged up to 24h with the exception of NCMe which double that 
value as seen in Table 10.    
Table 10: Equivalents of CO liberated after 1h or 24h upon reaction of [Cp2Fe]BF4 and 
CpMo(CO)3(CH2CONH2) in 1:1 molar ratio, at room temperature, under N2 and in the 
dark in several solvents. 
Equiv. CO released from CpMo(CO)3(CH2CONH2) with [Cp2Fe]+ (time; h)* 
H2O(1h) CH2Cl2(1h) (CH3)2CO(1h) THF(1h) CH3CN(1h) CH3CN(24h) 
0.3 0.1 0.3 0.3 0.3 0.6 
*CO2 was present but not quantified 
 
Although the redox reaction was fast, as judged by the rapid disappearance of the 
characteristic color of [Cp2Fe]+, it is obvious that CO release stopped at ca. 10% 
after 1h for all solvents, except for NCMe where it reached 20% CO release after 
24h. This is also visible in the IR spectra of the solutions because the stretching 
CO vibrations of CpMo(CO)3(CH2CONH2) remained unchanged in all solvents 
except NCMe. CpMo(CO)3(CH2CONH2) has 2 bands at 2025 and 1932cm-1. 
After reaction with ferrocenium in NCMe they shifted to 2032 and 1942 cm-1 with 
a new band appearing at 2082 cm-1 (see Fig. 1). To exclude the possibility that 
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these changes were caused by reaction of CpMo(CO)3(CH2CONH2) with the 
solvent a control spectrum of the compound alone was recorded in NCMe and no 
differences were observed showing clearly that it is not solvent interference. The 
spectra of free chloroacetamide, pure ferrocenium and ferrocenium with 
chloroacetamide were also recorded as controls and no reaction is observed 
between both species. 
The slight change of νCO values to higher energy in NCMe, where the reaction 
was a bit more extensive, agrees with the expected formation of cationic species 
that should present increased values for νCO.  
The analogous reaction of CpMo(CO)3(CH2CONH2) with AgBF4 was performed 
in dichloromethane both in 1:1 (from now on designated R1) and 1:10 (from now 
on designated R10) molar ratios and followed by solution IR, CO release and 1H 
NMR. In the R1 reaction the IR spectrum shows that after 24h some of the 
original CpMo(CO)3(CH2CONH2) is still unreacted in solution after a steady 
concentration decrease (see Fig. 3). The total amount of CO released was 0.46 
equiv. CO. After 48h the reaction mixture was evaporated to dryness and the 
residue taken up in CD2Cl2, filtered and examined by 1H NMR. The spectrum 
(Fig. 5) shows two small signals of the initial CpMo(CO)3(CH2CONH2) (δ 5.42 
ppm (C5H5) and δ 1.80 ppm CH2). There is a slighlty more intense signal in the 
region typical of the η5-Cp protons (δ 5.42 ppm) but the largest signal appears as 
a sharp singlet at δ 1.26 ppm and a multiplet at δ 0.88 ppm. These signals and 
other smaller ones remained unassigned. In contrast, all the CO ligands were 
removed from CpMo(CO)3(CH2CONH2) after 3h in the presence of a 10-fold 
excess Ag+, as can be concluded from the disappearance of the CO stretching 
vibrations in the IR spectrum of Figure 4. 1H NMR analysis of the residue of the 
reaction after 48h (Fig. 6) shows the same resonances at δ 1.26 ppm and a 
multiplet at δ 0.88 ppm. However no resonance is present in the region assigned 
to the η5-Cp protons and a new multiplet appears at δ 1.37 ppm.  
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Figure 1: IR spectra of 
CpMo(CO)3(CH2CONH2) and of 
CpMo(CO)3(CH2CONH2) + [Cp2Fe]BF4 
(1:1) in NCMe solution (carbonyl region) 
Figure 2: IR spectra of 
CpMo(CO)3(CH2CONH2) and of 
CpMo(CO)3(CH2CONH2) + [Cp2Fe]BF4 
(1:1) in CH2Cl2 solution (carbonyl region) 
  
Figure 3: IR transmittance spectra of 
CpMo(CO)3(CH2CONH2) and AgBF4 
(R1) in CH2Cl2 over time (carbonyl 
region). 
Figure 4: IR transmittance spectra of 
CpMo(CO)3(CH2CONH2) and AgBF4 
(R10) in CH2Cl2 over time (carbonyl 
region). 
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In summary, 1 equivalent of Ag+ is not enough to induce quantitative CO release 
from CpMo(CO)3(CH2CONH2), even after 48h in CH2Cl2. However, use of a 10-
fold excess of Ag+ in the same solvent leads to quantitative decarbonylation of 
CpMo(CO)3(CH2CONH2) in less than 3h (Fig. 4).   
A similar experiment carried out in water, using AgNO3 instead of AgBF4, 
corroborated these results. FT-IR and 1H NMR spectra of the product obtained 
after 24h reaction of CpMo(CO)3(CH2CONH2) with 10-fold excess Ag+ showed 
no CO bands and no Cp ring proton resonances, respectively. When the reaction 
was done in a 1:1 stoichiometry part of the initial CpMo(CO)3(CH2CONH2) is 
still unchanged in the reaction mixture after 24h as shown by IR and 1H NMR 
spectroscopies.  
These data agree with the CO release reported in table 10 but the mass balance of 
the initial CO cannot be done because CO2 was detected but not quantified. 
 
 
 
 
 
  
Figure 5: 1H NMR spectra of 
CpMo(CO)3(CH2CONH2) (top) and 
CpMo(CO)3(CH2CONH2) with AgBF4 
(R1) in CD2Cl2 after 48h reaction 
Figure 6: 1H NMR spectra of 
CpMo(CO)3(CH2CONH2) (top) and 
CpMo(CO)3(CH2CONH2) with AgBF4 
(R10) in CD2Cl2 after 48h reaction 
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Table 11: Equivalents of CO released in the reactions of CpMo(CO)3(CH2CONH2) and 
AgNO3 and Ag[BF4] in the molar ratios 1.1 and 1.10 measured with the vial method at 
24h. Reagents were mixed together in degassed water, under N2, in the dark and at room 
temperature. 
Equiv. CO released from CpMo(CO)3(CH2CONH2) with Ag+ (24h)* 
Reagent / Solvent Reagent ratio 1:1 Reagent ratio 1:10 
Ag[BF4] /CH2Cl2 0.46±0.04 1.67±0.03 
AgNO3 / Water 0.60±0.04 1.91±0.03 
* CO2 was present but not quantified.  
 
Nevertheless, the amounts of CO released with excess oxidant far exceed those 
measured in aerobic RPMI.  
This behavior is also in agreement with the results obtained by Tyler and co-
workers, who generated water-soluble radicals by photolysis of (CpCOO-
)2W2(CO)6,[89] (CpCH2CH2NH3+)2Mo2(CO)6[90] and 
(CpCH2CH2NMe3+)2Mo2(CO)6 dimers and showed that their behavior in aqueous 
solution is analogous to the chemistry in organic solvents. 
 
4.5.2 Reaction with peroxides 
 
The complex CpMo(CO)3(CH2CONH2) (12) is strongly activated by a 100-fold 
excess H2O2, as shown in table 4. In order to better understand this process, we 
first tried to determine the course of this reaction at lower H2O2:12 ratios. As 
shown Table 12, after 3h the amount of CO released from 12 is the same with a 
10-fold or a 100-fold excess H2O2. In practice, the reaction is complete in both 
cases with a total amount of 3 equivalents of CO being liberated. If the 
stoichiometry is 1:1 then only ca. 2 equivalents of CO are released after 3h but the 
liberation of CO continues slowly as seen at 24h.  
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Table 12:  Equivalents of CO released by CpMo(CO)3(CH2CONH2) with aqueous H2O2 
at room temperature, in the dark, under air. Gas samples were taken after 3h, 5h and 24h 
and quantified by GC/TCD. 
Time 1eq. H2O2 10eq. H2O2 100eq. H2O2 
3h (1.74±0.03) (2.65±0.04) (2.64±0.04) 
5h (1.77±0.03) (2.57±0.04) (2.64±0.04) 
24h (2.11±0.03) (2.47±0.04) ----- 
 
These results show that the 100-fold excess is actually not necessary to drive all 
CO out of the initial complex. In another experiment, summarized in Table 13, it 
again becomes clear that the reaction is indeed completed in less than 30 min 
when a 10-fold excess H2O2 is used.  
Table 13: Equivalents of CO released by CpMo(CO)3(CH2CONH2) in H2O2 at room 
temperature, in the dark, under air. Gas samples were taken after 30min, 1h and 2h and 
quantified by GC/TCD. 
Time 1eq. H2O2 10eq. H2O2 
30min (1.37±0.03) (2.56±0.04) 
1h (1.62±0.03) (2.64±0.04) 
2h (1.69±0.03) (2.63±0.04) 
 
Since 12 is light sensitive, the experiments need to be carried out in the dark. If 
they are carried out under ordinary laboratory light the amount of CO liberated is 
slightly more elevated (5-8%) in some measurements. In the presence of light the 
solutions of 12 in any solvent slowly change color to green while releasing some 
CO. The 1:1 stoichiometry reaction between 12 and H2O2 also goes green in the 
light or turquoise blue in the dark. However, when the 10-fold excess H2O2 is 
added to 12, these color variations are no longer observed and the initial dark 
yellow/orange solution of 12 rapidly becomes light yellow.  
The presence of such a rapid, reproducible and quantitative reaction prompted the 
identification of its product. So, the reaction was performed on a preparative scale 
between CpMo(CO)3(CH2CONH2) (1.14 mmol) and H2O2 (11.6 mmol) in H2O 
for 1h. In a first attempt, excess H2O2 was quenched with MnO2 and a sensitive 
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yellow product was isolated. However, this product was paramagnetic as shown 
by ESR spectroscopy and result from the reaction of the initial reaction product 
with added MnO2. This result was later confirmed as described below. 
In order to avoid these problems, the synthesis was then repeated under similar 
conditions but a different method was used to isolate the reaction product. 
Ethanol was added to the reaction mixture at the end of the reaction and the 
resulting solution placed at 4ºC overnight.  The yellow precipitate that separated 
was filtered and dried in vacuum. Unfortunately, we were unable to characterize 
this product because it readily explodes when dry and touched with a spatula. 
Such explosive properties are known for peroxo complexes[91]. 
Since the oxidation reaction seemed rather fast and clean, we attempted to study it 
by means of HPLC/MS, thereby avoiding the need to isolate the reaction product 
as a dry solid. This work was performed in collaboration with Bruno Guerreiro, a 
chemist from Alfama Inc., working in the laboratories of IKARIA Inc., Seattle, 
WA, USA, within a protocol of collaboration between both companies.  
The compound dissolved in saline (NaCl 0.9%) was oxidized with 14 equiv. of 
H2O2 at room temperature under air and in the dark. The HPLC chromatogram of 
this mixture was analyzed at several time points and compared to the HPLC trace 
of the starting compound.  
As can be seen in Fig. 7, the starting material was completely absent after 1h and 
only one new peak was detected with a retention time, RT=6.01 min. This result 
confirms that the removal of CO by H2O2 oxidation is very fast and is essentially 
complete in less than 1h in agreement with the results reported in Table 13. This 
was confirmed after 3h when the IR spectrum showed that all CO ligands present 
in the original complex had been removed (see Fig. 8). 
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Figure 7: (top) HPLC trace of CpMo(CO)3(CH2CONH2) in saline solution before 
addition of H2O2 (14 molar equivalents); (bottom) HPLC trace of the reaction mixture 
after 1h reaction time. 
 
 
 
 
 
 
 
 
 
 
Figure 8:: IR spectra of CpMo(CO)3(CH2CONH2) in saline solution before and 3h after 
adding H2O2 (14 molar equivalents). Experiment performed at room temperature, in the 
dark and under air.  
 
The ESI-MS of the single product at RT=6.01 min has its main peak at a m/z = 
269.98 and a possible structure is (MW (Cp98MoO(η2-O2)(CH2CONH2) + H+ = 
270.06). In order to carry out a better characterization of the compound, it was 
then isolated by preparative HPLC using a C18 reverse phase column and a 
MeOH/water gradient.  
1 h
0 h
 
after 3 h of H2O2
control
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A new HPLC-MS analysis of the fraction corresponding to the product was 
carried out and the corresponding MS is given in Fig. 9. 
 
 
 
 
 
 
 
 
 
Figure 9: HPLC-MS analysis of the fraction corresponding to the product with RT=6.01 
min. 
 
The mass pattern is coherent with the oxo-peroxo structure proposed for the 
compound. This type of compound was first identified by Trost and Bergman 
who isolated Cp*MoO(η2-O2)Cl from the reaction of Cp*Mo(CO)3Cl  and O2 
with light.[40] Also, the 1H NMR spectrum of the compound isolated by 
preparative HPLC supports the structure of the oxo-peroxo species (Fig. 10). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: 1H NMR spectrum 
in D2O (δ 4.79 ppm) of the 
species isolated in the HPLC at 
RT=6.01 min which is assigned 
as CpMoO(η2-O2)CH2CONH2. 
The Cp signal is observed at δ 
6.66 ppm (s,5H) and the 
protons from the amide 
observed at δ 3.31 (d,1H) and 
3.47 (d,1H) ppm. 
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The signal corresponding to the Cp protons appears at δ 6.66 ppm in D2O and the 
diastereotopic protons of the acetamide ligand appear as a pair of doublets at δ 
3.47 and δ 3.31 ppm.  
According to our HPLC analysis of the reaction of CpMo(CO)3(CH2CONH2) with 
14 equivalents of H2O2 (a reasonable excess), the oxo-peroxo complex 
CpMoO(η2-O2)(CH2CONH2) is initially formed (RT=7.70 min) but after 1.5 h it 
starts to decompose as shown in Fig. 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following this decay by HPLC/MS, a very small peak with RT=7.58 min 
appeared. It was identified as the protonated form of the dioxo complex 
CpMoO2(CH2CONH2) with m/z (Cp98MoO2(CH2CONH2) + H+) = 254.06. This 
dioxo complex is similar to CpMoO2Cl, one of the first ever reported molecular 
organometallic oxides that was formed, isolated and characterized in organic, 
water free solvents.[92] More recent work has proposed CpMoO2X (X = Cl, CH3) 
as the active species in the epoxidation and sulfoxidation reactions catalyzed by 
the system CpMo(CO)3X + TBHP in CHCl3.[41, 51, 93] The relationship between the 
oxo-peroxo and the dioxo complexes was first identified in the reaction of 
Equation 11.[40]  
 
Figure 11: Formation and decay of CpMoO(η2-O2)CH2CONH2 in aqueous saline 
solution, evaluated by HPLC. 
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Cp*MoO2Cl + TBHP Cp*MoO (!
2 " #2) Cl + H2O         Equation 11 
  
However, CpMoO2X complexes have never been identified in aqueous solution 
with H2O2 as oxidant and their stability in such media has been a matter of some 
controversy. The fact that the system CpMo(CO)3X + H2O2 is completely 
inefficient for the epoxidation of olefins in the presence of water has been taken 
as a hint that CpMoO2Cl is not stable in aqueous media. As a matter of fact, our 
HPLC/MS experiments show that the concentration of CpMoO2(CH2CONH2) 
does not build-up in the reaction medium. On the contrary, highly ring substituted 
analogues CpRnMoO2X are perfectly stable in water and active oxidation catalysts 
with H2O2 as oxidant.[51, 94, 95]  
A similar decay study of CpMoO(η2-O2)(CH2CONH2) was done in the presence 
of MnO2, showing that the disappearance of the oxo-peroxo complex is faster. 
This observation helps explaining our failure in isolating this complex when we 
attempted to destroy excess H2O2 with MnO2 (vide supra).  
Interestingly, attempts to follow the reaction of CpMo(CO3)(CH2CONH2) with 
TBHP in aqueous solution (water or saline) only gave very complicated HPLC 
chromatograms with a large number of peaks in low concentrations. A similar 
procedure was adopted, dissolving the compound in saline and oxidation was 
carried out with 14 equiv. of TBHPaq at room temperature, under air and in the 
dark. The HPLC chromatogram of this mixture was analyzed at several time 
points and compared to the HPLC trace of the starting compound. After 7h a 
major peak at retention time RT=8.64 min was observed, corresponding to the 
parent complex. Although its intensity and AUC decreased over time this was still 
the major species in solution together with some minor peaks at RT=7.56 min and 
9.32 min but with lower AUC values. The reaction proceeded up to 24h at which 
time several minor peaks (parent compound included) were observed, all with 
similar low intensities. Due to the complicated distribution of small peaks in the 
HPLC the identification of the reaction products was not possible. One could 
assign the peak at RT=7.56 min to the dioxo compound, CpMo(O)2(CH2CONH2). 
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This would be the expectable result bearing in mind the high yield formation of 
CpMo(O)2Cl from CpMo(CO)3Cl and TBHP in CH2Cl2.[41] However, we were 
unable to obtain a clean, positive ESI-MS spectrum that could confirm this 
expectation. 
In summary, the experiments described in this case study clearly show that 
oxidation is an effective way of triggering CO release from an otherwise rather 
water and air stable metal carbonyl complex such as CpMo(CO)3(CH2CONH2).  
The rapid disappearance of the violet color of Fc+ and the immediate appearance 
of metallic Ag when Fc+ and Ag+, respectively, are mixed with 1 equivalent of 
CpMo(CO)3(CH2CONH2) show that one electron oxidation of the Mo complex is 
very rapid. Although this oxidation is not followed by extensive CO release, some 
CO is still set free in solution.  In other words, the process is not catalytic in the 
presence of the solvent.  More equivalents of oxidant are necessary to result in 
extensive liberation of CO.  
This is also seen in the reactions of CpMo(CO)3(CH2CONH2) with H2O2: a 
quantitative liberation of CO only takes place when a certain threshold excess of 
H2O2 is present. In this case, a molar ratio of H2O2:CpMo(CO)3(CH2CONH2) of 
14:1 leads to total CO release in less than 1h, as ascertained by HPLC. The 
reaction product accumulates in high quantities exemplifying what may happen to 
a molecular MCC scaffold when activated by H2O2. The activation with TBHP is 
also effective to induce CO release but produces a much more complicated range 
of reaction products which we did not consider important to identify.  
 
5. Final Remarks and Conclusions 
 
The study that is described in this Chapter of CO release MCCs induced by t-
BuOOH and/or H2O2, as representative examples of ROS present and active in 
biological media, and namely in inflamed tissues, is a screening that intends to:  
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• reveal the possibility of stimulating MCCs to release CO by reaction with 
ROS type oxidants; 
• reveal the possibility that MCCs may discriminate between different ROS 
oxidants; 
• draw a first draft of Structure Activity Relationships (SAR)  for this type of 
chemistry.  
 
The results reported lead to the following main conclusions:  
 
• The concept of using oxidation as a trigger to start/enhance CO release 
from a MCC has been shown to be valid even in the case of some 
stoichiometric 1-electron oxidations; 
• The number of complexes tested that resisted oxidation by ROS oxidants is 
very small; 
• In most of the families of MCCs studied the release of CO is effectively 
enhanced relative to the spontaneous value at least by one of the two ROS 
oxidants tested, TBHP and H2O2; 
• High lipophilicity and encapsulation slows down but does not prevent 
oxidation by ROS; 
• Oxidation by ROS can be tuned by the nature of the ancillary ligands; the 
broadest spectrum of reactivities was found for MnI(CO)5X, Mo0(CO)5X 
and  CpMoII(CO)3X complexes; 
• Most MCCs tested react preferentially with one of the two ROS used 
depending on their ancillary ligands and oxidation state;  
• Derivatives of MnI(CO)3 and RuII(CO)3 do not respond to the ROS used; 
the former do not react, whereas the later rapidly decompose the ROS 
reagent to release O2 and/or induce strong catalytic oxidation with 
formation of  CO2;  
• CpFe(CO)2X complexes do not react with TBHP but react with H2O2 to 
produce more CO2 than CO (CO:CO2 < 1); a weak catalytic oxidation 
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activity is observed in these systems contrary to those of Mn and Mo where 
CO:CO2  is usually > 2. 
 
The ultimate purpose of this study was to test the possibility of using the naturally 
occurring oxidizing ROS as a means of inducing or triggering release of CO from 
MCCs at the places of inflammation or oxidative stress where they are 
particularly abundant and damaging. The results just summarized confirm that 
this strategy of passive, anti-ROS targeting mode is indeed a possibility. The 
oxidants used are only a minor fraction of the possible in vivo oxidizing triggers, 
and these crude tests were performed in conditions of large excess of ROS which 
surpass, by far, those concentrations found in vivo. Nevertheless it is possible to 
see that the oxidation of some MCCs turns them into CO-RMs because they 
release mostly CO and do not act just as simple peroxide scavengers or do not 
catalyze CO oxidation to CO2. The last situations are also possible and seen to be 
the real ones for the Ru(CO)3 complexes.   
Some specificity was achieved since in some cases the complexes could 
discriminate between oxidizing agents. This can be an advantageous property that 
may allow even more specificity since the nature of the ROS produced 
endogenously is also dependent on the site of inflammation. Not all the tissues or 
organs have the same anti-inflammatory response and different tissues “request” 
different intermediates that produce different responses depending on the 
aggression and localization. Therefore, a distinct response towards oxidative 
stimuli may be a very effective method to ensure that CO is delivered to the exact 
target. 
Of course, this does not exclude the utility of the indiscriminate CO releasers that 
may be useful for different indications where the need of CO delivery in multiple 
sites of inflammation is requested.  
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An important final note contemplates the fact that it is possible to tune the 
sensitivity towards ROS which is a most useful handle to improve the therapeutic 
effectiveness of the Metal Carbonyl based CO-RMs.  
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Chapter IV: Study of reactivity between Metal 
Carbonyl Complexes and Heme Proteins 
 
1. Summary 
 
Myoglobin (Mb) and Hemoglobin (Hb) are strong scavengers for CO. Upon CO 
binding to deoxy-Mb this is converted into carboxy-myoglobin, CO-Mb (also 
called carbonmonoxy-myoglobin). This can be quantified using the characteristic 
optical absorption spectrum of CO-Mb. In this Chapter, Section 4.1, the rate of 
CO release from several MCCs is evaluated by incubating them with deoxy-Mb 
and following the rise of CO-Mb. Since MCCs are electron-rich species, they may 
engage in electron transfer processes with redox active proteins, namely Mb or 
Cytochrome C. A selected group of MCCs was also used to survey this problem 
as described in Section 4.2.  Finally, Section 4.3 deals with the transfer of CO 
from MCCs to whole blood in vitro.  
 
2. Introduction  
 
Myoglobin can exist in three different redox forms: deoxy-Mb, oxy-Mb (O2-Mb) 
and met-myoglobin (met-Mb).[1] The latter contains Fe(III) while the other ones 
contain Fe(II) bound to the heme. In the presence of CO, another ferrous form can 
be formed, namely carbonmonoxy-myoglobin (CO-Mb) since CO strongly binds 
to the reduced heme center. The optical absorption spectrum of Mb varies among 
all these species. A strong Soret band is observed in the 400 nm region and a 
weaker absorption due to the α and β bands is observed in the 500 to 600 nm 
region, where the number and location of maxima strongly depends on the ligand 
bound to the heme FeII ion (see Table 1).[2] 
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The spectra depicted in Fig.1 show 
that met-Mb has two broad and low 
intensity absorbance bands with 
maxima at 531 nm and 504 nm 
(orange line) and when the protein is 
reduced (deoxy-Mb) they are 
replaced by one single band with the 
maximum at 555 nm (green line). The Soret band, at 409 nm in the oxidized 
protein (met-Mb; orange line) moves to 433 nm after reduction (green line). 
 
 
 
 
 
 
 
 
Figure 1: UV-VIS absorbance spectrum of deoxy-Mb (Fe2+), O2-Mb (Fe2+), CO-Mb 
(Fe2+) and met-Mb (Fe3+) in PBS.74 at a concentration of 11µM. Left: Soret band; Right: 
α and β bands 
 
When CO is bubbled into the met-Mb (Fe3+) solution no changes are observed 
(data not shown), however, when CO is bubbled in the reduced protein solution, 
two major changes occur (red line). The peak at 555 nm disappears and two new 
peaks with maxima at 541 nm and 578 nm appear, and the Soret band shifts to 
422 nm. On the other hand, when O2 is bubbled into the deoxy-Mb preparation 
oxy-Mb is formed (blue line). This has a spectrum very similar to that of CO-Mb 
with the maxima at 543 and 581 nm and the Soret band at 416 nm. 
These very characteristic spectral changes are also observed with hemoglobin and 
have proven useful as an indirect method to quantify the amount of CO in blood 
through the spectrophotometric determination of carboxy-hemoglobin.[3-6]  
  
Table 1: Maxima of the UV-VIS 
absorbance spectrum of several Mb forms 
Mb-Form Soret band/nm 
500-600 nm 
region 
deoxy-Mb 433 555 
CO-Mb 422 541; 578 
O2-Mb 416 543; 581 
met-Mb 409 504; 531 
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Based on these observations Motterlini and coworkers developed a new 
methodology that measures the amount of CO in solution by following the 
conversion of added deoxy-myoglobin into carbonmonoxy-myoglobin.[7] This 
spectrophotometric method was then applied to the quantification of CO release 
from CO-RMs through the quantification of CO-Mb measured by the absorbance 
at 540 nm (ε540 = 15.4 mM-1.cm-1).  
 
3. Experimental Section 
 
 3.1 Methodology 
 
CO release determination with the Mb assay: 
Method: 
The following experiments were performed using the method developed by 
Motterlini,[7] however, the quantification of the amount of CO liberated was 
calculated in a different way.  
Typically, a stock solution of Myoglobin (Mb) from equine skeletal muscle was 
prepared by dissolving the protein in PBS7.4. From this solution aliquots were 
taken to a cuvette (final concentration between 50 µM to 70 µM) and Na2S2O4 in 
PBS7.4 (10 mg/ml solution; 0.1% final concentration) was added to convert met-
Mb into deoxy-Mb. The yellow brown-red met-Mb solution turns yellow-red after 
being reduced. 
Since Mb was purchased and used without purification for each new batch of 
protein the molar extinction coefficient (ε) was determined. A series of standards 
were prepared, at different concentrations and the absorbance read at 555 nm. The 
experimental plot of Abs vs Concentration allowed the experimental ε value to be 
determined as (9.6±0.3) mM-1.cm-1 for batch#1, (11.5±0.5) mM-1.cm-1 for batch#2 
and (9.2±0.3) mM-1.cm-1 for batch#3. This discrepancy among the values obtained 
is not surprising since among the published literature independent determinations 
of the molar extinction coefficient by different authors do not agree.[8] The 
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reactions were done by mixing in the same cuvette and by this order, the Mb 
stock solution, the Na2S2O4 solution, a calculated amount of a solution of the CO-
RM and adding PBS to obtain the desired final volume. The cuvettes were sealed 
with parafilm. 
Before adding the CO-RM solution a control spectrum was always acquired to see 
if the protein had been properly reduced with sodium dithionite.  
Two controls were done in duplicate, the negative control (0% CO-Mb), a deoxy-
Mb solution and the positive control (100% CO-Mb), obtained by bubbling pure 
CO gas into the deoxy-Mb solution for 10-15 min. 
The experimental spectrum was fitted as a weighted sum of the deoxy-Mb and the 
CO-Mb spectra. The Solver function in MS Excel was used to calculate the 
percentage of CO-Mb by deconvolution of the spectra using as controls both 
positive and negative standards.[9]  
The absorbance spectrum was converted into a percentage of CO-Mb and 
presented as a function of time. Based on the initial amount of CO-RM in solution 
the amount of CO liberated was calculated as equivalents of CO. 
Material: 
Myoglobin, from equine skeletal muscle, 95-100%, essentially salt free, 
lyophilized powder from Sigma; Disposable Polystyrene Cuvettes (b=10mm); 
Sodium dithionite pa. from Panreac. 
 
UV-VIS absorbance spectrophotometric measurement of the reaction 
between MCCs and Cytochrome C:  
Method: 
Native oxidized Cytochrome C (5 µM) was mixed with the metal complex (50 
µM) in PBS7.4. The UV-VIS absorbance spectrum was recorded immediately 
after mixing the species and depending on the result, in some cases 1h and 2h 
later. In a different experiment Cytochrome C was reduced with Na2S2O4 (0.1%) 
and then the compound added in a suitable solvent. The spectrum was recorded 
immediately after mixing the species and depending on the result, in some cases 
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also 1h and 2h later. As a control CO gas was bubbled into both the oxidized and 
reduced Cytochrome C solutions for 20 min. No changes were observed in both 
spectra. 
Material: 
Cytochrome C provided by Dra. Célia Romão at ITQB; Disposable Polystyrene 
Cuvettes (b=10mm); Sodium dithionite pa. from Panreac. 
 
UV-VIS absorbance spectrophotometric measurement of the reaction 
between MCCs and Myoglobin:  
Method: 
A stock solution of Myoglobin (11 µM) was prepared by dissolving the protein in 
PBS7.4 and the compound (50 µM) added in a suitable solvent. The UV-VIS 
absorbance spectrum was recorded immediately after mixing the species and in 
some cases 1h later.  
Material: 
Myoglobin, from equine skeletal muscle, 95-100%, essentially salt free, 
lyophilized powder from Sigma; Disposable Polystyrene Cuvettes (b=10mm); 
Sodium dithionite pa. from Panreac. 
 
In vitro measurement of CO-Hb levels in blood: 
Method: 
A CO-RM solution was prepared in a suitable medium (PBS (pH7.4), DMSO or 
MeOH), and 50 µL are added to 1 mL of blood and incubated at 37ºC. Samples 
were kept inside closed plastic culture tubes with closures (5 mL; 12x75 mm) and 
analyzed over time in the oximeter following the raise in CO-Hb levels. The 
amount of CO liberated was calculated based on the amount of compound 
initially added, total amount of Hemoglobin and %CO-Hb (both given by the 
oximeter). Each compound was tested in a concentration previously calculated in 
order to mimic relevant in vivo doses (typically 25 mg/kg and 50 mg/kg). 
Assuming a 20 g mouse with 8% blood volume (1.6 mL), 25 mg/kg correspond to 
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0.5 mg of compound/animal, therefore 0.5 mg/1.6 mL blood, there is 0.313 
mg/mL. Conversely, the final CO-RM concentration in blood mimicking 50 
mg/kg is 0.626 mg/mL. 
Control spectra were always recorded with the medium alone without compound. 
 
Material: 
Avoximeter 4000 from A-vox Instruments Inc.; Disposable Cuvettes for 
Avoximeter 4000 from A-vox Instruments Inc.; Sheep whole blood in alsevers 
solution, from Innovative Research. 
 
 3.2 Technical Details 
 
Synthetic Work: 
All the compounds were prepared as described in Chapter II or table A1 in Annex 
I.  
 
 
4. Results and Discussion 
 
4.1 Evaluating CO release through CO transfer from 
Metal Carbonyls to Myoglobin 
 
In the following study we adopted the method developed by Motterlini but 
modified the way in which the amount of CO liberated was calculated as 
explained in the Experimental Section. With this methodology it is possible to 
follow the rise in CO-Mb concentration along the time in a mixture of deoxy-Mb 
and CO-RM and calculate the equivalents of CO released. The experiments were 
performed with the compounds fully dissolved. In some cases this required a 
water miscible co-solvent to increase solubility. The experiments were carried out 
under normal atmosphere. Control experiments showed that under the conditions 
used, deoxy-Mb is not oxidized by O2 for a period up to 2 hours. For this reason 
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all experiments were stopped after 2h. The experiments performed under N2 were 
done with degassed solvents and the solutions prepared in a schlenk tube, under 
N2. 
Since Mb is a very strong scavenger for CO one may assume that no gas is lost 
from the solution and all the CO liberated from the molecule is captured by the 
protein. The CO-Mb formation can be interpreted as a 2 step reaction, first 
through dissociation of the CO group which then is captured by deoxy-Mb 
(Equation 1).  
 
LM(CO)n + deoxy-Mb LM(CO)n - 1 + CO + deoxy-Mb
k1
LM(CO)n - 1 + Mb-COLM(CO)n - 1 + CO + deoxy-Mb
k2
   Equation 1 
 
 It is plausible to consider that CO binding to deoxy-Mb is much faster than the 
decarbonylation process (k2 >> k1), therefore, no free gaseous CO exists in 
solution and the reaction can be properly written as follows: 
 
LM(CO)n + deoxy-Mb LM(CO)n - 1 + Mb-CO  Equation 2 
 
Taking reaction 2 into consideration it’s possible to determine the CO-RM half-
life (t1/2) as the time needed for the formation of [CO-Mb] corresponding to half 
of the initial CO-RM concentration. 
Typically, when 50 µM of a given compound is incubated with deoxy-Mb (60 
µM), the half-life (t1/2) is achieved when 25 µM of CO-Mb are obtained. This 
value corresponds to half of the initial CO-RM concentration and also to the 
liberation of 0.5 equivalents of CO.  
Since the Mb stock solutions don’t always have the same concentration the half-
life measurement allows a comparison between all the experiments without the 
need for highly reproducible conditions. One can also determine the influence of 
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different effects like the medium, pH or different CO-RM concentrations on the 
rate of release by comparing the different half-lives in the respective conditions.  
Table 2 lists the experimentally determined half-lives for a wide range of 
complexes (Figure 2), the total amount of CO released after 2h reaction and the 
reaction conditions. Indeed, comparing half-lives provides information about the 
rate of CO release but doesn’t reveal the extent of the reaction. Measuring these 2 
parameters allows the distinction between fast and slow releasers and to account 
for the total capacity of CO release from a given compound.  
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Table 2: Half-life and amount of CO transferred to deoxy-Mb after 2h incubation. The 
amount of CO transferred is expressed in equivalents of CO and percentage of the 
maximum amount of CO possible to liberate. Half-lives were calculated adjusting the 
experimental data to fitted curves. Experiments were performed under normal 
atmospheric air at room temperature. Solvent is PBS7.4 unless stated otherwise. 
Entry Half-life/ min 
Equiv. CO 
transferred after 
2h (% of 
maximum CO) 
Reaction conditions 
1 115 0.50 (25%) [1] = 50 µM [deoxy-Mb] = 62 µM 
2 
64 
 
 
14 
 
 
27939 
0.61 (12%) 
 
 
0.73 (15%) 
 
 
0.25 (5%) 
 
a) [2] = 50 µM (0.9% MeOH) 
    [deoxy-Mb] =56 µM 
 
b) [2] = 51 µM (1.7% DMSO) 
     [deoxy-Mb] =55 µM 
 
c) [2] = 50 µM 
    [deoxy-Mb] = 57 µM 
3 25 0.94 (31%) [3] = 50 µM [deoxy-Mb] = 62 µM 
4 11 1.41 (47%) [4] = 30 µM [deoxy-Mb] = 62 µM 
5 9 1.02 (33%) [5] = 30 µM [deoxy-Mb] = 62 µM 
6 42 0.86 (29%) [6] = 30 µM [deoxy-Mb] = 62 µM 
7 60 0.87 (29%) [7] = 30 µM [deoxy-Mb] = 62 µM 
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Figure 2: Structure of the MCCs tested in this Chapter. 
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8 11 1.10 (37%) [8] = 50 µM (2.5% MeOH) [deoxy-Mb] = 62 µM 
9 120 0.50 (17%) [9] = 100 µM (5.2% DMSO) [deoxy-Mb] = 62 µM 
10 ∞ 0 (0%) [10] = 100 µM (1.1% DMSO) [deoxy-Mb] = 56 µM 
11 449 0.24 (8%) [11] = 50 µM [deoxy-Mb] = 62 µM 
12 195  0.36 (12%) 
[12] = 100 µM (4.7% MeOH) 
[deoxy-Mb] = 56 µM 
13 101  0.51 (17%) 
[13] = 30 µM 
[deoxy-Mb] = 62 µM 
14 105 0.53 (18%) [14] = 30 µM [deoxy-Mb] = 62 µM 
15 832 0.13 (4%) [15] = 80 µM [deoxy-Mb] = 62 µM 
16 308 0.20 (7%) [16] = 100 µM (1% MeOH) [deoxy-Mb] = 62 µM 
17 822 0.14 (5%) [17] = 100 µM [deoxy-Mb] = 62 µM 
18 27 1.00 (33%) [18] = 50 µM (2.4% MeOH) [deoxy-Mb] = 62 µM 
19 134 0.47 (9%) [19] = 100 µM (6.1% MeOH) [deoxy-Mb] = 63 µM 
20 ∞ 0 (0%) [20] = 47 µM [deoxy-Mb] = 55 µM 
21 <2 1.00 (33%) [21] = 50 µM [deoxy-Mb] = 57 µM 
22 <1 1.5-2 (25%-33%) [22] = 20 µM (0.5-1.6% DMSO) [deoxy-Mb] = 61 µM 
 
 
 
To set up the basis for this discussion it is useful to start our analysis with 
compound 1, which is a reversible CO carrier[10, 11] that is believed to form in vivo 
as an intermediate of the catalytic oxidation reaction of cysteine which may occur 
in living cells[12] (Equation 3) 
 
Fe(cysteine)2(CO)2 Fe(cysteine)2 + 2CO  Equation 3  
 
In terms of the CO release rate 1 can be classified as a slow releaser that presents 
a continuous, slow increase in CO-Mb, liberating 0.5 to 0.6 equiv. CO after 2h. 
This result matches exactly the one obtained in the standard, macroscopic 
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chemical CO release tests in RPMI in the absence of Mb: 26% CO liberated to the 
gas phase, during the same period of time in the apparatus of Fig.1 (Chapter II).  
As can be seen in Fig.3 this amount of CO is not strongly affected by the presence 
of O2 meaning that oxygen is not triggering the CO release.  
 
Although the compound has a 
limited solubility at the 
concentrations used in the GC 
experiments, some of these 
compounds have shown that 
the rate of CO release wasn’t 
affected by pH changes or 
addition of ROS species and 
remained similar to the one 
measured in the presence of 
the strong CO scavenger, Mb. 
The rate of release is therefore 
dependant on the dissociation 
of the compound, slowly liberating CO at a constant rate over a large period of 
time. 
Compound 2 exhibits a rather different profile. Incubation of 2 with deoxy-Mb 
was performed under different conditions, with 2 being pre-dissolved in distilled 
water, MeOH and DMSO and tested with deoxy-Mb at different concentrations. 
The results obtained showed that the solvent interferes with the amount of CO 
released. 
As can be observed from the Fig. 4 the amount of CO released varies with the 
solvent in the order H2O < MeOH < DMSO. 
Although the absolute amounts of CO released are different, similar kinetic 
profiles are observed, suggesting that the differences observed are mainly due to 
the initial solubilization. In the macroscopic GC assays 2 is able to release 5 
equivalents of CO in 2h when dissolved in DMSO but only 2.1 equiv. within the 
 
Figure 3: Equiv. CO released to deoxy-Mb by 1 
in air and under N2. Assays performed in PBS7.4 
at room temperature with [deoxy-Mb] = 56 µM 
and [1] = 100 µM (air assay); [deoxy-Mb] = 56 
µM and [1] = 50 µM (N2 assay). 
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same period, when dissolved in MeOH and 1.4 equiv. in H2O, however, these 
results also reflect the different solubility (or insolubility) in the media. On the 
contrary, at 50 µM concentration the compound is fully solubilized in the three 
solvents but still the same variability is observed supporting that most probably 
the initial solubilization and 
reactivity towards the 
solubilizing solvent is the 
rate determinant step.  
Compounds 3 to 7 are a 
group of water-soluble 
compounds that were 
presented in Chapter II as 
fast and spontaneous CO 
releasers. It was also 
demonstrated that O2 was 
triggering the CO release 
(see Chapter II) since no CO 
was detected in the 
headspace of their solutions 
under N2. 
As seen in table 2, when incubated with Mb these compounds form CO-Mb at a 
rate that corresponds to some of the shorter values of t1/2 among all the 
compounds presented. Compounds 3, 4, and 5 are among the fastest CO releasers 
to Mb. Besides the rate, the extension of the transfer of CO is also high. Indeed, 
the total amount of CO released reaches ca. 1 equiv. CO after 2h. Compound 4, 
whose reactivity is still poorly understood liberates 1.4 equiv. CO after 2h, which 
is the maximum amount obtained in this assay.  
Although compounds 6 and 7 are slower and less extensive CO releasers to Mb, 
the complexes 3 to 7 show an overall similar behavior. This is not surprising in 
 
Figure 4: Equiv. CO released to deoxy-Mb by 2 
at 50 µM, pre-dissolved in different solvents. The 
values in MeOH are the average of 2 assays with 
final MeOH content of 1.9% and 0.9%. The 
values in DMSO are the average of 2 assays with 
final DMSO content of 1.7% and 3%. Assays 
performed in PBS7.4 under air at room 
temperature with [deoxy-Mb]= 56µM. 
Experiments performed with different [2] 
presented similar CO release rates. 
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view of the fact that they all have the same kind of structure where a Mo(CO)3 
core is coordinated to anionic hard N and O donors.  
As mentioned before, in the absence of Mb, O2 is necessary to trigger off the 
release of CO from these complexes to the headspace. One would hypothesize 
that the interactions between the complexes and the protein might change this 
situation. This was probed by performing the incubation of Mb with compounds 3 
and 4 under N2, using degassed PBS7.4 solution. As can be seen in Table 3, CO is 
still being transferred to Mb although there is a marked increase in t1/2 and a 
decrease of the total amount of CO liberated when compared to the similar 
aerobic experiments. 
 
 
 
 
 
 
 
 
 
 
This slower decarbonylation process is also depicted in Figure 5, where one can 
observe a clear difference between aerobic and anaerobic CO release. 
Under N2, roughly half of the CO is transferred and it takes 1h to achieve the 
same amount that is liberated in air within 5 min!  
The GC experiments had shown that 3 doesn’t release CO in aqueous solution, 
namely in PBS7.4 under N2, at least during 6h. The results obtained with Mb 
under N2 (which were replicated at different concentrations but not shown) 
demonstrate that CO-Mb formation is still occurring in 2h. One may, therefore, 
conclude that Mb is able to abstract CO from the complex following some 
interaction between both and not simply scavenging free, dissolved CO. To this 
process we herein call CO donation. 
 
Table 3: Half-life and amount of CO transferred from 3 and 4 to deoxy-Mb after 2h 
incubation. Half-lives were calculated adjusting the experimental data to fitted curves. 
Experiments were performed under N2, at room temperature. 
Entry Half-life/ min 
Equiv. CO transferred 
after 2h (% of 
maximum CO) 
Reaction conditions 
3 97 0.61 (20%) [3] = 60 µM [deoxy-Mb] = 62 µM 
4 45 1.32 (44%) [4] = 30 µM [deoxy-Mb] = 62 µM 
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The class of compounds that don’t release CO to the headspace but rather deliver 
it directly to the CO-Mb target we termed CO donors. The donation process 
consists on the specific delivery of CO to a target instead of dissociation from the 
CO-RM followed by capture of the free gaseous CO.  
With the present data nothing can be said on the mechanism leading to this CO 
donation but interactions between both CO-RM and Mb are certainly present and 
relevant. Evidences of Mb-CO-RM adducts for compounds 3, 4, 6 and 7 were 
observed through UV-VIS and ICP-AES and the data is currently being 
rationalized by other collaborators. 
Nevertheless, even in the presence of the transfer mechanism the rate of CO-Mb 
formation in aerobic conditions is faster than in anaerobic medium. This suggests 
that in aerobic conditions compound 3 is liberating CO through 2 different 
mechanisms, the donation and a spontaneous release triggered by O2.  
The ability to donate CO to Mb in opposition to release from the molecule will be 
further addressed in Chapter V. 
 
Figure 5: Equiv. CO released to deoxy-Mb (62µM) by 3 at 60µM (under N2) and 50µM 
(under air). The assay under N2 was performed in degassed PBS7.4 and prepared inside 
a schlenk apparatus under anaerobic conditions and the assay under air performed in 
normal aerated PBS7.4. Both assays performed at room temperature. 
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Compound 4 is relatively similar to 3 in terms of CO transfer to Mb but has a 
smaller rate difference between aerobic and anaerobic conditions, as can be seen 
in Figure 6. 
The half-life of 4, didn’t change as much as that of 3 and the same amount of CO 
is donated in aerobic and anaerobic conditions after 2h. Since 4 is also stable 
under N2 for several hours this results suggest that in the case of 4 CO-Mb 
formation is occurring mainly through a CO donation process.  
In principle, the same behavior could be expected for the complexes 9 and 10 
which also have a fac-Mo0(CO)3 fragment.  However, both compounds have very 
long half-lives and only a 
marginal amount of CO is 
transferred to Mb. In Chapter  
II we hypothesized that 
complex 10 wasn’t liberating 
any CO to the headspace due 
to the lack of solubility. 
However, at the 100 µM 
concentration used in the 
experiments with Mb it is fully 
solubilized and yet it is highly 
inert towards CO loss. This 
fact is best ascribed to the 
extraordinary stabilization 
provided by the macrocyclic 
trithianonane ligand. The tris-
phosphine complex 11, Mo(CO)3(PTA)3 is not totally inert towards CO loss to 
Mb but the amount released is also very small.  
Also for 12 and its ionized analogues with lysine (13) and choline (14) salts long 
t1/2 values are obtained, reflecting the stability of the complex anion which is not 
affected by the negative charge present at the distal ligand free arm. 
 
Figure 6: Equivalents of CO released after 
incubation of deoxy-Mb (58 µM) and 4 (30 µM) 
under air (black) and deoxy-Mb (62 µM) and 4 
(30 µM) under N2 (grey). Assay under N2 was 
performed in degassed PBS7.4 and prepared 
inside a schlenk apparatus under anaerobic 
conditions and assay under air performed in 
normal aerated PBS7.4. Both assays performed at 
room temperature. 
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At the µM range all these three compounds are fully solubilized in the PBS 
medium and the total amount of CO delivered to Mb after 2h, is similar for the 3 
compounds (12%, 17% and 18%, for 12, 13 and 14 respectively).  
As discussed in Chapter II, generally, the bond between alkenes and metal 
carbonyls is often weak and labile since CO removes most of the electronic π 
density thereby weakening the alkene-metal backbonding. This lability is even 
more pronounced in solvents with pi-donor atoms such as ethers, alcohols or 
water. Therefore, in such solvents, the lability of ligands like the cycloheptatriene 
of complex 8 is well established. Once the double bonds are successively pushed 
away from the metal center, open coordination positions are available for O2 
attack according with Scheme 1 (Chapter II) which then promotes fast 
decomposition kinetics with a rapid liberation of CO. The profile exhibited by 8 is 
in accordance with these observations, since it presents a very short half-life (t1/2= 
11 min) with a large amount of CO being released after 1h (1.1 equiv. CO). The 
same experiment performed under N2, leads to the increase of half-life to 91min 
and decrease of the total amount of CO liberated to 0.63 equiv. after 1h. This 
supports the role of O2 in the decomposition profile of the compound with 
concomitant CO release.  
In contrast to the simple alkenes, the delocalized, aromatic, cyclopentadienyl 
anion Cp forms very stable Cp-M bonds and CpM(CO)x complexes. The stability 
of this motif is reflected in the group of Cp’-MoII complexes 15, 16 and 17 which 
are poor CO releasers with very long half–lives (> 300 min) and low amounts of 
CO released within 2h (< 0.3 equiv. CO).  
As in Chapter II, the CpMo(CO)3-alkyl family shows a relatively good thermal 
and oxidative stability and CO substitution at mild temperatures is only afforded 
via photoactivated reactions, nucleophilic substitutions with phosphines or 
oxidation with  NO.[13, 14] Monoalkyl-substitutions on the Cp ring, like the one 
introduced in 17 vs. 15, often lead to differences in the solubility properties but no 
relevant differences were expected or obtained regarding the CO release kinetics. 
If any, CO release should be slower due to a stronger Mo-CO bond.  
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On the contrary, ring substitutions like that of 18 should favor CO release due to 
the weakening of the Mo-CO bonds which results from the increased electron-
withdrawing power of the Cp ring substituted with an electron-withdrawing 
group. Although 18 presents a much shorter half-life than the other Cp analogues 
(t1/2=27 min), liberating a higher amount of CO after 2h (1.0 equiv.) it is not 
possible to assign this higher activity to the ring-substitution since the ancillary 
chloride ligand may play a more relevant role in electron depletion from the metal 
than the ring substitution. Indeed, the chloride lowers the electron density at the 
metal relative to the -CH2CONH2 substituent in 15, by virtue of its higher 
electronegativity. Moreover, the stabilized alkyl substituent, -CH2CONH2 does 
not undergo hydrolysis at physiological pH (see Chapter III, section 4.2) whereas 
the Mo-Cl bond is likely to undergo such a reaction which favors the 
decomposition of the complex in comparison with the alkyl derivatives. 
Incubation of 18 with Mb under N2 did not change much the profile of the 
carbonylation of Mb relative to the aerobic reaction.  In fact, both processes have 
a similar rate of CO release with minor changes in half-life and total CO release 
values (t1/2=59 min and 0.93 eq. CO released in 2h). This supports the idea that O2 
is not the main promoter of CO release for the Cp’Mo(CO)3X complexes. The 
known chemistry of CpMo(CO)3X complexes strongly suggests that Mo-Cl 
hydrolysis is most probably initiating decomposition and CO release.  
The different profile between an alkyl and halide substituent is also noted in the 
pair of Mn pentacarbonyl complexes 19 and 20. Although complex 19 with a 
bromide substituent presents a fairly stable profile, only losing ca. 10% of the 
total CO amount after 2h, it is nevertheless a much better CO releaser than the 
totally inert analogue 20, which has the -CH2CONH2 ancillary ligand.  
The ruthenium complexes 21 and 22 showed the unique property of producing an 
immediate donation of CO to deoxy-Mb. These compounds do not release CO to 
the headspace in any conditions tested in aqueous media. However, when 
incubated with deoxy-Mb the Mb-CO formation is almost immediate. The 
donation process was previously observed with other compounds but never at 
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such a fast rate and so evident. The CO donation is completed within the first 5 to 
10 min and exactly one equivalent of CO is donated to deoxy-Mb. This very fast 
CO transfer is an exclusive property of the ruthenium compounds and it occurs 
either under air or under N2. 
Due to this very fast profile of CO-Mb formation the reaction of 21 with deoxy-
Mb was followed minute-by-minute during the first 10 min and then every 2 min 
until 20 min to determine when the maximum CO-Mb values were reached. The 
CO donation profile of 22 is also presented for comparative purposes (Fig. 7).  
 
 
 
 
 
 
 
 
 
Figure 7: Equiv. CO transferred to deoxy-Mb by 21 and 22. Left: Assays performed in 
PBS7.4 under air at room temperature with [deoxy-Mb]= 57 µM and [21] = 50 µM 
(average of 2 assays). Right: Assays performed in PBS7.4 under air at room temperature 
with [deoxy-Mb]= 61 µM and [22] = 20 µM (average of 3 assays; final DMSO content 
0.5-1.6%). 
 
The CO donation capacity of 21 and 22 was already reported in the literature, 
although with a mechanistically loose denomination – CO release.[7, 15]  
The amount of CO released from 21 (1 equiv. CO) is in agreement with the 
results reported in the aforementioned study[7] but the results obtained with 22 are 
different. Motterlini and co-workers reported that 0.7 moles of CO were released 
per molecule of [Ru(CO)3Cl2]2, a value obtained by titrating deoxy-Mb with a 
DMSO solution of 22. A more recent study[15] followed the same methodology 
and reported 0.46 mol per molecule of 22.  
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The discrepancies found are associated with the different methodology adopted in 
our system and in the reported studies. The [Ru(CO)3Cl2]2 dimer is unstable in 
DMSO leading to the formation of different species with different donation 
capacity. These different equilibria originate the variety of results obtained and 
will be addressed in detail in Chapter V. 
 
4.1.1 Discussion  
 
The results just described suggest two topics for discussion: methodological 
questions and chemical questions. 
The former consider the two methodologies used to evaluate and quantify CO 
release: measuring CO in the headspace of a solution or measuring CO-Mb 
formed upon incubation of a CO-RM with deoxy-myoglobin solutions. 
The chemical questions compare the CO release profile of the compounds tested 
as measured by the Myoglobin method. 
  
Quantification of CO release: GC or Myoglobin?  
 
In Chapters II and III we studied the ability of metal carbonyls to release CO 
under different chemical conditions by measuring the amount of CO liberated to 
the headspace of solutions of CO-RMs exposed to several media and chemical 
conditions. These very versatile and practical measurements were, however, 
subject to an important drawback. Due to the range of concentrations of CO gas 
that could be measured with accuracy with TCD detection, the concentrations of 
the CO-RMs used were typically in the order of the 10-3 M. These relatively high 
concentrations posed severe problems in the measurement of the CO release 
properties of sparingly soluble compounds and precluded the proper evaluation of 
water insoluble compounds. However, this concentration range posed yet another 
important problem: the minor biological relevance of this concentration range. 
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Since the vast majority of biological in vitro tests are performed in the 1-100 µM 
range the compounds should also be studied in this concentration range.   
When the working range changes 1000-fold, from mM to µM, obvious 
differences are observed. In the µM range solubility becomes a less problematic 
issue and the CO releasing rate is strongly modulated by the very low 
concentrations of the CO-RM in the medium. At these low concentrations all 
compounds are fully dissolved and, therefore, CO release data becomes more 
precise. Moreover, the low concentrations also minimize the influence of the 
nature of the vehicle that may have to be used to facilitate the solubilization of the 
compound in the aqueous media, because reactions are much slower. Therefore, 
the measurement of CO release with the Myoglobin method developed by 
Motterlini has many advantages over the GC/TCD method due to elimination of 
mass transfer limitations. Of course, this would no longer be true if the GC 
method would allow a higher sensitivity for CO quantification. In principle this 
could be achieved with a FID detection system operating downstream of a 
methanizer. However, in spite of hard and prolonged efforts, supported by the 
technical assistance of the supplier of the appropriate chromatograph, we were 
unable to use CO detection in the range required by CO-RM concentrations of ca. 
10-50 µM due to the formation of impurities in the methanizer that distorted the 
base line beyond acceptable values. The recent acquisition of a GC/RCP 
(Reducing Compound Photometer), specific only for CO and H2 overcomes this 
problem and allows measurements of CO in the low ppb range without any 
interferences. However, this range is unfortunately too low for the routine 
evaluation of CO-RMs because the amount of CO needed for the measurement is 
too low and successive gas dilutions are necessary. 
In spite of its mentioned advantages, the Mb method has some disadvantages 
because it requires a critical interpretation.  
In fact, the incubation of a CO-RM with Mb is not a straightforward process 
because several situations may occur that lead to CO-Mb formation: 
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1. The CO-RM independently liberates CO which is simply 
scavenged by Myoglobin; 
2. Myoglobin reacts with the CO-RM abstracting its CO directly; 
3. Both previous situations compete. 
 
Under the conditions of item 1 the amount of CO-Mb measured in an experiment 
should match the amount of CO measured by the appropriate GC method. The 
CO-RM may simply dissociate CO or may be activated by some chemical trigger 
independent of Mb (e.g. O2).  Free CO is then scavenged, and as pointed out in 
the beginning of this section, no CO should escape due to the high affinity and 
reactivity of deoxy-Mb towards CO. 
The prototypical example of this situation was provided by compound 1 which 
gives the same CO release profile in both methods. The dissociation of 1 is not 
influenced by Mb or O2 and both methods give the same result (see below). 
On the contrary, large deviations between both methods are observed in some 
aerobic Mb assays when compared with the GC experiments: the amount of CO 
liberated to deoxy-Mb (either by donation or spontaneous release) is always less 
than the amount obtained by GC. Complexes 3, 6 and 7 are the most elucidative 
examples since the Mb method only accounts for 1/3 of the amount of CO 
liberated in PBS7.4 in the GC experiments. The same is observed with other 
sparingly soluble complexes like 2 and 12. These results are due to an 
experimental artifact, needed to create the proper conditions to the Mb assay; the 
addition of sodium dithionite removes O2 from O2-Mb and reduces met-Mb 
(unable to bind CO) to deoxy-Mb  
 
S2O4
2-
 + O2 + 2 OH
-
SO3
2-
 + SO4
2-
 + H2O  Equation 4 
 
S2O4
2- 2 SO2
.-
Fe(III)
SxOy + Fe(II)   Equation 5 
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Sodium dithionite is widely used in biochemical assays to generate or maintain 
reduced states of enzymes. However, it also creates artificial anoxic conditions 
since it removes dissolved O2 from the aqueous medium.[16-21] This decrease in 
normal [O2] prevents or slows down CO dissociation from the most O2 sensitive 
complexes. Molybdenum (0) compounds like 2, 3, 6 and 7 to which O2 is the 
main CO release trigger are the most affected by this factor. As a consequence of 
the deoxygenated conditions created by dithionite the compounds become more 
stable and don’t release as much CO as they would in aerated PBS. This is a 
general behavior observed with all the O2 induced releasers (all the Mo(0) 
compounds) that showed levels of CO-Mb formation much lower than those 
expected from CO release experiments by Gas Chromatography. 
However, the amount of dithionite is not enough to totally prevent O2 assisted 
decomposition due to several factors: the dithionite has limited life-time in PBS 
solution, the solvents are not deoxygenated (in experiments performed under air) 
and the system is not closed so oxygen from air does induce some decomposition 
in aerobic assays. Since these factors are not easily controllable or accounted for, 
the results obtained by the CO-Mb method are highly biased by dithionite when 
the compound is activated by O2 unless they are strictly performed under N2 
atmosphere which, in turn, has no biological relevance. This is clearly the major 
limitation of this assay and one that affects the vast majority of CO-RMs which 
react under the conditions of item 3 above, that is, are sensitive to oxygen or 
triggers other than Mb (e.g. pH, light). 
Of course, the greatest advantage of the Mb method is that it is the only way to 
identify compounds that, like the Ru(II) derivatives 21 and 22 cannot release CO 
to the headspace but do transfer CO to Mb. This advantage is non-obvious and 
applies only to a handful of compounds as will be discussed more extensively in 
Chapter V. 
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4.1.2 Comparing CO release profiles by the Mb method 
 
By eliminating the mass transfer limitations interesting details of the kinetics of 
CO release are revealed. Compound 1 is a rare case of a compound with a purely 
dissociative decomposition rate. It is totally unaffected by the [O2], shows a 
identical rate of decomposition at 14 mM and 50 µM despite not being totally 
solubilized at higher concentrations and is not affected by the presence of deoxy-
Mb. This is the clearest case of CO release controlled by the self-dissociation rate 
of the Fe-CO bond.  This should be the typical CO release profile of reversible 
CO carriers of which this is the only example in the present dissertation. 
Compound 2, on the other hand, shows different results from the GC assay which 
are no longer plagued by the uncontrollable effects of low solubility. The GC 
assays were helpful to determine the influence of the several media in the CO 
release rate, however, since the compound was not completely soluble in all the 
media an effective comparison couldn’t be performed. The results of the Mb 
assay showed slightly different rates, but not so distinctive as in the GC 
experiments. Nevertheless, the influence of the co-solvent is obvious but we do 
not have data that allows its interpretation.  
At this point it is important to remember that higher solubility does not imply a 
higher rate of CO release. In fact 10 that was shown in Chapter II to be strictly 
ROS activated and totally insoluble in water was solubilized in DMSO but still 
unable to deliver any CO to Mb after 2h. The same lack of reactivity towards Mb 
is observed with several complexes, e.g. 9, 10, 11, 15-17, 20. These compounds 
are all very stable, both thermodynamically and kinetically, and the GC 
experiments showed that they only release CO when activated by ROS. 
Obviously, Mb is not capable of interacting with these highly substitutionally 
inert MCCs to scavenge CO. In agreement with this view, the Cp’ derivative 18 
which has a substitutionally labile Mo-Cl bond (more so in aqueous media) that 
may allow for O2 entry or Mb attack has a much higher rate of release than that of 
the other Cp derivatives 15-17. Some interaction with Mb due to the acetyl group 
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can’t be discarded however it is more likely that a different hydrolytic process is 
taking place, namely Mo-Cl bond rupture. 
The notion that ligand lability goes hand-in-hand with easy reaction with Mb and 
concomitant CO-Mb formation is exemplified by the chemically labile, ionic, 
water-soluble compounds 3-7. These are stable in aqueous solution under N2 but 
in the presence of Mb they also form CO-Mb very rapidly and extensively. This 
can only mean that they reacted with deoxy-Mb in a way that allowed the transfer 
of CO from Mo(0) to Fe(II). These complexes, together with the RuII(CO)3 
analogues are the best examples of the CO donation process to Mb. 
Two major processes originate the formation of CO-Mb from a MCC: CO 
dissociation from the MCC as a free molecule and capture by deoxy-Mb, and a 
direct donation between the compound and Mb. In some cases e.g. 1, 15 and 17 
only the first mechanism seems to be present; in others only the second 
mechanism is present e.g. 21 and 22; The cases in which the mixed situation 
predicted in item 3 above where both mechanisms are simultaneous, is 
exemplified by 3 and 4. Only the combination of the results from the two 
techniques allowed the discovery of the ability to donate CO to Mb and this new 
feature wouldn’t be detected if only a single assay was used to quantify CO 
release. 
The interactions between the CO-RMs and Mb have to be taken into account 
since it is sometimes determinant for the fate of reaction (this issue will be further 
developed in Chapter VI). In spite of all limitations, the Mb assay is extremely 
useful to understand some properties of the compounds and without it wouldn’t 
be possible to detect some special features like the CO donation of the ruthenium 
complexes.  
 
 
 
 
Chapter IV 
 
 
163 
4.2 Redox interaction between Metal Carbonyl Complexes, 
Cytochrome C and Myoglobin  
 
Since these metal carbonyls possess a metal center in low oxidation state, they 
may behave as reductants in biological conditions thereby assuming other roles 
beyond CO release. An exploratory study was performed, in which the redox 
behavior of some metal carbonyl complexes was studied with two different heme-
proteins, Cytochrome C and Myoglobin. 
Cyt C mediates single electron transfer between the protein complex ubiquinol-
Cytochrome C oxidorreductase to the complex Cytochrome C oxidase thereby 
playing a pivotal role in the respiratory chain reactions.[22] This protein undergoes 
reversible oxidation-reduction steps, and when isolated pure does not bind O2 or 
CO under physiological conditions.[23, 24] However, it was recently found that CO 
can associate to the complex Cyt C-cardiolipin with extraordinary positive 
consequences on anti-apoptotic mechanisms.[25]  
Although they are involved in different functions both proteins are part of the 
complex process where CO may be involved and so this study may contribute for 
further understanding of interactions between metal carbonyls and heme proteins.  
 
4.2.1. Results 
 
Cytochrome C 
 
Native oxidized Cytochrome C (5 µM) was incubated with the metal complex in 
10-fold excess in PBS7.4. The UV-VIS absorbance spectrum was recorded 
immediately after incubation and if no reaction was taking place the spectrum was 
recorded again 1h and 2h later. The same procedure was performed with reduced 
Cyt C. As a control CO gas was bubbled into both the oxidized and reduced Cyt 
C solutions for 20 min, however no changes were observed in both spectra. 
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The reaction between the compounds and the reduced Cyt C didn’t show any 
modification in the absorption spectrum of Cyt C. 
On the other hand, three distinct behaviors were observed among the compounds 
that were incubated with oxidized Cyt C (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: A - UV-VIS absorbance spectrum of reduced and oxidized Cyt C (5 µM) before 
and after CO bubbling for 20min. Spectrum recorded in PBS7.4 at RT; B - Typical UV-
VIS absorbance spectrum of class I compounds (data from 3) with oxidized Cyt C (10:1). 
Spectrum recorded in PBS7.4 at RT immediately after incubation with Cyt C; C - Typical 
UV-VIS absorbance spectrum of class II compounds (data from 15) with oxidized Cyt C 
(10:1). Spectrum recorded in PBS7.4 at RT immediately after incubation with Cyt C and 
after 1h; D - UV-VIS absorbance spectrum of 21 with oxidized Cyt C (10:1). Spectrum 
recorded in PBS7.4 at RT immediately after incubation with Cyt C, after 1h and 2h. 
 
 
Class I compounds (2, 3, 4, 6 and 7) were able to immediately reduce oxidized 
Cyt C at the time of addition. Class II compounds (15 and 17) were only able to 
  
  
A B 
C D 
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complete reduction after 1h. Class III (21) didn’t reduce the cytochrome. 
However, after 2h incubation it was observed a very slight shift of the Soret band 
and also the formation of a peak characteristic of the Cyt reduced form (at 548 
nm). 
The small group of compounds tested clearly showed distinct activities, 
depending on the oxidation state of the metal or its reducing capability. Class I 
compounds are the air sensitive, ionic Mo(0) complexes, while class II are rather 
air stable neutral Mo(II) complexes. It was observed that the Mo(0) complexes 
were able to immediately reduce Cyt C while Mo(II) compounds were slower in 
achieving this reduction, since it was only observed after 1h. There is an 
interesting correlation between this redox activity and the CO releasing capacity 
of these two classes of compounds. While Class I integrates fast spontaneous 
releasers, the Class II contains more stable complexes, and only ROS induced 
releasers. However, the controls performed with CO gas showed that this Cyt C 
reduction is totally independent of the CO release rate and only dependent on the 
reducing potential of the complexes.  
Another important issue that shouldn’t be neglected is the electrostatic interaction 
between the MCC-Cyt C couple. The binding surface of Cyt C includes several 
lysine residues[26-30] which at physiological pH have a net charge of +8. This 
charged state may repel positively charged complexes like 17 and delay the 
reduction reaction. However, this interpretation is entirely speculative at the time.   
The only compound that didn’t reduce Cyt C was the Ru(II) complex 21. 
Interestingly, after 2h some minor deviations are observed in the Soret and β sheet 
region. This may indicate that a partial reduction is occurring although with a 
slower kinetics. In fact, 21 can be reduced as a consequence of OH- attack at the 
coordinated CO. Hydride species are identified by NMR in its aqueous solutions 
(see Chapter V). 
In view of the classical observation that reduced Cyt C is unable to bind CO these 
results might not look particularly important. However, the very recent finding 
that reduced Cyt C is able to bind CO when associated with the phospholipid 
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cardiolipin[31, 32] completely changes this view.[25] In fact, recent data suggest that 
the carbonylation of the Cyt C-cardiolipin complex stabilizes the Cyt C against its 
detrimental peroxidative activity[33] and may prevent its leaking out the 
mitochondial membrane.  
The release of Cyt C from mitochondria to cytoplasm is believed to trigger the 
apoptotic cascade through two different mechanisms: one involving Apaf-1, pro-
caspase-9 and dATP/ATP interactions[34] and another based on the interaction of 
Cyt C with cardiolipin prior to its release from the mitochondria.[33, 35, 36] 
Having this in mind it is hard to imagine a better explanation for the well-
established anti-apoptotic activity of CO[37-39] than its stabilization of the Cyt C 
inside the mitochondrion. In this case, the coupling of reduction with CO transfer 
should play a powerful role in the anti-apoptotic activity of CO-RMs.  
 
Myoglobin 
 
Due to its biological function Mb is necessarily a different protein than Cyt C. 
One relevant aspect is the fact that Mb, when in its reduced form is able to bind 
O2 and CO, but with much higher affinity for the later.  
This behavior is reflected in the present study, since it is observed that when the 
protein is reduced it is immediately carbonylated with the CO liberated from the 
complexes. The Mb reduction is achieved through oxidation of the metal carbonyl 
which, when oxidized, liberates CO that carbonylates the reduced Mb. This is 
observed by the changes in the Soret band that moved accordingly with figure 9 
CO gas doesn’t react with native, oxidized Mb. 
The results obtained allowed the division of the compounds tested into two 
classes; Class I are compounds that reduce and carbonylate Mb and Class II are 
compounds that do not reduce the protein.  
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Figure 9: Left: Typical UV-VIS absorbance spectrum of class I compounds  (50 µM)  
with Oxidized Mb (11 µM). Spectrum recorded in PBS7.4 at RT immediately after 
incubation with Fe3+-Mb (data from 5). Right: Typical UV-VIS absorbance spectrum of 
class II compounds (50 µM)  with Oxidized Mb (11 µM). Spectrum recorded in PBS7.4 at 
RT immediately after incubation with Fe3+-Mb (data from 21).  
 
Table 4: Results of the incubation of Fe3+-Mb (11 µM) with different MCCs (50 µM). 
Class I compounds immediately reduce and carbonylate Mb while class II compounds do 
not have any redox action on Mb.  
Class I Class II 
Mo(0) Mo(0) Mo(II) Ru(II) Fe(II) Mn(I) 
3 
4 
5 
6 
7 
8 
9 
12 
13 
14 
2 
10  
23 
 
15 
17 
18 
 
21 
22  
1 
24 
25 
19 
20 
26 
27 
 
 
Similarly to what was observed with Cyt C, most of the Mo(0) compounds 
rapidly reduced Myoglobin and transferred CO immediately to give CO-Mb, with 
only three exceptions, 2, 23 and 10. Whereas the later two compounds are very 
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stable even in the presence of ROS (see Chapter III) and therefore not prone to 
react with Mb, 2 is an unexpected case since it was unable to reduce Mb even on 
a 5 to 10-fold excess. However Mb was effectively reduced and carbonylated in a 
1 mM solution of 2 and 10 µM of Mb. Most likely, the true reducing compound is 
some decomposition product of 2. 
The largest fraction of complexes are class II compounds that don’t reduce Mb. 
None of the Mo(II), Ru(II), Fe(II) or Mn(I) complexes were able to reduce Mb 
despite the different ligands, CO release rate or structure of the complexes. The 
assays with Ru complexes were followed up to 2h and still no reduction was 
observed, contrary to the observed with 21 and Cyt C. These data suggests that 
the results obtained are primarily dependent on the redox potential of the 
complexes which, of course, is lower in the Mo(0) complexes than in all other 
class II complexes. Nevertheless, ligand lability seems to be an important 
property to ensure rapid reduction of Mb by Mo(0) metal carbonyls.  
 
4.2.2 Discussion 
 
The results obtained are per se revealing. Most of the compounds tested do not 
interfere with the redox state of heme-proteins but almost all the Mo(0) 
complexes are strongly reducing agents and this reduction is accompanied by CO 
transfer to the reduced Myoglobin to give CO-Mb. This effect in vivo doesn’t 
seem to block any vital process of the respiratory pathway since none of the 
compounds shown here presented high toxicity levels in vivo or led to fatal 
episodes following administration. 
The reducing activity of Mo(0) compounds towards Mb may unveil a different 
type of activity. The impact on the metabolic process is for now unknown but the 
same behavior is observed with hemoglobin (data not shown), reducing met-
hemoglobin to deoxy-hemoglobin and carbonylating it to give carboxy-
hemoglobin. 
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Met-hemoglobin has been ascribed as playing a major role in several iron-related 
diseases, like methemoglobinemia which is characterized by inadequate tissue 
oxygenation caused by excessive levels of met-hemoglobin in blood.[40, 41] 
Recently, it was also related with cerebral malaria[42] as a key factor during the 
disease development. The reported results may represent a window of opportunity 
for the development of this family of compounds due a set of specific redox 
properties. 
 
4.3 Behavior of CO-RMs in blood 
 
Once administered to an animal, a CO-RM will enter the blood circulation which 
carries and distributes it around the whole body. During this process the CO-RM 
will interact with all the blood components, namely proteins and red blood cells 
(RBC). If a CO-RM is meant to be delivered intact to a certain tissue it must be 
able to survive these interactions in the blood stream until it finally reaches the 
target cells where CO will be released. The interaction of drugs in circulation with 
blood proteins such as albumin and transferrin (addressed in Chapter VI) is a 
matter of great importance since it strongly influences the stability and the half-
life of the drugs in circulation. In the case of CO-RMs these interactions may 
affect the stability of the coordination sphere and thereby alter the kinetics of CO 
release which may be a positive or a negative event depending on whether 
interaction results in CO-RM stabilization or destabilization, respectively. This is 
particularly important in the blood stream because the hemoglobin in red blood 
cells is actually capable of removing and scavenging any CO that is set free. 
Therefore, viable CO-RMs must be designed to resist decomposition by the blood 
components and to be unable to enter RBC where hemoglobin will most likely 
scavenge their CO load. Altogether, this can be readily evaluated by measuring 
the values of CO-Hb that are reached when a given CO-RM is incubated with 
blood. If the CO-RM is stable and doesn’t enter RBC the values of CO-Hb should 
remain low. If the compound is unstable in the blood stream or enters RBC, the 
values of CO-Hb will be clearly raised with a certain kinetic profile.  
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This problem was studied experimentally by incubating the compounds with 
sheep blood and following the evolution in CO-Hb levels over time by means of a 
standard oximeter. The concentration of the CO-RMs was adjusted to mimic the 
administration of doses of 25 or 50 mg/kg in in vivo animal experiments (see 
experimental part for details). From the experimental values of CO-Hb measured 
for a given amount of blood and CO-RM concentration the number of equivalents 
of CO transferred to Hb was calculated. The results presented were selected from 
a large amount of collected data and are judged adequate to illustrate the typical 
profile of several CO-RM families studied. 
 
4.3.1 Results and Discussion 
 
The experimental values are collected in Table 5. Some CO-RMs required pre-
dissolution in small amounts of DMSO or MeOH to improve their solubility to 
the desired concentration range. Since these solvents, especially DMSO, have a 
slight interference in the exact measurement of CO-Hb in the oximeter, the 
amount of CO liberated (in equivalents) was rounded to the closest integer value 
and the CO-Hb levels below 0.5 equiv. CO were labeled as < 0.5 equiv. CO, 
meaning that the compounds are stable in the assay.  
 Although the values of CO-Hb were measured at several time points, only the 
one at which the highest value of CO-Hb was reached is reported. This option 
stems from the simple observation of the values reported in the table 5.  Indeed, 
the first immediate conclusion drawn from that table is that very few compounds 
present a slow, regularly increasing CO-Hb formation profile. 
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On the contrary, the vast majority 
of the complexes tested either 
release CO to the blood in a very 
fast manner or are fairly stable 
over time liberating only small 
amounts of CO to Hb. This is a 
very surprising result which casts 
a dark shadow on most of the 
previously expended arguments 
concerning the fine-tuning of CO 
release with different ligands.  
Most of the previously discussed 
electronic considerations 
regarding CO-RM stability, 
although still valid do not reflect 
the behavior of CO-RMs in blood. 
Indeed, all the compounds 
previously classified as 
spontaneous CO releasers and 
described as the fastest and more 
extensive CO-RMs present an 
enhanced capability to release CO in blood. 
Their kinetics of CO dissociation in blood is much faster than in the several media 
tested. For the vast majority of compounds in this class all the 3 CO ligands are 
released to blood within minutes. Compound 3 liberates exactly 3 CO equivalents 
to hemoglobin within the time of mixing with blood and measuring in the 
oximeter. In this way its administration can be described as a bolus injection of 
“solid CO”. If applied intravenously these compounds do not afford an effective 
delivery of CO to tissues but may effectively mimic a fast administration of 
Table 5: Amount of CO transferred from CO-
RMs to Hb in blood at 37ºC. Time at which 
the maximum levels of CO-Hb are attained 
(Tmax).  
Entry Equivalents of CO 
transferred to Hb Tmax/min 
2* 5 75 
3 3 0 
4 1 2 
5 3 2 
6 3 4 
7 3 8 
8* 2 2 
9** 2 2 
11 <0,5 30 
12* 3 10 
13 2 10 
14 3 30 
15 <0,5 120 
19** 2 4 
20 <0,5 30 
21 <0,5 120 
22** <0,5 30 
28 <0,5 30 
29* <0,5 30 
30 <0,5 30 
31** <0,5 120 
32** <0,5 30 
33** <0,5 40 
*   compounds pre-dissolved in MeOH 
** compounds pre-dissolved in DMSO 
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gaseous, inhaled CO. In this case Hb will be the main CO carrier, similarly to 
what happens with CO gas therapy. 
A similar profile is observed with 5, 6 and 7 that lose 3 carbonyls within 2, 4 and 
8 min, respectively. Compound 4 is once more an exception within this family 
releasing less CO than the remaining compounds (only 1 CO). However, it must 
be noted that it releases only 1 equivalent of CO also very fast and then CO 
release stops. It is tempting to interpret these CO release profiles as the result of 
very strong interactions with blood proteins. In the case of 4 these interactions 
may be stabilizing whereas in the other four examples, they are obviously quite 
destabilizing in terms of facilitating liberation of CO. Further evidence for these 
strong interactions will be presented in Chapter VI.  
The action of aerated blood upon other neutral Mo(0) compounds results in the 
unexpectedly fast and extensive decomposition profile observed with 8, 9 and 12. 
Within a few minutes of incubation with blood these CO-RMs release 2 to 3 
equivalents of CO to Hb, which corresponds to more than 65% of the CO 
available in the molecule. Another relevant aspect is that this takes place with 
three compounds that have quite different ancillary ligands and donor atoms. In 
previous experiments compound 9 proved to be rather stable due to its 
macrocyclic triazacyclononane ligand. Nevertheless, in blood it behaves like the 
much more labile and flexible 12 with its tripodal pyridine ligand and 8 with its 
labile triene ligand. The rate of Hb carbonylation is quite similar and even the 
extent of CO release is very close. 
On the other end of the stability spectrum, we find compounds with several 
different characteristics. The two Mo(II) complexes CpMo(CO)3{CH2C(O)NHR} 
15 and 31 or  the tris-phosphine Mo0(CO)3 (11) do not liberate CO up to 30 min 
in blood. In fact, the phosphine derivatives Mo0(CO)n(PR3)6-n (n = 3,4,5) are 
highly stable molecules, independently of the number of carbonyls, as can be 
observed with the series of 11, 30, 32 and 33. Stability in blood is also observed 
for the air stable, water soluble ionic species Na[Mo(CO)5(CN)] (29).  
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Table 5 also presents three examples of Mn based CO-RMs which provide some 
very important insights for the interpretation of the data described for the Mo 
compounds. Of these three complexes, the only one that has a very fast release to 
blood is 19. This compound is air stable but its reactivity, which has been 
extensively studied in carbonyl substitution reactions[43-46] is dominated by the 
sequential replacement of two CO ligands cis to Br- according to equation 6. 
 
Mn(CO)5Br + L              cis - Mn(CO)4LBr
Mn(CO)4LBr + L'                fac - Mn(CO)3LL'Br  Equation 6 
 
This process is dissociatively activated and induced by the pi-donation ability of 
the bromide ligand. Therefore one expects that suitable nucleophiles will rapidly 
replace the two CO ligands of 19 (cis to Br-) forming a derivative of the fac-
MnI(CO)3 fragment which is well know to be highly kinetically and 
thermodynamically stable towards oxidation and further CO loss. Blood proteins 
are the most likely sources of the nucleophiles responsible for these substitution 
reactions. Complex 28 exemplifies the stability of a derivative of the fac-
MnI(CO)3 fragment and stays in strong contrast to the blood labile analogue 9. 
Complex 20, isostructural and isoelectronic with 19 is also oxidatively stable to 
O2. However, it is substitutionally inert and hydrolytically stable because its -
CH2C(O)NH2 ligand lacks the ability to activate CO dissociation. Therefore its 
stability to blood is understandable.  
Complex 2 represents the best instance of a compound that slowly but steadily 
delivers all its CO ligands to blood Hb. Unfortunately, the complexity of the 
decomposition chemistry of this complex prevents any safe explanation for this 
behavior. In Chapter II we have seen that 2 releases CO in different rates and 
amounts depending on a series of variables and experimental conditions, e.g. 
concentration of compound, solvent, medium, [O2]. However, loss of 5 
equivalents of CO was only observed in pure DMSO. The decomposition 
pathway of the chromium analogue [Et4N][Cr(CO)5Br] was established in water 
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by real time IR spectroscopy.[47] It was shown that hydrolysis is more important 
than oxidation for the initiation of decomposition. Therefore, it is quite likely that 
the initial steps of decomposition of 2 also result from hydrolysis or protein attack 
on the complex and the final stages involve oxidation by O2 with CO release from 
Mo species in higher oxidation states. Like this the release of CO increased 
steadily with time until all CO was scavenged by blood Hb.  
A set of interesting results was obtained with the Ruthenium compounds 21 and 
22. None of these complexes elevated baseline CO-Hb levels higher than 2% 
corresponding to CO amounts of 0.1 to 0.2 equiv. The ruthenium compounds 
have a very special chemical behavior and this was again observed in this 
experiment. Although they’re able to donate 1 CO to Mb and free-Hb (data not 
shown) no CO-Hb elevation is observed when the compounds are incubated in 
blood. This is a curious observation but these results reinforce the donation 
concept, that a direct interaction between the Ru CO-RMs and the heme protein 
target is needed for CO transfer to occur. As it has been demonstrated in Chapter 
II the Ru compounds do not liberate CO to the headspace. As shown in the 
previous section they only transfer it to the target heme protein (Mb) in its direct 
presence.  In blood the compounds do not cross the RBC membrane and therefore 
no CO is transferred to Hb. Indeed, treatment of a sample of lyzed RBC with 
RuII(CO)3 compounds like 21 or 22 leads to instantaneous and complete transfer 
of CO to free Hb (data not shown). 
From all these observations we can conclude that kinetic stability towards CO 
substitution is the main factor necessary to achieve stability of transition metal 
based CO-RMs in blood.  Although oxidation obviously plays a role, which can 
even synergize with substitutional lability, it is not the key factor to determine 
stability of transition metal CO-RMs in blood.  
A second factor which is less obvious would be CO-RM permeation into RBC 
membranes which would take the CO-RM close to the Hb and facilitate CO-Hb 
formation. With the present data it is not possible to judge on this effect.  
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5. Final remarks and conclusions 
 
In this chapter, the results of the interactions of several MCCs with heme centers 
were presented. They include Mb, Hb and Cyt C heme carbonylation as well as 
Mb and Cyt C reduction by the low valent MCCs.  
The reaction of Mb with MCCs introduced by Motterlini, is a very convenient test 
to evaluate the CO donation capability of CO-RMs because it can easily 
accommodate experiments with water insoluble or sparingly soluble molecules by 
means of their previous dissolution in biologically compatible co-solvents like 
DMSO or MeOH.  
In fact, at the concentration needed for this test (ca. 50 µM) completely water 
insoluble compounds can be previously dissolved in DMSO or MeOH solutions 
and then added to aqueous solutions of Mb (ca. 50 µM) to determine the accurate 
rate of CO-Mb formation. Following Motterlini, such rate was taken as the rate of 
CO release of a given CO-RM in aqueous medium. The results obtained 
supported those determined by the GC assays for all complexes except those of 
Mo(0) and Ru(II). The former are highly sensitive to O2 and give imprecise 
results due to the variable, uncontrolled anoxic conditions created by sodium 
dithionite in the Mb test. The latter transfer CO to deoxy-Mb but do not liberate 
CO to the headspace in this process. We named this direct mechanism of CO 
transfer from a CO-RM to Mb as CO donation. This type of mechanism is 
observed with other compounds like the tricarbonyl Mo0(CO)3 anionic complexes 
but the donation effect is not as fast or extensive as with the RuII(CO)3 
compounds.  
This study shows that both the term and the underlying concept of “CO release” 
are ambiguous and can be applied to two different situations. In one situation the 
CO-RM is expected to liberate free CO gas which may escape the solution and 
can be quantified by GC or even MS methods. In the other situation, the CO-RM 
reacts with Mb and CO is donated (transferred) from the CO-RM to the Mb heme 
without accumulation in the solution and/or headspace. Therefore, the combined 
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use of both techniques is necessary to identify the behavior of each given family 
of compounds in a safe way. For example, a complex like Ru(CO)3Cl(glycinate) 
wouldn’t have been considered a CO-RM if it was studied exclusively by GC or 
MS methods.  
Therefore, it is important to mention which method is being used to evaluate “CO 
release rates” before any comparative conclusions between different types of 
complexes are attempted.  
Regardless of merits and flaws which of these methods is the most useful guide to 
establish the profile of a CO-RM with useful therapeutical properties?   
To be therapeutically useful a CO-RM will have to be administered to an animal 
or human and enter the blood stream in order to reach the diseased tissue. In fact, 
one of the advantages of using CO-RMs over CO gas is exactly the possibility of 
delivering CO directly to tissues instead of loading blood Hb with CO and expect 
that Hb carries it to the right place. 
According to the results obtained with the tests carried out with whole blood, 
none of the above “CO release” tests has a clear predictive value, that is, none of 
them simulates the in vivo situation when the compound enters the blood stream. 
Indeed, it seems that blood separates the MCCs into two rather distant groups: 
one where all the compounds expel all its CO within a very short period of time 
after incubation, and other where they fully resist decomposition in the sense that 
they do not release free CO that can be scavenged by Hb within intact red blood 
cells.  
Therefore, we must conclude that the interaction of a MCC with whole blood is 
the decisive test that allows the identification and subsequent dismissal of the 
complexes that are too fragile to resist decomposition and release CO shortly after 
entering circulation, thereby leading to therapeutically unacceptable, toxic, high 
levels of CO-Hb (>10-12%).  
The blood assay has a crucial role in understanding the CO release profile of the 
molecules in vivo and is completely reliable for the determination of the 
maximum amount of CO-Hb levels obtained with different doses of compounds. 
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It is a clean, cheap, fast and solid in vitro assay that also avoids the use of mice to 
determine CO-Hb levels. 
Although pivotal for the identification of the non-candidate CO-RMs, the blood 
test is unable to provide other types of positive markers that enable a selection 
among the MCCs which resist decomposition in blood. Other types of tests have 
to be taken into consideration in order to make such a selection.  
What is the cause for this “differentiating” effect of blood?  This was indeed a 
totally unexpected observation and at present no specific tests have yet been 
designed to characterize its origin. However, a superficial analysis of the data in 
Table 5 strongly suggests that the high lability of the ancillary ligands leads to 
blood unstable species. If this is so, it is quite likely that the plasma proteins are 
playing a decisive role in substituting these ligands and promoting CO release. 
Since studies of the reactivity of MCCs and plasma proteins are virtually 
inexistent, we cannot firmly corroborate this hypothesis but studies in this 
direction are clearly necessary.  
The results obtained with the Ruthenium complexes are another example where 
the reaction of the complexes with proteins may be controlling the chemistry of 
CO transfer. Indeed these RuII(CO)3 complexes are very fragile molecules in 
aqueous solution and are excellent CO donors to deoxy-Mb most likely because 
they react with it and facilitate the transfer of CO from the Ru ion to the heme.  
The redox experiments with Cyt C and Mb showed a new kind of reactivity of a 
specific family of compounds. The impact of this discovery in the mitochondrial 
system (if any) remains to be determined but opens a new window of possibilities 
and questions about the mode of action of this specific class of compounds and 
the possibility of a concerted mechanism coupling redox activity with CO release. 
Last, but not least, the data collected with all these assays revealed that 
organometallic carbonyl complexes can be engineered to provide a favorable 
stability profile in blood and still be able to release CO under biological 
conditions. 
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Chapter V: Chemical and biological studies 
with Ruthenium-based CO-RMs 
 
1. Summary 
 
CORM-2 and CORM-3 are the most studied CO-releasing molecules in the 
literature. Their CO release profile is quite similar and carbonylation of deoxy-
Mb solutions upon incubation with these compounds occurs in minutes. Given the 
widespread use of these molecules in several in vivo and in vitro models of 
disease, a thorough study of the CORM-2 decomposition profile is presented as 
well as the identification of the active species formed.  
The ability of these species to decompose hydrogen peroxide, in a similar way to 
catalytic peroxide scavengers was evaluated and found to be much less extensive 
than other known compounds. These results are presented at the end of this 
Chapter. 
A new series of Ru-tricarbonyl compounds of the general formula Ru(CO)3Cl2L 
have been prepared, where L is a ligand with a N-, O-, P- or S- donor atom. These 
complexes were characterized and their CO releasing profile evaluated by Gas 
Chromatography and in the presence of Myoglobin. None of the compounds 
releases CO to the headspace of their solutions, measured by GC, but all are able 
to transfer CO to deoxy-Mb. The amount of CO transferred varies from 0.2 equiv. 
(when L is a strong donating ligand) to 1 equiv. CO  (when L is a weak donating 
ligand).   
 
2. Introduction 
 
The use of Ruthenium complexes as metallopharmaceuticals[1] has been 
developed mainly as anticancer compounds. NAMI, Na{trans-
[RuCl4(DMSO)(Im)]} was the first ruthenium complex entering clinical trials and 
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is one of the most studied anticancer organometallic complexes after cis-platin.[2-7] 
NAMI was later transformed into NAMI-A (ImH){trans-[RuCl4(DMSO)(Im)]} 
and KP1019 (IndH){trans-[RuCl4(Ind)2]}, two more stable and reproducible 
derivatives with similar pharmacological properties[8-11] which displayed a high 
degree of anti-cancer activity and represent some of the most promising Ru-based 
drug candidates. 
 
   
    
Figure 1: The chemical structure of KP1019, NAMI-A and NAMI.  
 
Since the development of the early Keppler’s compounds of general formula 
trans-HL+[RuIIIL2Cl4]- where L is a heterocycle like indazole or imidazole,[12, 13] 
the quest for new ruthenium-based complexes didn’t explore many possibilities 
for ligands, remaining “restricted” mainly to ammine, amine and imines. 
Complexes with different ligands were also developed but abandoned due to 
different reasons. Thiolate ligands are often kinetically unstable[14] and pterins and 
flavins tend to be photochemically unstable[15, 16] Ammine and amine Ru(II) 
complexes are usually octahedral, fairly inert to ligand substitution and tend to 
selectively bind to imine sites in biomolecules, serving as target device for 
specific tissues. More recently, the ligand field was diversified and some Ru(II) 
arene complexes are being developed for different applications with very 
promising in vitro and in vivo results.[17-19]  
Apart from their applications in antitumoral therapy and diagnosis, Ru complexes 
present a wide variety of biological effects that makes their use as drugs not 
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confined to this field. Cyclosporin A is the most widely used immunosuppressant 
agent and interferes with the calcium-dependent step in the immune response[20] 
and also prevents Ca2+-dependent opening of a megachannel permeability 
transition pore in the inner mithochondrial membrane. Ruthenium red and Ru360 
interfere with Ca2+ uptake[21-23] leading to the assumption that ruthenium red 
related complexes may interfere with the immune response. Indeed, several 
studies showed that Ru(II/III) complexes with nitrogen ligands[24] (NH3, 
imidazole, py) can be potent immunosupressants.[25, 26]  
Another interesting application is found in the radiopharmaceutical field. The 
radiophysical properties of 97Ru are very good for some radiodiagnostic imaging. 
It decays by electron capture with t½ of 2.88 days and emits a 216 KeV γ-ray that 
can be used in common radioscintigraphic instruments.  
NO releasers are another field of application. The similarities between Fe and Ru 
suggest Ru complexes as alternatives to nitroprusside (Na2[NO(CN)5Fe].2H2O) 
where the rate of NO release can be modulated by the introduction of different 
ligands.  
A similar approach can be applied to the development of CO-RMs, and indeed 
Ruthenium complexes are among the leading CO releasing molecules. The 
lipophilic CORM-2 ([Ru(CO)3Cl2]2) and water-soluble CORM-3 
(Ru(CO)3Cl(glycinate)) are the most studied compounds in the literature with 
good in vitro  and in vivo results in many cell tests and animal models of disease 
which have been subject of several publications and also some reviews.[27, 28]   
CORM-3 has a variety of reported biological effects; induces vasorelaxation,[29] 
prevents hypoxia-reoxygenation damage in rat cardiomiocytes and protects 
against ischemia/reperfusion injury in isolated hearts.[30, 31] In mice CORM-3 
reduces infarct size and prolongs the viability of cardiac allografts following 
transplantation.[30, 32] It also showed renoprotective effects in mice following 
ischemia-reperfusion induced renal failure[33] and in a model of cis-platin induced 
nephrotoxicity in rats.[34] CORM-3 also improved renal function following cold 
ischemia in isolated rabbit kidneys and this effect was associated with increased 
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vascular perfusion, glomerular filtration rate and mitocondrial respiration.[35] It is 
also an effective anti-inflammatory agent inhibiting NO and TNFα production in 
macrophages and microglia stimulated with pro-inflammatory mediators,[36-38] 
attenuates the adhesion of polymorphonuclear neutrophils to endothelial cells in 
vitro and in vivo,[39] down-regulates the responsiveness of human neutrophils to 
inflammatory stimuli by decreasing superoxide production and CD-11 
expression[40] and protects against ischemia-reperfusion injury in an experimental 
model of controlled nonheartbeating donor kidney.[41] Recently, CORM-3 also 
exhibited some anti-bactericidal effect since it was effective against Escherechia 
Coli[42] and Pseudomonas aeruginosa.[43] 
Similarly, CORM-2 is also vasoactive[44, 45] (showing vasodilatory effects both in 
isolated vessels and hearts as well as in rats in vivo).[46] CORM-2 mimicked the 
antiproliferative effect of HO-1-derived CO in both arterial and airways smooth-
muscle cells as well as in human Jurkat T-cells. CO-mediated guanylate cyclase 
and potassium channel activation by CORM-2 have also been implicated in 
inhibition of afferent arteriole constriction in kidney,[47] anal sphincter relaxation, 
[48] non-adrenergic non-cholinergic inhibitory neurotransmission in porcine 
jejunum,[49] immunophotoprotection against UV radiation in rat skin,[50] 
modulation of ion transport in human intestinal epithelial cells[51] and 
vasorelaxation in hypertensive animals following exercise training.[44] CORM-2 
also protects against cell death and increase in ROS induced by 3-NP,[52] protects 
against lung injury by limb ischemia-reperfusion,[53] modulates the inflammatory 
process[54] and protects against ischemia induced acute renal failure.[33]  
It showed good anti-inflammatory properties on leukocyte sequestration in lung 
thermally injured mice.[55] Furthermore it showed good bactericidal properties 
activity in models developed by Alfama and others.[43, 56, 57]  
The vast panoply of positive results obtained both in vitro and in vivo with these 2 
molecules, justifies a more detailed study of this class of compounds. Moreover, 
the ruthenium complexes were the only compounds that showed the ability to 
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transfer CO to deoxy-Mb without previous liberation of the gas to the headspace, 
which suggests a rather distinctive mode of action in their CO release chemistry. 
 
3. Experimental Section 
3.1 Methodology 
 
Gas Chromatography: 
Gas Chromatography assays were performed as described in Chapter II. 
 
Quantification of CO release through the Mb assay: 
CO release/donation to deoxy-Mb was performed as described in Chapter IV. 
The CO donation capacity of aged solutions was determined as follows: 
The compound was dissolved in the suitable medium and the solution kept on the 
bench for the desired period of time, under normal atmospheric air, at room 
temperature. After this “ageing” period, the sample was added to the deoxy-Mb 
preparation and incubated for a period no less than 15 min and no more than 30 
min. This is the period of time needed to complete the deoxy-Mb carbonylation 
process and reach the maximum levels of CO-Mb. The deconvolution procedure 
explained in Chapter IV is applied to calculate the percentage of CO-Mb and 
correspondent amount of CO transferred from the molecule to the protein. 
 
High-Pressure Liquid Chromatography: 
HPLC trace of the compounds was acquired using the method described in 
Chapter II. 
 
Horseradish Peroxidase Assay: 
These assays were performed by Dr. Ana Rita Marques, a colleague biologist in 
ALFAMA. 
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Method: 
The ability of the compounds to decompose H2O2 was investigated using a 
horseradish peroxidase (HRP)-based assay. The assay is based on the HRP 
oxidation of phenol red by H2O2 which results in the formation of a compound 
demonstrating increased absorbance at 655 nm. A linear relationship between 
absorbance at 655 nm and concentration of H2O2 was found in the 1–250 µM 
range. 
 Serial ½ dilutions of H2O2 were prepared in water and were incubated with the 
compounds in the ratio 1:1, 1:10, 1:50 or 1:100 (compound: H2O2) for up to 240 
minutes. At specific time points, 10 µl of H2O2 solutions were removed and were 
allowed to react in the wells of a 96-well plate in the presence of 3 units of HRP, 
0.5 mM phenol red in sodium phosphate buffer 0.1M (pH 7). The control of the 
experiment was performed in the same way but using the different H2O2 solutions 
prepared that have not been incubated with compounds. The reaction was stopped 
after 10 minutes by the addition of 10 µl of 1N NaOH and the plate was read at 
655 nm in a microplate reader (Bio-RAD). The amount of H2O2 present in 
solution at the different time points was calculated based on the linear range of 
the calibration curve of the control performed with the different H2O2 solutions 
prepared. The results were plotted in a graph as percentage of H2O2 present in 
solution at the different time points considering the control as 100%. 
Material: 
HRP was acquired from Sigma (ref. P6782); Phenol red was acquired from Sigma 
(ref. P3535); H2O2 was acquired from Sigma Aldrich and titrated prior to use. 
 
3.2 Technical Details 
 
General Considerations: 
Elemental Analysis were performed at ITQB, Oeiras, in the Elemental Analysis 
Laboratory by Engª Conceição Almeida and at the Elemental Analysis Service of 
the London Metropolitan University by Stephen Boyer. Infrared spectra were 
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recorded on a Unicam Mattson 7000 FTIR spectrophotometer using KBr pellets. 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance III 400mHz. 
Chemical shifts are quoted in parts per million from SiMe4 (TMS). UV-VIS 
spectra were acquired in Perkin Elmer Lamda35 spectrophotometer. 
 
Synthetic Work: 
All the reactions were carried out under a nitrogen atmosphere, using common 
schlenk techniques. Solvents were dried by standard procedures, distilled under 
N2 and kept over 4Å molecular sieves, except DMSO that was used as received 
(p.a. from Panreac). [Ru(CO)3Cl2]2 was bought from Strem Chemicals; DL-
Methionine sulfoxide, L-Methionine sulfoxide and 2-Hydroxy-4-
(methylthio)butyric acid calcium salt were bought from Fluka; the pyridine 
ligands were bought from Asis Chem. Inc.; 1,3,5–Triaza–7–phosphaadamantane 
(PTA), methyl β-D-thiogalactoside (Gal-S-Me) and N-acetyl-cysteine (NAC) 
were bought from Aldrich; Ru(DMSO)4Cl2 was bought from Strem Chemicals. 
3,7-diacetyl-1,3,7–triaza–5–phosphabicyclo[3.3.1]nonane (DAPTA) was prepared 
from PTA according to published literature as referred in Chapter II. The 
compound Ru(CO)3(DMSO)Cl2 (1) was prepared according to the method 
described in the literature.[58]  
 
Ru(CO)2(DMSO)2Cl2 (2) 
[Ru(CO)3Cl2]2 (0.398g; 0.778E-03mol; 512.02g/mol) was dissolved in 3 ml of 
DMSO. An orange solution was obtained and small bubbles were released from 
solution. After 30min, Et2O was added and the solution placed at 4ºC overnight. 
A biphasic solution was obtained and separated. The orange DMSO solution was 
extracted several times with Et2O until the extracts were colorless. The ether 
filtrates were collected together and concentrated. The solution was placed at 4ºC 
overnight. An off-white powder was obtained and dried in vacuum. Yield: 90%.  
IR (KBr/cm-1; C≡O): 2077(s) 2020(s); 
E.A.: Calc. for RuC6H12O4S2Cl2: %C:18.75, %H:3.15, %S:16.69; Found: 
%C:19.31, %H:2.73, %S:16.10;  
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1H NMR (CDCl3, 400MHz, rt, δ in ppm): δ = 3.44 (s, 2H) assigned to cis, trans, 
cis- isomer; 3.43 (s,1H), 3.17 (s,1H), 2.88 (s,1H), 2.85 (s,1H) assigned to cis, cis, 
cis- isomer; 
13C NMR (CDCl3, 100MHz, rt, δ in ppm): δ = 185.7 (CO), 45.1 assigned to cis, 
trans, cis- isomer; 186.1  (CO), 47.5, 42.2, 39.3, 38.9 assigned to cis, cis, cis- 
isomer. 
 
Ru(CO)(DMSO)3Cl2 (3) 
[Ru(CO)3Cl2]2 (0.53 g; 1.035 mmol; 512.02 g/mol) was dissolved in 15 ml of 
DMSO giving an orange solution to which toluene (15 ml) was added. The 
solution was heated to reflux for 2h becoming light yellow. It was cooled to room 
temperature, giving a turbid suspension that was filtered. To the filtrate, Et2O was 
added and the solution placed at -30ºC overnight.  
An oily yellow residue mixed with a white crystalline product was precipitated. 
From the cold filtrate, another fraction of white crystalline product with yellow 
contamination was obtained. This was extracted with ether, leaving a yellow 
powder behind and a white powder started to precipitate from the ethereal 
solution. After concentration and cooling the precipitate was filtered, washed with 
hexane and dried in vacuum affording a white powder (Fraction 1). The yellow 
solid left behind was recrystallized from CH2Cl2/hexane at -30ºC affording yellow 
crystals (Fraction 2). Yield: 31%. 
IR (KBr/cm-1; C≡O): Fraction 1: 2001(vs); Fraction 2: 2003(vs); 
E.A.: Calc. for RuC7H18O4S3Cl2: %C:19.36, %H:4.18, %S:22.15; Found (Fraction 
1): %C:19.40, %H:3.84, %S:22.40; Fraction 2: %C:19.83, %H:3.81, %S:22.32; 
1H NMR (CDCl3, 400MHz, rt, δ in ppm): Both fractions present the same 
isomers but in different ratios: δ = 2.75 (s,1H), 2.78 (s,1H), 3.17 (s,1H), 3.45 
(s,2H), 3.52 (s,1H) assigned to the cis, cis, cis- isomer; 2.85 (s,2H), 3.25 (s,2H), 
3.43 (s,2H) assigned to the cis, cis, trans- isomer; 3.41 (s,2H), 3.43 (s,2H), 3.51 
(s,2H) assigned to the cis, mer- isomer; 
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13C NMR (CDCl3, 100MHz, rt, δ in ppm): δ = 38.5, 39.0, 43.5, 45.3, 46.8, 50.2 
assigned to the cis, cis, cis- isomer; 39.1, 43.7, 47.6 assigned to the cis, cis, trans- 
isomer; 42.9, 46.4, 47.4 assigned to the cis, mer- isomer. 
Fraction 1 has CO resonances at δ = 192.3 and 191.0 ppm; In Fraction 2, the CO 
resonances were not observed. 
 
The same procedure was used to prepare complexes 5, 6, 7 and 12. The synthesis 
of 6 is presented. 
 
L-Ru(CO)3Cl2(H3CSO(CH2)2CH(NH2)CO2H) (6) 
[Ru(CO)3Cl2]2 (0.918 g; 1.793 mmol; 512.02 g/mol) and L-methionine sulfoxide 
(0.592 g; 3.586 mmol; 165.21 g/mol) were mixed together in 100 ml of acetone. 
A slightly yellow suspension with some insoluble product was obtained and 
stirred overnight at room temperature. After 20h the reaction was stopped and a 
small amount of a white powder remained insoluble in the bottom. The pale 
yellow solution was filtered and concentrated. The concentrated solution was 
slowly added via cannula to another schlenk, already partially filled with a large 
portion of Et2O. An abundant white precipitate was formed. The solution was 
filtered and the precipitate washed with 2x20 ml of Et2O. It was dried in vacuum 
giving an off white powder. Yield: 83%.  
IR (KBr/cm-1): 2131(s), 2055(s)  (C≡O); 1651(s) (C=O); 
E.A.: Calc. for RuC8H11NO6SCl2: %C:23.07, %H:2.64, %N:2.73, %S:7.57; 
Found: %C:22.73, %H:2.99, %N:2.95, %S:7.48;  
1H NMR (MeOD, 400MHz, rt, δ in ppm): δ = 4.1-3.8 (m,1H), 3.1-2.9 (m,2H), 
2.70 (s,3H), 2.5-2.1 (m,2H).    
 
 
D,L-Ru(CO)3Cl2(H3CSO(CH2)2CH(NH2)CO2H) (5) 
Precipitation of the complex was induced at -30ºC overnight. 
Yield: 36%; IR (KBr/cm-1): 2133(s), 2056(s) (C≡O); 1651(s) (C=O); 
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E.A.: Calc. for RuC8H11NO6SCl2: %C:23.07, %H:2.64, %N:2.73, %S:7.57; 
Found: %C:23.17, %H:2.79, %N:3.11, %S:7.21; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 4.06 (m,1H), 3.09 (m,2H), 2.76 
(s,3H), 2.39 (m,2H)  
 
Ru(CO)3Cl2(3-NC5H4(CH2)2SO3Na) (7) 
Precipitation of the complex was induced at -30ºC overnight. 
Yield: 63%; IR (KBr/cm-1; C≡O): 2137(s), 2053(s); 
E.A.: Calc. for RuC10H8NO6SNaCl2: %C:25.82, %H:1.73, %N:3.01, %S:6.89; 
Found: %C:25.40, %H:1.98, %N:2.77, %S:7.12; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 8.75 (s,1H), 8.67 (d,1H), 8.58 (d,1H), 
8.03 (t,1H), 3.34 (s,4H).  
 
Ru(CO)3Cl2(H3CS(CH2)2CH(OH)CO2H) (12) 
The ligand was first synthesized through the following procedure: 
[H3CS(CH2)2CH(OH)COO]2Ca (0.880 g; 2.600 mmol; 338.45 g/mol) was 
dissolved in 30 ml of water and the solution stirred for a couple of minutes, after 
which all the product was dissolved. Sulfuric Acid (1M) was slowly added (2.6 
ml; 1 equiv.) and the clear solution became turbid after some minutes. It was 
further stirred for 90 min after which the reaction was stopped. A white 
precipitate (CaSO4) was filtered off and washed with a small amount of MeOH. 
The solution was taken to dryness affording a pale yellow oily residue. It was 
extracted with MeOH, leaving a small amount of a white powder behind (CaSO4). 
The pale yellow filtrate was taken to dryness affording a yellow oil that was kept 
at - 30ºC. Yield: 85%. 
IR (KBr/cm-1): 1733 (s) (C=O); 1437(m), 1276(w), 1224(m), 1173(m), 1096(s), 
970(w), 799(w), 752(w), 656(w), 647(w); 
1H NMR (CD3OD, 400MHz, rt, δ in ppm): δ = 4.26 (m,1H), 2.62 (t,2H), 2.09 
(s,3H), 2.03 (m,1H), 1.88 (m,1H);  
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13C NMR (CD3OD, 100MHz, rt, δ in ppm): δ = 177.6 (CO), 70.0, 34.8, 30.6, 
15.1. 
 
The complex 12 was obtained following the procedure described above for 6 but 
precipitating the product at -90ºC. Yield: 83%. 
IR(KBr/cm-1): 2141(s), 2077(s), 2063(s) (C≡O); 1793(s) (C=O); 
E.A.: Calc. for RuC8H10O6SCl2: %C:23.66, %H:2.48, %S:7.89; Found: 
%C:23.56, %H:3.40, %S:7.94; 
1H NMR (MeOD, 400MHz, rt, δ in ppm): δ = 2.65 (m,1H), 2.09 (s,3H), 1.55-1.63 
(m,4H).  
 
The following complexes (8, 9, 10, 11, 13 and 14) were synthesized with slight 
modifications of the previous method, using MeOH instead of acetone. The use of 
MeOH as solvent implies some limitations in the crystallization procedure since 
the compounds should not be precipitated at low temperature due to the risk of 
esterification in one of the carbonyl groups, affording compounds of the type 
RuCl2(CO)2(COOMe)L as described by Moreno at al.[59]  
A standard preparation is described for 8, and deviations from this procedure are 
mentioned for each case. 
 
Ru(CO)3Cl2(4-NC5H4(CH2)2SO3Na) (8) 
The ligand (0.320 g; 1.530 mmol; 209.2012 g/mol) was dissolved in 50 ml of 
MeOH and added to [Ru(CO)3Cl2]2 (0.392 g; 0.765 mmol; 512.02 g/mol) 
dissolved in 20 ml of MeOH. The clear colorless solution was stirred at room 
temperature overnight. 
The slightly turbid solution was filtered giving a colorless solution that was 
concentrated. Et2O was slowly added and a precipitate started to form. The 
solution was filtered and a white aggregate was obtained. It was washed with 
2x10 ml of Et2O and dried in vacuum giving a white powder. Yield: 53%. 
IR (KBr/cm-1; C≡O): 2137(s), 2053(s); 
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E.A.: Calc. for RuC10H8NO6SNaCl2: %C:25.82, %H:1.73, %N:3.01, %S:6.89; 
Found: %C:26.10, %H:2.20, %N:3.21, %S:6.96; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 8.69 (d,2H), 8.02 (d,2H), 3.40 (s,4H). 
 
Ru(CO)3Cl2(3-NC5H4(CH2)2NMe3I) (9) 
Yield: 12%; E.A.: Calc. for RuC13H17N2O3Cl2I: %C:28.48, %H:3.13, %N:5.11; 
Found : %C:29.00; %H:3.30; %N:5.53; 
IR (KBr/cm-1; C≡O): 2129(s); 2051(s); 1981(s); 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 8.78-8.73 (d,2H); 8.52 (d,1H); 8.02 
(t,1H); 3.74-3.43 (m,4H); 3.27 (s,9H). 
 
Ru(CO)3Cl2(PTA) (10) 
The reaction was performed in 15min after which a large amount of white product 
precipitated. It was washed with MeOH and dried in vacuum. 
Yield: 56%; E.A.: Calc. for N3O3PCl2RuC9H12: %C:26.16, %H:2.93, %N:10.17;  
Found: %C:25.90, %H:3.30, %N:10.18; 
IR (KBr/cm-1; C≡O): 2134(w), 2060(s), 1994(s); 
The compound is insoluble in all the deuterated solvents tested. It could only be 
solubilized in d6-DMSO but with decomposition. 
 
Ru(CO)3Cl2(DAPTA) (11) 
The reaction time was 2h and the product was washed with CH2Cl2 instead of 
Et2O. 
Yield: 75%; E.A.: Calc. for C12H16Cl2N3O5PRu: %C:29.70, %H:3.32, %N:8.66; 
Found: %C:29.34, %H:3.65, %N:8.47;  
IR (KBr/cm-1): 2135(w), 2067(s), 2001(s) (C≡O); 1635(s) (C=O); 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 5.7-3.8 (m,8H), 3.28 (s,2H), 2.12 (s, 
6H); 
31P NMR (D2O, 162MHz, rt, δ in ppm): δ = 5.87.  
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Ru(CO)3Cl2(Gal-S-Me) (13) 
Yield: 79%; E.A.: Calc. for O8SCl2RuC10H14: %C:25.76, %H:3.03, %S:6.88; 
Found: %C:25.68, %H:3.74, %S:6.73; 
IR (KBr/cm-1; C≡O): 2138(s), 2057(s); 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 4.38 (d,1H), 3.98 (m,1H), 3.75-3.58 
(m,5H), 2.23 (s,3H). 
 
Ru(CO)3Cl2(NAC) (14) 
The reaction time was 4h and the precipitation was induced at -30ºC overnight. 
Yield: 61%; E.A.: Calc. for C8H8Cl2NO6RuS: %C:22.98, %H:1.93, %N:3.35, 
%S:7.67; Found: %C:23.20, %H:2.03, %N:3.11, %S:7.32; 
IR (KBr/cm-1): 2126(s), 2062(s) (C≡O); 1749(s) (C=O); 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 4.46 (m,1H), 3.78 (m,2H), 3.0-3.34 
(m,1H), 2.05 (s,3H). 
 
4. Results and Discussion 
4.1 Identification of the species present in DMSO 
solutions of [Ru(CO)3Cl2]2 (CORM-2) 
 
4.1.1 Chemical and spectroscopical studies 
 
Di-µ-halobis(halotricarbonylruthenium) complexes of formula [Ru(CO)3X2]2 
(X=Cl, Br) are known since the 1960s and can be obtained through different 
methodologies.[60-66] Their chemical reactivity with oxygenated solvents and N-, 
O-, P- and S-donor ligands was object of interest for many decades,[67-71] but it 
was just recently that their potential as CO-releasing drugs was evaluated. 
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In 2002, Motterlini and co-workers published the first paper introducing the 
concept of CO-releasing molecules, as well as their biochemical and vascular 
activity.[46]   
In this same paper [Ru(CO)3Cl2]2 is named as CORM-2 and its biochemical and 
vascular properties are described. Its CO release capacity was also determined by 
adding aliquots of the complex in DMSO directly into a deoxy-Mb preparation in 
a similar setup to what has been described in Chapter IV. As recognized by the 
authors, [Ru(CO)3Cl2]2 reacts with DMSO upon dissolution and the reaction 
products between the compound and DMSO were identified by NMR analysis.[46]  
[Ru(CO)3Cl2]2 was dissolved in DMSO and diluted in CDCl3. The spectra were 
taken during the first 23 min following dissolution and show that DMSO breaks 
the dimer into two monomers of 1, and further replacement of one carbonyl 
occurs with species 1 and 2 co-existing in solution. 
The observed 13C NMR chemical shifts coincide with those published and 
assigned by Alessio et al.[58] to fac-RuCl2(DMSO)(CO)3 (1, δ 183.0 (2 CO), 187.0 
(1 CO)) and cis,trans,cis-RuCl2(DMSO)2(CO)2 (2a, δ 185.0 (2 CO)). 
 
Ru
OC
Cl Cl
CO
SOMe2
SOMe2
DMSO
+ CO
 
CORM-2          1    2a 
Scheme 1: CORM-2 decomposition in DMSO to give tri-(1) and di-carbonyl (2a) species 
through displacement of CO. 
 
 
The sample was then heated to 50ºC for 5 min and a new spectrum accumulated 
overnight. Two new peaks appear from a new species cis,cis,cis-
RuCl2(DMSO)2(CO)2 (2b, δ 186.1 and 191.9 ppm)  as well as two different 
carbonyl signals at δ 187.9 and 190.5 ppm from an unidentified species.  
Ru
OC
Cl Cl
CO
OSMe2
CO
Ru
OC
OC
Cl
CO
Ru
Cl
Cl CO
CO
Cl
CO
DMSO
2
Chapter V 
 
 
195 
It is important to note that the isomers formed have 
been described in the literature using different 
nomenclatures, depending on the way the coordination 
formula was written. For clarity reasons and to allow an 
unambiguous identification of the compounds in this 
text we will adopt the nomenclature 
RuCl2(DMSO)n(CO)4-n (n=1-3) where the cis, trans, mer or fac italicized prefixes 
will refer to the pairs and/or triplets of ligands, respectively, as they appear in the 
formula, from the left to right. Moreover, since the sulfoxide ligand(s) can 
coordinate via the sulfur or the oxygen atom, the coordinating atom will be 
indicated in italics when relevant.  
Since Motterlini’s initial comunication[46] CORM-2 has been extensively used in 
biological studies because of its convenient commercial availability. In all these 
studies the compound is first dissolved in DMSO and the solution diluted in 
aqueous buffers to biological compatible DMSO concentrations. Due to the above 
mentioned equilibria it is not clear which species are actually present in the 
solutions when they are applied in the biological tests, and it is not determined 
which one (or ones) of these isomers is the therapeutically active CO releaser.  
In order to attempt answering this question, monomeric compounds with different 
CO/Ru stoichiometries ranging from 3 to 1 were prepared separately in order to 
test and compare their properties, namely biological activity. The corresponding 
CO free analogue, RuCl2(DMSO)4 was used as a form of negative control for 
CORM-2. In principle, all these species might be present in a solution of CORM-
2 in DMSO. To initiate this study, the several possible species were first 
synthesized and individually characterized both by NMR and FT-IR. 
The tricarbonyl compound fac-RuCl2(DMSO)(CO)3 (1) was prepared by bubbling 
CO in a solution of  Ru(DMSO)4Cl2 according to literature procedures (see 
Experimental Section). The IR spectrum of (1) in KBr has a band at 903 cm-1 
showing that the Me2SO group is coordinated through the oxygen atom. In the 
carbonyl region there’s a sharp peak at 2131 cm-1 and another broader peak at 
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Cl SOMe2
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OSMe2  
Figure 2: Structure of 
2b cis,cis,cis - 
RuCl2(DMSO)2(CO)2 
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2060 cm-1. The 1H NMR in CDCl3 has a singlet at δ 2.82 ppm from the 6 protons 
of the coordinated Me2SO group. 13C NMR spectrum in d6-DMSO showed 2 
peaks at δ 188.3 and 184.3 ppm in a 1:2 ratio that correspond to the CO ligands of 
a fac-M(CO)3 compound. 
The dicarbonyl analogue RuCl2(DMSO)2(CO)2 was prepared by a different 
method and was directly separated from the reaction mixture of [Ru(CO)3Cl2]2 in 
DMSO (see Experimental Section). The IR spectrum of RuCl2(DMSO)2(CO)2 in 
KBr has two very sharp peaks with similar intensities in the carbonyl region at 
2077 and 2020 cm-1. In the Me2SO region there are three major peaks, two at 927 
and 1132 cm-1 characteristic of oxygen and sulfur coordinated Me2SO, 
respectively, and other peak at 1029 cm-1 from another sulfur coordinated Me2SO. 
 
Table 1: 1H and 13C chemical shifts of RuCl2(DMSO)2(CO)2 (2) in CDCl3. 
 
a -cis,trans,cis-
RuCl2(DMSO)2(CO)2 
b - cis,cis,cis-
RuCl2(DMSO)(DMSO)(CO)2 
1H chemical 
shift/ppm 
3.44(12) 2.85(3); 2.88(3); 3.17(3); 3.43(3) 
13C chemical 
shift/ppm 
45.1 
185.7 
38.9; 39.3; 42.2; 47.5 
186.1; 191.9* 
* from the literature, not observed 
 
The Me2SO bands showed the presence of different isomers 2a and 2b that were 
identified by 1H NMR in CDCl3, by comparison with the published literature.[58]  
The mono-carbonyl complex RuCl2(DMSO)3(CO) (3) was obtained from the 
reaction of [Ru(CO)3Cl2]2 in DMSO (see Experimental Section). As stated above, 
DMSO has 2 different coordinating atoms therefore a high number of isomers 
could possibly be obtained, some being linkage isomers.  
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Figure 3: Isomeric structures of RuCl2(DMSO)3(CO). A-D were isolated and 
characterized and are the most electronic favored isomers (D not included in the DFT 
study). E is electronically favored but was never observed in solution while F and G are 
electronically disfavored. S-bonded DMSO trans to CO has never been observed in Ru-
DMSO carbonyls.[58, 72] A is a linkage isomer of C and E; B is a linkage isomer of F and 
G. 
 
 
However, DFT calculations[73] showed that the most energetically favored are the 
cis,cis,cis- (3a), cis,cis,trans- (3b), and cis,mer-RuCl2(DMSO)3(CO) (3c) isomers. 
These have been isolated and characterized separately.[74] Another isomer, 
cis,trans,cis- (3e) although energetically favored, was never detected in solution 
maybe due to kinetic factors.  
From our reaction of [Ru(CO)3Cl2]2 in DMSO two different fractions (F1 and F2) 
were obtained, both containing a mixture of the three most common isomers 3a, 
3b and 3c, which were assigned based on published data.[74]  
 
 
 
3e - cis,trans,cis  3f -cis,cis,trans          3g - cis,fac 
 
Ru
Cl
Me2OS CO
Cl
OSMe2
SOMe2
Ru
Cl
Me2OS SOMe2
Cl
OSMe2
CO
Ru
Cl
Me2OS CO
Cl
SOMe2
SOMe2
3a - cis,cis,cis              3b -cis,cis,trans            3c - cis,mer 
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Table 2: 1H and 13C NMR chemical shifts of RuCl2(DMSO)3(CO) (3) (fraction F2) in 
CDCl3.  
 A - cis, cis, cis B - cis,cis,trans C - cis,mer 
1H 
chemical 
shift/ppm 
2.75(3); 2.78(3); 
3.17(3); 3.45(6); 
3.52(3) 
2.85(6); 3.25(6); 3.43(6) 3.41(6); 3.43(6); 3.51(6) 
13C* 
chemical 
shift/ppm 
38.5; 39.0; 43.5; 
45.3; 46.8; 50.2 
39.1; 43.7; 47.6 42.9; 46.4; 47.4 
* carbonyl resonances were observed at δ 191.0 and 192.4 ppm 
 
The 1H NMR spectra of both fractions showed different ratios between the 
isomers but more importantly, it was observed that independently of the ratio 
between the isomers in the solid state, the abundance of the isomers formed in 
solution is strongly influenced by the medium where they are dissolved. In 
CDCl3, formation of 3a and 3c is favored over 3b, but in CD2Cl2 the equilibrium 
is inverted and formation of 3b is favored over the other 2 species. 
In d6-DMSO, the 13C NMR spectrum of fraction F1 presents two peaks at δ 191.3 
and 193.3 ppm. Although it is not clear to which isomer they correspond, after 
28h a new peak is observed at δ 197.7 ppm, arising from a new isomer formed. In 
CDCl3, the same fraction shows two major carbonyl peaks at δ 191.0 and δ 192.4 
ppm, however, after 29h no changes are detected. These differences reinforce the 
importance of the solvent in the equilibrium between the isomers formed.  
The ratio between the isomers also influences the product’s color in the solid 
state. Fraction F1 is white and the most abundant isomer is 3a which is colorless 
while fraction F2 gets the yellow color of its main component 3b. In spite of the 
differences in the solid state the IR spectrum of both fractions is similar and 
shows one single carbonyl peak of high intensity at 2003 cm-1. Regarding the 
coordinated Me2SO there are two peaks corresponding to oxygen coordination at 
924 and 985 cm-1 and two other peaks at 1023 and 1115 cm-1 corresponding to 
sulfur coordination. 
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The isostructural and isoelectronic carbonyl free compound, RuCl2(DMSO)4 (4),  
provides fundamental information that may be useful for understanding similar 
processes with the carbonyl analogues in aqueous solution. 
Analysis of commercial RuCl2(DMSO)4 shows that it is a mixture of trans and cis 
isomers. The cis isomer has both S- and O- bonded Me2SO while the trans isomer 
only has S- bonded Me2SO. 
In the solid state the IR spectrum has the most intense peaks at 1108 cm-1 and 
1087 cm-1 (both from S- bonded Me2SO) and 926 cm-1 (from O- bonded) 
characteristic of the cis isomer. The 1H NMR spectrum in CDCl3 presents two 
singlets at δ 3.50 and 3.33 ppm that correspond to the two S- bonded Me2SO, and 
another singlet at δ 2.73 ppm that corresponds to the O- bonded Me2SO. These 
peaks integrate in a 3:1 ratio against a singlet at δ 2.61 ppm that corresponds to 
the free Me2SO. A major peak at δ 3.43 ppm that is due to the S-bonded Me2SO 
of the trans isomer is also observed. This lability of Me2SO is due to a constant 
exchange with H2O; the exchange with (CD3)2SO is fairly rapid and after 24h 
complete exchange has taken place.[75] The resulting equilibria, characterized by 
the groups of Wilkinson and Alessio, are quite complex with different products 
obtained for each isomer as shown in Schemes 2 and 3. [75, 76]  
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Scheme 2: Behavior of cis- RuCl2(DMSO)4 in aqueous solution 
 
 
Ru
Me2OS
Me2OS SOMe2
SOMe2
Cl
Cl
2 H2O
very fast
Ru
Me2OS
Me2OS OH2
OH2
Cl
Cl
Ru
Me2OS
Me2OS OH2
OH2
OH2
Cl
slow, H2O
Cl-
 
Scheme 3: Behavior of trans- RuCl2(DMSO)4 in aqueous solution 
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This type of substitution process may also occur with the other carbonyl 
molecules leading to complicated and unforeseen equilibria in vivo.  
After having characterized the three different carbonyl derivatives, 1-3, they were 
studied in DMSO to follow their possible modifications, and to make a 
parallelism to the behavior of CORM-2. Changes in the carbonyl pattern were 
monitored by IR and 13C NMR in d6-DMSO. 
 
a. Reactivity in DMSO 
 
The 13C NMR spectrum of the monocarbonyl complex (3) immediately after 
dissolution in d6-DMSO presents carbonyl peaks at δ 191.3 and 193.3 ppm 
corresponding to different isomers, most probably 3a and 3b although it is not 
known which corresponds to which. The same sample recorded after 28h presents 
a new peak at δ 197.7 ppm probably from 3c. The new isomer formed was not 
detectable in the initial period, most probably because it was present in low 
concentration.  
The changes were also followed by IR. A concentrated solution of (3) in DMSO 
(1.4 mg in 100 µL; 32 mM) was prepared and sample drops from this solution 
were taken and added to a KBr pellet along the time. A single broad band was 
observed at 2000 cm-1 which remained unchanged after 2h, 5h and 24 hours. 
Therefore, the possible substitution of the carbonyl 3 by DMSO to give 
RuCl2(DMSO)4 (4) does not take place at room temperature  in pure DMSO 
solvent. The same kind of study done with the dicarbonyl species 2 (9.1 mg in 
300 µL DMSO; 79 mM) demonstrated that it doesn’t undergo CO substitution to 
give either the monocarbonyl compound 3 or the carbonyl free 4. The bands at 
2012 and 2076 cm-1 in the IR spectrum of 2 dissolved in DMSO remain 
unchanged up to 51h (Figure 4).  
The 13C NMR spectrum of 2 dissolved in d6-DMSO presented carbonyl peaks at δ 
193.0 and 187.9 ppm corresponding to the cis,cis,cis- (2b) isomer and another one 
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at δ 186.8 ppm from the cis,trans,cis- (2a) isomer. A similar spectrum is obtained 
after 51h reaction (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Time evolution of the IR spectrum of 2 in DMSO at room temperature. Drop of 
solution over a KBr pellet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Time evolution of 13C NMR spectrum of 2 in d6-DMSO, at room temperature, 
in the carbonyl region at t=0; t=1h; t=3h; t=5h; t=51h. Each spectrum was acquired over 
29 min. 
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The same procedure was followed for complex 1. A solution of 1 in DMSO was 
prepared (6.1 mg in 200 µL DMSO; 91 mM) and the changes followed by IR 
taking sample drops that were added to a KBr pellet. The spectra were recorded 
periodically and the changes in the CO pattern monitored (Figure 6).  
At the time of dissolution two 
strong bands at 2121 and 2076 
cm-1 are obtained, the later 
being broader as expected for 
a M(CO)3 fragment. After 5 
min some shoulders are 
already noted and 15 min later 
these bands decrease intensity 
and 2 new bands start to 
appear at 2077 and 2012 cm-1. 
After 30 min the new bands 
are already higher in intensity 
than the initial ones. After 3h the spectrum shows a similar profile to the one 
presented after 24 hours with two major bands of equal intensity at 2079 and 2014 
cm-1 which are characteristic of complex 2.  
It was also noted that when the compound is dissolved in DMSO a colorless 
solution is obtained that turns yellow within some seconds. The yellow solution 
deepens color with time during the first 5 to 15 min and some bubbles are 
observed. Then, after some minutes it slowly starts to lose color and after 24h is 
almost colorless. 
A similar study was performed by 13C NMR periodically recording spectra of a 
sample of 1 dissolved in d6-DMSO (Figure 7). 
 
 
 
 
 
Figure 6: Time evolution of the IR spectrum of 1 
in DMSO. Drop of solution over a KBr pellet. 
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Figure 7: Time evolution of the 13C NMR spectrum of 1 in d6-DMSO in the carbonyl 
region at t=0; t=6h; t=19h; t=25h; t=4 days. Each spectrum was acquired over 29 min. 
 
As can be seen from Figure 7, at the time of dissolution 1 has 2 peaks at δ 188.3 
and δ 184.3 ppm in a 1:2 ratio, corresponding to the tricarbonyl compound. These 
values are slightly different from the ones obtained by Alessio et al for the same 
compound (δ 186.7 and 183.4 ppm in CDCl3) however the differences in the 
solvent account for this discrepancy. 
In this spectrum the peak at δ 188.3 ppm has almost disappeared, while 4 new 
peaks from the dicarbonyl species 2 appeared meanwhile at δ 193.0, 187.9, 186.8 
and 186.5 ppm. The first two peaks were assigned to the 2b isomer, the one at δ 
186.8 ppm to the 2a isomer and the one at δ 186.5 ppm cannot be clearly assigned 
to any species, based on the data collected. 
After 19h the tricarbonyl compound 1 was already totally converted into 
dicarbonyl species 2  and the 2a isomer is increasing in solution, while the species 
corresponding to the peak at δ 186.5 ppm is decreasing. This tendency is 
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reinforced after 25h with only minor amounts of the unknown species present. 
After 4 days in solution only the 2a and 2b isomers are present in solution and a 
new peak at δ 190.5 ppm is observed. The origin of this peak is unknown and we 
didn’t attempt to assign it because its slow formation makes it irrelevant for the 
biological studies. 
The same experiment was performed with CORM-2. In the solid state, the 
CORM-2 dimer has a IR spectrum with 3 equivalent CO stretching bands at 2145, 
2092 and 2066 cm-1. When it is dissolved in DMSO (9.7 mg in 300 µL; 63 mM) 
the IR spectra start evolving similarly to those of 1 (Figure 8). 
At the time of dissolution 
there are two strong 
bands at 2121 and 2046 
cm-1, the later being 
broader. After 15 min 
these bands decrease in 
intensity and 2 new bands 
start to appear at 2077 
and 2013 cm-1. This 
evolution continues up to 
24h when two major 
bands appear at 2077 and 
2012 cm-1 with only 
small shoulders at 2037 and 2122 cm-1.  
These latter bands arise from the new species into which CORM-2 has converted 
and are characteristic of the dicarbonyl species. 
When CORM-2 is dissolved in DMSO the initial colorless solution turns yellow 
within minutes. The yellow solution deepens color during the first 5 to 15 min 
and some gas bubbles are formed. After a while the color starts to become lighter. 
This sequence is identical to that observed in the dissolution of 1 in DMSO. The 
13C NMR spectrum in d6-DMSO was recorded along time and the changes in the 
 
Figure 8: IR spectrum of CORM-2 in DMSO solution 
at RT; Drop of solution over a KBr pellet. 
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carbonyl peaks were followed (Figure 9). The observed peaks were assigned on 
the basis of the previously characterized individual species. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Time evolution of 13C NMR spectrum of CORM-2 in d6-DMSO, at room 
temperature, in the carbonyl region at t=0; t=1h; t=18h; t=25h; t=42h. Each spectrum was 
acquired over 29min, except t=1h that was acquired over 3h. 
 
At the time of dissolution 3 peaks are observed, two at δ 184.3 and 188.3 ppm 
from 1 and one peak at δ 186.5 ppm from 2a. After 1h three isomers of 
dicarbonyl species are observed and an unknown peak is observed at δ 190.5 
ppm. Later in time, after 18h 1 and 2a concentrations’ decreased and 2b isomer 
increased in solution. This tendency results in the formation of dicarbonyl isomers 
with the cis,trans,cis- as the main species after 42h. 
 
 
 
 
 
 
Chemical and biological studies with Ruthenium-based CO-RMs 
 
 
206 
Table 3: Identification of the carbonyl peaks observed in the 13C NMR spectrum of 
CORM-2 dissolved in d6-DMSO. 
TIME SPECIES 13C chemical shift (CO) 
0 
1 fac- RuCl2(DMSO)(CO)3 
2a cis,trans,cis -RuCl2(DMSO)2(CO)2 
184.3; 188.3 
186.5 
1h 
1 fac-RuCl2(DMSO)(CO)3 
2a cis,trans,cis -RuCl2(DMSO)2(CO)2 
2b cis,cis,cis-RuCl2(DMSO)2(CO)2 
Unidentified   
Unidentified 
184.3; 188.3 
186.5 
187.9; 193.0 
186.8 
190.3 
18h 
1 fac-RuCl2(DMSO)(CO)3 
2a cis,trans,cis -RuCl2(DMSO)2(CO)2 
2b cis,cis,cis-RuCl2(DMSO)2(CO)2 
Unidentified   
Unidentified 
184.3; 188.3 
186.5 
187.9; 193.0 
186.8 
190.3 
25h 
2a cis,trans,cis -RuCl2(DMSO)2(CO)2 
2b cis,cis,cis-RuCl2(DMSO)2(CO)2 
Unidentified   
Unidentified 
186.5 
187.9; 193.0 
186.8 
190.3 
42h 
2a cis,trans,cis -RuCl2(DMSO)2(CO)2 
2b cis,cis,cis-RuCl2(DMSO)2(CO)2 
Unidentified  
Unidentified 
186.5 
187.9; 193.0 
186.8 
190.3 
 
 
b. Summary 
 
The results presented showed that when CORM-2 is dissolved in DMSO a 
tricarbonyl complex fac-Ru(CO)3(DMSO)Cl2 (1) is immediately formed, as well 
as a dicarbonyl complex cis,trans,cis-RuCl2(DMSO)2(CO)2 (2a). Over time the 
tricarbonyl complex is fully converted into dicarbonyl species and several isomers 
are present in solution. 13C NMR shows the presence of an unidentified peak at δ 
190.5 ppm after 1h in solution. 
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Figure 10: Time evolution of the species formed after dissolving CORM-2, 1, 2 and 3 in 
DMSO, at room temperature. 
 
The reaction profile is similar to the one observed with 1 in DMSO with two 
major differences. Upon dissolution of CORM-2 in DMSO the cis,trans,cis-
RuCl2(DMSO)2(CO)2 isomer is  immediately formed, together with the 
tricarbonyl 1. However, when pure 1 is dissolved in DMSO the formation of a 
dicarbonyl species doesn’t occur immediately.  The other major difference is the 
unknown peak with a 13C resonance at δ 190.5 ppm that is observed after 1h with 
CORM-2 but only starts to appear after 25h in the case of the dissolution of 1 in 
DMSO.  
The origin of this peak is unknown and although it could arise from a 
monocarbonyl compound it is highly improbable based on the other spectroscopic 
evidences. The 13C NMR (and also IR) spectrum evolution of 2 in DMSO didn’t 
reflect any changes in the CO pattern (Figures 6 and 7), therefore, the formation 
of a monocarbonyl complex through substitution of one CO is not expected under 
these experimental conditions. Moreover, the new peak formation occurs readily 
after 1h therefore a monocarbonyl compound is less likely to form so fast. 
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An alternative explanation is the formation of different dicarbonyl isomer not 
previously characterized and is more viable based on the spectroscopic arguments 
stated above. 
In addition, exchanges between coordinated and free DMSO, as well as H2O, 
occur at fast rates and are dependent on the amount of water present in the system 
and the concentration of the complex in DMSO solution. Since d6-DMSO is not 
100% dry, some water is present in solution. This water effect was observed in 
the 1H NMR spectra of the samples through the changes in the water chemical 
shift. These changes suggest that water coordinates to the metal and a dynamic 
equilibrium is obtained between free and coordinated water which strongly 
influences the nature of the species formed. Therefore, this “hydration” leads to 
the formation of new carbonyl species with H2O ligands through replacement of 
the DMSO and chloride ligands. 
This is a similar process to what is observed with 4 (Schemes 2 and 3) and the 
unidentified carbonyl peaks at δ 190.5 and 186.5 ppm are likely to be due to these 
new species. 
Although conclusions regarding the number of carbonyl groups in the molecule 
are valid based on the 13C NMR and FT-IR studies, caution has to be taken when 
making considerations regarding the remaining ligands in the molecule.   
In summary, incubation of CORM-2 in DMSO may afford tri- and dicarbonyl 
ruthenium dichloride dimethylsulfoxide complexes in a manner dependent on 
factors such as compound concentration, compound:DMSO ratio and %H2O in 
the DMSO vehicle.  
The full characterization of the CO release profile of this set of compounds was 
studied by the two different methods already explained in Chapters II and IV – 
gas chromatography and the Mb assay. 
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4.1.2 CO release profiles of CORM-3, CORM-2 and its derivatives in DMSO 
 
a. CO release to the headspace in aqueous media 
 
The GC assays were performed with the complexes 1, 2, 3, CORM-3 and CORM-
2. The CO release rate of the compounds was evaluated under the standard 
conditions described in Chapter II, Figure 1, in RPMI (10% FBS), PBS7.4 and 
H2O. The same result was obtained with the 5 complexes in the different media – 
no CO was detected during 24 hours in the headspace of their solutions (ca. 14 
mM) using TCD detection. CORM-2 and CORM-3 were tested with a variety of 
solvents and buffers at different pH values (pH2 to pH9) and from the media 
tested only DMSO could promote some CO displacement, although in very low 
amounts (less than 5% after 24h). 
 
b. CO transfer to deoxy-Myoglobin 
 
On the contrary, the Mb assay showed very interesting results with different 
amounts of CO donated to deoxy-Mb, depending on the number of carbonyls in 
the molecule, as can be seen in Figure 11. The monocarbonyl 3 does not transfer 
any CO to deoxy-Mb, the dicarbonyl 2 donates around 0.5 equiv. CO and the 
tricarbonyl 1 donates 1.0 equiv CO. The same donation profile is observed with 
CORM-2 and CORM-3 (see Chapter IV, Fig. 7), with CO-Mb formation 
completed after 5 min. After this rapid transfer has taken place a plateau is 
maintained over time without further carbonylation or decarbonylation of Mb. 
The amount of CO donated by 1 is the same as that of CORM-3, showing that the 
amount of CO donated is clearly related to the number of carbonyls and not the 
co-ligands: the Ru(CO)3 complexes are able to transfer 1 CO to deoxy-Mb and 
not more. 2 only transfers half equivalent, meaning that decreasing the number of 
carbonyls from 3 to 2 decreases the amount of CO donated to deoxy-Mb. This 
trend continues to the mono-carbonyl complex that is not able to transfer its CO 
to deoxy-Mb. 
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Figure 11: Equivalents of CO transferred from compounds 1, 2 and 3 to deoxy-Mb in 
PBS7.4 at room temperature. Compound 1 was pre-dissolved in MeOH and added to a 
deoxy-Mb solution (58µM) giving a final concentration of 50µM (2.8% MeOH). 
Compound 2 was pre-dissolved in MeOH and added to a deoxy-Mb solution (58µM) 
giving a final concentration of 50µM (2.4% MeOH). Compound 3 was pre-dissolved in 
DMSO and added to a deoxy-Mb solution (58µM) giving a final concentration of 50µM 
(2.4% DMSO).  
 
These data help to understand the results obtained with CORM-2 that donates 
around 1.7 equiv. CO to deoxy-Mb. Pre-mixing the compound in DMSO gives a 
mixture of 1 and 2 and if this ratio is 1:1 then 1.5 equiv. CO would be obtained (1 
equiv. from 1 and 0.5 equiv. from 2). Depending on factors such as the 
concentration of the stock solution or the amount of time evolved before adding 
the solution to Mb the ratio between 1 and 2 varies giving no more than 2 equiv. 
CO  (if only 1 is present in solution) and no less than 1 equiv. CO (if only 2 is 
present in solution). 
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4.1.3 Final Remarks 
 
The study performed allowed the identification of the species formed when 
CORM-2 is dissolved in DMSO, a tricarbonyl and dicarbonyl complexes. The 
results obtained must be interpreted with a degree of tolerance, since it shouldn’t 
be assumed that in vivo a monocarbonyl complex can’t be formed or even a 
totally CO-depleted molecule through displacement of CO by different triggering 
agents.  
However, for in vitro studies CORM-2 is always pre-dissolved in DMSO and this 
has to be considered when interpreting the results. For example, as DMSO 
breakes the dimeric structure of CORM-2 the molar concentration of active Ru 
doubles. 
Complexes 1, 2 and 3 were tested in 2 models where CORM-2 had shown 
positive results, bacterial infection by Escherichia coli and Staphylococcus aureus 
and cerebral malaria infection (unpublished results). 
In the bacterial model, 1 was effective at a slightly higher concentration than the 
one used for CORM-2 (250 µM). In addition, CORM-3 was also effective in this 
model at the same concentration as 1. 
In a malaria model, CORM-2 was able to rescue infected mice and the same result 
was replicated by 1. Neither 2 nor 3 showed any protection in the same model. 
Although these results arise only from 2 models, the data collected demonstrates 
that CORM-2 is actually a pro-drug, since the active molecule is in fact the 
tricarbonyl complex formed when the dimer is broken with DMSO. Together with 
the good results demonstrated by CORM-3 in several in vivo and in vitro models 
it became obvious that 3 carbonyls are needed to afford a biologically active 
compound, although as shown by the Mb assay, in principle only one is 
transferred to the target.  
Since the “active ingredient” of CORM-2 is actually the tricarbonyl complex, the 
use of CORM-2 as a tricarbonyl source is therefore a “waste” from the point of 
view of atom economy. The loss of active compound due to side-formation of 
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dicarbonyl species is a drawback that decreases the efficacy. Using 1, one may 
assure that only the active species is being administered without losing active 
compound in formulation. Unfortunately 1 is not totally soluble in water but its 
efficacy was proven beyond doubt.  
This was the starting point for the development of a new group of dichloro 
ruthenium tricarbonyl complexes prepared in order to get new compounds with 
better properties like water-solubility, higher activity or efficacy both in vitro and 
in vivo. 
 
4.2 Development of new Ruthenium tricarbonyl compounds 
Ru(CO)3Cl2L 
 
4.2.1 Synthesis and Characterization 
 
Given the success and widespread use of CORM-2 and CORM-3 for proof-of-
concept studies on the viability of the use of CO-RMs as vectors for the delivery 
of CO to biological systems in vitro and in vivo, it felt reasonable to extend this 
family of compounds in order to reach better pharmacological properties and 
higher therapeutic activities. As shown above, CO release is favored by Ru(CO)3 
fragments and, therefore, it seems that the reaction in Equation 1 would be 
appropriate to obtain the desired complexes in which L imparts biocompatibility, 
water solubility and eventually targeting ability to the final analogues of 1. 
 
[Ru(CO)3Cl2]2 + 2L 2 Ru(CO)3Cl2L  Equation 1  
 
Tuning this type of properties should lead to better complexes in terms of drug-
like properties and therapeutic efficacy.   
Synthesis of neutral ruthenium tricarbonyl complexes of the type Ru(CO)3Cl2L 
(L=water-solubilizing agent) is not straightforward since it often leads to 
undesired substitution of another carbonyl. Several pathways can be envisaged as 
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summarized in Scheme 4. Intermediates of the type Ru(CO)3Cl2S with a labile S 
molecule such as THF, Et3N or OPPh3[62, 66] can be prepared in situ but the 
following step (the nucleophilic substitution by the ligand L) may be problematic. 
Using Ru(CO)4X2 as starting material is an alternative used with success to 
prepare the di-halo tricarbonyl complexes of the type Ru(CO)3Cl2(OX) with O-
donor ligands like Opy or OPPh3,[67] but the use of the readily commercially 
available [Ru(CO)3Cl2]2 starting material is preferable. 
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Scheme 4:  Possible reaction pathways involving [Ru(CO)3Cl2]2 and mono- (L) or 
bidentate (L-L) ligands in alcoholic media (ROH). 
 
Since the new compounds should be water-soluble in order to facilitate their 
pharmacological study and application, the L ligand introduced was usually 
highly hydrophilic. This reduces the number of solvents available to perform the 
reaction and the solvents used are polar such as alcohols or acetone. Dissolution 
of the starting material in these solvents results in the cleavage of the halogen 
bridge with formation of monomeric species[68] of the type Ru(CO)3Cl2(Solv). 
Reactions of the dimer with N-donors, like N-coordinated nitriles and pyridines[68] 
results in the desired product but amines, diamines, bipy and phenantrolines, P- 
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and S- donors[62, 69-71, 77, 78] may also lead to CO replacement forming 
RuX2(CO)2L2 complexes. 
Reactions with aromatic nitrogen donor ligands in alcoholic media also proceed 
through a complicated pathway, dependent on the solvent and the other 
reagents.[59] For instance [Ru(CO)3Cl2]2 reacts with py to give Ru(CO)3Cl2py or 
Ru(CO)2Cl2py2 depending on the concentrations; reacts with pz (pyrazine, 
NC4H4N) to give [Ru(CO)3Cl2(pz)Ru(CO)3Cl2] and reacts with N-N chelating 
ligands to give [Ru(CO)3Cl(N-N)][Ru(CO)3Cl3] species. 
If we change the solvent to ethylene glycol the reaction with 2,2'-bipyridine may 
give Ru(bpy)(CO)2Cl(C(O)OCH2CH2OH), [Ru(bpy)(CO)2Cl]H and 
[Ru(bpy)(CO)2Cl]2, which were formed consecutively and isolated by adjusting 
the reaction conditions.[79] In alcoholic media the same esterification of the third 
carbonyl occurs at low temperature, giving species of the type 
Ru(CO)2(COOR)Cl2L. 
Obviously, there’s not a standard procedure to perform these reactions. Each 
reaction is unique and the methodology developed must be determined case-by-
case depending on the donor ability and solubility of the ligands.  
The reactions with monodentate ligands proceeded without problems, with 
coordination to the metal center through the donor atom present in the molecule. 
Reactions with ligands containing more than one donor atom afforded mixtures of 
compounds, mainly bridged dimers.   
With these provisos in mind, the following Ru(CO)3Cl2L compounds were 
synthesized (Table 4): 
L = D,L-H3CSO(CH2)2CH(NH2)CO2H (5); L-H3CSO(CH2)2CH(NH2)CO2H) (6); 
3-NC5H4(CH2)2SO3Na (7); 4-NC5H4(CH2)2SO3Na (8); 3-NC5H4(CH2)2NMe3I (9);  
PTA (10); DAPTA (11); H3CS(CH2)2CH(OH)CO2H (12); GaL-S-Me (13); NAC 
(14). For synthetic details see Experimental Section. 
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Table 4: Spectroscopic information, solubility data and synthetic information for several 
Ru(CO)3Cl2L complexes. 
Entry Structure Solubility in H2O 
νCO bands Color Yield 
CORM-3 
CO
Ru
O
Cl
OC N
H2
OC
C
O
 
>20 mg/ml  
2139(s) 
2057(s) 
1981(w) 
pale 
yellow 50-90% 
1 
OC
Ru
Cl
ClOC
CO
SO  
2 mg/ml 2134(s) 2068(s) white 23% 
5 OC Ru
Cl
ClOC
CO
S OH
O
NH2
O  
>5 mg/ml 2133(s) 2056(s) 
off-
white 36% 
6 OC Ru
Cl
ClOC
CO
S OH
O
NH2
O  
>5 mg/ml 2131(s) 2055(s) 
off-
white 83% 
7 CO Ru
Cl
Cl
CO
N
OC
SO3Na
 
>5 mg/ml 2137(s) 2053(s) 
pale 
yellow 63% 
8 CO Ru
Cl
Cl
CO
N
OC
SO3Na 
>5 mg/ml 2137(s) 2053(s) white 53% 
9 CO Ru
Cl
Cl
CO
N
OC
NMe3I 
Insoluble 
2130(w) 
2047(s) 
1975(s) 
orange 12% 
10 CO
Ru
Cl
Cl
CO
OC
N
N N
P
 
Insoluble 
2134(w) 
2060(s) 
1994(s) 
white 56% 
11 CO
Ru
Cl
Cl
CO
OC
N
N N
P
O
O
 
>5 mg/ml 
2135(w) 
2067(s) 
2001(s) 
white 75% 
12 
OC
Ru
Cl
ClOC
CO
S
OH
O
OH
 
5 mg/ml 
10% 
DMSO/ 
water 
2137(s) 
2053(s) white 85% 
13 
OC
Ru
Cl
ClOC
CO
O
HO
HO
OH
HO
S
 
>5 mg/ml  2138(s) 2057(s) white 73% 
14 OC Ru
Cl
ClOC
CO
S
H
COOH
NHAc  
>5 mg/ml 2126(s) 2062(s) 
light 
yellow 53% 
 
Generally, the complexes 5-14 were obtained from reaction of  [Ru(CO)3Cl2]2 
with the ligand in MeOH or acetone, depending on the ligand solubility. The 
reactions were performed at room temperature according to Equation 2 but the 
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reaction time varied from case to case, ranging from 15min (10), to 2h (11), 4h 
(14) or reacting overnight (8). 
 
[Ru(CO)3Cl2]2 + 2L 2 Ru(CO)3Cl2L
MeOH or acetone
RT
  Equation 2 
 
The long reaction periods were employed to ensure the total solubilization of the 
ligands in the reaction medium. The solids were isolated in fairly good yields as 
white to pale yellow solids except 9 that was isolated as an orange solid with only 
12% yield. 
All the compounds were duly characterized by the usual spectroscopic (IR and 
NMR) and analytical (EA) methods. Mass spectrometric studies were undertaken 
and will be mentioned in the next section. The IR spectra of most of the 
compounds present the usual pattern corresponding to the fac-M(CO)3 fragment 
with two CO stretching bands: a sharp strong vibration at ca. 2135 cm-1 and a 
broader band at ca. 2055 cm-1. Compounds 9, 10 and 11 have a different IR 
carbonyl pattern with a weaker band at ca. 2135 cm-1, and two other strong and 
broader bands at ca. 2060 cm-1 and 2000 cm-1. We did not find any explanation 
for the pattern observed, but some possible causes may be attributed to secondary 
effects such as Fermi resonance and overtone interactions that alter the “normal” 
IR spectrum.  
 From the values collected in table 4 it is clear that there are not major differences 
in the νCO of the different complexes. This data shows that the different ligands 
coordinated to the Ru(II) center do not have a major electronic effect on the M-
CO bond, although different donor atoms as N, O, S or P are present. 
Nevertheless, the high wavenumber at which the carbonyl stretching vibrations 
are observed reflects the weak coordination of the carbonyls to the Ru center. An 
important difference is observed between the coordination mode of 1, 5 and 6, 
which isn’t shown in table 4. Compound 1 has a band at 903 cm-1 which was 
assigned to a Me2SO group coordinated through the oxygen atom while 
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complexes 5 and 6 have bands at 1016 and 1017 cm-1, respectively, assigned to a 
Ru-S coordination. The versatility of the sulfoxide functionality allows different 
coordination modes[80] and the unexpected coordination through the sulfur atom 
was indeed the driving force to use ligands with tioether functional groups leading 
to the synthesis of 12 and 13. In these complexes the Ru-S bands are at 1125 and 
1090 cm-1, respectively, meaning that they’re shifted to higher wavenumber when 
compared with the sulfoxides, showing evidence of stronger Ru-S bonds.  
The 1H NMR spectra show the ligand protons usually shifted downfield due to the 
electropositive character of the Ru(CO)3Cl2 fragment. A special behavior is 
observed with complexes 5-8 in D2O. In the free ligands, the two CH2 groups of 
the linear chain are observed as multiplets but after coordination to the metal they 
become equivalent, affording one singlet in the same location. 
 
4.2.2 CO release profiles of the new [Ru(CO)3Cl2L] complexes 
 
Since all these new compounds were intended to perform as CO-RMs, their CO 
release profile has to be evaluated as for the other MCCs already discussed in this 
and previous chapters. 
 
a. CO release to the headspace in aqueous media 
 
Following the behavior already described for CORM-2 and CORM-3 none of the 
compounds in table 4 released CO to the headspace of their solutions in PBS7.4 at 
the level of the GC/TCD detection used in macroscopic assays (ca. 10 mg of 
compound in 2 mL of medium). Instead, like in the cases of 1 and CORM-3, large 
amounts of CO2 were detected (see table 5). 
On the contrary, no CO2 was generated in the analogous solutions of the 
dicarbonyl complex 2 or the monocarbonyl 3. 
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The release of CO2 is the result of the known water-gas shift reaction (WGSR) 
where CO reacts with H2O to give CO2 and H2.  
 
CO + H2O CO2 + H2              Water-Gas Shift Reaction  
 
Since the first report of homogeneous WGSR catalyzed by ruthenium complexes 
in 1977 by Laine and co-workers,[81] this reaction has been widely studied 
employing mono- and polynuclear transition metal carbonyl complexes[82-87] of 
which ruthenium carbonyl clusters were actively studied.[88-93]  
The studies performed elicited the general pathway shown in scheme 5.  
In one pathway, a nucleophilic attack by OH- or H2O on the carbonyl leading to 
the formation of a metallo-carboxylate[94-97] (i); followed by decarboxylation with 
hydride formation (iia); the hydride may then react with H+ from the medium and 
release H2 (iiia). 
Compound Equiv. CO2 
CORM-3 0.68 (PBS7.4) 
0.29 (H2O) 
1 0.71 (H2O) 
5 0.98 (H2O) 
6 1.20 (H2O) 
7 0.96 (H2O) 
8 1.00 (H2O) 
9 0.53 (H2O) 
10 0.28 (H2O) 
11 0.19 (H2O) 
12 0.40 (H2O) 
13 0.71 (H2O) 
14 0.65 (H2O) 
Table 5: Equiv. CO2 released by ruthenium tricarbonyl compounds after 24h in H2O 
or PBS7.4, at room temperature under N2. 
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Alternatively, the metal carboxylate may be deprotonated by an incoming base 
(iib) and then lose CO2 to give M2- (iiib). This may be protonated to give MH2 
(ivb). The dihydride may reductively eliminate H2 (vb) to give M. All the 
equilibria will be dependent on pH and the co-ligands. 
These features have been observed in related complexes. The group of Tanaka 
showed that [Ru(bipy)2(CO)Cl]+ and [Ru(bipy)2(CO)2]2+ are good catalysts for 
WGSR in alkaline medium, and isolated and characterized the species involved in 
the catalytic cycle.[98]    
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5: General WGS reaction pathway leading to CO2 and H2 release.  
  
Pakkanen and co-workers showed the activity of Ru(bipy)2(CO)2Cl2 and 
Ru(bipy)2(CO)2ClH supported on SiO2 [99] and the effect of modifying the bipy 
rings[100] or the influence of the medium[79] with the complexes of the type 
Ru(bipy)(CO)2X2. In fact, bipyridine and phenantroline ligands are some of the 
most used ligands for WGSR Ru catalysts.[101]  
Most of these catalysts are active in reactions performed in basic medium[102] but 
acid catalyzed WGSR is also possible,[103, 104] as well as water attack on 
tricarbonyl ionic complexes if the carbon atom is highly electrophilic.[105]  
M - CO + OH- M - COOH-
M - H-
- CO2
+ B-
[M - COO]2- + BH
+ H+ - CO2
M2-
+ 2H+
-H2
M
i
iia
iib
iiia iiib
ivb
vb
M + H2
MH2
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Evidence that this mechanism is occurring with these compounds is supported by 
different observations in aqueous solution. The aqueous chemistry of CORM-3 
was extensively studied by Brian Mann’s group, who found that a complex set of 
equilibria were taking place in water.[106]  
Several important observations are fundamental and may help explaining the 
reaction pathway: 
1. When the compound was dissolved in pure distilled water the pH of the 
solution dropped from ca. 5.5 to pH=2-3 depending on the concentration; 
2. The typical tricarbonyl pattern of the IR bands changes and a new band 
appears in the carboxylate region ~1700cm-1; 
3. At low pH the compound is stable but decomposes rapidly at high pH; 
 
These observations support the WGS reaction detected in the GC assays.  
When the compound is dissolved in water one of the carbonyls is immediately 
attacked by hydroxide anion. The corresponding H+ becomes free and the pH 
lowers drastically, similarly to what is reported[105] for [Ru(CO)3(H2O)3]2+ which 
gives a  pH 1.6 solution at 0.4 M, with formation of [Ru(CO)2(COOH)(H2O)3]+.  
If a decarboxylation occurs, CO2 is liberated and a hydride is formed (detected by 
1H NMR after 24h in D2O at δ -14.5 ppm). This step is not as fast as with 
[Ru(CO)2(COOH)(H2O)3]+ that completely loses CO2 within 3h (cited in 
reference [106]) .  
The hydride [RuH(CO)2(H2O)3]+ preferentially reacts with H+ from the medium 
and H2 is released. Indeed, H2 release was detected by GC-RCP after 24h in water 
and PBS7.4. In summary, a dicarbonyl complex is obtained as end-product of the 
reaction of a RuII(CO)3 derived complex in water.  
In the case of CORM-3, the IR spectrum of the product of this reaction, obtained 
after evaporation of the water shows the presence of 2 bands of terminal 
carbonyls. This species was termed in literature “i-CORM-3” (from inactivated 
CORM-3) since it has no biological effect and is used as a negative control for 
CORM-3 activity.[30]  
Chapter V 
 
 
221 
The aqueous chemistry of the remaining complexes was not so extensively 
studied but the majority of them showed several aspects common to the chemistry 
of CORM-3 and [Ru(CO)3(H2O)3]+. Apart from the already mentioned CO2 
release, the formation of acidic solutions in water is common to all the water 
soluble compounds in Table 4 and the formation of a hydride after 24h in D2O 
was also observed for 6 (δ  -13.96 ppm), 7 (δ  -13.94 ppm), 8 (δ  -13.94 ppm), 13 
(δ  -13.97 ppm) and 14 (δ  -15.29 ppm). 
The HPLC trace of these water-soluble compounds was acquired in a 
MeOH/Water gradient. The chromatograms obtained reveal the presence of 
several species in solution.  Typically two main groups of peaks are observed at 
retention times of ca. 2-3 min and 9-11 min but more peaks are sometimes 
observed. As exemplified in Figure 12, compound 1, presents three major peaks 
at retention times of 3.0, 6.6 and 8.7 min while for compound 5 two major peaks 
are registered at retention times of 3.0 and 10.0 min. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Time evolution of the HPLC trace of compounds 1 (left) and 5 (right).  
 
Analysis and resolution of each peak eluted by LC-MS-ESI in positive ion mode 
was attempted with compounds 1, 5 and 13. The results further revealed that each 
of the chromatographic peaks contained several species eluting at very close 
retention times. In most of the cases a mixture of species was detected including 
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aggregates and oligomers, the identification of which was not pursued. The 
lability of these compounds in solution has become very clearly demonstrated and 
certainly will pose problems when it comes to interpret their biological activity.  
 
b. CO transfer to deoxy-Myoglobin 
 
The incubation of the compounds in Table 4 with deoxy-Mb resulted in similar 
profiles of carbonylation of Mb but with different reaction extensions since the 
amount of CO transferred is not the same for all compounds.  
All the compounds shown in 
Figure 13 are able to 
complete CO transfer to 
deoxy-Mb within 5 min of 
incubation. That maximum 
reached 0.9 to 1 equivalent 
for compounds 5, 6 and 7, 
and 0.7 equiv for 8. 
Compounds 5 and 6 only 
differ in the chiral purity of 
the methionine sulfoxide 
ligand, therefore, similar 
results (rate and extension of 
reaction) are expected and 
indeed observed both in 
PBS and H2O.  Compounds 
7 and 8 are pyridine 
derivatives that only differ 
in the position of the ethyl-sulfonate substituent which is 3 and 4, respectively. 
 
Figure 13: Equivalents of CO transferred from 
compounds 5, 6, 7 and 8 to deoxy-Mb in PBS7.4 at 
room temperature. Compound 5 was pre-dissolved 
in PBS7.4 and added to a deoxy-Mb solution 
(55µM) giving a final concentration of 50µM. 
Compound 6 was pre-dissolved in PBS7.4 and 
added to a deoxy-Mb solution (58µM) giving a final 
concentration of 50µM. Compound 7 was pre-
dissolved in PBS7.4 and added to a deoxy-Mb 
solution (58µM) giving a final concentration of 
50µM. Compound 8 was pre-dissolved in PBS7.4 
and added to a deoxy-Mb solution (58µM) giving a 
final concentration of 50µM. 
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While 7 transferred roughly 1 equiv. CO to Mb very rapidly in both PBS and 
water (0.9 equiv. donated in PBS and 1.1 equiv. donated in water (data not 
shown), 8 transferred a slightly lower amount of CO (0.7 equiv.) in the same time 
span in PBS7.4. It is tempting to assign this difference of CO transfer rates to the 
difference in the σ-donating ability of both substituted pyridine ligands which is 
expected to decrease in the order 4-NC5H4(CH2)2SO3Na > 3-NC5H4(CH2)2SO3Na. 
Figure 14 depicts the 
results obtained for 
compounds 9, 10 and 11. 
One would expect that 9 
would have a similar result 
to that of 8. 
Experimentally, 9 only 
transferred ca. 0.4 equiv. 
CO to deoxy-Mb.  
Despite the use of different 
solvents (9 was pre-
dissolved in MeOH) this 
shouldn’t interfere with 
their transfer capacity like 
is demonstrated by 10 and 
11. Although different 
media were employed to 
solubilize the compounds, 10 and 11 both transferred 0.3 equiv. CO to deoxy-Mb. 
This very small amount which contrasts with that of all the other compounds in 
Table 4, strongly reinforces the suggestion that strong, substitutionally inert Ru-L 
bonds, hamper the CO transfer process between Ru(CO)3Cl2L complexes and 
myoglobin.  
 
Figure 14: Equivalents of CO transferred from 
compounds 9, 10 and 11 to deoxy-Mb in PBS7.4 at 
room temperature. Compound 9 was pre-dissolved in 
MeOH and added to a deoxy-Mb solution (58µM) 
giving a final concentration of 50µM (5.5% MeOH). 
Compound 10 was pre-dissolved in DMSO and added 
to a deoxy-Mb solution (58µM) giving a final 
concentration of 51µM (2.2% DMSO). Compound 11 
was pre-dissolved in PBS7.4 and added to a deoxy-
Mb solution (61µM) giving a final concentration of 
58µM. 
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Compounds 12 and 13 transferred, respectively, 0.7 equiv. and 0.8 equiv. CO to 
deoxy-Mb. Although 12 needed to be solubilized in MeOH, we already observed 
that the solubilizing medium does not greatly interfere with the donation capacity. 
In fact, this is confirmed by the similar profile observed with 12 and 13 (Fig. 15) 
The broad picture of these 
CO transfer studies is that 
all the compounds in Table 
4 are able to complete their 
CO transfer to deoxy-Mb 
within 5 min of incubation. 
This transfer is > 0.7 
equivalents for most 
compounds and seems to 
decrease with decreasing 
donor strength of the ligand 
L in the following way: 
R2SO > R2S ~ py >>>PR3. 
Under this light, it seems 
quite plausible that it is the 
substitutional stability of 
the coordination sphere of the Ru(CO)3Cl2L complexes and not the 
electrophilicity of their CO ligands that controls their reactivity towards 
myoglobin.    
 
c. Deactivation of the CO transfer capacity 
 
Given the high reactivity and lability of these Ru(CO)3Cl2L complexes it became 
important to establish their ability to retain the initial capacity to transfer CO once 
they are dissolved in pharmacologically or biologically compatible media. The 
importance of this study derives from the fact that many biological tests are 
 
Figure 15: Equivalents of CO transferred from 
compounds 12, 13 and 14 to deoxy-Mb in PBS7.4 at 
room temperature. Compound 12 was pre-dissolved 
in MeOH and added to a deoxy-Mb solution (68µM) 
giving a final concentration of 50µM (2% MeOH). 
Compound 13 was pre-dissolved in PBS7.4 and 
added to a deoxy-Mb solution (61µM) giving a final 
concentration of 51µM. Compound 14 was pre-
dissolved in PBS7.4 and added to a deoxy-Mb 
solution (68µM) giving a final concentration of 
50µM. 
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performed with stock solutions from which aliquots are successively administered 
to cells or animals along the time or, at least, after some time has passed. 
This behavior was first recognized with CORM-3 which was not able to transfer 
the full CO equivalent to deoxy-Mb if the addition of its solution to the deoxy-Mb 
preparation wasn’t performed immediately after dissolution. To determine if the 
donating ability of the compound is retained after staying in solution for a 
determined period of time, a series of studies were conducted with fresh and 
“aged” solutions (see Experimental Section for details). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Left: Equivalents of CO donated to deoxy-Mb from CORM-3 freshly 
dissolved solution in PBS7.4. CORM-3 was pre-dissolved in PBS7.4 and added to a 
deoxy-Mb solution (57µM) giving a final concentration of 50µM; Right: Equivalents of 
CO donated to deoxy-Mb from CORM-3 aged solution in PBS7.4. CORM-3 was pre-
dissolved in PBS7.4 and added to a deoxy-Mb solution (57µM) giving a final 
concentration of 50µM. 
 
When CORM-3 is dissolved in PBS and the solution immediately added to the 
protein (deoxy-Mb), it rapidly donates 1 equivalent of CO to deoxy-Mb as seen in 
Figure 16-left. If the compound is left standing in PBS7.4 solution for some time 
(ageing period) it loses the capacity to transfer one CO ligand to deoxy-Mb as 
seen in Figure 16-right. If the solution of the compound is added to deoxy-Mb 5 
min after being prepared around 50% donation capacity is lost. This very rapid 
inactivation observed in the first 3 to 4 minutes lowers the donation capacity to 
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ca. 0.3 equiv. CO, remaiuiug almost constant up to 3h ageing period. After 24 
hours ageing time, only 0.2 equiv. of CO are transferred to deoxy-Mb (Table 6). 
This decrease in the CO donation capacity is 
Table 6: Amount of CO 
transferred to deoxy-Mb from herein called deactivation, since it reflects 
aged CORM-3 solutions in the loss of capacity to deliver the active 
PBS7.4. 
Ageing 
period 
0 
5 min 
15 min 
60 min 
180 min 
24h 
Equiv.CO 
donated to Mb 
1 
0.4 
0.4 
0.3 
0.3 
0.2 
principle CO. The deactivation of stock 
solutions in PBS poses a major limitation for 
biological work since it is difficult to have a 
control on the CO transferring ability of 
CORM-3. However, we hypothesized that 
such deactivation might be dependent on the 
medium as we know that coordinated CO is 
attacked by water in aqueous solutions of 
CORM-3. We therefore studied CO transfer from CORM-3 to deoxy-Mb in 
different media: distilled water (PH-55). DMSO and saline (0.9% NaCI). At the 
shortest possible ageing time, which we take as zero ageing time, the compound 
Table 7: Amount of CO transferred from 
CORM-3 to deoxy-Mb in PBS7.4, H20, 
DMSO and saline 0.9% after 15min 
incubation. 
Medium Equiv.CO 
PBS7.4 1.0 
H2O 0.9 
DMSO 0.8 
Saline (0.9% NaC!) 1.1 
has a very similar behavior in the three 
media (see Table 7). transferring close 
to I equivalent CO to deoxy-Mb 
within the first 15 min of incubation. 
Nevertheless, it is clear that saline 
somehow increases the CO transfer 
capacity which actually exceeds 1 
equiv. while water and DMSO are 
essentially the same. 
When CORM-3 solutions are aged before being added to deoxy-Mb, the 
deactivation observed is clearly dependent on the medium. As seen in Figure 17, 
saline effectively stabilizes the solutions of CORM-3 which lose only a little of 
their CO transfer ability in the first 4 hours. This strongly contrasts with the very 
226 
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fast deactivation observed in PBS7.4. Distilled water is also more stabilizing than 
PBS7.4.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Equivalents of CO donated to deoxy-Mb from CORM-3 aged solutions in 
different media. The experiments were performed in similar setups as described above, 
dissolving the compound in the respective medium and adding to the deoxy-Mb 
preparation samples of the aged solutions, periodically. 
 
Obviously, the high pH of PBS7.4 compared to saline and distilled water leads to 
a faster inactivation of one CO due to the higher concentration of OH-. Consistent 
with this, the fast deactivation in PBS7.4 is accompanied by a high rate of CO2 
release as observed in the GC experiments. 
The deactivation profile in DMSO is different. The initial amount of CO donated 
is slightly lower (0.8 equiv. CO), some deactivation is observed after 15min (to 
0.4 equiv. CO) but this value is kept constant up to 24h. The data suggest that a 
stable species is formed within the first 15min, most probably a dicarbonyl 
compound since the amount of CO donated to deoxy-Mb is roughly the same of 
the dicarbonyl complex 2 (0.5 equiv. CO). The dicarbonyl structure was later 
confirmed by IR studies in DMSO. 
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Beyond pH influence, the stability in saline parallels that seen when NAMI-A is 
solubilized in saline: the presence of NaCl stabilizes the complex by preventing 
loss of chloride ligand. This suggests that such loss accelerates nucleophilic attack 
at the coordinated CO, which results in deactivation due to consumption of the 
“transferable” carbonyl. Indeed, aquation of the Ru-Cl bond increases the positive 
charge of the complex and favors nucleophilic attack by water. However, this is 
not the only process going on in solution since CORM-3 in isotonic NaCl 
exchanges glycine and is converted into [Ru(CO)3Cl3]- over a day at room 
temperature.[106] In summary, CORM-3 has a very labile coordination sphere 
particularly sensitive to H2O and pH variations. 
The deactivation process was also evaluated with the other ruthenium complexes 
described above. However, since not all are water soluble, the ageing process was 
performed in different solvents, which limits the comparison between all the 
complexes.  
Compounds 1, 9 and 12 that were solubilized and aged in MeOH before addition 
to deoxy-Mb did not show any important loss of donation capacity within 2h 
ageing time. This is not entirely unexpected since MeOH is probably unable to 
replace Cl- and to esterify the complexes and form “Ru(CO)2(COOMe)” 
containing species at room temperature, within 1h. Compounds 10 and 1 were 
also aged in DMSO, the only useful solvent for the former. In the case of 1 in 
DMSO, the amount of CO donated to deoxy-Mb was roughly 1 equiv. and the 
donation was completed after 5min. Solutions aged 1h lost ca. 30% CO transfer 
capacity, a fact that contrasts with the very high rate of deactivation of CORM-3 
in DMSO.  
Compound 10 was found to transfer as little as ca. 0.3 equiv. CO to deoxy-Mb but 
retained this capacity up to 1h ageing time. Of course, this is a situation 
chemically different from the compounds in water since in DMSO solution no 
attack occurs at CO and CO substitution is the only deactivation process 
available. However, the same exact profile was observed with 11 which is water 
soluble. This result shows the influence of the strong phosphine ligand that 
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produces a slow transfer but doesn’t deactivate contrary to the remaining S- and 
N- bonded ligands.  
 
Table 8: Deactivation of the ruthenium tricarbonyl compounds in the medium used for 
solubilization.  
Compound Structure Medium 
Equiv. CO 
donated 
at t=0 
Equiv. CO 
donated 
after 1h 
deactivation 
1 
OC
Ru
Cl
ClOC
CO
S
O  
DMSO 
MeOH 
1.1 
1.0 
0.7 
0.8 
5 
OC
Ru
Cl
ClOC
CO
S OH
O
NH2
O  
PBS7.4 0.9 0.7 
6 
OC
Ru
Cl
ClOC
CO
S OH
O
NH2
O  
PBS7.4 
H2O 
1.1 
1.1 
0.6 
0.7 
7 
CO
Ru
Cl
Cl
CO
N
OC
SO3Na
 
PBS7.4 
H2O 
0.9 
1.1 
0.7 
0.2 
8 
CO
Ru
Cl
Cl
CO
N
OC
SO3Na 
PBS7.4 
H2O 
0.7 
0.9 
0.6 
0.2 
9 
CO
Ru
Cl
Cl
CO
N
OC
NMe3I 
DMSO 0.4 0.3 
10 
CO
Ru
Cl
Cl
CO
OC
N
N N
P
 
DMSO 0.3 0.2 
11 
CO
Ru
Cl
Cl
CO
OC
N
N N
P
O
O
 
PBS7.4 
H2O 
0.3 
0.4 
0.2 
0.2 
12 
OC
Ru
Cl
ClOC
CO
S
OH
O
OH
 
MeOH 0.7 0.8 
13 
OC
Ru
Cl
ClOC
CO
O
HO
HO
OH
HO
S
 
PBS7.4 
H2O 
0.8 
0.9 
0.8 
0.3 
14 
OC
Ru
Cl
ClOC
CO
S
H
COOH
NHAc  
PBS7.4 
H2O 
0.7 
0.8 
0.5 
0.6 
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The water-soluble methionine-oxide complexes 5 and 6 donate roughly 1 equiv. 
CO to deoxy-Mb at ageing time zero in PBS7.4 but solutions aged for 1h lose the 
donation capacity by ca. 60% and 40% respectively.  
The thioether counterpart 13 shows a different deactivation profile in H2O and 
PBS7.4. In water, a 67% decrease in CO donation capacity is observed, from 0.9 
equiv. CO in fresh solutions to 0.3 equiv. after 1h in H2O. In PBS no deactivation 
is observed and the donation capacity is retained for 1h.  
Compound 7 was also tested in PBS7.4 and water and was able to donate 1 CO to 
deoxy-Mb very rapidly in both solvents (0.9 equiv. donated in PBS and 1.1 equiv. 
donated in water). Similarly to 13 and in contrast to the case of CORM-3, the 
compound is more stable in PBS than in water. In PBS the amount of CO donated 
only decreases from 0.9 equiv. CO to 0.8 equiv. after 10 min and 0.7 equiv. after 
2h. In water a very rapid decay is observed with the initial value of 1.1 equiv. CO 
decreasing to 0.3 equiv. after 20 min, that is a 70% activity loss. 8 also showed a 
good stability in PBS, decreasing from 0.7 equiv. CO to 0.6 equiv. after 10 min 
and remaining stable after 1h. 
Compound 14 has the same behavior in PBS and H2O and similar deactivation 
profiles are observed. In PBS a 29% decrease is observed after ageing 1h while in 
water the decrease in the donation capacity was 25%. 
 
4.2.3 Conclusions 
 
The studies performed showed very important features regarding the behavior of 
the RuII tricarbonyl complexes [Ru(CO)3Cl2L] in aqueous systems. It was 
observed that this class of compounds is able to transfer up to 1 CO to Mb, 
depending on the nature of the sixth ligand. Similarly to CORM-2 and CORM-3, 
all the compounds are able to carbonylate deoxy-Mb within 5 to 15 min and if the 
compounds are left in solution for a large period of time, their donation capacity 
decreases.  
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It is observed that stronger σ donating ligands decrease the capacity of CO 
donation to Mb. We attribute these differences to the substitutionally stability 
provided by the strong ligands which are harder to displace and, therefore, protect 
the coordination sphere. 
Interestingly, the amount of CO transferred to Mb is roughly the same as the 
amount of gas detected in the GC experiments and liberated as CO2 into the 
headspace of aqueous solutions after 24h (see tables 5 and 8). In the presence of a 
heme scavenger, the carbonyl group is mobilized and transferred to the heme 
center as CO. In aqueous solutions, without protein present, the carbonyl is also 
liberated in the same extent, but at a much slower rate and as CO2 instead of CO. 
The HPLC trace didn’t show any correlation between the decomposition profile 
and the rate of gas release. Two major peaks are observed at 2-3 min and 9-11 
min and each of them contains several species each one with a specific CO 
release capacity.   
Importantly, however, the profile of Mb carbonylation by the [Ru(CO)3Cl2L] 
complexes can be tuned by the nature of L. Although the differences are not 
overwhelming they are clear in showing that the stronger Ru-L bond slow down 
CO transfer to deoxy-Mb. We believe that this finding is crucial to start 
understanding the mechanism of CO donation from a CO-RM to a heme protein.  
 
4.3 Anti-oxidant activity of RuII carbonyl complexes   
 
The relevant role of ROS in several pathological processes was highlighted in 
Chapter III, section 2.1 and includes tissue injury,[107] inflammatory disorders,[108] 
cardiovascular diseases,[109] pulmonary disease[110] and neurodegenerative 
diseases.[111] Catalytic decomposition of radical species has often been suggested 
as a therapeutic approach to several inflammatory diseases.[112, 113] The use of the 
natural catalytic antioxidant proteins like SOD and catalase as therapeutic agents 
showed severe limitations such as a short circulating half-life, low cell 
permeability and antigenicity, all due to their large sizes. A new series of low 
Chemical and biological studies with Ruthenium-based CO-RMs 
 
 
232 
molecular weight metal based catalytic antioxidants featuring macrocycles, salens 
and metalloporphyrin ligands were developed and showed excellent results in 
several in vitro, ex vivo and in vivo models (see Scheme 6). The successful results 
were obtained in a large number of rat and mice models of diseases such as lung, 
renal and liver diseases or cardiovascular and central nervous systems disorders 
(for a complete review see reference [114]). Successful results were also obtained 
with higher animals like preterm baboons where catalytic antioxidants were able 
to suppress lung inflammation and improve lung function in a hyperoxic model of 
bronchopulmunary dysplasia.[115] M40403[116] improves the analgesic profile of 
morphine and passed phase II clinical trials for post-surgical pain as an additive to 
morphine.  EUK134 was developed by Eukarion and later licensed by Modex to 
treat induced skin damage while AEOL10150 is currently under clinical trials to 
be used as a countermeasure for radiation exposure to the gastrointestinal tract 
(http://www.aeoluspharma.com/index.html).[113] 
 
     
              
    
 
 
 
 
Scheme 6: Catalytic antioxidants macrocycles (M40403), salens (EUK134) and 
metalloporphyrins (AEOL10150). 
 
One of the most striking observations one makes when looking at the long list of 
diseases that can be treated with these catalytic antioxidants,[114] is that it is 
essentially superimposable on the list of indications for the therapeutic use of 
CO.[117] 
The large number of positive biological results obtained with CORM-3 and 
CORM-2 has always been assumed to be the result of CO release. However, as 
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we have extensively shown 
above, none of them releases 
CO spontaneously to the 
headspace of their solutions in 
biologically compatible media 
or conditions. On the contrary, 
the formation of CO2 in these 
solutions implies the “neutralization” of the labile CO in these complexes, leaving 
a dicarbonyl complex devoid of CO releasing ability (iCORM). Furthermore, 
reaction of these complexes with H2O2 or TBHP (in the standard conditions 
shown in Experimental Section Chapter II) do not release CO. Instead, CO2 is 
produced as can be seen in the example of Table 9 obtained for CORM-3. These 
results show that TBHP completely oxidizes the 3 carbonyls to CO2 and if the 
reaction is not stopped it proceeds with the partial oxidation of the aminoacid 
which is the only other source of carbon in the reaction mixture. With H2O2 a 
smaller amount of CO2 is liberated, however, a very important observation was 
made: like some iron compounds, CORM-3 produced high amounts of O2 from 
H2O2. The O2 quantification was not performed but the amount of O2 produced 
was higher when compared to all other iron compounds tested. Like iron[118, 119] 
and manganese[120] compounds, catalase-like activity of Ru(II) compounds is not a 
new subject[121] but the issues that this behavior brought up are relevant. Indeed, 
these observations raise the hypothesis that both CORM-2 and CORM-3 (and 
other Ru derivatives) could be exerting their therapeutic action as a result of their 
antioxidant and ROS scavenging activity.  
To look deeper into this behavior a series of experiments were conducted, 
evaluating the ability of the ruthenium complexes to decompose H2O2. An 
enzymatic assay with horseradish peroxidase (HRP) was performed in order to 
check the anti-oxidant properties of CO-RMs. These experiments allowed the 
quantification of H2O2 breakdown by CO-RMs measured through the decrease in 
HRP activity. For details see Experimental Section. 
Table 9: Equivalents of CO2 released from 
CORM-3 to headspace after 1h, 3h, 5h and 24h 
with 100 molar equivalents of H2O2 and TBHP 
under N2, at RT. 
 1h 3h 5h 24h 
H2O2 1.0 1.2 1.3 1.5 
TBHP 2.1 2.4 3.0 3.7 
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The results obtained are graphically depicted in Figures 18-23 and show that all 
the compounds are able to decompose H2O2 at different rates. However, there are 
differences which have important consequences in terms of the interpretation of 
the biological results obtained with these compounds.  
Since it is devoid of CO ligands and bears both chloride and DMSO which are 
unavoidable in tests with CORM-2, the complex RuCl2(DMSO)4 has been used as 
a negative control for CO activity in many biological experiments. Figure 18 
shows that RuCl2(DMSO)4 has the highest rate of H2O2 decomposition. In 1:1 and 
1:10 ratios when the compound is present in 198 µM and 19.8 µM concentrations 
in a 198 µM H2O2 solution, all hydrogen peroxide was decomposed within 15 
min; at the 1:50 ratio total H2O2 decomposition took 30 min and with 1:100 ratio 
the H2O2 decreased to 87%, 53% and 15% after 15 min, 30 min and 1h 
respectively. A linear correlation was observed between the compound:H2O2 ratio 
and the rate of H2O2 decomposition.  
Replacement of one DMSO by one CO ligand, as in RuCl2(CO)(DMSO)3 (Figure 
19), markedly slows the activity of H2O2 decomposition. In equimolar and 1:10 
complex:H2O2 ratios the decomposition of H2O2 after 15min decreases 
respectively to 57% and 64% from the almost quantitative values recorded for 
RuCl2(DMSO)4 under the same conditions. An initial induction period without 
decomposition of H2O2 is apparent at the 1:50 and 1:100 ratio.  Although different 
rates are observed roughly the same amount of decomposition is obtained after 60 
min for all tested complex:H2O2 ratios. 
The next compound in the series, RuCl2(CO)2(DMSO)2 (Fig. 20), which has one 
more CO and one less DMSO in the coordination sphere, does not change the 
reactivity in any marked way and the total H2O2 decomposition is essentially the 
same as that of the previous compound although a little slower at 15 min time 
point. The main difference is that the 1:1 ratio has a much slower evolution than 
the ratios where excess H2O2 is present. 
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Figure 18: H2O2 concentration decrease 
expressed in percentage of initial 
concentration, as a function of time for 1:1, 
1:10, 1:50 and 1:100 RuCl2(DMSO)4:H2O2 
ratios, calculated against a [H2O2] = 198 µM 
control. Data collected after 15min, 30min 
and 1h incubation of RuCl2(DMSO)4 with 
H2O2. 
Figure 19: H2O2 concentration decrease 
expressed in percentage of initial concentration, 
as a function of time for 1:1, 1:10, 1:50 and 
1:100 RuCl2(CO)(DMSO)3:H2O2 ratios, 
calculated against a [H2O2] = 198 µM control. 
Data collected after 15min, 30min and 1h 
incubation of RuCl2(CO)(DMSO)3 (3) with 
H2O2. 
 
 
Figure 20: H2O2 concentration decrease 
expressed in percentage of initial 
concentration, as a function of time for 1:1, 
1:10, 1:50 and 1:100 
RuCl2(CO)2(DMSO)2:H2O2 ratios, calculated 
against a [H2O2] = 234 µM control. Data 
collected after 15min, 30min, 1h and 2h 
incubation of RuCl2(CO)2(DMSO)2 (2) with 
H2O2. 
Figure 21: H2O2 concentration decrease 
expressed in percentage of initial concentration, 
as a function of time for 1:1, 1:10, 1:50 and 
1:100 RuCl2(CO)3(DMSO):H2O2 ratios, 
calculated against a [H2O2] = 234 µM control. 
Data collected after 15min, 30min, 1h, 2h and 
4h incubation of RuCl2(CO)3(DMSO) (1) with 
H2O2. 
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Figure 22: H2O2 concentration decrease 
expressed in percentage of initial 
concentration, as a function of time for 1:1, 
1:10, 1:50 and 1:100 CORM-2:H2O2 ratios, 
calculated against a [H2O2] = 198 µM control. 
Data collected after 15min, 30min, 1h, 2h and 
4h incubation of CORM-2 with H2O2. 
Figure 23: H2O2 concentration decrease 
expressed in percentage of initial concentration, 
as a function of time for 1:1, 1:10, 1:50 and 
1:100 CORM-3:H2O2 ratios, calculated against 
a [H2O2] = 220 µM control. Data collected after 
15min, 30min, 1h and 2h incubation of CORM-
3 with H2O2.  
 
With the tricarbonyl complex RuCl2(CO)3(DMSO) (Fig. 21) only the highest 
excesses of H2O2 1:100 and 1:50 lead to H2O2 decomposition. No H2O2 
decomposition is observed with a 1:1 or a 1:10 complex:H2O2 ratios, not even 
after 4h incubation. With 1:50 and 1:100 ratios a longer induction period is 
observed since after 1h there’s still 76% and 71%, respectively, of the initial H2O2 
amount. After 2h, 90% of H2O2 decomposition is observed and the reaction is 
completed after 4h, showing clearly a slower kinetics than the previous 
compounds. It is now very clear that the increase in the number of CO ligands 
significantly stabilizes the Ru(II) complex against H2O2. 
CORM-2 (Fig. 22) showed a similar profile to RuCl2(CO)3(DMSO) which is not 
surprising in view of the relationship of both compounds in DMSO solvent 
needed to solubilize CORM-2. A long induction period was observed with stable 
levels of H2O2 between 65% and 80% up to 1h with all the concentration ratios 
tested. The total decomposition of H2O2 is only observed with the more diluted 
samples 1:50 and 1:100 after 4h. The more diluted sample 1:100 shows the fastest 
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reaction where only 16% H2O2 is left after 2h while with 1:50 ratio 37% H2O2 
was obtained after 2h. In equimolar conditions and 1:10 dilution more than 60% 
H2O2 is still present after 4h incubation with compound.  
CORM-3 (Fig. 23) is different from all other compounds because it showed a 
time-dependent decomposition profile when incubated with H2O2 in equimolar 
conditions but virtually no reactivity to large excesses of H2O2 in incubations up 
to 1h. After 2h though, all the concentration ratios tested induced a H2O2 
decomposition of about 80% of the initial concentration.  
In order to compare the different reaction profiles more clearly, Figure 24 
represents the consumption of H2O2 as a function of time at the ratio 
complex:H2O2 = 1:50 for the several complexes tested. It is clear that the 
derivatives of the “Ru(CO)3” fragment all have long induction periods before they 
actually start to react with and decompose H2O2. A CO saturated solution was 
also tested at 1 mM concentration and no effect on HRP or H2O2 was observed 
showing that CO doesn’t react with H2O2 under these conditions. DMSO was also 
tested in the same concentration as it is present as the solvent of some of the 
complexes and it also didn’t have any effect on H2O2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Comparative H2O2 concentration decrease expressed in percentage of initial 
concentration, as a function of for 1:50 dilutions for compounds RuCl2(DMSO)4, 
RuCl2(CO)(DMSO)3, RuCl2(CO)2(DMSO)2, RuCl2(CO)3(DMSO), CORM-2 and 
CORM-3.  
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The data collected is too few to accurately calculate reaction rates and 
substantiate mechanistic proposals. Nevertheless, some information can be 
extracted out from the results obtained under fixed conditions. 
Quantitative comparison with other catalysts is also difficult since the 
experimental conditions (pH, buffers, concentrations) are not the same in all the 
experiments and the observed rate laws are not identical.  
In Table 10 are presented data collected by Waldmeier and Sigel[122] that 
compared the initial reaction rate of several catalysts under standard conditions. 
These data are the result of direct experimental calculation or calculations from 
the determined rate laws.  
Although our experimental 
conditions are far from the 
standardized conditions 
presented in Table 10, the 
cleanest and fastest 
decomposition profiles 
observed (Fig 18 at 1:100 
ratio, Fig. 19 and Fig. 20 at 
both 1:50 and 1:100 ratios) 
provide information that 
allows the calculation of 
the magnitude of the initial 
rate of H2O2 
decomposition. These 
values are given in Table 
11. 
 
 
 
 
Table 10: Comparison of the initial rates v0 of 
hydrogen peroxide decomposition for several catalysts 
in standard conditions ([H2O2]=10-2M; [catalyst]=10-4 
M; pH8; aqueous solution; room temperature). 
Catalyst v0(M-1s-1) Reference 
Cu(bipy)2+ 6.8 x 10-4 [123] 
TETAFe(OH)2+ 3.9 x 10-4 [124] 
Mn(bipy)2+ 3.2 x 10-4 [125] 
L2(di-µ-oxo)Mn(III/IV) 2.4 x 10-4 [126] 
McRu(DMSO)2(H2O) 6.0 x 10-5 [121] 
MnIII(saltm)Br 3.4 x 10-5 [127] 
Mn2+ 2.0 x 10-4 [128] 
Fe(III)PTS 2 x 10-5 [122] 
TETA = triethylenetetramine 
L=[N,N’-bismethyl,bis(2-pyridylmethyl)-1,2-
ethanediamine] 
Mc is a macrocycle with pyrazole and tertiary amine 
atoms as donor sites[121,129] 
saltm = [N,N’ bis (salicylidene) propylenediamine] 
PTS = 4,4’,4’’,4’’’ - tetrasulfophtalocyanine 
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Table 11: Comparison between the initial rates v0 of hydrogen peroxide decomposition 
for RuCl2(DMSO)4, RuCl2(CO)(DMSO)3 and RuCl2(CO)2(DMSO)2. 
Compound Compound Concentration v0(M-1s-1) 
RuCl2(DMSO)4 1.98 µM 
3.96 µM 
4.9 x 10-8 
9.5 x 10-8 
RuCl2(CO)(DMSO)3 1.98 µM 
3.96 µM 
5.6 x 10-8 
4.8 x 10-8 
RuCl2(CO)2(DMSO)2 2.34 µM 
4.68 µM 
5.6 x 10-8 
5.4 x 10-8 
 
As could be observed from Figure 24 and corroborated from Table 11 
RuCl2(DMSO)4 is the fastest compound decomposing H2O2. However, its ability 
to decompose hydrogen peroxide is at least three orders of magnitude slower than 
other catalytic peroxide scavengers, or catalytic anti-oxidants given in table 10. 
Ruthenium complexes are known to be good oxidation catalysts. The RuIV oxides 
are able to oxidize H2O2 to O2 and these structures resemble the FeIV=O porphyrin 
group invoked as the active site in heme catalases.[130, 131] This disproportionation 
process may occur through two different pathways: the complexes may have a 
vacant or labile coordination site or it can occur through an outer-sphere reaction.  
Given the lability of the ligands for CORM-3 and RuCl2(CO)3(DMSO), in the 
present case an inner-sphere oxidation process is most probably taking place. Of 
course, the rate of hydrolysis is different depending on the ligands, leading to 
different oxide-formation time. The identity of the catalyst formed is unknown 
and probably different catalysts are formed with different complexes. 
It has already been shown that other Ru(II) complexes like [cis-
Ru(dmp)2(H2O)2]2+( where dmp is 2,9-dimethyl-1,10-phenantroline)[132] and 
(Mc)Ru(DMSO)2(H2O)2]2+ (where Mc is a bidentate coordinating macrocycle) 
[121] are oxidized by hydrogen peroxide to give [cis-RuIVO(dmp)2(H2O)2]2+ and 
(Mc)RuIVO(DMSO)2(H2O)]2+. (Mc)Ru(DMSO)2(H2O)2]2+ (which has the same 
chloride and DMSO ligands like Ru(CO)2(DMSO)2Cl2) is obtained from 
hydrolysis of (Mc)Ru(DMSO)2Cl2]2+ in water. Interestingly, the efficiency of 
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Ru(CO)2(DMSO)2Cl2 in degrading H2O2 is several orders of magnitude slower, 
most probably due to the different stability provided by the macrocyclic ligand in 
comparison to the oxidazible carbonyls (see table 9). 
 
Regardless of the reaction mechanisms involved, which can vary from compound 
to compound, a number of conclusions may be safely withdrawn from the above 
data. 
1.  In all the above compounds Ruthenium is responsible for the 
decomposition of H2O2; 
2. Carbonyl ligands seem to slow down this process, that is, seem to 
stabilize the Ru(II) complexes; 
3. The observed overall reaction rate of H2O2 decomposition by the 
compounds tested is not comparable to that of actual biologically active 
anti-oxidant catalysts (peroxide scavengers) let alone catalase; 
4. These results strongly disfavor the hypothesis that the biological effects 
of CORM-2 and CORM-3 result from their anti-oxidant (peroxide 
scavenging) properties due to the prolonged induction periods needed to 
trigger this kind of reactivity and to its relatively slow rate.  
 
 
5. Final Remarks and Conclusions 
 
CORM-2 is undoubtedly the CO releasing compound to which scientists working 
on the CO field have devoted more attention, since it is a commercially available 
CO source. However, the activity observed with CORM-2 arises from one of the 
several species obtained when the compound is dissolved in DMSO. The 
identification of this species was performed and several analogues of this 
compound were prepared in order to get more drug-like water-soluble molecules. 
A simple, efficient and clean methodology was developed to prepare these 
compounds from commercially available CORM-2 and the activity in several in 
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vitro and in vivo models is currently under evaluation. Some insights over the 
specific reactivity of these molecules revealed the capacity to decompose H2O2 
into O2. However, the low rates of these reactions seems to rule out the possibility 
that the anti-inflammatory activity of Ru(CO)3Cl2L complexes, including CORM-
2 and CORM-3, originates from their anti-oxidant activity. 
 
6. References  
 
1. Clarke, M.J., Coord. Chem. Rev. 2002, 232, 69. 
2. Sava, G., Pacor, S., Coluccia, M., Mariggio, M., Cocchietto, M., Alessio, E., 
Mestroni, G., Drug Investigation 1994, 8, 150. 
3. Sava, G., Pacor, S., Mestroni, G., Alessio, E., Clin. Exp. Metastasis 1992, 10, 
273. 
4. Sava, G., Pacor, S., Bergamo, A., Cocchietto, M., Mestroni, G., Alessio, E., 
Chem.-Biol. Interact. 1995, 95, 109. 
5. Capozzi, I., Clerici, K., Cocchietto, M., Salerno, G., Bergamo, A., Sava, G., 
Chem.-Biol. Interact. 1998, 113, 51. 
6. Sava, G., Pacor, S., Mestroni, G., Alessio, E., Anti-Cancer Drugs 1992, 3, 25. 
7. Bergamo, A., Cocchietto, M., Capozzi, I., Mestroni, G., Alessio, E., Sava, G., 
Anti-Cancer Drugs 1996, 7, 697. 
8. Sava, G., Gagliardi, R., Cocchietto, M., Clerici, K., Capozzi, I., Marrella, M., 
Alessio, E., Mestroni, G., Milanino, R., Pathol. Oncol. Res. 1998, 4, 30. 
9. Zorzet, S., Sorc, A., Casarsa, C., Cocchietto, M., Sava, G., Metal-based drugs 
2001, 8, 1. 
10. Geremia, S., Alessio, E., Todone, F., Inorg. Chim. Acta 1996, 253, 87. 
11. Bouma, M., Nuijen, B., Challa, E.E., Sava, G., Flaibani, A., Bult, A., Beijnen, 
J.H., J. Oncol. Pharm. Pract. 2004, 10, 7. 
12. Keppler, B.K., Rupp, W., Juhl, U.M., Endres, H., Niebl, R., Balzer, W., Inorg. 
Chem. 1987, 26, 4366. 
13. Pieper, T., Keppler, B.K., Analusis Magazine 1998, 26, M84. 
14. Kuehn, C.G., Taube, H., J. Am. Chem. Soc. 1976, 98, 689. 
15. Clarke, M.J., Dowling, M.G., Inorg. Chem. 1981, 20, 3506. 
16. Abelleira, A., Galang, R.D., Clarke, M.J., Inorg. Chem. 1990, 29, 633. 
17. Yan, Y.K., Melchart, M., Habtemariam, A., Sadler, P.J., Chem. Commun. 2005, 
4764. 
18. Peacock, A.F.A., Sadler, P.J., Chem.- Asian J. 2008, 3, 1890. 
19. Allardyce, C.S., Dyson, P.J., Ellis, D.J., Salter, P.A., Scopelliti, R., J. 
Organomet. Chem. 2003, 668, 35. 
20. Belshaw, P.J., Schreiber, S.L., J. Am. Chem. Soc. 1997, 119, 1805. 
21. Charuk, J.H.M., Pirraglia, C.A., Reithmeier, R.A.F., Anal. Biochem. 1990, 188, 
123. 
22. Reed, K.C., Bygrave, F.L., Biochem. J. 1974, 140, 143. 
23. Smaili, S.S., Russell, J.T., Cell Calcium 1999, 26, 121. 
24. Clarke, M.J., Bailey, V.M., Doan, P.E., Hiller, C.D., LaChanceGalang, K.J., 
Daghlian, H., Mandal, S., Bastos, C.M., Inorg. Chem. 1996, 35, 4896. 
Chemical and biological studies with Ruthenium-based CO-RMs 
 
 
242 
25. Ocain, T.D., Bastos, C.M., Gordon, K.A., Granstein, R.D., Jenson, J.C., Jones, 
B., McAuliffe, D.J., Newcomb, J.R., Transplant. Proc. 1996, 28, 3032. 
26. Bastos, C.M., Gordon, K.A., Ocain, T.D., Bioorg. Med. Chem. Lett. 1998, 8, 147. 
27. Johnson, T.R., Mann, B.E., Clark, J.E., Foresti, R., Green, C.J., Motterlini, R., 
Angew. Chem. Int. Ed. Engl. 2003, 42, 3722. 
28. Motterlini, R., Mann, B.E., Foresti, R., Expert Opin. Investig. Drugs 2005, 14, 
1305. 
29. Foresti, R., Hammad, J., Clark, J.E., Johnson, T.R., Mann, B.E., Friebe, A., 
Green, C.J., Motterlini, R., Br. J. Pharmacol. 2004, 142, 453. 
30. Clark, J.E., Naughton, P., Shurey, S., Green, C.J., Johnson, T.R., Mann, B.E., 
Foresti, R., Motterlini, R., Circ. Res. 2003, 93, e2. 
31. Varadi, J., Lekli, I., Juhasz, B., Bacskay, I., Szabo, G., Gesztelyi, R., Szendrei, 
L., Varga, E., Bak, I., Foresti, R., Motterlini, R., Tosaki, A., Life Sci 2007, 80, 
1619. 
32. Guo, Y., Stein, A.B., Wu, W.J., Tan, W., Zhu, X., Li, Q.H., Dawn, B., 
Motterlini, R., Bolli, R., Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H1649. 
33. Vera, T., Henegar, J.R., Drummond, H.A., Rimoldi, J.M., Stec, D.E., J. Am. Soc. 
Nephrol. 2005, 16, 950. 
34. Tayem, Y., Johnson, T.R., Mann, B.E., Green, C.J., Motterlini, R., Am. J. 
Physiol. Renal Physiol. 2006, 290, F789. 
35. Sandouka, A., Fuller, B.J., Mann, B.E., Green, C.J., Foresti, R., Motterlini, R., 
Kidney international 2006, 69, 239. 
36. Sawle, P., Foresti, R., Mann, B.E., Johnson, T.R., Green, C.J., Motterlini, R., Br. 
J. Pharmacol. 2005, 145, 800. 
37. Bani-Hani, M.G., Greenstein, D., Mann, B.E., Green, C.J., Motterlini, R., J. 
Pharmacol. Exp. Ther. 2006, 318, 1315. 
38. Bani-Hani, M.G., Greenstein, D., Mann, B.E., Green, C.J., Motterlini, R., 
Pharmacol. Rep. 2006, 58 Suppl, 132. 
39. Urquhart, P., Rosignoli, G., Cooper, D., Motterlini, R., Perretti, M., J. 
Pharmacol. Exp. Ther. 2007, 321, 656. 
40. Vannacci, A., Giannini, L., Fabrizi, F., Uliva, C., Mastroianni, R., Masini, E., 
Motterlini, R., Mannaioni, P.F., Inflamm. Res. 2007, 56 Suppl 1, S13. 
41. Bagul, A., Hosgood, S.A., Kaushik, M., Nicholson, M.L., Transplantation 2008, 
85, 576. 
42. Davidge, K.S., Sanguinetti, G., Yee, C.H., Cox, A.G., McLeod, C.W., Monk, 
C.E., Mann, B.E., Motterlini, R., Poole, R.K., J. Biol. Chem. 2009, 284, 4516. 
43. Desmard, M., Davidge, K.S., Bouvet, O., Morin, D., Roux, D., Foresti, R., 
Ricard, J.D., Denamur, E., Poole, R.K., Montravers, P., Motterlini, R., 
Boczkowski, J., FASEB J. 2008. 
44. Boissiere, J., Lemaire, M.C., Antier, D., Courteix, D., Bonnet, P., Med. Sci. 
Sports Exerc. 2006, 38, 652. 
45. Stanford, S.J., Walters, M.J., Mitchell, J.A., Eur. J. Pharmacol. 2004, 486, 349. 
46. Motterlini, R., Clark, J.E., Foresti, R., Sarathchandra, P., Mann, B.E., Green, 
C.J., Circ. Res. 2002, 90, E17. 
47. Botros, F.T., Navar, L.G., Am. J. Physiol. Heart Circ. Physiol. 2006, 291, 
H2772. 
48. Rattan, S., Al Haj, R., De Godoy, M.A., Am J Physiol Gastrointest Liver Physiol 
2004, 287, G605. 
49. Matsuda, N.M., Miller, S.M., Sha, L., Farrugia, G., Szurszewski, J.H., 
Neurogastroenterol. Motil. 2004, 16, 605. 
Chapter V 
 
 
243 
50. Allanson, M., Reeve, V.E., J. Invest. Dermatol. 2005, 124, 644. 
51. Uc, A., Husted, R.F., Giriyappa, R.L., Britigan, B.E., Stokes, J.B., Am J Physiol 
Gastrointest Liver Physiol 2005, 289, G202. 
52. Orozco-Ibarra, M., Estrada-Sanchez, A.M., Massieu, L., Pedraza-Chaverri, J., 
Int. J. Biochem. Cell Biol. 2009, 41, 1304. 
53. Zhou, J.L., Li, G., Hai, Y., Guan, L., Huang, X.L., Sun, P., Chin. J. Traumatol. 
2009, 12, 71. 
54. Sun, B.W., Sun, Y., Sun, Z.W., Chen, X., World J. Gastroenterol. 2008, 14, 547. 
55. Sun, B., Sun, H., Liu, C., Shen, J., Chen, Z., Chen, X., J. Surg. Res. 2007, 139, 
128. 
56. Nobre, L.S., Seixas, J.D., Romao, C.C., Saraiva, L.M., Antimicrob. Agents 
Chemother. 2007, 51, 4303. 
57. Davidge, K.S., Sanguinetti, G., Yee, C.H., Cox, A.G., McLeod, C.W., Monk, 
C.E., Mann, B.E., Motterlini, R., Poole, R.K., J. Biol. Chem. 2008. 
58. Alessio, E., Milani, B., Bolle, M., Mestroni, G., Faleschini, P., Todone, F., 
Geremia, S., Calligaris, M., Inorg. Chem. 1995, 34, 4722. 
59. Moreno, M.A., Haukka, M., Kallinen, M., Pakkanen, T.A., Appl. Organomet. 
Chem. 2006, 20, 51. 
60. Collman, J.P., Roper, W.R., J. Am. Chem. Soc. 1965, 87, 4008. 
61. Johnson, B.F.G., Johnston, R.D., Josty, P.L., Lewis, J., Williams, I.G., Nature 
1967, 213, 901. 
62. Bruce, M.I., Stone, F.G.A., J. Chem. Soc. A 1967, 1238. 
63. Braca, G., Sbrana, G., Pino, P., Benedetti, E., Chimica & L Industria 1967, 49, 
1381. 
64. Cotton, J.D., Bruce, M.I., Stone, F.G.A., J. Chem. Soc. A 1968, 2162. 
65. Johnson, B.F.G., Johnston, R.D., Lewis, J., J. Chem. Soc. A 1969, 792. 
66. Trovati, A., Araneo, A., Uguagliati, P., Zingales, F., Inorg. Chem. 1970, 9, 671. 
67. Araneo, A., Trovati, A., Inorg. Chim. Acta 1969, 3, 471. 
68. Benedetti, E., Braca, G., Sbrana, G., Salvetti, F., Grassi, B., J. Organomet. 
Chem. 1972, 37, 361. 
69. Hieber, W., Heusinger, H., J. Inorg. Nucl. Chem. 1957, 4, 179. 
70. Kingston, J.V., Jamieson, J.W., Wilkinso.G, J. Inorg. Nucl. Chem. 1967, 29, 133. 
71. Irving, R.J., J. Chem. Soc. 1956, 2879. 
72. Alessio, E., Bolle, M., Milani, B., Mestroni, G., Faleschini, P., Geremia, S., 
Calligaris, M., Inorg. Chem. 1995, 34, 4716. 
73. Calligaris, M., Panina, N.S., J. Mol. Struct. 2003, 646, 61. 
74. Alessio, E., Iengo, E., Geremia, S., Calligaris, M., Inorg. Chim. Acta 2003, 344, 
183. 
75. Evans, I.P., Spencer, A., Wilkinso.G, J. Chem. Soc.-Dalton Trans. 1973, 204. 
76. Alessio, E., Mestroni, G., Nardin, G., Attia, W.M., Calligaris, M., Sava, G., 
Zorzet, S., Inorg. Chem. 1988, 27, 4099. 
77. Cenini, S., Pizzotti, M., Porta, F., Lamonica, G., J. Organomet. Chem. 1977, 125, 
95. 
78. Kingston, J.V., Mahmoud, F.T., Scollary, G.R., J. Inorg. Nucl. Chem. 1972, 34, 
3197. 
79. Haukka, M., Hirva, P., Luukkanen, S., Kallinen, M., Ahlgren, M., Pakkanen, 
T.A., Inorg. Chem. 1999, 38, 3182. 
80. Calligaris, M., Carugo, O., Coord. Chem. Rev. 1996, 153, 83. 
81. Laine, R.M., Rinker, R.G., Ford, P.C., J. Am. Chem. Soc. 1977, 99, 252. 
82. Darensbourg, D.J., Rokicki, A., Organometallics 1982, 1, 1685. 
Chemical and biological studies with Ruthenium-based CO-RMs 
 
 
244 
83. Pearson, R.G., Mauermann, H., J. Am. Chem. Soc. 1982, 104, 500. 
84. Yoshida, T., Okano, T., Ueda, Y., Otsuka, S., J. Am. Chem. Soc. 1981, 103, 
3411. 
85. Baker, E.C., Hendriksen, D.E., Eisenberg, R., J. Am. Chem. Soc. 1980, 102, 
1020. 
86. Sato, S., White, J.M., J. Am. Chem. Soc. 1980, 102, 7206. 
87. Ford, P.C., Acc. Chem. Res. 1981, 14, 31. 
88. Inkrott, K.E., Shore, S.G., J. Am. Chem. Soc. 1978, 100, 3954. 
89. Inkrott, K.E., Shore, S.G., Inorg. Chem. 1979, 18, 2817. 
90. Ford, P.C., Rinker, R.G., Ungermann, C., Laine, R.M., Landis, V., Moya, S.A., 
J. Am. Chem. Soc. 1978, 100, 4595. 
91. Laine, R.M., J. Am. Chem. Soc. 1978, 100, 6451. 
92. Nagel, C.C., Bricker, J.C., Alway, D.G., Shore, S.G., J. Organomet. Chem. 1981, 
219, C9. 
93. Bricker, J.C., Nagel, C.C., Bhattacharyya, A.A., Shore, S.G., J. Am. Chem. Soc. 
1985, 107, 377. 
94. Darensbourg, D.J., Froelich, J.A., J. Am. Chem. Soc. 1977, 99, 5940. 
95. Lane, K.R., Lee, R.E., Sallans, L., Squires, R.R., J. Am. Chem. Soc. 1984, 106, 
5767. 
96. Lane, K.R., Sallans, L., Squires, R.R., Inorg. Chem. 1984, 23, 1999. 
97. Trautman, R.J., Gross, D.C., Ford, P.C., J. Am. Chem. Soc. 1985, 107, 2355. 
98. Ishida, H., Tanaka, K., Morimoto, M., Tanaka, T., Organometallics 1986, 5, 724. 
99. Haukka, M., Venalainen, T., Kallinen, M., Pakkanen, T.A., J. Mol. Catal. A: 
Chem. 1998, 136, 127. 
100. Luukkanen, S., Homanen, P., Haukka, M., Pakkanen, T.A., Deronzier, A., 
Chardon-Noblat, S., Zsoldos, D., Ziessel, R., Appl. Catal., A 1999, 185, 157. 
101. Aguirre, P., Lopez, R., Villagra, D., Azocar-Guzman, I., Pardey, A.J., Moya, 
S.A., Appl. Organomet. Chem. 2003, 17, 36. 
102. Frediani, P., Faggi, C., Salvini, A., Bianchi, M., Piacenti, F., Inorg. Chim. Acta 
1998, 272, 141. 
103. Fachinetti, G., Funaioli, T., Lecci, L., Marchetti, F., Inorg. Chem. 1996, 35, 
7217. 
104. Ford, P.C., Yarrow, P., Cohen, H., Musto, J., Rinker, R.G., Abstr. Pap. Am. 
Chem. Soc. 1980, 180, 93. 
105. Funaioli, T., Cavazza, C., Marchetti, F., Fachinetti, G., Inorg. Chem. 1999, 38, 
3361. 
106. Johnson, T.R., Mann, B.E., Teasdale, I.P., Adams, H., Foresti, R., Green, C.J., 
Motterlini, R., Dalton Trans. 2007, 1500. 
107. Freeman, B.A., Crapo, J.D., Lab. Invest. 1982, 47, 412. 
108. McCord, J.M., Fridovich, I., Ann. Intern. Med. 1978, 89, 122. 
109. Maxwell, S.R., Lip, G.Y., Br. J. Clin. Pharmacol. 1997, 44, 307. 
110. Kinnula, V.L., Chang, L.Y., Ho, Y.S., Crapo, J.D., Exp. Lung Res. 1992, 18, 655. 
111. Halliwell, B., J. Neurochem. 1992, 59, 1609. 
112. Fisher, A.E.O., Maxwell, S.C., Naughton, D.P., Inorg. Chem. Commun. 2003, 6, 
1205. 
113. Golden, T.R., Patel, M., Antioxid. Redox Signal. 2009, 11, 555. 
114. Day, B.J., Drug Discov Today 2004, 9, 557. 
115. Chang, L.Y., Subramaniam, M., Yoder, B.A., Day, B.J., Ellison, M.C., Sunday, 
M.E., Crapo, J.D., Am. J. Respir. Crit. Care Med. 2003, 167, 57. 
116. Di Napoli, M., Papa, F., IDrugs 2005, 8, 67. 
Chapter V 
 
 
245 
117. Ryter, S.W., Otterbein, L.E., BioEssays 2004, 26, 270. 
118. Autzen, S., Korth, H.G., de Groot, H., Sustmann, R., Eur. J. Org. Chem. 2001, 
3119. 
119. Sustmann, R., Korth, H.G., Kobus, D., Baute, J., Seiffert, K.H., Verheggen, E., 
Bill, E., Kirsch, M., de Groot, H., Inorg. Chem. 2007, 46, 11416. 
120. Kurz, P., Berggren, G., Anderlund, M.F., Styring, S., Dalton Trans. 2007, 4258. 
121. Choua, S., Pacheco, P., Coquelet, C., Bienvenue, E., J. Inorg. Biochem. 1997, 65, 
79. 
122. Waldmeier, P., Sigel, H., Inorg. Chem. 1972, 11, 2174. 
123. Sigel, H., Flierl, C., Griesser, R., J. Am. Chem. Soc. 1969, 91, 1061. 
124. Wang, J.H., J. Am. Chem. Soc. 1955, 77, 4715. 
125. Tiginyanu, Y.D., Sychev, A.Y., Berdnikov, V.M., Russ. J. Phys. Chem. 1971, 45, 
975. 
126. Delroisse, M., Rabion, A., Chardac, F., Tetard, D., Verlhac, J.B., Fraisse, L., 
Seris, J.L., J. Chem. Soc.-Chem. Commun. 1995, 949. 
127. Salem, I.A., Polyhedron 1994, 13, 1547. 
128. Stadtman, E.R., Berlett, B.S., Chock, P.B., Proc. Natl. Acad. Sci. U. S. A. 1990, 
87, 384. 
129. Bienvenue, E., Choua, S., Loborecio, M.A., Marzin, C., Pacheco, P., Seta, P., 
Tarrago, G., J. Inorg. Biochem. 1995, 57, 157. 
130. Gilbert, J., Roecker, L., Meyer, T.J., Inorg. Chem. 1987, 26, 1126. 
131. Gilbert, J.A., Gersten, S.W., Meyer, T.J., J. Am. Chem. Soc. 1982, 104, 6872. 
132. Goldstein, A.S., Beer, R.H., Drago, R.S., J. Am. Chem. Soc. 1994, 116, 2424. 
 
 
7. Acknowledgments 
 
Ana Rita Marques is acknowledged for performing the Horseradish Peroxidase 
assays and helpful contribution for rationalizing the data obtained. 
Ana Margarida Gonçalves is acknowledged for measurements of CO2 release 
through GC.  
Gonçalo Bernardes is acknowledged for the preparation of complexes 
Ru(CO)3Cl2(DAPTA) and Ru(CO)3Cl2(NAC). 
 
 
 
Chapter VI 
 
 
247 
Chapter VI: Interaction of Metal Carbonyl 
Complexes with serum proteins 
 
1. Summary 
 
The interaction between several types of MCCs and both Bovine Serum Albumin 
(BSA) and human Apo-Transferrin (h-Tf) was investigated with Circular 
Dichroism and UV/Vis absorbance spectrophotometry techniques.  
Mo0 complexes [Et4N][Mo(CO)5Br] and Na3[Mo(CO)3(cit)] showed a high 
degree of association with BSA, while the MoII and RuII complexes 
CpMo(CO)3CH2CONH2 and Ru(CO)3Cl(glycinate) showed minor or no 
interaction with the carrier protein. 
With h-Tf only Ru(CO)3Cl(glycinate) showed some binding activity after 24h 
incubation. 
 
2. Introduction 
 
The interaction of MCCs with myoglobin, a simple and yet very important 
hemeprotein, was studied in Chapter IV. In these studies it was shown that many 
MCCs are able to transfer CO to the heme of reduced deoxy-myoglobin, therefore 
carbonylating it.  This kind of transfer of CO from the MCC or CO-RM to a 
hemeprotein, namely NADPH,[1] cytochrome c oxidase and mithocondrial 
complexes[2-4] has been considered as the decisive event in the mechanism of 
therapeutic CO delivery from CO-RMs to biological targets.   
However, CO also activates/inhibits several signaling pathways that are not 
directly related to heme binding. CO appears to modulate mitogen activated 
protein kinases (MAPK)-related pathways through down-regulation of ERK1-2[5] 
and suppression of inflammatory cytokine production by CO appears to involve 
the JNK pathway.[6] These proteins do not have a metal center so the CO 
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signaling process is necessarily different. It had already been suggested that it 
may arise from different interactions like non-covalent bonding to sites within 
protein.[7]  
In any case, the use of CO-RMs as CO delivering devices raises new questions in 
regard to how CO is carried and reaches the targets. Although CO-RMs are in fact 
pro-drugs which transport and liberate the active principle CO, they must interact 
with biological entities on their way to the targets just like any other drug. In this 
respect, interaction of drug molecules with serum proteins plays an important role 
in the distribution of the drug in the body and affects properties like toxicity and 
biological activity.  
The results presented in Chapter IV regarding the release of CO from several 
MCCs to whole blood clearly suggest that plasma proteins have a decisive effect 
on the rate of release of CO from a CO-RM to the circulating blood. 
Albumin is the most abundant protein in blood plasma (60% of the total plasma 
protein) and functions as a transporter both to endogenous and exogenous 
compounds. Binding to Human Serum Albumin (HSA) is one of the most 
determinant aspects of the pharmacokinetics of drugs.[8-11] Especially for highly 
albumin bound drugs (e.g. NSAIDs) the equilibrium between bound and free drug 
is many times determinant for changes in drug effects[12-14] since it reduces free 
drug in solution for penetration into tissue to reach the therapeutic target or to the 
liver and kidneys for elimination. In addition, binding affinities allow a better 
understanding of the pharmacological profile of the drug and may also help 
determining a better dosage regimen.[15, 16]  
Another serum protein, human Transferrin (Tf), is mainly an iron transport 
protein but with a very important role in delivering drugs to the cells. Apart from 
the natural iron binding properties Tf also exhibited binding affinities for several 
metals with different biological effects. Tf has an important role in transport and 
delivery of 67Ga3+[17-20] and 111In3+[21, 22] for diagnostics, it binds vanadium[23] and 
other trivalent ions such as Al3+[24, 25] and Bi3+[26, 27] interfering with iron uptake, 
and delivers Ru3+[28, 29] and Ti4+[30] to cells through specific Tf receptors. Tf 
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receptors are a major target for site-specific metallodrug delivery and also allow 
cellular uptake via the receptors mediated endocytosis.  
The association between drugs and these proteins has been extensively studied 
and typically the interaction of drug molecules with plasma proteins is 
electrostatic and hydrophobic, the binding is usually rapid and reversible with an 
average equilibrium time of 20 ms.  Not only the binding capacity is an important 
factor, but also the on/off rate of binding can act as a major determining step. 
However, since CO-RMs are organometallic compounds their interaction with 
serum proteins is expected to be quite different from that of other drugs. Indeed, 
the tridimensional bulk of MCCs is rather different from the relatively “flat” 
shape of most drug molecules, and the intermolecular interactions between 
hydrophobic CO ligands and the mostly polar surface of proteins in aqueous 
solution has not been studied in any detail.   The possibility of reactions occuring 
between proteins and MCCs has only been barely tested in cases where MCCs 
were deliberately designed to enhance such reactivity in order to enable their use 
as protein markers. [31, 32] 
In this chapter the interaction between several types of MCCs and both BSA and 
h-Tf was investigated with Circular Dichroism and UV/VIS absorbance 
spectrophotometry techniques. A short number of compounds was studied but the 
complexes selected present specific properties common to a wide variety of other 
complexes which allows them to be classified as prototypes of a determined 
family of possible CO-RMs with biological activity. Their structures are 
represented in Scheme 1. 
Circular Dichroism[33] (CD) has long been used to provide information on protein 
structure, and also as a simple way to probe the interaction between metal ions 
and proteins, the formation of adducts and analysis of the protein secondary and 
tertiary structure and how it is affected upon drug binding.  
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Scheme 1: Structure of the complexes [Et4N][Mo(CO)5Br] (1), CpMo(CO)3CH2CONH2 
(2), Ru(CO)3Cl(glycinate) (3) and Na3[Mo(CO)3(cit)] (4). 
 
3. Experimental Section 
 
3.1 Methodological remarks on the Circular Dichroism and UV-
Vis studies with Bovine Serum Albumin and human Apo-
Transferrin 
 
The CD studies were performed in the laboratory of Prof. João Costa Pessoa in 
Instituto Superior Técnico, Lisboa, with the help and guidance of Dr. Isabel 
Tomaz and Dr. Isabel Correia. 
In the CD study, the compounds were incubated with the proteins at different 
complex:protein ratios and the CD spectra were typically recorded in the 205-230 
nm  and 250-800 nm spectral range with BSA and from 195-260 nm and 250-800 
nm spectral range with h-Tf. 
The characteristic CD α-helix signal obtained in the far UV region arises from the 
chiral amide chromofore transitions which have a negative (n⇒π*) band at 222 
nm, parallel negative (π⇒π*) at 206 nm and perpendicular positive (π⇒π*) at 
190 nm.[34] The near UV region (250-350 nm) of CD spectra may give 
information on tertiary structure and in the visible region the induced CD signal 
obtained arises from the metal complex d electrons.  
The characteristic CD signals are coming from tryptophan (290 nm), tyrosine 
(284 nm) and phenylalanine residues (254 nm) as well as broad band disulfide 
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bonds (near-UV). The protein is CD-silent in the visible region and any induced 
signal arises from the metal complex d electrons.  
The optimal concentrations of BSA are: 30–50 µM for the near UV and visible 
range with the spectra recorded with a 1 cm pathlength cell; 3 µM for the far UV 
region, using a 1 mm pathlength cell. The spectra were acquired immediately 
after incubation with BSA. Incubation of 2 with BSA in the near UV-VIS region 
was performed with a 2 cm pathlength cell. 
The optimal concentration of h-Tf is 30 µM in the near UV and visible range, 
recorded with a 1 cm pathlength cell, and 5 µM in the far UV region, using a 1 
mm pathlength cell. The spectra were acquired immediately after incubation with 
h-Tf and also after 24h. 
The CD spectrum of all the complexes was recorded at the maximum 
concentration used and no CD signal was obtained with the complex alone.  
The CD signal (in mdeg) was converted to mean residual ellipticity ([θ] in 
deg.cm2.dmol−1) defined as  
   
10.c.l.n
!obs
! =
               Equation 1 
        
where θobs (mdeg) is the experimental ellipticity, c (mol.dm−3) is the protein 
concentration, l (cm) is the cell pathlength, and n is the number of residues in the 
protein - 583 aminoacids for BSA[35] and 678 for h-Tf.[36] 
Isotropic UV-VIS absorbance spectra of the complexes and of the complexes with 
protein were recorded in PBS7.4 at room temperature in the dark, under normal 
air. The spectra were collected over 4h, in 10 min intervals, from 250 nm to 800 
nm in Quartz cells.  
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Circular Dichroism: 
Method description: 
The experiments were performed in a spectropolarimeter Jasco J-720, either with 
a red-sensitive photomultiplier (EXEL-308) suitable for the 400-1000 nm range 
or a photomultiplier suitable for the 200-700 nm range. The parameters used were 
the following: 
Band width: 2.0 nm; response: 4 sec; measurement range:  450-250 nm (near UV) 
- cells with l = 1 cm and 260-190 nm (far UV) - cells with l = 1 mm ; data pitch: 
0.2 nm; scan speed: 20 nm/min; accumulation: 1; temperature: RT (23-25ºC). 
The compounds were dissolved in PBS7.4 and added to a previously prepared 
BSA or h-Tf solution in PBS7.4. [Et4N][Mo(CO)5Br] was dissolved in MeOH due 
to its insolubility in PBS giving a final concentration of 5% MeOH in the cuvette. 
Material: 
Bovine Serum Albumin – fraction V – and Human Apo-Transferrin were acquired 
from Roche; Circular dichroism 1 mm, 1cm and 2 cm pathlength quartz cuvettes; 
PBS7.4 was prepared by dissolving PBS tablets from Gibco in 500 mL of distilled 
water giving a final concentration of 0.14 M NaCl, 0.01 M PO42- buffer and 0.003 
M KCl. 
 
UV/Vis absorbance spectrophotometry: 
Method description: 
The experiments were performed in Perkin Elmer Lambda35 spectrophotometer 
as follows:  
A stock solution of the complex was prepared in PBS7.4 or MeOH in the case of 
[Et4N][Mo(CO)5Br]. A calculated amount from this solution was added to the 
cuvette in order to obtain the desired final concentration and PBS7.4 added to 
perform 1 ml total volume. In the case of [Et4N][Mo(CO)5Br] a 4% final 
concentration of MeOH was obtained. The absorbance spectrum was recorded 
from 250 nm to 800 nm with 10 min interval.  
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A similar experiment was performed but in addition to the complex, a calculated 
amount of protein was added in PBS7.4. This was taken from a previously 
prepared stock solution in order to give a final concentration of typically 30 µM 
h-Tf and 50 µM BSA in the cuvette. The absorbance spectrum was recorded from 
250 nm to 800 nm with 10 min interval.  
Material: 
Bovine Serum Albumin – fraction V – and Human Apo-Transferrin were acquired 
from Roche; Quartz SUPRASIL® cuvettes with 10 mm pathlength from Hellma; 
PBS7.4 was prepared by dissolving PBS tablets from Gibco in 500mL of distilled 
water giving a final concentration of 0.14 M NaCl, 0.01 M PO42- buffer and 0.003 
M KCl. 
3.2 Technical Details 
 
Synthetic Work: 
All the compounds were prepared as described in Chapter II or table A1 in Annex 
I.  
 
4. Results and Discussion 
 
4.1 Interactions with Bovine Serum Albumin  
 
Human serum albumin (HSA) is a largely α-helical single-chain 66 kDa protein, 
consisting of three structurally homologous domains that assemble to form a 
heart-shaped molecule. Each domain has two sub-domains, which are 
predominantly helical (67% of the protein is helical with a total of 28 helices) and 
extensively cross-linked by several disulfide bridges.[37] From a total of 585 
aminoacids its sequence contains a total of 17 disulphide bridges, one free thiol 
(Cys 34) and a single tryptophan (Trp 214). This configuration was shown to 
possess at least 6 primary binding sites of high specificity. HSA primarily binds 
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strongly to organic anions (e.g. carboxilates, phenolates) but it can also bind basic 
and neutral drugs.  
The hydrophobic cavities of the protein exhibit similar chemistry and are the main 
regions of ligand binding sites. The binding sites are located in sub-domains IIA 
and IIIA and have been determined crystallographically for several ligands. There 
is a large number of secondary binding sites with low affinity that allows binding 
of a high number of ligands, mainly by hydrophobic interactions. Imipramine, 
that binds up to 30 molecules per albumin unit is one such ligand. 
The IIIA sub-domain is the preferential receptor for several molecules such as 
digitoxin, ibuprofen and tryptophan. On the other hand, warfarin prefers binding 
to the IIA[38] sub-domain while aspirin shows nearly equal distributions between 
binding sites located in IIA and IIIA sub-domains. The high-affinity site for 
bilirubin has been isolated in domain II[39] and the main binding site for long- 
chain fatty acids has been shown to occupy the domain III.[40] The likely location 
of the multi-metal site in human albumins is thus the area of contact of domains I 
and II.[41, 42] Ligand binding to one domain induces distinct conformational 
changes in the other domain, as both sub-domains share a common interface. 
Thus, the binding of a particular drug molecule to serum albumin may change 
considerably the binding abilities of HSA towards other molecules. BSA is quite 
often used as an in vitro mimic of HSA due to the similarities of properties 
between both proteins. In the present study, BSA was used as a model of HSA 
since their drug-binding capacities are very similar. 
 
 
 
 
 
 
 
 
 
 
Figure 1: BSA structure 
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4.1.1 Study of the interaction of [Et4N][Mo(CO)5Br] (1) and BSA 
 
Circular Dichroism  
 
BSA (30 µM) and 1 were incubated in 1:1, 1:2, 1:15 and 1:20 protein:complex 
ratio and the CD spectra recorded from 300 to 600 nm (see Fig. 2 left). 
Assays at 50 µM protein concentration were performed with 1:5 and 1:10 ratio 
between 300 and 500 nm. These showed the same bands observed at 1:2 ratio but 
not the broad negative band at 480 nm (see Fig. 2 right). 
 
 
 
 
 
 
 
Figure 2: Left: CD spectra of BSA (30µM) incubated with 1 at RT, in PBS7.4 at 1:1, 1:2, 
1:15 and 1:20 protein:complex ratio. The spectra were recorded from 300 to 600 nm. 
Right: CD spectra of BSA (50 µM) incubated with 1 at RT, in PBS7.4 at 1:5 and 1:10 
protein:complex ratio. The spectra were recorded from 300 to 500 nm. Insert – Time 
stability of 1:10 sample at t=0, t=1h and t=4h. 
 
 
Different ratios gave very distinct spectra. At low BSA/compound ratio (1:1 and 
1:2) a low intensity positive band is observed at 408 nm and a negative band is 
observed at 374 nm. These bands increase in intensity and at a 1:15 ratio are very 
intense.  
The fact that a CD signal is observed in this region shows undoubtedly the 
binding of a metallic fragment (or the whole complex) to a chiral environment of 
the protein since neither the protein nor the metal complex alone have a CD signal 
in this wavelength range. The CD spectra obtained correspond to an induced CD 
signal at the same wavelength where the compound absorbs (Fig.5A). A slight 
deviation from protein’s baseline CD signal is observed at 480 nm when the ratio 
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increases to 1:20.  
The interactions observed are stable up to 4h (see insert Fig. 2), however, this 
only occurs if both species are incubated at the same time. If the compound is left 
in solution alone for 2h and then incubated with BSA no induced CD signal is 
observed. As shown in Fig. 5A, the compound rapidly decomposes in PBS7.4 and 
the product of decomposition no longer binds to BSA. 
The highest ratios used allowed the identification of new bands, not observed on 
the remaining spectra. This signal arises from some changes in the protein 
structure that allowed the interaction of the protein with the metal, most probably 
from some metal-to-ligand charge-transfer, MLCT. In order to get a CD signal at 
a certain wavelength the sample must be active and absorb light at that 
wavelength. Therefore, CD spectra are observed at the same wavelengths as the 
absorption spectra of the sample. In some cases, when high complex:protein 
ratios are used very high absorbance values are obtained and the CD signal 
becomes saturated. 1 has a strong absorbance band centered at 401 nm and 
another shoulder in the 288 nm region (Fig. 5A) and therefore to study the 250-
350 nm region with a protein concentration of 30 µM, only 1:1 and 1:2 samples 
could be used due to the aforementioned absorbance limitation. 
The spectra only show a minor influence on a positive band centered at 258 nm, 
arising from the phenylalanine residues showing that the tertiary structure of the 
protein isn’t strongly affected (see Fig. 3).  
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In Fig. 4 is possible to observe that the variation of the mean residual ellipticity 
([θ]) with different ratios of 1, followed at λmax(+) (407 nm) and λmax(-) (374 nm)  
shows an increase of [θ] up to 10 molar excess of 1 over BSA. This shows the 
high binding capacity of this transport protein and supports the strong affinity 
between the protein and the compound with a high degree of association.  
 
UV-VIS absorbance 
 
The UV-VIS absorption spectrum of 1 was recorded with and without BSA. The 
spectrum of the complex alone was followed over time and the same procedure 
was followed with a BSA:complex sample with 1:20 ratio. This ratio was the 
highest used in the CD study (Fig. 2) and gave a strong induced CD signal. The 
spectrum of BSA alone shows a very well defined absorption peak at 278 nm. 
1 has 2 major absorption bands, one centered at 401 nm and another broad 
shoulder at 288 nm and both rapidly decay over time (Fig.5 A and C).  
 
 
 
 
 
 
Figure 4: Variation of the mean residual 
ellipticity ([θ]) with the molar excess of 
1, followed at λmax(+) (407 nm) and λmax(-) 
(374 nm). 
 
 
 
Figure 3: CD spectra of BSA (30µM) 
incubated with 1 at RT, in PBS7.4 at 1:1 and 
1:2 protein:complex ratio. The spectra were 
recorded from 250 to 350 nm. 
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Figure 5: Time evolution of UV-VIS absorption spectrum of 1 (600 µM) in PBS7.4 
(4%MeOH) at RT. A – 1 alone; B – 1 and BSA  (30 µM; BSA spectrum subtracted); C – 
Decay in absorbance measured at 401 nm with 1 alone; D – Decay in absorbance 
measured at 387 nm with 1 and BSA (30 µM). 
 
It had been already demonstrated in Chapter II through CO release experiments 
that the parent compound is unstable in solution and this behavior is supported by 
this absorption profile. Within 2h virtually no absorption is observed at 401 nm 
and the band at 286 nm has very low intensity (Fig.5 C).  
When incubated with BSA, a major band is observed at 395 nm and another at 
294 nm. The highest wavelength band slightly shifts within the first 10 min to 387 
nm without a rapid decay in intensity. The band at 294 nm shifts to 292 nm after 
10 min and 291 nm after 20 min. Notably, the 2 bands are quite stable over 4h 
(Fig.5 D)  
These results strongly support the data obtained from the CD study, showing a 
clear and strong interaction between 1 and BSA, which completely alters the 
decomposition profile of the compound in solution. The decrease in the 
absorbance is much less pronounced suggesting that BSA partially prevents the 
decomposition of the complex. 
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4.1.2 Study of the interaction of CpMo(CO)3CH2CONH2 (2) and BSA  
 
Circular Dichroism 
 
Interaction between 2 and BSA was studied in the far-UV and near UV-VIS 
region using 1:1 and 1:10 protein:complex ratios. 
An exploratory fast scan was recorded from 250 to 800 nm with a 1:10 (50 µM 
BSA:2) sample and no signal was obtained so it was decided to decrease the 
scanning range. 
2 and BSA (50 µM) were incubated in 1:1 and 1:10 protein:complex ratio and the 
spectrum recorded from 250 to 450 nm with a 2 cm pathlength cell (Fig. 6 left). In 
the far-UV region the compound was incubated with BSA (3 µM) at 1:1, 1:3, 1:5, 
1:10 and 1:25 protein:complex ratio and the spectra recorded from 190 to 250 nm 
(see Fig. 6 right).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Left: CD spectra BSA (50 µM) incubated with 2 at RT, in PBS7.4 at 1:1 and 
1:10 protein:complex ratio. The spectra were recorded from 250 to 450 nm. Right: CD 
spectra of BSA (3 µM) incubated with 2 at RT, in PBS7.4  at 1:1, 1:3, 1:5, 1:10 and 1:25 
protein:complex ratio. The spectra were recorded from 190 to 250 nm. 
 
Incubation of 2 with BSA did not produce any effects on the CD signal of protein 
either at low (1:1) or high (1:10) ratios in the near UV and visible range. No 
binding activity is detected since the spectrum didn’t change. In the far UV region 
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a consistent signal is observed that changes with concentration. These small 
changes are due to some interference of the compound in the protein secondary 
structure. Possibly, the amide group of the complex is able to interact through 
hydrogen bonding with some protein sites and these oscillations may be reflected 
in the helical arrangement of the protein. Also the Cp ring may account for some 
spatial disorder that is reflected in the CD signal changes in the far UV range.  
To determine the degree of influence in the helical arrangement of the protein, the 
α-helical content was estimated from the mean residue ellipticity at 222 nm[43] 
taking into account a helix length-dependent factor according to equation 2 where 
n represents the number of residues in the protein.[34] 
 
% !- helix  =
(")222nm
-39500 x (1 - 2.57/ n)
x 100
   Equation 2 
 
From Figure 7 one can see that the % 
of α-helical content does not change 
upon incubation with up to 25-fold 
excess of 2. These observations 
show that contrary to what was 
observed with 1, this complex 
doesn’t covalently bind BSA. Only 
minor electrostatic interactions are 
observed but these don’t affect the 
protein secondary structure.  
 
 
 
 
 
 
 
Figure 7: % α-helix obtained using Eq. 2 
for BSA in the presence of 0, 1, 3, 5, 10 
and 25 molar excess of 2. 
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UV-VIS absorbance 
 
The absorbance spectrum of 2 was recorded in the presence and absence of BSA. 
The incubation with the protein was performed with a 10-fold excess of complex 
over protein, since this was the highest ratio used in the CD assays. 
The absorption spectrum of 2 shows two bands with maxima located at 314 nm 
and 382 nm (Fig. 8A). The lowest wavelength maximum has higher intensity than 
the highest wavelength one and a highly stable profile is observed, with no 
changes in absorption during 4h (Fig. 8C). When incubated with BSA a similar 
spectrum is observed, with both maxima at the same wavelength together with 
another maximum at 290 nm obtained after subtraction of the BSA spectrum 
which has a maximum absorption at 279 nm (Fig. 8B). All the maxima are highly 
stable over 4h (Fig. 8D) and no changes on the absorption profile are observed 
thus not showing any kind of interaction between the complex and BSA, 
supporting the CD observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Time evolution of UV-VIS absorption spectrum of 2 (500 µM) in PBS7.4 at 
RT. A – 2 alone; B – 2 and BSA  (50 µM; BSA spectrum subtracted); C – Decay in 
absorbance measured at 314 nm and 382 nm with 2 alone; D – Decay in absorbance 
measured at 290 nm, 314 nm and 383 nm with 2 and BSA (50 µM; BSA spectrum 
subtracted). 
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4.1.3 Study of the interaction of Ru(CO)3Cl(glycinate) (3) and BSA  
 
Circular Dichroism 
 
Compound 3 was incubated with BSA (50 µM) in 1:3, 1:10, 1:15 and 1:25 
protein:complex ratios and the spectra recorded from 250 to 800 nm (see Fig. 9 
left). In the far UV range the compound and BSA (3 µM) were incubated in 1:1, 
1:3, 1:5, 1:10, 1:25 and 1:50 protein:complex ratios and the spectrum recorded 
from 194 to 260 nm (see Fig. 9 right). 
The results obtained suggest that the complex is not covalently bound to albumin. 
The spectrum doesn’t show any differences in the visible range and some 
interaction is observed in the far and near UV region. A positive band appears 
around 336 nm and increases consistently with increasing complex:BSA ratios. 
 
 
 
 
 
 
 
 
 
Figure 9: Left: CD spectra of BSA (50 µM) incubated with 3 at RT, in PBS7.4 at 1:3, 
1:10, 1:15 and 1:25 protein:complex ratio. The spectra were recorded from 250 to 800 nm. 
Right: CD spectra of BSA (3 µM) incubated with 3 at RT, in PBS7.4 at 1:1, 1:3, 1:5, 
1:10, 1:25 and 1:50 protein:complex ratio. The spectra were recorded from 194 to 260 nm. 
 
This signal clearly shows an interaction between the protein and the compound 
although this is not a strong binding effect. In the far UV-region no clear pattern 
is detected but some deviations to the native protein CD signal are observed. 
These most probably arise from the same interactions which do not influence the 
overall protein structure but exert some local electrostatic forces that induce the 
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CD signal. As explained in the previous Chapter this compound undergoes a 
WGS reaction with the formation of a 
metalo-carboxylate group, which may be 
responsible for H bonding with other 
residues from the protein. 
The α-helical content was calculated 
from the mean residue ellipticity at 222 
nm and no significant changes were 
observed even when a 50-fold molar 
excess of complex was incubated with 
the protein (see Fig. 10). These results 
show that the secondary structure of the 
protein isn’t affected even in the presence of a large excess of complex.  
 
 
UV-VIS absorbance 
 
The UV-VIS absorption spectrum of 3 was recorded with and without BSA. The 
incubation with the protein was performed with 1:15 protein:3 ratio, since this 
was the highest ratio used in the CD assays. 
Compound 3 has no absorbance peak but rather a broad band from 250 nm to 350 
nm (Fig. 11A). This band shows a quick decay in absorbance after the first 10 
min but then maintains a complete stability up to 4h in solution (Fig. 11C). With 
BSA an identical spectrum is obtained (Fig. 11B), with the maximum at 292 nm 
(obtained after subtraction of BSA spectrum) and also a rapid decay in 
absorbance is observed within the first 10 min followed by a high stability profile 
up to 4h (Fig. 11D). 
 
 
 
 
 
Figure 10: % α-helix obtained using 
Equation 2 for BSA in the presence of 
0, 1, 3, 5, 10, 25 and 50 molar excess 
of 3. 
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Figure 11: Time evolution of UV-VIS absorption spectrum of 3 (750 µM) in PBS7.4 at 
RT. A – 3 alone; B – 3 and BSA  (50 µM; BSA spectrum subtracted); C – Decay in 
absorbance measured at 292 nm with 3 alone; D – Decay in absorbance measured at 292 
nm with 3 and BSA (50 µM; BSA spectrum subtracted). 
 
  
From the observed profile it isn’t possible to infer if any kind of interaction is 
established between the protein and the complex since no changes are observed in 
the absorption spectra. However, the absence of differences suggests that no 
interaction is taking place between both species.  
 
4.1.4 Study of the interaction of Na3[Mo(CO)3(cit)] (4) and BSA 
 
Circular Dichroism 
 
Compound 4 and BSA (50 µM) were incubated in 1:5, 1:10, 1:25 and 1:50 
protein:complex ratio and the spectrum recorded from 250 to 800 nm (see Fig. 
12). 
In the far-UV region the compound was incubated with BSA (3 µM) in 1:1, 1:10, 
1:25 and 1:50 protein:complex ratio and the spectrum recorded from 190 to 300 
nm. Neither the complex 4 (2.5 mM) nor the sodium citrate ligand (2.5 mM) 
alone are CD active. In addition sodium citrate (2.5 mM) was also incubated with 
BSA (50 µM) and no induced CD signal was obtained in the whole spectrum.  
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Figure 12: CD spectra of BSA (50 µM) incubated with 4 at RT, in PBS7.4 at 1:5, 1:10, 
1:25 and 1:50 protein:complex ratio. The spectra were recorded from 250 to 800 nm. 
 
A clear induced CD signal is observed in the near UV-VIS range. At 1:5 
BSA/compound ratio a low intensity positive band is observed at 408 nm. When 
the ratio is increased to 1:10 two new negative bands are observed at 374 nm and 
450 nm together with a positive broad band centered at 690 nm. When the 
BSA/complex ratio is increased to 1:25 and 1:50 all the bands increase 
accordingly except the negative band at 374 nm. This is due to signal saturation 
that doesn’t allow the identification of bands in the near UV region. 
Like in the case of 1 the extremely high ratios used allowed the identification of 
new bands not observed on the remaining spectra. The CD signal observed in the 
visible region shows the covalent binding of a metallic core to the protein in a 
chiral environment. 
The very high concentrations used (1:50) distorted the signal in the near UV 
region of the spectrum due to a high absorbance of the complex in this range. 
Decreasing the amount of complex to a lower ratio (1:10) made it possible to 
clearly identify the different bands formed as well as their stability. 
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Figure 13: Time evolution of the CD spectra of BSA (50 µM) incubated with 4 at RT, in 
PBS7.4 at 1:10 (left) and 1:25 (right) protein:complex ratio. The spectra were recorded 
from 250 to 800 nm. 
 
 
With 1:10 ratio after 1h incubation, all the bands disappear except the positive 
loop at 408 nm (see Fig. 13 left). With higher ratios, like 1:25 the other bands are 
kept during the first hour but also disappear after 17h30min (see Fig. 13 right). 
Nevertheless, the positive band at 408 nm is kept up without significant 
modifications. The same behavior is observed when aged solutions of 4 are added 
to BSA. If 4 is aged, standing in PBS7.4 solution for 80 min (same procedure like 
in Chapter V) and added to BSA in 1:10 ratio only the 408 nm band is observed 
(see Fig. 14).  
This result shows that the changes in the visible CD spectra are due to some 
transient bands arising from weak interactions established at earlier times and not 
effective strong binding that stabilizes the complex like the band at 408 nm. 
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Figure 14: CD spectra of BSA(50 µM) incubated with 4 at RT, in PBS7.4 at 1:10 
protein:complex ratio. Red – Spectrum acquired immediately after mixing a fresh 
complex solution and protein. Green – Spectrum acquired after 80 min incubation of 
complex with protein. Blue – Spectrum acquired after mixing an aged solution of complex 
(aged for 80 min in PBS7.4) and protein. The spectra were recorded from 250 to 800 nm. 
 
From Fig.15 it is possible to observe the 
variation of the mean residual ellipticity 
([θ]) with the molar excess of 4, 
followed at three different λ values (690, 
590 and 448 nm) which correspond to a 
positive band, neutral and negative band, 
respectively. Increasing the molar excess 
of 4 over BSA leads to a continuous 
increase of the mean residual ellipticity 
according with the sign of the band. 
Once again, this shows the high binding 
capacity of this transport protein and evidentiates the strong affinity between the 
protein and the compound with a high degree of association.  
 
 
Figure 15: Variation of the mean 
residual ellipticity ([θ]) with the molar 
excess of 4, followed at λ1+(690 nm), 
λ2 (590 nm) and λ3- (448 nm). 
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In the far-UV region once more some changes are observed but not a consistent 
concentration-dependent signal change (see Fig. 16). 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Left: CD spectra of BSA (3 µM) incubated with 4 at RT, in PBS7.4 at 1:1, 
1:10, 1:25 and 1:50 protein:complex ratio. The spectra were recorded from 190 to 300 nm. 
Right: % α-helix obtained using Equation 2 for BSA in the presence of 0, 1, 10, 25 and 50 
molar excess of 4. 
 
These results indicate that the binding observed is not strongly influencing the 
protein secondary structure. The compound is bound to the protein and the overall 
spatial arrangement of the protein remains intact with the adduct. This 
observation is reflected in the percentage of α-helical content that was calculated 
and showed a stable amount independently of the high concentrations of complex 
used (see Fig. 16). 
The data show that in spite of the strong binding observed, the secondary 
structure of the protein is not affected. 
 
UV-VIS absorbance 
 
The absorbance spectrum of 4 was recorded in the presence and absence of BSA. 
The incubation with the protein was performed with a 10-fold excess of complex 
over protein. This ratio was selected since in the CD assays it induced a strong 
CD signal that showed variability along time (see Fig. 17). 
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Figure 17: Time evolution of UV-VIS absorption spectrum of 4 (500 µM) in PBS7.4 at 
RT. A – 4 alone; B – 4 and BSA (50 µM; BSA spectrum subtracted); C – Decay in 
absorbance measured at 397 nm and 305 nm with 4 alone; D – Decay in absorbance 
measured at 383 nm and 292 nm with 4 and BSA (50 µM; BSA spectrum subtracted). 
 
Compound 4 shows a distinct behavior from the previous compounds. As 
detected by the CO release experiments, the compound gradually decomposes in 
PBS. At the time of dissolution it has one major band absorption at 308 nm and 
another small and broad band centered at 395 nm (Fig. 17A). During the 
following 10 min the absolute maximum rapidly decreases in intensity and the 
highest wavelength peak increases intensity. After this initial “rearrangement” 
both bands slightly shift the maxima and decrease over time (Fig. 17C). 
Incubation with BSA also affords a slight shift of the maximum at 302 nm 
(observed at t=0) to 296 nm (at t=10 min) and lately to 292 nm (at t=30 min). The 
broad band observed at the initial time in the 350-400 nm region gives rise to a 
local maximum at 383 nm (Fig. 17B) after 10 min, but a higher degree of stability 
is achieved (Fig. 17D). This suggests that a protein-complex adduct is formed and 
the molecular rearrangement leads to the formation of a new species stable over 
time.  
Also, the absorbance baseline level of 4 increases with time due to an increased 
turbidity of the sample (Fig. 17A) and BSA is able to keep the complex in 
solution (Fig. 17B) giving evidence, once more, of the interaction between the 
two species. 
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4.2 Interactions with Human Apo-Transferrin  
 
The transferrins are a family of non-heme iron-binding glycoproteins containing 
ca. 700 aminoacids (Human apo transferrin has 678 residues)[36, 44] with molecular 
mass ca. 80 kDa.  These are single-chain glycoproteins of which three major types 
were characterized: ovotransferrin,[45, 46] lactoferrin[47-49] and serum transferrin 
which occurs in blood and other mammalian fluids like bile, amniotic fluid, 
cerebrospinal fluid, lymph and milk. 
There is a high sequence identity between different species and different members 
of the same family and the high levels of conservation in their primary structures 
are also reflected in their three-dimensional structures. Many crystal structures of 
transferrins (different species and some fragments) are available and have been 
reviewed previously.[50] Briefly, the polypeptide chain is folded into two 
structurally similar but functionally different lobes, referred to as N- and C-lobe, 
respectively. The two lobes are connected by a short peptide and each lobe can be 
further divided into two domains enclosing a deep hydrophilic cleft where the 
iron-binding site is located. Here, Fe3+ (and other metals) coordinates with 
distorted octahedral geometry to two oxygens from Tyrosine, one nitrogen from 
Histidine, one oxygen from Aspartate, and two oxygens from a bidentate 
carbonate that acts as synergistic anion. The ligands are from two domains and 
two polypeptide strands, which cross over between the two domains at the back of 
the iron site. This kind of arrangement is crucial to ensure that the domains are 
able to move apart to form an open conformation, hinged by the backbone 
strands, which leads to iron release. An important feature is the conformational 
changes that the protein suffers during iron uptake and release, which is also 
important for the Tf receptor recognition. 
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4.2.1 Study of the interaction of [Et4N][Mo(CO)5Br] (1) and h-Tf 
 
Circular Dichroism 
 
Compound 1 and h-Tf (30 µM) were incubated in 1:1, 1:3, 1:5, 1:10 and 1:20 
protein:complex ratio and the spectrum was recorded from 250 to 800 nm (see 
Fig. 19). 
 
 
Figure 19: CD spectra of h-Tf (30 µM) incubated with 1 at RT, in PBS7.4 at 1:1, 1:3, 1:5, 
1:10 and 1:20 protein:complex ratio. The spectra were recorded from 250 to 800 nm. 
 
The presence of the complex doesn’t change either the intensity or the shape of 
the CD spectrum of the protein. In the visible range no induced CD signal is 
detected and in the near UV region only minor differences are detected in the 
Figure 18: Human apo-
Transferrin  structure exhibiting 
the N and C lobe 
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negative loop centered at 297 nm. However, the CD spectrum of h-Tf is not 
significantly changed by the presence of the complex, even for very high complex 
excess like 1:10 and 1:20 ratios. Also, no differences were observed in the CD 
spectra over a 24h incubation period, therefore, CD data does not suggest an 
interaction between complex and protein. 
 
UV-VIS absorbance 
 
The UV-VIS absorption spectrum of 1 was recorded alone and with h-Tf (see Fig. 
20). The spectrum of complex alone was followed over time and the same 
procedure was followed with a h-Tf:complex sample with 1:20 ratio which was 
the highest ratio used in the CD assays. h-Tf spectrum alone was also recorded 
and the protein has a very well defined absorption peak at 279 nm. 
 
 
 
 
 
 
 
 
 
Figure 20: Time evolution of UV-VIS absorption spectrum of 1 (600 µM; 4%MeOH) in 
PBS7.4 at RT. A – 1 alone; B – 1 and h-Tf  (30 µM; h-Tf spectrum subtracted); C – Decay 
in absorbance measured at 401 nm with 1 alone; D – Decay in absorbance measured at 
387 nm and 296 nm with 1 and h-Tf (30 µM; h-Tf spectrum subtracted). 
 
Like previously shown in Fig. 5, 1 has 2 major absorption bands, one centered at 
401 nm and another broad shoulder at 288 nm and both rapidly decay over time, 
also in 600 µM concentration (Fig. 20A and C). Again, after 2h virtually no 
absorption is observed at 401 nm and the band at 286 nm has very low intensity 
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(Fig. 20C). When incubated with h-Tf the maximum at 400 nm is only observed 
immediately after addition and shifts to 387 nm after 10 min. Another maximum 
is observed at 296 nm and doesn’t shift position along time (Fig. 20B). A similar 
profile is observed in both peaks, with a rapid decay within the first 80 min to 90 
min of reaction, followed by a slightly stable plateau between 90 min to 160 min 
and then again another less pronounced decay in absorbance (Fig. 20D).  
The behavior observed in the presence of h-Tf is different from the decomposition 
profile of the complex alone. The absorbance decrease is less pronounced and 
suggests a 2-step decomposition. This may indicate a slower decomposition 
process, first, corresponding to the bromide loss and which is followed by a 
second step. This decay is in agreement with the profile observed by Lynam and 
co-workers[51] who identified the formation of an intermediate species on the 
decomposition of the Cr analogue [Cr(CO)5Cl]-. 
Although there’s no evidence of association between the two species, the 
presence of the protein clearly interferes with the decomposition pathway of the 
complex. 
 
4.2.2 Study of the interaction of CpMo(CO)3CH2CONH2 (2) and h-Tf 
 
Circular Dichroism 
 
The CD signal was recorded in the UV-VIS range (280 nm - 800 nm) for 1:1, 1:2, 
1:3, 1:5 and 1:10 protein(30 µM)/complex ratios and in the far UV range (198 nm 
– 260 nm) for 1:1, 1:3, 1:5, 1:10 and 1:15 protein (5 µM)/complex ratios and no 
interaction was observed (see Fig. 21). 
No measurable differences were detected in the protein spectrum in the presence 
of the metal complex at any ratio studied even after a 24h incubation period. CD 
data thus suggests that there is no measurable interaction between h-Tf and 2. 
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Figure 21: Left: CD spectra of h-Tf (30 µM) incubated with 2 at RT, in PBS7.4 at 1:1, 
1:2, 1:3, 1:5, 1:10 and 1:20 protein:complex ratio. The spectra were recorded from 250 to 
800 nm. Right: CD spectra of h-Tf (5 µM) incubated with 2 at RT, in PBS7.4 at 1:1, 1:2, 
1:3, 1:5 and 1:10 protein:complex ratio. The spectra were recorded from 198 to 260 nm. 
 
 
UV-VIS absorbance 
 
The absorbance spectrum of 2 was recorded in the presence and absence h-Tf. 
The incubation with the protein was performed with a 20-fold excess of complex 
over protein, since this was the highest ratio used in the CD assays. 
 
 
 
 
 
 
 
 
 
 
Figure 22: Time evolution of UV-VIS absorption spectrum of 2 (600 µM) in PBS7.4 at 
RT. A – 2 alone; B – 2 and h-Tf  (30 µM; h-Tf spectrum subtracted); C – Decay in 
absorbance measured at 314 nm and 382 nm with 2 alone; D – Decay in absorbance 
measured at 289 nm, 293 nm, 313 nm and 382 nm with 2 and h-Tf (30 µM; h-Tf spectrum 
subtracted). 
 
2 has a highly stable profile in PBS7.4. It has two bands with maxima at 314 nm 
and 382 nm that do not change absorption during 4h (Fig. 22A). When incubated 
with h-Tf two new maxima are obtained at 289 nm and 293 nm resulting from the 
A 
C 
B 
D 
  
Chapter VI 
 
 
275 
subtraction of the h-Tf spectrum which has the maximum absorption at 279 nm 
(Fig. 22B). A completely stable profile is observed over a period of 4h (Fig. 22C 
and D) which doesn’t suggest any kind of interaction between 2 and h-Tf thus 
supporting the CD observations. 
 
 
4.2.3 Study of the interaction of Ru(CO)3Cl(glycinate) (3) and h-Tf 
 
Circular Dichroism 
 
The interaction of 3 with h-Tf was studied in the near-UV and visible range with 
protein/complex ratios of 1:1, 1:3, 1:5, 1:10 and 1:15. CD spectra were recorded 
immediately after mixing and after a 24h incubation period. Although no 
interactions were observed immediately after incubation (see Fig. 23 - left), 
significant changes are detected in the near UV region of the spectrum after a 24h 
incubation period (see Fig. 23 - right). However, in the visible range no induced 
CD signal is detected, not even after a 24h incubation period (see Fig. 23 - right). 
The native protein has two negative bands centered at 297 nm and 286 nm and a 
positive band at 291 nm. Low protein/complex ratios (1:1 and 1:3) seem not to 
disturb the protein’s tertiary structure since similar CD spectra are obtained. 
However, when the ratio increases to 1:5 a consistent change is observed, 
decreasing the intensity of both negative and positive bands. This tendency is 
confirmed at even higher ratios (1:10 and 1:25).  
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Figure 23: Left:CD spectra of h-Tf (30 µM) incubated with 3 at RT, in PBS7.4 at 1:1, 
1:3, 1:5, 1:10 and 1:15 protein:complex ratio. The spectra were recorded from 250 to 800 
nm immediately after mixing both species. Right: CD spectra of h-Tf (30 µM) after 24h 
incubation with 3 at RT, in PBS7.4 at 1:1, 1:3, 1:5, 1:10 and 1:15 protein:complex ratio. 
The spectra were recorded from 250 to 800 nm.  
 
Plotting the mean residual ellipticity 
vs the molar excess (Fig. 24) at the 
minima (286 nm and 296 nm) and 
maximum (291 nm) we can see a 
continuous increase of [Θ] up to 10-
fold excess of 3. The slope of [Θ] 
variation decreases when increasing 
from 10 to 25 molar excess of 
complex. This suggests that at 10 
fold excess the maximum binding 
interaction was already achieved. 
In the far UV region no changes are observed, not even after 24h. This data 
strongly suggest that the protein’s secondary structure is not altered upon metal 
binding. The lack of changes in the secondary structure of h-Tf upon metal 
binding has been previously observed with Bi3+, In3+ and even Fe3+ that bind 
transferrin in an open state and even after metal coordination the protein stays in 
the same configuration, which is energetically favored.[27]   
  
 
Figure 24: Variation of the mean residual 
ellipticity ([θ]) with the molar excess of 3, 
followed at λ1- (296 nm), λ2+ (291 nm) and 
λ3- (286 nm). 
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The CD data thus suggest a weak interaction between protein and metal complex, 
which isn’t covalent but most probably electrostatic.  
 
 
UV-VIS absorbance 
 
The UV-VIS absorption spectrum of 3 was recorded with and without h-Tf. The 
incubation with the protein was performed with 1:25 protein:3 ratio, since this 
was the highest ratio used in the CD assays and showed some interaction after 
24h. 
 
 
 
 
 
 
 
Figure 25: CD spectra of h-Tf (5 µM) after 24h incubation with 3 at RT, in PBS7.4 at 
1:1, 1:2, 1:3, 1:5 and 1:10 protein:complex ratio. The spectra were recorded from 250 to 
800 nm. 
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Figure 26: Time evolution of UV-VIS absorption spectrum of 3 (750 µM) in PBS7.4 at 
RT. A – 3 alone; B – 3 and h-Tf  (30 µM; h-Tf spectrum subtracted); C – Decay in 
absorbance measured at 294 nm with 3 alone; D – Decay in absorbance measured at 294 
nm with 3 and h-Tf (30 µM; h-Tf spectrum subtracted). 
 
As previously shown in Fig. 11, 3 has a broad band from 250 nm to 350nm (Fig. 
26A) that quickly decays in absorbance after the first 10 min but then maintains a 
complete stability up to 4h in solution (Fig. 26C). With h-Tf an identical spectrum 
is obtained (Fig. 26B), with the maximum at the same wavelength and totally 
stable over 4h (Fig. 26D). These results do not show if any kind of interaction is 
taking place between both species, and like we have seen in the incubation with 
BSA the UV-VIS absorbance profile is not a useful tool to determine protein 
binding in this case. 
 
4.2.4 Study of the interaction of Na3[Mo(CO)3(cit)] (4) and h-Tf 
 
Circular Dichroism 
 
The CD spectra of h-Tf with 4 were recorded between 250 nm and 400 nm with 
protein/complex ratios of 1:1, 1:5, 1:7.5 and 1:15. A sample with 1:25 ratio was 
recorded up to 800 nm and no induced CD signal was observed in the visible 
range. 
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Figure 27: Left: CD spectra of h-Tf (30µM) after incubation with 4 at RT, in PBS7.4 at 
1:1, 1:5, 1:7.5 , 1:10 and 1:15 protein:complex ratio. The spectra were recorded from 250 
to 400 nm. Right: Variation of the mean residual ellipticity ([θ]) with the molar excess of 
4, followed at λ1- (296 nm), λ2+ (291 nm) and λ3- (286 nm). 
 
The 1:1 and 1:5 samples do not exhibit changes in the CD spectra but at higher 
ratios such as 1:7.5 and 1:10, some changes are observed starting from 385 nm to 
lower wavelengths. A clear shift is observed from the original spectrum and both 
negative (297 nm and 286 nm) and positive bands (at 291 nm) show interference 
of the metal complexes with the CD signal.  
Plotting the mean residual ellipticity vs the molar excess (Fig. 27 right) at the 
minima (286 nm and 296 nm) and maximum (291 nm) it is clear that two 
different profiles are observed. The same variance is obtained with 1- and 5- fold 
excess and a different one with 7.5-, 10- and 15-fold excess. 
There’s not a continuous increase of [Θ] but a gap, between lower and higher 
concentrations, but not in a clear direction. 
The induced signal differences are not long-lasting like observed with BSA, and 
also depend on the concentration. With 1:5 ratio the differences observed in the 
CD signal remain unchanged up to 24h (Fig. 28 left) and with higher metal 
complex excess (1:10 ratio) the initial changes in the CD signal tend to decrease 
over time and after 4h30m the differences to the protein signal are less 
pronounced (Fig. 28 right). Nevertheless, this CD spectrum is kept up to 24h.    
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Figure 28: Time evolution of the CD spectra of h-Tf (30 µM) incubation with 4 at RT, in 
PBS7.4 at 1:5 (left) and 1:10 (right) protein:complex ratio. The spectra were recorded 
from 250 to 400 nm.  
 
 
In the far UV region, a clear difference is observed between the native protein and 
the complex adducts. These differences are detected immediately after incubation 
with protein and remain up to 4h. 
 
 
 
 
 
 
 
 
Figure 29: Left:CD spectra of 4 and h-Tf (5 µM) after 24h incubation at RT, in PBS7.4 at 
1:1, 1:3, 1:5, 1:10 and 1:20 protein:complex ratio. The spectra were recorded from 198 to 
260 nm. Right: % α-helix obtained using Equation 2 for h-Tf in the presence of 0, 1, 3, 5, 
10 and 20 molar excess of 4. 
 
In the far UV range a sudden change is observed in the h-Tf spectrum in the 
presence of equimolar ratio of protein to complex that is not sensitive to excess of 
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complex (up to 20-fold excess). The a helical content was calculated and showed 
a decrease of 3% of a helice. CD data suggests an interaction between the 
complex and the protein by the observation of a weak induced CD signal and a 
change of its secondary structure upon binding (see Figure 29 right). 
UV- VIS absorbance 
The absorbance spectrum of 4 was recorded in the presence and absence of h-Tf. 
The incubation with the protein was performed with a 10-fold excess of complex 
over protein. This ratio induced some changes in the CD signal and was also 
followed along the time (Fig. 30). 
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Figure 30: Time evolution of UV-VIS absorption spectrum of 4 (300 /lM) in PBS7.4 at 
RT. A - 4 alone; B - 4 and h-Tf (30 /lM; h-Tf spectrum subtracted); C - Decay in 
absorbance measured at 399 nm and 286 nm with 4 alone; D - Decay in absorbance 
measured at 387 nm and 293 nm with 4 and h-Tf (30 /lM; h-Tf spectrum subtracted). t=o 
blue line; t= 1 Omin red line 
The UV -VIS absorbance spectra of 4 shows a slightly different profile than the 
one previously observed at 500 /lM (Fig. 17). 
At the time of dissolution it has one major absorption peak with maximum 
located at 307 nm and another small broad band from 370 to 400 nm (Fig. 30A). 
After 10 min, the absolute maximum decreases intensity and a lower intensity 
band (shoulder) is observed centered around 285 nm. At the highest wavelength 
281 
Interaction of Metal Carbonyl Complexes with Serum Proteins 
 
 
282 
band the intensity slightly increases and a local maximum is observed at 400 nm. 
Both maxima then decrease over time (Fig. 30C). Incubation with h-Tf also 
affords a slight shift of the maximum at 303 nm (observed at t=0) to 295 nm (at 
t=10 min) and lately to 293 nm (at t=30 min), similarly to what is observed with 
BSA. The broad band observed at the initial time in the 350-400 nm region 
slightly decreases in intensity but a local maximum is observed at 387 nm (Fig. 
30B) after 10 min. Contrary to what was observed with BSA a stable adduct is not 
achieved, but a slower decay in absorbance is observed (Fig. 30D). The time 
evolution spectrum of 4 alone is slightly different when followed at 300 µM or 
500 µM, giving different absorption profiles in the 300 nm region. Since a new 
spectrum is obtained after 10 min, with new maxima located at different 
wavelengths (and higher absorbance values) this suggests different decomposition 
profiles, dependent on the formation of some intermediates, and therefore, 
possibly concentration-dependent. Interaction with h-Tf clearly interferes with the 
decomposition profile of 4, however, the data doesn’t suggest any kind of 
covalent interaction between the protein and the complex.   
 
4.3 Discussion 
 
The incubation of CO-RMs with BSA revealed a tendency of interaction between 
the carrier protein and the complexes. 
Complexes 1 and 4 were already previously characterized as spontaneous CO 
releasers due to their low stability in aerobic aqueous solutions. The time 
evolution of the UV-VIS absorbance spectra of these species in PBS7.4 showed 
that the complexes decompose rapidly and in the case of 4 giving intermediate 
species with different absorption maxima. Moreover, the decomposition profile of 
4 is concentration dependent as different concentrations lead to different 
absorbance peaks. Addition of BSA in a 1:20 (protein:complex) ratio leads to the 
formation of a new species highly stable up to 4h with both compounds. The new 
protein-associated complexes are clearly observed in the CD spectra recorded.  
Incubation of 1 with BSA afforded very intense circular dichroic changes in the 
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350 to 550 nm region owed to the binding of metal complexes to the protein. The 
same behavior is observed with 4 in the 360 to 800 nm region showing effective 
binding between protein and metal complex. Interestingly, these two complexes 
also share another common feature, which is the lack of interaction of aged 
solutions with BSA. The binding is only observed when the fresh compound is 
added to BSA and if the compound is left in solution for 2h (in the case of 1) or 
80 min (in the case of 4) no interactions are observed at low complex:protein 
ratios. This data shows that BSA is an effective carrier of these two compounds 
and the integrity of the protein-metal complex adduct is maintained for a large 
period of time, therefore increasing their half-life in circulation. On the other 
hand, when the compound decomposes, the metabolites are no longer transported 
by BSA since no evidence of association was found with aged solutions. 
Incubation with h-Tf gave different interaction profiles. 1 does not interact with h-
Tf, in the several protein:complex ratios tested (ranging from 1:1 to 1:20), not 
even after 24h incubation. However, binding to h-Tf is not as fast as it is observed 
with BSA and since the complex is not stable in PBS solution it is possible that a 
larger period of time would be needed for some binding to occur but after which 
no more compound is present in solution. The decomposition of the complex was 
clearly observed due to a high degree of turbidity in solution. 
With 4 no binding to h-Tf is observed and only minor changes in the CD 
spectrum are observed. With 1:7.5 and 1:10 ratios a small interaction is observed 
between the metal complex and the protein and this interaction may induce some 
changes in the secondary structure of the protein. This explains why in the far UV 
region, a clear difference is observed between the native protein and the complex 
adducts. These differences are immediate after incubation with protein and the 
induced CD signal  is maintained after 4h.  
It is known that binding does not specifically occur at the C- and N-lobe iron-
binding cleft of the protein, but can also occur at histidine residues on the surface 
of the protein. Binding to the binding site is usually accompanied with major 
changes since the protein can balance between two configurations, open and 
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closed.[52] Binding of metal ions to the phenolic groups of the tyrosine residues in 
the specific metal binding sites of apo-Tf leads to the production of two new 
absorption bands centered at ca. 240 nm and ca. 295 nm in the UV-difference 
spectra. When metals bind to Tf usually intense tyrosinate–to-metal charge 
transfer bands (LMCT) are observed in the visible region (400-500 cm-1) which 
could originate CD signal in the visible range. Therefore, the results obtained with 
4 may be due to surface binding instead of specifically to the binding site.  
The h-Tf binding cleft is designed to accommodate Fe3+ atoms which have an 
ionic radius of 0.65 Å[53] and previous studies[54] suggest that neither N- nor C-
lobe are able to accommodate metals with radii larger than 0.95 Å. The strength 
of the metal binding strongly depends on the metal[55] so in the present case both 
compounds would require total CO depletion, ligand dissociation and oxidation in 
order to coordinate the metal ion in the binding cleft and with the residues in the 
vicinity. 
Compound 2 is a completely different complex from the two discussed above. It 
is very stable in aqueous solution, as reflected by the absence of changes in the 
UV-VIS spectra observed over 4h (Fig. 12). Incubation with BSA does not 
produce any differences in the absorption spectrum, but since it has very weak 
absorbance bands these differences would hardly be noted unless a totally 
different association complex would be formed. This clearly isn’t the case as the 
CD spectra reinforce the idea of a very weak interaction between the complex and 
BSA. A consistent signal variation is observed in the far UV region, probably 
arising from some weak interaction with the complex, since a strong binding is 
clearly not present. 
Incubation with h-Tf didn’t afford any type of association between both species. 
The CD spectra recorded do not detect any kind of interaction between the metal 
complex and the protein not even after 24h. Apart from the natural low affinity of 
h-Tf for Mo complexes also the piano stool geometry may account for some steric 
hindrance. As already explained, the approach to the binding cavity of the protein 
requires labile ligands that allow an easy exchange or hydrolysis and with 2 the 
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hydrolysis or ligand substitution doesn’t occur as confirmed by the CO release 
rate and UV-VIS spectrum in PBS7.4. The amide functionality and Cp ring may 
still be responsible for some electrostatic interactions between the compound and 
some residues in the protein, but not a strong binding. 
Compound 3 showed a distinct interaction with both proteins. With BSA only 
minor interactions were observed probably due to some surface reactivity and not 
effective binding. Incubation with h-Tf gave different results with a clear binding 
being observed. The changes in the CD spectra are only observed after 24h 
showing that the reaction between both species is not immediate. The changes 
observed in the CD spectra show the increase of intensity of the aromatic residues 
but in the far UV region no changes are observed suggesting that the protein 
secondary structure is not altered upon metal binding.  
A possible explanation for the fact that binding only occurs after 24h incubation 
may lie on a possible conversion or decomposition of the initial compound. 3 is a 
Ru(II) species but oxidation may lead to Ru(III) species which like Fe(III) have 
high affinity for phenolate ligands[56] which are involved in the Tyr residues of 
transferrin-binding site.[57] Ru(III) ions are relatively hard and therefore have high 
attraction for halides and anionic oxygen ligands, all of which are retained for 
fairly long periods. Conversely, Ru(II) ions are relatively soft and have little 
affinity for these ligands so it is not surprising that binding activity could only be 
observed after 24h, increasing the affinity for this plasma protein. However, at 
this stage, this is only a speculative interpretation, as we don’t have any 
experimental evidence to support this possibility. 
As stated in the beginning of the Chapter, the compounds studied were selected 
because each of  them possesses a set of properties that exemplify several families 
of compounds which actually produced therapeutically positive results in vivo.  
2 is the prototype of a large family of very stable organometallic carbonyl 
compounds, activated by oxidation or light, with a Cp ring as ligand in a piano 
stool geometry around a Mo(II) metal center. One can extrapolate that 
CpM(CO)xL compounds behave similarly and will be poorly transported by 
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albumin in blood. Interaction with h-Tf doesn’t occur either. Therefore other 
specific receptor-mediated transport mechanisms to tissues are required for CO to 
reach the targets if these compounds are to be actively transported as CO-RMs.  
1 and 4 are Mo(0) compounds that liberate CO at high rates but have different 
coordination spheres. With 5 and 3 carbonyl groups per molecule, respectively, 1 
and 4 are negatively charged, have hard labile ligands (bromide or citrate) but 
interestingly behave similarly in albumin binding. In both cases the labile ligands 
are most probably removed and a protein-metal complex adduct is formed. 
Contrary to substitutionally inert 2 there is evidence of strong binding which is 
most likely made possible by the lability of the ligands. With h-Tf no interaction 
was observed. Indeed, a low valent metal complex is not fit to coordinate the h-Tf 
binding site. Higher oxidation products of Mo are likely to have Mo=O bonds and 
will have small negative charges inappropriate to bind a site designed for hard 
Fe(III) cations.  
Compound 3 shows a very weak interaction with albumin which indicates that the 
compound circulates with a low degree of association with this carrier. Several 
studies[58, 59] have shown that albumin can specifically bind Ru(III) complexes like 
HInd[RuInd2Cl4] (Ind=indazole) or Na[RuImCl4Me2SO] (Im=Imidazole). Initial 
results suggested that the kinetics of association is very slow and takes several 
hours to obtain the final adducts. However, a very recent study showed that 
Na[RuImCl4Me2SO] (NAMI-A) reacts very fast with BSA with total replacement 
of the coordination sphere of Ru(III) by albumin based ligands! The most 
interesting fact is that this binding of the Ru(III) to albumin is responsible for the 
biological anti-metastic activity formerly attributed to the precursor complex 
NAMI-A.[60]   
The transferrins are primarily iron binding proteins but in serum only about 30% 
is saturated with iron, leaving a high potential to other metal ions in circulation. 
Given the similarities between Ruthenium and Iron it was expected that this 
compound could actually bind transferrin. The data collected shows that it’s 
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plausible to think that delivery of ruthenium complexes similar to 3 to cells may 
be mediated by transferrin receptors.[29, 61, 62] 
Furthermore, the results obtained from the incubation of compounds 1 and 4 with 
BSA suggest an extrapolation to what has been observed both in vivo and in vitro 
in blood. 
The data presented in Chapter IV showed that compound 1 undergoes a steady 
and continuous liberation of CO in blood while compound 4 readily liberates 1 
CO to Hb and doesn’t increase CO-Hb levels over the next 30 min. From Fig. 5D 
one can see that 1 has a slow and continuous decay over time since is stabilized 
by the  carrier protein. On the other hand, 4 shows a very rapid decay in Abs 
during the first 10 min with the formation of a new species which then shows a 
highly stable profile over time (Fig. 17B). Although only CO release experiments 
performed under the same conditions could explain if the adducts formed promote 
or prevent CO release, all the spectroscopic data suggests that CO-RM-protein 
association could be responsible for the profile observed in blood.  
 
5. Final Remarks and Conclusion 
 
The distribution of a drug through the bloodstream following its administration is 
largely dependent on plasma protein binding which conditions the 
pharmacological profile of the drug, the dosing regimen and even the clearance 
process. Only unbound drug is able to permeate the blood vessels and enter the 
tissues.  
In the case of CO-RMs, where the active drug is in fact CO, this association may 
accelerate the release of the active principle, which is then trapped by hemoglobin 
losing its therapeutic effect and increasing toxicity. Understanding the nature of 
these associations is therefore relevant for the design of better CO-RMs, in order 
to either prevent destructive interaction with these carriers or conversely to make 
stable adducts that interact without decomposition and enhance the stability of the 
CO-RM in circulation and its half-life in vivo. The few compounds studied 
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provided different examples of behaviors that may be helpful for the design of 
future molecules. 
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Chapter VII: Conclusions and Prospects 
 
 
The main purpose of the work presented in this Thesis was the development of 
CO-releasing molecules for the treatment of inflammatory diseases. In this 
quest, a large variety of molecules, with different metals, number of carbonyl 
groups and co-ligands were studied for the first time in aqueous environments. A 
large number of existing metal carbonyl complexes could eventually be used as 
CO-RMs, however, very few (if any) exhibit pharmacological profiles that 
allowed them to be developed as drugs. In this sense, the thorough study 
presented in Chapter II set the basis for a better understanding of which families 
of compounds could possibly be used for further drug development and elicited 
the viability of using MCCs to deliver CO in biological media. Furthermore, it 
also demonstrated the effect of different biological relevant parameters such as 
pH or pO2. 
Although this first screening did not intent to draw any structure-activity 
relationships it allowed the determinations of a structure-properties relationships, 
helping to understand the main molecular properties that contribute to the profile 
of CO release of MCCs. Indeed, the fastest and more extensive CO releasers were 
identified among the Mo0 octahedral derivatives  [Mo0(CO)3L3]0/z- bearing hard 
donor ligands mainly those of biological relevance, e.g. amines, carboxylates, 
aminoacids. From these, CO release can be regulated via appropriate π-acceptor 
ligands. On the contrary, cyclopentadienyl complexes of MoII, FeII, RuII and MnI 
are very weak CO releasers. 
A different profile is exhibited by the MnI(CO)5L and  MnI(CO)4L2 complexes 
which lose CO dissociatively to form stable, inert [Mn(CO)3X3]+ products.  A 
totally unexpected behavior was observed with [RuII(CO)3L3] complexes that do 
not release CO to the headspace of their aqueous solutions.  
One of the main advantages of using CO-RMs over CO inhalation is the 
possibility of delivering CO locally to the diseased tissues, without loading 
hemoglobin with CO. In pathophysiological scenarios some of the injury 
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mediators expressed may become advantageous in order to promote an increased 
CO delivery. In Chapter III, an extensive study was presented where it was shown 
that in the presence of oxidants such as H2O2 or TBHP, the CO release rate is 
accelerated. The nature of the gases evolved from the oxidation of these carbonyl 
complexes was undoubtedly established, contrary to most of the studies reported 
in the literature concerning oxidation of metal carbonyls and where the nature of 
the gases evolved is missing or is contradictory. In the studies presented, it was 
shown that very few compounds resist oxidation under the standard conditions 
and proved that this could be an advantageous strategy to increase the amount of 
CO released to inflamed tissues, where large amounts of ROS are present. 
The exceptions were the derivatives of MnI(CO)3 and RuII(CO)3 that do not 
respond to the ROS used since the former do not react whereas the latter rapidly 
decompose the ROS reagent to release O2 and/or induce strong catalytic oxidation 
with formation of  CO2. 
It was observed that most MCCs tested react preferentially with one of the two 
ROS used depending on their ancillary ligands and oxidation state. The 
CpFe(CO)2X complexes do not react with TBHP and react with H2O2 to produce 
more CO2 than CO (CO:CO2 < 1); a weak catalytic oxidation activity is observed 
in these systems contrary to those of Mn and Mo where CO:CO2  is usually > 2. 
In summary, the main goal was to evaluate the possibility of using the naturally 
occurring oxidizing ROS as a means of inducing or triggering release of CO from 
MCCs at the places of inflammation or oxidative stress and it it was demonstrated 
that it is a viable possibility. 
In Chapter IV, the CO release rate of MCCs was evaluated using a different 
method, spectrophotometric measurement of CO-Mb formation. This method has 
some pros and cons when compared with the gas chromatography measurements 
performed in Chapter II, however, it allowed the identification of a new feature, 
only detected in this assay – CO donation. This is a specific property of the 
RuII(CO)3 complexes, which do not liberate CO to the headspace of aqueous 
solutions as observed in Chapter V, but are able to transfer CO directly to the 
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heme center of Mb. This unique property of this family of compounds may be 
responsible for their pharmacological activity, which has been observed in several 
different models of disease. Among other factors, this lead us to develop a series 
of Ru(CO)3Cl2L complexes, which were studied and evaluated for their capacity 
to release CO and become useful drugs (Chapter V). Furthermore, some 
ruthenium carbonyls exhibited the capacity to decompose H2O2, liberating O2. 
The catalytic decomposition of H2O2 by these compounds was also evaluated and 
found to be very weak, when compared with other existing peroxide scavengers. 
Another study presented in Chapter IV, shows the CO release profile of different 
compounds in blood. The most striking feature is that most of the compounds 
tested showed a very rapid (in some cases almost instantaneous and quantitative!) 
CO release burst. Indeed, blood is somehow different from the biological relevant 
medium used for the assays presented in Chapter II and strongly labilizes the 
compounds with amino or hydroxyl ligands in Mo(0) carbonyl complexes. 
Possibly in a medium rich in proteins the amine ligands of the complex exchange 
with amines from proteins and during these rapid exchanges, more 
thermodynamically labile complexes may form, or oxidation may happen leading 
to CO release. 
The interaction between some model complexes and the plasma proteins Albumin 
and Transferrin is presented in Chapter VI. The interaction between drugs and 
plasma proteins is one fundamental aspect ruling pharmacological activity so 
some Circular Dichroism and UV-VIS absorbance spectroscopy studies were 
undertaken to study this interaction. It was demonstrated that some compounds 
could easily bind to Albumin in a small period of time while others with strong or 
labile ligands showed a minor degree of interaction. With Transferrin, only a 
ruthenium complex (CORM-3) showed some degree of interaction after 24h. 
Binding of MCCs to these proteins is therefore difficult to predict at this stage. 
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Taken altogether, the studies presented in this Thesis showed undoubtedly the 
potential of MCCs to be used as CO-RMs. Their modulation through different 
substitution degrees and the use of diverse ancillary ligands, strongly influences 
their ability to release CO. This versatility gives to CO-RMs the possibility of 
being used in different pathological scenarios, where the need for CO varies 
according with the disease.  
Understanding the chemical behavior of these molecules under biological 
conditions allowed the development of new compounds, with improved 
pharmacological profiles.  
Given the high number of unmet needs in Medicine, hopefully, in a near future 
these molecules may be used as drugs for the treatment of diseases which haven’t 
been addressed so far. 
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Table A1: List of MCCs synthesized and evaluated for CO release in RPMI (10%FBS) 
under CO2 free reconstituted air, at 37ºC and in the dark. 
 
Formula Structure Reference 
Mn2(CO)10 
CpMn(CO)3 
Mo(CO)6 
Cr(CO)6 
Fe2(CO)9 
[Ru(CO)3Cl2]2 
CpRu(CO)2I 
Commercial 
 
  
Mn(CO)5Br@TRIMEB 
[Et4N][Mo(CO)5Br]@TRIMEB 
CpMo(CO)3Cl@TRIMEB 
(η5-C5H4COOMe)Mo(CO)3Cl@TRIMEB 
CpMo(CO)3Cl@TRIMEB 
CpFe(CO)2Cl@TRIMEB 
CpFe(CO)2Cl@β-CD 
Prepared in the group of Prof. Isabel S. 
Gonçalves in Universidade de Aveiro, 
Portugal. 
The “free” complexes were prepared as stated 
next. 
   
   
Mn(CO)5CH3 
CO
Mn
CO
CO
OC CH3
OC
 
[1] 
Mn(CO)5CH2CONH2 
CO
Mn
CO
CO
OC
OC
C
NH2
O  
[2] 
Mn(CO)5OSO2CF3 
CO
Mn
CO
CO
OC O
OC
S CF3
O
O  
[3] 
Mn(CO)5Cl 
CO
Mn
CO
CO
OC Cl
OC
 
[4] 
Mn(CO)5Br 
CO
Mn
CO
CO
OC Br
OC
 
[4] 
[Et4N][Mn(CO)4Br2] 
CO
Mn
Br
CO
OC Br
OC
[NEt4]
 
[5] 
Mn(CO)4S2CPh Mn
CO
CO
OC
OC
S
S
 
Provided by 
Prof. Brian 
Mann from 
hemoCORM 
[Mn(CO)3(TACN)]Br 
N
N
N
Mn
CO
OC CO
Br
 
[6] 
[Et4N][Mn2(CO)6Br3] 
CO
Mn
OC
OC
CO
Mn
CO
COBr
Br
Br [NEt4]
 
[7] 
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Mo(CO)5PTA 
CO
Mo
CO
CO
CO
OC
N
N N
P
 
[8] 
AIP 
Mo(CO)5PTA.HCl 
CO
Mo
CO
CO
CO
OC
N
N NH
P
Cl
 
AIP 
Mo(CO)5P(4-SO3Na-C6H4)3 
CO
Mo
CO
CO
OC P(C6H4SO3Na)3
OC
 
[9] 
Mo(CO)5P(CH2OH)3 
CO
Mo
CO
CO
OC P(CH2OH)3
OC
 
AIP 
Mo(CO)5P(CH2CH2CH2OH)3 
CO
Mo
CO
CO
OC P(CH2CH2CH2OH)3
OC
 
AIP 
Mo(CO)5P(CH2CH2COOH)3 
CO
Mo
CO
CO
OC P(CH2CH2CO2H)3
OC
 
AIP 
Mo(CO)5(HN(CH2CH2)2O) Mo
CO
CO
CO
OC
OC
NH
O
 
AIP 
[Bu4N][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
[NBu4]
 
[10, 11] 
[Et4N][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
[NEt4]
 
[10, 11] 
[Na(15-crown-5-ether)][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
O
O
O
O
O
Na
 
AIP 
[Na(diglyme)2][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
Na(diglyme)3
 
AIP 
[K(diglyme)3][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
K(diglyme)3
 
[10] 
[NH4(diglyme)3][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
NH4(diglyme)3
 
AIP 
[Ca1/2(diglyme)2][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
Ca(diglyme)22
 
AIP 
[Mg1/2(diglyme)2][Mo(CO)5I] 
CO
Mo
CO
CO
OC I
OC
Mg(diglyme)22
 
AIP 
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[Et4N][Mo(CO)5Br] 
CO
Mo
CO
CO
OC Br
OC
[NEt4]
 
[10, 11] 
[Na][Mo(CO)5CN] 
CO
Mo
CO
CO
OC CN
OC
Na
 
[12] 
   
Mo(CO)4(bipy) 
COMo
CO
OC
OC
NN
 
[13] 
Mo(CO)4(4,4’-HOOC-bipy) 
MoOC CO
OC CO
N N
OH
O
HO
O
 
AIP 
Mo(CO)4(4,4’-NaO3SCH2CH2OOC-bipy) 
MoOC CO
OC CO
N N
O
O
O
O
SO3Na
NaO3S
 
AIP 
Mo(CO)4(Me-DAB) 
COMo
CO
OC
OC
NH3C N CH3
 
AIP 
Mo(CO)4(p-tolil-DAB) COMo
CO
OC
OC
NN
 
[14] 
Mo(CO)4(Cy-DAB) 
COMo
CO
OC
OC
NN
 
[14, 15] 
Mo(CO)4(Me-pip-DAB) OC Mo CO
OC CO
N NNNN N
 
AIP 
Mo(CO)4(3-COOH-py)2 
COMo
CO
OC
OC
NN O
OH
O
HO
 
adapted from 
[16] 
see Chapter II 
Experimental 
Section 
Mo(CO)4(Me-pip)2 
OC Mo CO
OC CO
NN
N N
 
AIP 
Mo(CO)4(morph)2 
OC Mo CO
OC CO
NN
O O
 
AIP 
Mo(CO)4(PTA)2 
Mo
CO
CO
CO
OC
N
N N
P
N
NN
P
 
AIP 
Annex I 
 
 
300 
Mo(CO)4(PTA)2.2HCl 
Mo
CO
CO
CO
OC
NH
+
N N
P
HN
+
NN
P
Cl
-
Cl
-
 
AIP 
Mo(CO)4(DAPTA)2 
CO
Mo
CO
CO
OC
N
N N
P
O
O
P
N
N
N
O
O
 
adapted from 
[17] 
see Chapter II 
Experimental 
Section 
Mo(CO)4(OPPh3)2 COMo
CO
OC
OC
OPPh3Ph3PO
 
[18] 
[Me4N]2[(Mo(CO)4(SPh)2] 
CO
Mo
CO
OC
OC
CO
Mo
CO
CO
CO
Ph
S
S
Ph
[NMe4]2
 
[19] 
[(Mo(CO)4(SPh)2] 
CO
Mo
CO
OC
OC
CO
Mo
CO
CO
CO
Ph
S
S
Ph  
[19] 
[Et4N][(Mo(CO)4(Me-acac)] MoCO
CO O
O
CO
CO
[Et4N]
 
AIP 
[Et4N][(Mo(CO)4(glycinate)] 
CO
Mo
CO
OOC
OC
O
N
H2
Et4N
 
adapted from 
[20] 
 
AIP 
   
Mo(CO)3(TACN) N
N
N
Mo
OC
OC CO  
[21] 
Mo(CO)3(TTCN) S
S
S
Mo
OC
OC
CO  
[22] 
Mo(CO)3(bpa) 
Mo
CO CO
N
CO
N
N
CO2H
 
adapted from 
[23] 
see Chapter II 
Experimental 
Section 
Mo(CO)3(PTA)3 Mo CO
CO
OC
N
N N
P
N
NN
P
NN
N
P
 
[24] 
AIP 
Mo(CO)3(η6-C7H8) 
Mo
OC
CO
CO
 
[25] 
Mo(CO)3I2(CH3CN)2 
CO
Mo
CO
I
OC
NCMeMeCN
I
 
[26] 
Mo(CO)3I2(p-tolil-DAB) Mo
N
OC
I
N
I
CO
CO  
[27] 
· " ............... 1' ............ 
<1,/;1 f::::J> 
V 'i 
11L1~.Jl.. 
." /').... 
., ' 
~> 
=<;'i 
\/ 
- -1\ 
[ .1 ... , I, 
"'I' ........ 1 
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Mo(CO)3I2(Cy-DAB) Mo
N
OC
I
N
I
CO
CyCy
CO  
[27] 
 DAB ligands  [28, 29] 
CpMo(CO)3I 
Mo
OC
OC CO
I
 
[30] 
CpMo(CO)3Cl Mo
OC
OC CO
Cl
 
adapted from 
[30] using 
CCl4 instead 
of CHCl3. 
 
Cp*Mo(CO)3Cl 
Mo
OC
OC CO
Cl
 
[31] 
CpMo(CO)3CH3 Mo
OC
OC CO
CH3
 
[32] 
CpMo(CO)3CH2CONH2 Mo
OC
OC CO
O
NH2 
[2] 
CpMo(CO)3CH2COOH Mo C
OH
O
OC
OC CO  
[2] 
CpMo(CO)3CH2CONHCH2OH MoOC
OC CO
O
N
H
OH
 
adapted from 
[33] 
 
AIP 
CpMo(CO)3CH2COOC(CH3)2Ph MoOC
OC CO
O
O
 
adapted from 
[33] 
 
AIP 
CpMo(CO)3CH2CONHCH2COOCH3 MoOC
OC CO
O
N
H
O
OCH3
 
adapted from 
[33] 
 
AIP 
CpMo(CO)3OC8H6OBF2 MoOC
OC CO
O
F2
B
O
 
AIP 
(η5-C5H4COOMe)Mo(CO)3Cl 
Mo
O
OMe
OC Cl
OC CO  
[34] 
(η5-C5Ph4OH)Mo(CO)3Cl 
Mo
OC
OC CO
Cl
Ph
OH
Ph
Ph
Ph
 
AIP 
(η5-C5H4COOH)Mo(CO)3I 
MoOC
OC
CO
I
OH
O
 
AIP 
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.. , , ..... 
~ 
I 
-, ,'" 
¥ 
.. ,\ ... 
~ 
.. , ,'" 
~ 
", ,-.-iZ 
~'I 
", t""'" .... 
9-'(.-A. 
"n 
~-.-iZ~ 
~ 
",,--'Z 1r 
, I"" ~~
"1\- ~ I 
~ , 
.. , ,-
-¥ 
.. , ,'" 
d 
I 
-'1 ... 
Annex I 
 
 
302 
(η5-C5H4CH2CH3)Mo(CO)3CH3 
MoOC
OC
CO
CH3
 
AIP 
(η5-C5H4CH2CH2CH3)Mo(CO)3CH3 
MoOC
OC
CO
CH3
 
AIP 
(η5-C5H4CH2CH2CH2CH3)Mo(CO)3CH3 
MoOC
OC
CO
CH3
 
AIP 
(η5-C5H4CH2Ph)Mo(CO)3CH3 
MoOC
OC
CO
CH3
 
AIP 
[(η5-C5Ph4O)Mo(CO)3]2 
Ph
Ph
O
Ph
Mo
OC
OC
CO
Ph
Ph
O Ph
Ph
Mo
CO
CO
OC
Ph
 
[35] 
[Na][Mo(CO)3(hist)] 
Mo
CO
OC
NH2
O
OC
N
HN
CH
C
O
Na
 
[36] 
[Et4N][Mo(CO)3(hist)] 
Mo
CO
OC
NH2
O
OC
N
HN
CH
C
O
[Et4N]
 
[36] 
[K][Mo(CO)3(hist)] 
 
Mo
CO
OC
NH2
O
OC
N
HN
CH
C
O
K
 
[36] 
[Et4N]3[Mo(CO)3(cit)] 
Mo
CO CO
O O
OH
CO
O
O
O
O
[Et4N]3
3-
 
[37] 
[Na]3[Mo(CO)3(cit)] 
Mo
CO CO
O
O
OH
CO
O
O
O
O
Na3
 
adapted from 
[37] 
see Chapter II 
Experimental 
Section 
[choline]3[Mo(CO)3(cit)] 
Mo
CO
CO
O
O
HO
OC
O
O
O
O
3-
N
HO
3
 
adapted from 
[37] 
see Chapter II 
Experimental 
Section 
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[Na]3[Mo(CO)3(nita)] 
Mo
OC
CO
CO
O
-
ONO
O
OO
3Na
+
 
adapted from 
[37] 
see Chapter II 
Experimental 
Section 
[Et4N]3[Mo(CO)3(nita)] 
[NEt4]3
Mo
CO CO
O O
-O
CO
OO N
O
 
adapted from 
[37] 
see Chapter II 
Experimental 
Section 
[Na]5[Mo(CO)3(detpa)] 
Na5Mo
CO CO
CO
-
O2C CO2
-
N
-
O2C
NN
CO2
-
-
O2C
 
adapted from 
[37] 
see Chapter II 
Experimental 
Section 
   
Mo(CO)2(S2CNMe2)2 Mo
CO
CO
S
S S
S
CNMe2Me2NC
 
[38] 
   
   
Fe(CO)4I2 Fe
CO
CO
I CO
OC I
 
[39] 
(η1-C3H5)Fe(CO)3Br Fe
OC
CO
CO
Br
 
[40] 
Cp*Fe(CO)2Cl Fe
OC
OC
Cl
 
 
CpFe(CO)2Cl Fe
OC
OC
Cl
 
[41, 42] 
CpFe(CO)2Br Fe
CO
BrOC
 
[41, 42] 
CpFe(CO)2I 
Fe
OC
OC
I
 
[42] 
CpFe(CO)2CH3 Fe
OC
OC
CH3
 
[43] 
CpFe(CO)2CH2Ph Fe
OC
CO  
adapted from 
[43] 
CpFe(CO)2(η1-C3H5) Fe
OC
CO
 
[44] 
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CpFe(CO)2CH2CH2CH2Cl Fe
OC
CO
Cl
 
[45] 
CpFe(CO)2CH2CONH2 Fe
NH2
O
OC
CO  
[2] 
CpFe(CO)2CH2COOH Fe
OH
OC
CO
O
 
[2] 
CpFe(CO)2COMe Fe
CO
C
O
CH3
OC
 
[46] 
CpFe(CO)2COPh Fe
CO
C
O
C6H5
OC
 
[47] 
CpFe(CO)2(OCOC6H4OCOCH3) O
O
O
Fe
OC
OC
 
AIP 
Fe(CO)2(cysteine)2 Fe
H2N
H2N CO
CO
S
S
HO2C
HO2C  
[48] 
CpFe(CO)2OCOC5H4NFe(CO)2Cp Fe
OC
CO
O
O
N
Fe
OC
CO  
AIP 
[CpFe(CO)2]2 Fe Fe
OC
C
O
O
C
CO
 
[49] 
   
   
Ru(CO)3Cl(glycinate) Ru
CO
OC
NH2
O
OC
Cl CH2
C
O 
[50] 
Ru(CO)3Cl2(DMSO) OC
Ru
Cl
ClOC
CO
S
O 
see Chapter V 
Experimental 
Section 
Ru(CO)3Cl2(methionine) OC
Ru
Cl
ClOC
CO
S
NH2
OH
O  
see Chapter V 
Experimental 
Section 
Ru(CO)3Cl2(methionine oxide) OC
Ru
Cl
ClOC
CO
OS
NH2
OH
O  
see Chapter V 
Experimental 
Section 
Ru(CO)3Cl2(DAPTA) 
CO
Ru
Cl
Cl
CO
OC
N
N N
P
O
O
 
see Chapter V  
Experimental 
Section 
Annex I 
 
 
305 
CpRu(CO)2Cl 
Ru
OC
OC
Cl
 
[51] 
   
   
[Co(CO)3]2(PhC≡CPh) 
Co
OC
OC
OC
Co
CO
CO
CO
Ph
Ph
 
[52, 53] 
AIP – Alfama’s Intelectual Property - Compounds prepared by other colleagues from Alfama’s 
Chemistry Department and that are part of Alfama’s portfolio of compounds. 
The compounds labeled with AIP and references were prepared using a different procedure from the 
literature. 
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